



ISSN 1820-9955  
UDK 619

Scientific Veterinary Institute „Novi Sad” Novi Sad  
Naučni institut za veterinarstvo „Novi Sad” Novi Sad

**Archives of Veterinary  
Medicine  
Arhiv veterinarske  
medicine**

Arch. vet. med.

Vol. 16

No. 2

Pg. 1-144

Novi Sad, 2023.



ISSN 1820-9955

UDK 619

Scientific Veterinary Institute „Novi Sad” Novi Sad  
Naučni institut za veterinarstvo „Novi Sad” Novi Sad

# **Archives of Veterinary Medicine**

## **Arhiv veterinarske medicine**

Arch. vet. med.	Vol. 16	No. 2	Pg. 1-144	Novi Sad, 2023.
-----------------	---------	-------	-----------	-----------------

CIP – Каталогизација у публикацији  
Библиотека Матице српске, Нови Сад

619

**Archives of Veterinary Medicine = Arhiv veterinarske medicine** / Editor in Chief Sava Lazić. – Vol. 1, br. 1 (2008) –.- Novi Sad : Scientific Veterinary Institute “Novi Sad”, 2014 –.- 25 cm

Published twice a year.

ISBN 1820-9955

COBISS.SR-ID 235692807

## EDITORIAL TEAM

### Editor in Chief:

**Sava Lazić**, Principal Research Fellow (lazic@niv.ns.ac.rs)  
Scientific Veterinary Institute “Novi Sad” (Serbia)

### Deputy Editor:

**Tamaš Petrović**, Principal Research Fellow, (tomy@niv.ns.ac.rs)  
Scientific Veterinary Institute “Novi Sad” (Serbia)

### Advisory Board Members:

**Neđeljko Karabasil**, Professor, Faculty of Veterinary Medicine, University of Belgrade (Serbia)  
**Milorad Mirilović**, Professor, Faculty of Veterinary Medicine, University of Belgrade (Serbia)  
**Ivan Toplak**, Assoc. Professor, Faculty of Veterinary Medicine, University of Ljubljana (Slovenia)  
**Vladimir Petrović**, Professor, Faculty of Medicine, University of Novi Sad (Serbia)  
**Dušan Petrić**, Professor, Faculty of Agriculture, University of Novi Sad (Serbia)  
**Dejan Vidanović**, Senior Research Fellow, Veterinary Specialist Institute „Kraljevo“, Kraljevo (Serbia)  
**Maja Velhner**, Principal Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Milica Živkov Baloš**, Principal Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Dubravka Milanov**, Principal Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Sara Savić**, Principal Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Vladimir Polaček**, Senior Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Aleksandar Potkonjak**, Professor, Dep. of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad (Serbia)  
**Ljubo Barbić**, Professor, Faculty of Veterinary Medicine, University of Zagreb (Croatia)

### Editorial Board Members

**Jelena Petrović**, Principal Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Igor Stojanov**, Principal Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Sandra Jakšić**, Senior Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Željko Mihaljev**, Senior Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Radimir Ratajac**, Senior Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Diana Lupulović**, Senior Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Jasna Prodanov Radulović**, Senior Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Dejan Bugarski**, Senior Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Dragana Ljubojević Pelić**, Senior Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Gospava Lazić**, Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Tamara Ilić**, Assoc. Professor, Faculty of Veterinary Medicine, University of Belgrade (Serbia)  
**Jakov Nišavić**, Professor, Faculty of Veterinary Medicine, University of Belgrade (Serbia)  
**Ksenija Nešić**, Senior Research Fellow, Scientific Veterinary Institute of Serbia, Belgrade (Serbia)  
**Vesna Milićević**, Research Fellow, Scientific Veterinary Institute of Serbia, Belgrade (Serbia)  
**Vladimir Radosavljević**, Principal Research Fellow, Scientific Veterinary Institute of Serbia, Belgrade (Serbia)  
**Branislav Kureljušić**, Senior Research Fellow, Scientific Veterinary Institute of Serbia, Belgrade (Serbia)  
**Milanko Šekler**, Senior Research Fellow, Veterinary Specialist Institute „Kraljevo“, Kraljevo (Serbia)  
**Sandra Stefan Mikić**, Professor, Faculty of Medicine, University of Novi Sad (Serbia)  
**Ivana Hranjaković Cvjetković**, Professor, Faculty of Medicine, University of Novi Sad (Serbia)

**Snežana Medić**, Assistant Professor, Faculty of Medicine, University of Novi Sad (Serbia)  
**Drago Nedić**, Professor, Veterinary Institute „Dr Vaso Butozan“, Banja Luka (Bosnia and Herzegovina)  
**Teufik Goletić**, Professor, Faculty of Veterinary Medicine, University of Sarajevo (Bosnia and Herzegovina)  
**Juan Carlos Saiz**, Principal Research Fellow, INIA, Madrid (Spain)  
**Igor Pajović**, Research Fellow, Biotechnical faculty, University of Montenegro, Podgorica (Montenegro)  
**Lazo Pendovski**, Professor, Faculty of Veterinary Medicine, University Ss. Cyril and Methodius, Skopje (North Macedonia)  
**Jovana Stefanovska**, Professor, Faculty of Veterinary Medicine, University Ss. Cyril and Methodius, Skopje (North Macedonia)  
**Kiril Krstevski**, Assoc. Professor, Faculty of Veterinary Medicine, University Ss. Cyril and Methodius, Skopje (North Macedonia)  
**Igor Džadžovski**, Assoc. Professor, Faculty of Veterinary Medicine, University Ss. Cyril and Methodius, Skopje (North Macedonia)  
**João R. Mesquita**, Assoc. Professor, Institute of Biomedical Sciences Abel Salazar, University of Porto (Portugal)  
**Željko Cvetnić**, Academician, Croatian Academy of Sciences and Arts, Zagreb (Croatia)  
**Vladimir Savić**, Principal Research Fellow, Croatian Veterinary Institute, Zagreb (Croatia)  
**Lorena Jemeršić**, Principal Research Fellow, Croatian Veterinary Institute, Zagreb (Croatia)  
**Relja Beck**, Principal Research Fellow, Croatian Veterinary Institute, Zagreb (Croatia)  
**Tatjana Vilbić-Čavlek**, Assoc. Professor, Faculty of Medicine, University of Zagreb (Croatia)  
**Aleksandar Mašić**, Senior Research Fellow, ZOETIS, Global Bios Research (USA)  
**Alessio Lorusso**, Principal Research Fellow, Institute IZSAM, Teramo (Italy)  
**Petra Vasicková**, Senior Research Fellow, Veterinary Research Institute (VUVEL), Brno (Czech Republic)  
**Wim van der Poel**, Professor, Wageningen University, Wageningen (The Netherlands)  
**Tamas Bakonyi**, Professor, European Centre for Disease Prevention and Control (ECDC), Solna, (Sweden)

#### **Technical Editor**

**Jelena Vranešević**, Research Associate, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Miloš Pelić**, Research Associate, Scientific Veterinary Institute “Novi Sad” (Serbia)

#### **English Language Editor**

**Dubravka Klajić**, translator and English language editor  
**Danka Vukašinović**, translator and English language editor

#### **Technical Support and Website Administrator**

**Vladimir Polaček**, Senior Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Dobrisav Vuković**, ing, Scientific Veterinary Institute “Novi Sad” (Serbia)

**Published twice a year.** Circulation: 100 copies

#### **Address:**

Scientific Veterinary Institute “Novi Sad”,  
21000 Novi Sad, Rumenački put 20  
Tel. 381 (0)21 4895 321  
E-mail: arhiv@niv.ns.ac.rs  
Account No: 355-1006444-18 Vojvodanska banka,  
ID No.: 08608857,  
PIB 100236555

Review article

UDK 579.86:615.33.015.8  
579.67

<https://doi.org/10.46784/e-avm.v16i2.334>

## COMBATTING METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) IN THE FOOD INDUSTRY BY HARNESSING THE POWER OF NATURE: A SYSTEMATIC REVIEW

Zahra Alinezhad<sup>1,2</sup>, Mohammad Hashemi<sup>1,2</sup>,  
Asma Afshari<sup>1,2</sup>, Golshan Shakeri<sup>2\*</sup>

<sup>1</sup> Medical Toxicology Research Center, Mashhad  
University of Medical Sciences, Mashhad, Iran

<sup>2</sup> Department of Nutrition, Faculty of Medicine, Mashhad  
University of Medical Sciences, Mashhad, Iran

### Abstract

Antibiotic resistance is a critical global health concern, with *Methicillin-resistant Staphylococcus aureus* (MRSA) posing a significant challenge due to its resistance to commonly used antibiotics. Recent research has revealed the potential of natural compounds and microorganisms in combatting MRSA and other antibiotic-resistant bacteria. In this systematic review, we studied the effect of essential oils, bacteriophages, bacteriocins, and probiotics on *S. aureus*, including MRSA in particular, in the food industry. Essential oils (EOs) have gained significant attention because of their antimicrobial properties, inhibiting MRSA growth by damaging bacterial cells and inhibiting essential enzymes and compounds. Cinnamon oil liposomes caused the most significant decrease in MRSA populations among our reviewed essential oils. Bacteriophages can lyse the bacterial host. They encode peptidoglycan hydrolases called endolysins that target the bacterial cell wall. In our study, *S. aureus* phage (containing CHAPLysGH15 and LysGH15), and phage SA11 endolysin (LysSA11) were the most effective against *S. aureus*. Bacteriocins, antimicrobial peptides produced by bacteria, also show potential in combatting MRSA, mainly by generating organic acids that interfere with bacterial metabolism. According to our review, the

---

<sup>1\*</sup> Golshan.shakeri@gmail.com

most effective bacteriocins against *S. aureus* were *Enterocin AS-48* with phenolic compounds or with *2NPOH*, Bacteriocin isolated from *Lactobacillus pentosus* - *Pentocin JL-1*, and bacteriocin produced by *S. pasteurii* *RSP-1*, respectively. Probiotics can compete with pathogens by producing antimicrobial compounds that disrupt *MRSA* cell production and ultimately lead to bacterial death. In our review, the most effective probiotics were *Streptomyces griseus*, *Pediococcus acidilactici* strains *A11* and *C12*, *Lactococcus lactis*, and *Lactobionic acid* respectively. A multi-hurdle approach combining these natural agents has shown promising results in targeting and eliminating *MRSA* cells. By harnessing the power of nature, we can potentially overcome the challenges posed by *MRSA* and other antibiotic-resistant bacteria.

**Key words:** *Methicillin-resistant Staphylococcus aureus (MRSA)*, Essential oils, Bacteriophage, Bacteriocin, Probiotic

## **BORBA PROTIV STAPHILOCOCCUS AUREUS-a (MRSA) OTPORNOG NA METICILIN U PREHRAMBENOJ INDUSTRIJI KORIŠĆENJEM SNAGE PRIRODE: SISTEMATSKI PREGLEDNI RAD**

Zahra Alinezhad<sup>1,2</sup>, Mohammad Hashemi<sup>1,2</sup>,  
Asma Afshari<sup>1,2</sup>, Golshan Shakeri<sup>2\*</sup>

<sup>1</sup> Istraživački centar za medicinsku toksikologiju,  
Univerzitet Mashhad, Mashhad, Iran

<sup>2</sup> Katedra za ishranu, Medicinski fakultet, Univerzitet Mashhad, Mashhad, Iran

### **Kratak sadržaj**

Otpornost na antibiotike je globalni zdravstveni problem, a meticilin rezistentan *Staphylococcus aureus* (MRSA) predstavlja značajan izazov zbog otpornosti na antibiotike koji se obično koriste. Skorija istraživanja otkrila su potencijal prirodnih jedinjenja i mikroorganizama u borbi protiv MRSA i drugih bakterija otpornih na antibiotike. U ovom preglednom radu proučavan je efekat eteričnih ulja, bakteriofaga, bakteriocina i probiotika na *S. aureus*, uključujući i izolate MRSA, u prehrambenoj industriji. Eterična ulja (EO) privukla su značajnu pažnju zbog svojih antimikrobnih svojstava, inhibirajući rast MRSA tako što oštećuju bakterijsku ćeliju i inhibiraju njihove esencijalne enzime i jedinjenja. Od svih ispitanih eteričnih ulja, lipo-



zomi ulja cimeta doveli su do najznačajnijeg smanjenja populacije MRSA. Bakteriofagi mogu da liziraju bakteriju koju napadaju. Oni sintetišu enzime peptidoglikan hidrolaze koji su poznati pod nazivom - endolizini, koji oštećuju bakterijski zid. U našoj studiji, *S. aureus* fage (koje sadrže CHAPLisGH15 i LisGH15) i fag SA11 endolizin (LisSA11) bili su najefikasniji protiv *S. aureus*. Bakteriocini, antimikrobni peptidi koje proizvode bakterije, takođe pokazuju potencijal u borbi protiv MRSA, uglavnom stvaranjem organskih kiselina koje ometaju metabolizam bakterija. Na osnovu rezultata našeg preglednog rada, najefikasniji bakteriocini protiv *S. aureus* su bili Enterocin AS-48 sa fenolnim jedinjenjima ili sa 2NPOH, Bacteriocin izolovan iz *Lactobacillus pentosus* - Pentocin JL-1 i bakteriocin proizveden od *S. pasteurii* RSP-1. Probiotici mogu da deluju na patogen tako što proizvode antimikrobna jedinjenja koja ometaju proizvodnju MRSA ćelija i na kraju dovode do smrti bakterija. U našem pregledom radu, najveću efikasnost pokazali su probiotici *Streptomyces griseus*, *Pediococcus acidilactis* sojevi A11 i C12, *Lactococcus lactis* i *Lactobionis acid*. Pristup koji kombinuje ove prirodne agense pokazao je zadovoljavajuće rezultate u prepoznavanju i eliminaciji MRSA ćelija. Koristeći snagu prirode, razvijamo potencijal za prevazilaženje infekcija uzrokovanih sa MRSA-ma i drugim bakterijama koje su otporne na antibiotike.

**Gljučne reči:** *Staphylococcus aureus* otporan na meticilin (MRSA), eterična ulja, bakteriofag, bakteriocin, probiotik

## INTRODUCTION

*Staphylococcus aureus* is a gram-positive pathogenic bacterium. The ability of *S. aureus* to adhere to specific host substrates and evade host defenses (Eom, et al. 2014; Lu, et al. 2021), as well as its ability to survive in various environmental conditions while posing different virulence factors (de Oliveira, et al. 2010; Eom, et al. 2014; Burris, et al. 2015; Lu, et al. 2021), makes it highly virulent and capable of causing life-threatening infections in both humans and animals (Zhu, et al. 2015; Catteau, et al. 2017; Lalouckova, et al. 2021). Food-borne diseases caused by *S. aureus* (Lee, et al. 2009; de Oliveira, et al. 2010; Keyvan and Tutun 2019; Prastiyanto, et al. 2020; Lalouckova, et al. 2021) are generally limited to food poisoning and gastroenteritis, resulting from enterotoxins produced by *S. aureus* (Lee, et al. 2009; Zhu, et al. 2015; AL-Saadi 2016; Prastiyanto, et al. 2020).

Antibiotic resistance is one of the most significant health challenges of the

century (Lee, et al. 2009; Chang, et al. 2017; Chang, et al. 2017; Prastiyanto, et al. 2020). Antibiotic-resistant forms of *S. aureus*, such as methicillin-resistant *Staphylococcus aureus* (*MRSA*), are multi-drug-resistant (Eom, et al. 2014; AL-Saadi 2016; Lu, et al. 2021) to  $\beta$ -lactam antibiotics (Eom, et al. 2014; Redwan et al. 2016; Catteau, et al. 2017; Lestari, et al. 2019; Prastiyanto, et al. 2020). Food-borne *MRSA* is a major concern for public health worldwide (Lee, et al. 2013; Redwan, et al. 2016; Kang, et al. 2020; Lu, et al. 2021), because it can enter the food chain as animal based food (Vaiyapuri, et al. 2019; Kang, et al. 2020) or by colonizing in food handlers and transferring from them to food (Eom, et al. 2014). A high rate of morbidity and mortality by *MRSA* have been reported worldwide (Zhu, et al. 2015; Redwan, et al. 2016; Zouhir, et al. 2016; Salem 2017; Zihadi, et al. 2019). *MRSA* has already been isolated from food, indicating that it is present as a contaminant in the food production chain (Ansari, et al. 2020; Afshari, et al. 2022). The presence of *MRSA* has been reported mainly in meat such as pork, beef, lamb, chicken, rabbit, and turkey, as well as in dairy products such as milk and cheese (Mohammed-Ali, et al 2015). This means that the food production chain is a pathway of transmission between resistant microorganisms and humans (Mohammed-Ali, et al 2015). Food safety is an important global concern in the food industry and public health. Many preservatives that are used to control microbial growth in foods not only increase the shelf-life of food products, but they also reduce the incidence of foodborne diseases (Xu, et al. 2016; Chang, et al. 2017). Due to consumer worries regarding safety of chemical preservatives utilized in food, there is an increasing need for natural alternatives that can function as food preservatives. (Gyawali, et al 2014). Therefore, it is critical to use natural agents that control or prevent foodborne pathogens, including *MRSA*, in food (Kang, et al. 2020). By utilizing these natural antimicrobials as food preservatives, the need for excessive physical and chemical food processing can be reduced while ensuring microbial safety and environmental preservation (Yusuf, 2018).

Several natural compounds from plants, animals, and microorganisms have been studied and applied in order to inhibit or control the growth of foodborne microorganisms, including *MRSA*. Plant-derived essential oils are commonly used as flavoring and preservation agents in food and drinks have antimicrobial and antioxidative activity (Cui, et al. 2018; Yuan, et al 2018).

Bacteriophages are viruses that infect bacteria and can exhibit inhibitory activity against *S. aureus*, particularly *MRSA*. Furthermore, since gram-positive bacteria lack an outer membrane, bacteriophages can directly lyse the cell wall from the outside (Lysis from without) (Lu, et al. 2021). Bacteriocins are proteins that exhibit bactericidal effects on a variety of bacteria, including *S. aureus*. They are considered as alternatives to traditional antibiotics (Zhu, et al.

2015; Chauhan, et al. 2017; Lestari, et al. 2019) and an effective approach for use in food against *MRSA* (Arumugam, et al. 2019). Probiotics are living organisms used as food additives to help maintain a healthy microbial balance in the gastrointestinal tract, leading to better health in humans (Lee, et al. 2021).

This review focuses on the effective natural antimicrobials originating from plants and microorganisms against *MRSA*, including essential oils, bacteriophages, bacteriocins, and probiotics. The mechanisms of action, as well as their effectiveness, are also surveyed. Our main aim was to review the efficiency of natural antimicrobial agents in combating *MRSA* in food.

## **MATERIAL AND METHODS**

### ***Study Design***

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were applied to conduct this systematic review. The main objective of this study was to review the literature on natural approaches for controlling *MRSA* in food.

### ***Search Strategy***

In this study, the main databases, including Scopus, PubMed, Google Scholar, and Science Direct, were searched. The literature review was limited to studies published from 2000 to 2023. The search was independently conducted for each database, focusing on controlling *Methicillin-resistant Staphylococcus aureus* OR *MRSA* in any food product worldwide. The keywords used were “*Methicillin-resistant Staphylococcus aureus*” OR “*MRSA*” AND “Dairy” OR “Milk” OR “Meat” OR “Food” AND “Essential Oils” OR “Probiotic” OR “Bacteriophage” OR “Bacteriocin” AND “Control”.

### ***Inclusion and Exclusion Criteria***

This review included articles (n = 83) that reported on the natural types of effective antimicrobials, including essential oils, bacteriophages, bacteriocins, and probiotics, against *MRSA*. The selection for inclusion eligibility was conducted by scanning the titles, abstracts, and full texts of retrieved articles. The focus of our study was on livestock-associated (*LA*) *MRSA*. All review studies, duplicate publications, as well as clinical reports and trials on healthcare-associated (*HA*) *MRSA*, were excluded.




Figure 1. PRISMA flowchart for studies selection

## RESULTS

### *Essential Oils*

Essential oils have shown an antimicrobial effect against *S. aureus* and *MRSA* in particular. For instance, Cinnamon oil, Thyme oil, and Lemongrass oil reduced the *MRSA* population in minced meat by 7.6, 6.53, and 5.94 log CFU/g, respectively, when applied at a concentration of 1.5% (Eom, et al. 2014). Cinnamon oil was bactericidal against the biofilm activity of *MRSA*. A concentration of 1.0 mg/mL of cinnamon oil was sufficient to eliminate *MRSA* biofilm (Cui, et al. 2016). *Syzygium aromaticum* (CLV) and *Cinnamomum zeylanicum* (CIN) exhibited bactericidal activity at a concentration of 200 µg/mL against *S. aureus* and reduced the population of *S. aureus* by 4.50 log<sub>10</sub> CFU/mL and 3.97 log<sub>10</sub> CFU/mL, respectively (Mandal, et al. 2011). *Cuminum cyminum* (CMN) exhibited bactericidal activity at 300 µg/mL and caused a reduction of 0.59 log<sub>10</sub> CFU/mL in *MRSA* after 24 hrs (Mandal, et al. 2011). The MIC concentration of the polyphenolic components of green tea, neem leaves extract, and a combination of green tea and neem were 15.62, 31.25,

and 46.87 mg/mL, respectively (Zihadi, et al. 2019). Allicin liquid was active against *S. aureus* strains, and all *MRSA* strains were inhibited by *allicin* at 32 µg/mL (Cutler, et al 2004). The indigenous cinnamon B leaf oil (*Cinnamomum osmophloeum*) had antibacterial effect against *MRSA* with an MIC of 250 µg/mL (Chang, et al. 2001). The *ethanolic* extract of *Elettaria cardamomum* displayed antibacterial activity against *MRSA*, with a minimum inhibitory concentration (MIC) of 0.25 mg/disk and minimum bactericidal concentration (MBC) of 0.50 mg/disk against *S. aureus* (Yassin, et al. 2022). *Nigella sativa* oil extract was effective against *MRSA*, with inhibition zones of  $7 \pm 1$  mm and  $10 \pm 0.9$  mm observed at concentrations of 400 µl and 800 µl, respectively (Abdullah, et al. 2021). *Litsea cubeba* essential oil (*LC-EO*) contained high percentages of *aldehydes*, primarily  $\beta$ -Citral (39.25%) and  $\alpha$ -Citral (30.89%). *LC-EO* caused a steady decrease in *MRSA* populations, with a 99.99% reduction observed after 2 hours of treatment with 0.25 mg/mL of *LC-EO* (Hu, et al. 2019). *Red propolis* extracts (*RPE*) had an inhibition zone of  $16.5 \pm 0.5$  mm and  $19.3 \pm 0.5$  mm against *S. aureus* and *MRSA*, respectively (Zhang, et al. 2022). The essential oil extracted from *Carum carvi* L. seeds completely prevented *MRSA* biofilm formation at a concentration of 1.28%, with decreasing inhibitory effects observed at lower concentrations (Liu, et al. 2023). The *ethanol* extract from *Psoralea corylifolia* seeds exhibited antibacterial activity against Gram-positive bacteria, with inhibition zones of 14 mm and 16 mm for *S. aureus* and *MRSA*, respectively. *MRSA* cells treated with 1600 µg/mL of the extract were deformed and collapsed (Li, et al. 2019). *Backhousia citriodora* essential oil significantly inhibited 90.01% to 93.39% of *S. aureus* biofilms (Lim, et al. 2022). *Oregano* (*Origanum vulgare*) and clove (*Eugenia caryophyllata*) essential oils were effective against *S. aureus* and *MRSA*, with complete inhibition at concentrations of 0.63 µg/mL and 10 µg/mL, respectively (Debiagi, et al. 2020). Finally, *Lippia micromera* and *Plectranthus amboinicus* exhibited potent antibacterial activity against *MRSA*, with large inhibition zones of 23.7 - 35.7 mm (Bugayong, et al. 2019). The MIC of a combination of *oregano* and *thyme* essential oils was found to be 320 µg/mL (Boskovic et al. 2015). Other studies reporting the effectiveness of essential oils are summarized in Table 1. According to Table 1, the most effective compound against *MRSA* is the *liposome* containing cinnamon oil, with a MIC of 0.25 mg/mL and MBC of 0.25 mg/mL, this compound resulted in a 99.99% decrease in *MRSA* populations after 4 hours and a decrease of 2.83 logs after 24 hours at a concentration of 1.0 mg/mL. Other most effective EOs against *MRSA* are *Cinnamomum zeylanicum*, *Syzygium aromaticum*, *Cuminum cyminum*, respectively. Additionally, *allicin*, *glabrol*, *clove buds*, and *Backhousia citriodora* essential oils  $s < 0$ , have shown significant effectiveness against *MRSA* with low MIC values.

Table 1. Effectiveness of essential oils against MRSA

Essential oils			
Name	Active Components	Effectiveness	References
Cinnamon oil, Thyme oil and Lemongrass oil	<i>Cinnamaldehyde, eugenol, Alpha and beta-citral, mycrene</i>	The initial count of MRSA after inoculation (at zero time) was 10.28(log CFU/g) which at a concentration of 1.5% Cinnamon oil, Thyme oil and Lemongrass oil reduced MRSA population by 7.6, 6.53, 5.94 log CFU/g, respectively.	(Salem 2017)
Liposome containing cinnamon oil	<i>Cinnamon oil</i>	After 4h there was a decrease of around 99.99% in the MRSA populations and after 24 h, the population of MRSA decreased by 2.83 logs using 1.0 mg mL <sup>-1</sup> . MIC (mg/mL): 0.25, MBC (mg/mL): 0.25	(Cui, et al. 2016)
Indian Spices	<i>Syzygium aromaticum (CLV), Cinnamomum zeylanicum (CIN) and Cuminum cyminum (CMN)</i>	After 24 h the CIN and CLV showed bactericidal activity at concentration 200 µg/mL against <i>S. aureus</i> reducing 4.50 log <sub>10</sub> cfu/mL and 3.97 log <sub>10</sub> cfu/mL, respectively; CMN exhibited bactericidal effects at 300 µg/mL, leaving 0.59 log <sub>10</sub> cfu/mL. Effectiveness order: <i>C.zeylanicum</i> > <i>S.aromaticum</i> > <i>C. cyminum</i>	(Mandal, et al. 2011)

Essential oils			
Name	Active Components	Effectiveness	References
Polyphenolic components of <i>Green tea</i> , Neem leaves extract of <i>Camellia sinensis</i> and <i>Azadirachta indica</i> leaves	<i>Catechin</i>	MIC (mg/mL): <i>Green tea</i> : 15.62 <i>Neem</i> : 31.25 <i>Green tea + Neem</i> : 46.87 ( <i>green tea</i> extract is more potent than <i>neem</i> against <i>MRSA</i> )	(Zihadi, et al. 2019)
<i>Allicin</i>	NR	MIC: 32 µg/ML, MBC: 128 µg/mL	(Cutler, et al 2004)
<i>Cinnamomum osmophloeum</i> leaf	<i>Cinnamaldehyde</i>	MIC: 250 µg/mL	(Chang, et al. 2001)
<i>Thyme</i> ( <i>Thymus vulgaris</i> ) and <i>Oregano</i> ( <i>Origanum vulgare</i> )	<i>Thymol</i> from <i>Thyme</i> and <i>Carvacrol</i> from <i>Oregano</i>	MIC of <i>Oregano</i> and <i>Thyme</i> : 320 µg/mL MBC of <i>Oregano</i> : 1280 µg/mL MBC of <i>Thyme</i> : 640 µg/mL	(Boskovic, et al. 2015)
<i>PFF</i> ( <i>phlorofucoxuroecko</i> , a marine-derived polyphenol found in brown algae)	NR	MIC: 64 µg/mL	(Eom, et al. 2014)
<i>URS</i> ( <i>ursolic acid 3-O-α-L-arabinopyranoside</i> was isolated from the leaves of <i>A. henryi</i> (Oliv) with <i>oxacillin</i> )	Urso-lic acid 3-O-α-L-arabinopyranoside with (URS) <i>oxacillin</i>	MIC: 6.25 µg/mL After 24 h, treatment with 1/2 MIC OXA and 3/4 MIC URS in combination resulted in combined group bacteria counts that decreased to 3 log <sub>10</sub> .	(Zhou, et al. 2017)

Essential oils			
Name	Active Components	Effectiveness	References
<i>Pink oyster mushroom Pleurotus flabellatus</i>	The terpenoid compound group	MIC: 62.5 mg/mL MBC: 250 mg/mL	(Ghosh, et al. 2016)
<i>Carvacrol</i>	NR	MIC: 0.11 mg/mL	(Keyvan, and Tutun 2019)
<i>Bulb Eleutherine Americana</i>	Naphtho-quinone	MIC: 125-500 g/mL, MBC: 250-1000 g/mL	(Ifesan, et al. 2009)
<i>Aloysia citriodora essential oils from Baqa al-Gharbiyye and Umm al-Fahm</i>	lipophilic structures like $\alpha$ - citral and $\alpha$ -curcumene	MIC: 2.5 $\mu$ g/mL	(Aru-mugam, et al. 2019)
<i>Garlic</i>	Allicin (allyl 2-propenethi- osulphinate)	MIC: 256 g/mL	(Prasti- yanto, et al. 2020)
<i>Cinnamon (Cinnamo- mum verum)</i>	Cinnamal- dehyde, eugenol	Against MSSA: MIC of 250 $\mu$ g/mL Against MRSA: MIC of 250 $\mu$ g/mL	(Prasti- yanto, et al. 2020)
<i>Thyme (Thymus vulgaris L.)</i>	Thymol, carvacrol	MIC of 0.25% (v/v)	(Prastiyanto, et al. 2020)
<i>Clove (Eugenia caryophyllata)</i>	Eugenol, Cariofilene	MIC of 0.25% (v/v)	(Prastiyanto, et al. 2020)
<i>Rosemary (Rosemarinus officinalis)</i>	Borneol, 1, 8-cineole	MIC of 1.0% (v/v) MIC of 0.5% (v/v)	(Prasti- yanto, et al. 2020)
<i>Sage (Salvia officinalis)</i>	Thujone, cin- eol, thymol	MIC of 1.0 (% v/v)	(Prastiyanto, A et al. 2020)
<i>Tea tree (Melaleuca alternifolia)</i>	Terpene	MIC of 0.5% (v/v)	(Prasti- yanto, et al. 2020)



Essential oils			
Name	Active Components	Effectiveness	References
<i>Flavonoids from licorice</i>	glabrol, licochalcone A, licochalcone C, and licochalcone E	After 3 h, at 8 mg/mL killed both MRSA T144 and MSSA ATCC29213 completely and after 1 h, all MRSA T144 and MSSA ATCC29213 cells were killed after exposure to glabrol at 4–16 mg/mL.	(Burgos, et al. 2015)
<i>Clove buds</i>	Eugenol	MIC: 0.62 mg/mL	(Xu, et al. 2016)
<i>Chuzhou chrysanthemum</i>	B-Eudesmene, L-Borneol, Camphor	MIC: 5 mg/mL, MBC: 10 mg/mL	(Cui, et al. 2018)
<i>Syzygium antisepticum plant</i>	b-caryophyllene	MIC: 0.12 mg/mL MBC: 0.5 mg/mL	(Yuan, et al 2018)
<i>Sanguisorba officinalis strains</i>	Ethanol	At the concentration of 10 mg/mL <i>S. officinalis</i> the growth of the MRSA was inhibited. at a low concentration (<2.5 mg/mL), inhibitory effect of <i>S. officinalis</i> on biofilm formation in the MRSA strain was obvious.	(Chen, et al. 2015)
<i>Korean soybean fermented product doenjang</i>	Methanolic	MIC: 2048 µg/mL	(Lalouckova, et al. 2021)

Essential oils			
Name	Active Components	Effectiveness	References
<i>Bisdemethoxycurcumin with three antibiotics (gentamicin, ampicillin and oxacillin)</i>	NR	MIC: 7/8 µg /mL for all S. aureus strains including MRSA. The combination of BDMC with antibiotics caused more than 3 log <sub>10</sub> cfu/mL reductions on all the three S. aureus strains.	(Her-mawati, et al. 2016)
<i>Thymol and carvacrol with organic acids (lactic acid)</i>	NR	Combination of thymol and carvacrol with organic acids results a reduction over two log cycles in initial bacterial after 24 h. Thymol and carvacrol showed MIC of 0.6 and 1.25 µL/mL and MIC of lactic acid was 2.5 µL/mL	(de Oliveira, et al. 2010)
<i>Elettaria cardamomum ethnolic extract</i>	a-terpinyl acetate and 1,8 cineole	MIC: 0.25 mg/disk, MBC: 0.50 mg/disk	(Yassin, et al. 2022)
<i>Nigella sativa (Black seed) Oil</i>	Heptanal, Benton 2,3-dimethyl, 1-OCTAN-1,1-D2-OL and Pentane, 2-cyclopropyl	MIC shows that at the concentration of 400 µl with (7± 1) mm of inhibition zone and 800mL concentration was (10± 0.9) mm	(Abdullah, et al. 2021)
<i>Litsea cubeba essential oil</i>	β-Citral and α-Citral	MIC 0.5 mg/ mL, MBC 1.0 mg/ mL	(Hu, et al. 2019)
<i>Red Propolis</i>	Pinobanksin, pinobanksin-3-acetate	MIC: of 50 µg/mL MBC: 200 µg/mL	(Zhang, et al. 2022)

Essential oils			
Name	Active Components	Effectiveness	References
<i>Essential Oil Extracted from Carum carvi L. seeds (CEO)</i>	Carvone and limonene	MIC: 6.4 µg/mL	(Liu, et al. 2023)
<i>Ethanol Extracts of Psoralea corylifolia Seeds</i>	Phenol, hydrazine, aldehyde, and ketone	MIC: 50 µg/mL MBC: 100 µg/mL	(Li, et al. 2019)
<i>Black seed (Nigella sativa) oil</i>	Heptanal, Benton 2,3-dimethyl, 1-OCTAN-1,1-D2-OL and Pentane, 2-cyclopropyl	MIC: 32.8 mg/mL MBC 42.2 mg/mL	(Abdullah, et al. 2021)
<i>Backhousia citriodora Essential Oil (BCEO) leaves</i>	oxygenated monoterpenes and neral phytochemicals	MIC: 6.25 µL/mL, MBC: 50 µL/mL	(Lim, et al. 2022)
<i>Pelargonium graveolens Oil</i>	citronellol, citronellyl formate	MIC: 1.56 µg/mL.	(Jaradat, et al. 2022)
<i>Origanum vulgare and Eugenia caryophyllata oil</i>	phenols components	MIC CEO: 10 µg/mL MIC OEO: 0.63 µg/mL	(Debiagi, et al. 2020)
<i>Essential Oils from Leaves of Some Aromatic Plants</i>	Monoterpenes	MIC :2.00 %, MBC>4.00 %	(Bugayong, et al. 2019)

Essential oils			
Name	Active Components	Effectiveness	References
<i>Essential Oils from Elettaria Cardamomum fruit capsules</i>	monoterpenes and sesquiterpenes	MIC: 250 µg/mL.	(Jha, et al. 2022)

NR: not reported

### **Bacteriophage**

A phage endolysin, *LysP108*, was able to decrease viable *MRSA* cells by approximately 2 log units within 30 minutes at an optimal concentration of 250 µg/mL. At an MIC of 100 µg/mL, while the antibiofilm activity of the endolysin resulted in the removal of 66% of *MRSA* biofilm (Lu, et al. 2021). Endolysin *LysSA11*, at a concentration of 450 nM, reduced the optical density of the *S. aureus* culture after 30 minutes. However, the efficacy of *LysSA11* declined by 50% at temperatures of 4 °C or 65 °C (Chang, et al. 2017). Two other endolysins, *CHAPLysGH15* and *LysGH15*, that were isolated from *S. aureus*, showed a rapid antibacterial effect on *MSSA* and *MRSA* strains. Although they became inactive when exposed to heat treatment, *CHAPLysGH15* demonstrated high activity at pH 7.0–10.0, and *LysGH15* was active in high-salt environments. Therefore, they can be used in salty foods, as well as alkaline foods, including raw beef, pork, fish, and chicken, which are prone to contamination with *S. aureus* (Yan, et al. 2021). A well-studied, *S. aureus*-specific bacteriophage, Phage K, demonstrated a good inhibitory effect on *S. aureus* strains, including *MRSA*. Furthermore, when this phage was combined with essential oils, such as *a-pinene*, the inhibitory effect was greater than either the phage or the essential oil alone (Ghosh, et al. 2016). When Phage *SapYZU11* was applied at a multiplicity of infection (MOI) of 100, it resulted in the maximum reduction of *MRSA* *JCSC 4744* and *S. aureus* cocktail after 4 days, with reductions of 0.33 log CFU/mL and 0.29 log CFU/mL, respectively. These findings suggest that *SapYZU11* could be utilized as a biocontrol agent to effectively combat *S. aureus* contamination in the food industry (Wen, et al. 2023). Good results have been reported for combinations of phages and other antimicrobials, such as bacteriocins. For example, a combination of phage *SAP84* and a bacteriocin from *L. lactis* *CJNU* demonstrated significantly better *anti-S. aureus* activity

compared to each one alone (Kim, et al. 2019). The synergistic inhibition of the combination of phage SAP84 and bacteriocin against *S. aureus* caused a reduction of more than 5 log in viable counts, while the phage alone led to only about a 2 log cfu/mL reduction in *S. aureus* counts (Kim, et al. 2019). In another study, a lower concentration of endolysin *LysH5* was required in combination with subinhibitory concentrations of nisin to achieve complete inhibition of *S. aureus* Sa9 (Arumugam, et al. 2019). After the treatment with 1  $\mu$ M of recombinant SAP8 endolysin, the initial MRSA count of 5.93 log CFU/mL was reduced to 3.64 log CFU/mL. In addition, the combination of 0.01  $\mu$ M of recombinant SAP8 endolysin and 18 IU/mL of nisin completely prevented the growth of MRSA (Hassan, et al. 2020). Also, the combination of bacteriophage endolysin *LysSA97* with *carvacrol* was found to significantly decrease the number of viable *S. aureus* cells (Chang, et al. 2017). When a combination of *S. aureus* phage (MOI 10) and 1% thyme oil was used, a greater reduction (87.22%) in *S. aureus* was achieved compared to using each treatment alone (Abdallah, et al. 2021). These examples indicate that phages can have a synergistic effect with other antibacterials. The effects of different bacteriophages and endolysins against *S. aureus*, including MRSA, have been reported in studies that are summarized in Table 2. Based on Table 2, the most effective phage compounds are *S. aureus* phage (containing *CHAPLysGH15* and *LysGH15*), phage SA11 endolysin *LysSA11*, endolysin *LysSA97* with *carvacrol*, and phage endolysin *LysH5* and *nisin*, respectively.

Table 2. Effect of bacteriophages and endolysins against MRSA

Bacteriophage			
Name	Active Components	Effectiveness	References
Endolysin <i>LysP108</i>	NR	MIC: 100 $\mu$ g /mL	(Lu, et al. 2021)
Staphylococcus aureus bacteriophage	<i>CHAPLysGH15</i> and <i>LysGH15</i>	MRSA was completely cleaved by 0.4 nmol/cm <sup>2</sup> of <i>CHAPLysGH15</i> . 1.0 Log <sub>10</sub> cfu/cm <sup>2</sup> of MRSA declined after adding 0.4 nmol/cm <sup>2</sup> of <i>LysGH15</i>	(Li, et al. 2011)

Bacteriophage			
Name	Active Components	Effectiveness	References
Endolysin <i>LysSA97</i> (an endolysin encoded by the bacteriophage SA97) with <i>carvacrol</i>	NR	The numbers of <i>S. aureus</i> cells were decreased by $0.8 \pm 0.2$ log cfu/mL and $1.0 \pm 0.0$ log cfu/mL at concentrations of 376 nm and 3.33 mm, respectively.	(Chang, et al. 2017)
EOCs ( <i>a-pinene</i> and <i>3-carene</i> ) combined with two types of <i>S. aureus</i> bacteriophage, <i>phage K</i> (ATCC 19685-B1) and <i>phage 92</i> (ATCC 33741-B1)	NR	Both phage of <i>S. aureus</i> -specific bacteriophage alone and EO ( <i>a-pinene</i> ) alone at 1.5 and 3.28 % yielded similar inhibition trends. However, with <i>phage K</i> and EOC (essential oil compounds) combinations, <i>phage K</i> with 3.28 % <i>a-pinene</i> inhibited <i>S. aureus</i> growth better than other combinations of EOCs and phage depending on the strain.	(Jaradat, et al. 2021)
<i>Phage SA11</i> endolysin <i>LysSA11</i>	NR	The highest dose of <i>Phage SA11 endolysin LysSA11</i> (450 nM of endolysin) yielded a 50% reduction in optical density in less than 20 min and a 70% reduction within 30 min. <i>LysSA11</i> treatment (3.37 $\mu$ M, 1 h) reduced the number of <i>staphylococcal cells</i> in milk by about 2.53 log/mL	(Chang, et al. 2017)
Phage endolysin <i>LysH5</i> and <i>nisin</i>	NR	The MICs of <i>nisin</i> and <i>LysH5</i> were 3 $\mu$ g/mL and 50u/mL, respectively but in the presence of subinhibitory concentrations of <i>nisin</i> , a lower endolysin concentration was needed to fully inhibit <i>S. aureus Sa9</i> . These values implied up to a 64-fold and 16-fold reduction of the <i>nisin</i> and endolysin MICs, respectively, when used in combination.	(Arumugam, et al. 2019)

NR: not reported

## **Bacteriocins**

According to studies, the growth of gram-positive pathogens, including *S. epidermidis*, *S. aureus*, and MRSA, was effectively inhibited by *NX371*, a novel class III bacteriocin gene. When *NX371* was added to milk, it moderately but significantly inhibited the growth of pathogens from day 1 to day 7, with reductions of 3.5 - 4.0 log in milk and 5.0 - 7.0 log in cheese, indicating its effectiveness as a food additive for controlling *S. aureus* in dairy products (Meng, et al. 2021). *Colicin* and *interocin* bacteriocins produced by *Escherichia coli* strains and *Enterococcus* species were found to have bactericidal effect against MRSA and other *Staphylococcal* isolates, with complete bactericidal action achieved after 18-24 hours of incubation (Bajlan, et al. 2018). Bacteriocin produced by *Lactobacillus plantarum* ZJ217 (*plantaricin* ZJ217) was found to significantly decrease the colony forming units (Log<sub>10</sub> CFU) of *S. aureus*, with viable cell counts decreasing from  $6.5 \pm 0.1$  to  $3.7 \pm 0.04$  log CFU/mL within 2 hours of incubation (Zhu, et al. 2015). Bacteriocin *KTH0-1S* produced by *Lactococcus lactis* *KTH0-1S* was found to significantly reduce the viable cell counts of *S. aureus* within 2 hours of incubation, with a higher proportion of dead cells compared to the control treatment (Saelao, et al. 2017). Bacteriocin *Paracin 54* produced by *Lactobacillus paracasei* *ZFM54*, was found to have a strong inhibitory effect on *Staphylococci*, with minimum inhibitory concentration values of 3.00 - 4.50 µg/mL (Zhu, et al. 2021). Bacteriocin producing *Pseudomonas aeruginosa* *TA6*, isolated from soil, was found to decrease the cell density of *S. aureus* rapidly, with cell lysis eventually occurring at concentrations of 100 AU/mL (Arumugam, et al. 2019). *Plantaricin 827*, produced by *Lactobacillus plantarum* *163*, was found to quickly decrease *S. aureus* cells within 150 minutes of treatment with 64 µg/mL, and all *S. aureus* cells were destroyed within 90 minutes of treatment with 128 µg/mL. Moreover, *plantaricin 827* exhibited a certain preservation effect in skimmed milk and significantly extended the shelf life of skimmed milk (Zhao, et al. 2022). Bacteriocins produced by two strains, *Lactobacillus helveticus* (*BLh*) and *Lactobacillus plantarum* (*BLp*), had significant activity against *S. aureus* and MRSA. *L. helveticus* (*BLh*) was the most effective against MRSA after 18 to 24 hours of incubation at 37°C, while *L. plantarum* (*BLp*) had a similar effect against MRSA after 24 to 48 hours of incubation at 37°C under anaerobic conditions. The bacteriocin extracted from *L. plantarum* (*BLp*) was active even after passing through high temperature and pressure during sterilization, but the bacteriocin synthesized by *L. helveticus* (*BLh*) was more labile to heat (Hassan, et al. 2020). *Nisin*, a bacteriocin produced by the *Lactococcus lactis subsp. lactis* bacterium, exhibited

bacteriostatic activity against MRSA alone and had no effect against *S. aureus* ATCC 25937, while some strains of *Lactobacillus reuteri* produced reuterin ( $\beta$ -hydroxypropionaldehyde) under anaerobic conditions, which was considered to have bactericidal effects against MRSA and *S. aureus* ATCC25937. The combination of nisin at a concentration of 25.6 and reuterin at a concentration of 5.2 mg/mL exerted a bactericidal effect on MRSA and *S. aureus* ATCC 25937 (Yehia, et al. 2022). Combinations of bacteriocins with other antimicrobials can increase their antibacterial efficacy. For instance, co-treatment of drinks with enterocin and phenolic compounds (2NPOH) resulted in the eradication of viable *staphylococci* after 24 hours (Burgos, et al. 2015). The effects of different types of bacteriocins against *S. aureus*, including MRSA, have been reported in studies that are summarized in Table 3. According to Table 3, the most effective bacteriocins against *S. aureus* are Enterocin AS-48 with phenolic compounds or with 2NPOH, Bacteriocin isolated from *Lactobacillus pentosus* – Pentocin JL-1, bacteriocin producing *Pseudomonas aeruginosa* TA6, and bacteriocin produced by *S. pasteurii* RSP-1, respectively.

Table 3. Effect of some bacteriocins against MRSA.

Bacteriocins			
Name	Active Components	Effectiveness	References
Bovine myeloid antimicrobial peptide (BMAP-28)	NR	20 mg/mL of BMAP-28 could inhibit the growth of the two kinds of bacteria (MRSA and MSSA). MIC range (mg/mL): 5–20	(Takagi, et al. 2012)
Cell-free extracts of <i>Bifidobacterium</i>	b1, b2, BL and BI	MIC: 1.0 mg/mL	(AL-Saadi 2016)
Bacteriocin Produced by <i>B. cereus</i> TSH5	NR	MIC: 80 $\mu$ g/mL	(Chauhan, et al. 2017)
Bacteriocin produced by <i>Staphylococcus pasteurii</i> RSP-1 ( <i>S. pasteurii</i> RSP-1)	NR	MIC: 5 AU/mL	(Hong, et al. 2018)



Bacteriocins			
Name	Active Components	Effectiveness	References
Bacteriocin isolated from <i>Lactobacillus pentosus</i>	<i>Pentocin JL-1</i>	MIC: 7.5 µg/mL	(Jiang, et al. 2017)
Enterocin AS-48 with phenolic compounds or with 2NPOH	NR	No viable <i>staphylococci</i> were detected after 24 h incubation with the combination of <i>enterocin AS-48</i> and 2NPOH	(Murray, et al. 2021)
Bacteriocin from <i>Lactococcus lactis KU24</i>	<i>Bacteriocin KU24</i>	<i>S. aureus ATCC 33591</i> was inhibited by <i>bacteriocin KU24</i> at 2 Log cfu/mL after 10 h of incubation. MIC: 400 to 800 AU/mL	(Lee, et al. 2013)
Bacteriocin producing <i>Pseudomonas aeruginosa TA6</i>	NR	MIC: 50 AU/mL the cell density of <i>S. aureus</i> decreased rapidly, and cell lysis occurred at 100 AU/mL concentrations	(Zhou, et al. 2017)
Bacteriocin producing <i>Lactobacillus acidophilus</i>	<i>bacteriocin gene NX371</i>	MIC <sub>90</sub> was ranged from 20 to 160 µg/mL	(Meng, et al. 2021)
Bacteriocins produced by <i>Escherichia coli</i> and <i>Enterococcus species</i>	<i>Colicin and interocin</i>	The incubation times for complete bactericidal action were 18-24h.	(Bajlan, et al. 2018)
Bacteriocin produced of <i>Lactococcus lactis KTH0-1S</i>	<i>Bacteriocin KTH0-1S</i>	The proportion of dead cells was significantly higher since viable cell counts decreased from 6.5±0.1 to 3.7±0.04 log CFU/mL within 2 h of incubation	(Saelao, et al. 2017)
Bacteriocin produced of <i>Lactobacillus paracasei ZFM54</i>	<i>Bacteriocin Paracin 54</i>	MIC: 3.50 µg/mL	(Zhu, et al. 2021)

Bacteriocins			
Name	Active Components	Effectiveness	References
Bacteriocin producing from <i>Pseudomonas aeruginosa</i> TA6	NR	Maximum bacteriocin activity (100AU/mL) was observed at 37 °C in 24 h time duration.	(Arumugam, et al. 2019)
Bacteriocin produced by <i>Lactobacillus plantarum</i> 163	<i>Plantaricin</i> 827	MIC: 64 µg/mL.	(Zhao, et al. 2022)
Bacteriocin produced by <i>Lactobacillus helveticus</i> and <i>Lactobacillus plantarum</i>		<i>L. helveticus</i> showed the activity against MRSA after 18 to 24 hours of incubation at 37°C. In comparison, <i>L. plantarum</i> showed similar activity against MRSA after 24 to 48 hours of incubation at 37°C under anaerobic conditions.	(Hassan, et al. 2020)
Bacteriocin produced by <i>Lactococcus lactis</i> subsp. <i>lactis</i> . and <i>Lactobacillus reuteri</i>	<i>Nisin and reuterin</i>	MIC of nisin: 51.2 mg/ mL, MIC of reuterin: 5.2mg/mL MBC of nisin: 5 mg/mL, MBC for reuterin: 5 mg/mL	(Yehia, et al. 2022)

NR: not reported

## Probiotics

The most common probiotics are *lactic acid bacteria* (LAB) strains, and they are considered safe. LAB can produce bactericidal bioactive peptides and enzymes that have antibacterial and antibiofilm effects (Hermawati, et al. 2016). For instance, *Lactobacillus* can inhibit *Staphylococcal cells*, including MRSA (Hermawati, et al. 2016). Several probiotics such as *Lactobacillus plantarum* (Lee, et al. 2021, Afshari, et al. 2022), *Lactobacillus acidophilus*, *Lactobacillus casei* (Hermawati, et al. 2016), *Streptomyces griseus*, *Lactococcus lactis*, *Streptococcus*, *Leuconostoc*, and *Pediococcus* (Li, et al. 2011) have demonstrated

inhibitory effects on *S. aureus* strains, including MRSA. Table 4 shows the effects of different probiotics on MRSA. According to Table 4, the most effective probiotics were *Streptomyces griseus*, *Pediococcus acidilactici* strains A11 and C12, *Lactococcus lactis*, and *Lactobionic acid*, respectively.

Table 4. Effect of some probiotics against MRSA

Probiotic			
Name	Active Components	Effectiveness	References
<i>Lactobacillus acidophilus</i> and probiotic <i>Lactobacillus casei</i>	NR	MIC: 3.12% for <i>Lactobacillus acidophilus</i> and 2% <i>Lactobacillus casei</i>	(Karska-Wysocki, et al. 2010)
Probiotic <i>Lactobacillus plantarum</i> KU200656	NR	MIC :12.5%	(Lee, et al. 2021)
<i>Pseudomonas fluorescens</i>	<i>Pseudomonic acids</i> and <i>Mupirocin</i>	MIC of 8-256 µg/mL for low level resistance and 512 µg/mL for high level resistance	(Prastiyanto, et al. 2020)
<i>Streptomyces griseus</i>	<i>Treptose</i> , <i>streptidine</i> , and <i>N-methyl- L -glycosamine</i> and <i>Streptomycin</i>	MIC: 1.56-6.25 µg/mL	(Prastiyanto, et al. 2020)
<i>Lactococcus lactis</i>	<i>Lnathionine (Lan)</i> , <i>methyllanthionine (MeLan)</i> , <i>didehydroalanine (Dha)</i> and <i>didehydroaminobutyric acid (Dhb)</i> and <i>Nisin</i>	MIC: 1.5 to > 1.6 mg/L	(Prastiyanto, et al. 2020)
<i>Streptococcus</i> , <i>Leuconostoc</i> , <i>Lactobacillus</i> , and <i>Pediococcus</i>	<i>Diacetyl</i>	MIC: 1.00 µg/mL	(Prastiyanto, et al. 2020)
<i>Pediococcus acidilactici</i> strains A11 and C12	NR	MIC: 25%, MBC: 12.5%	(Lestari, et al. 2019)

NR: not reported

## DISCUSSION

### *Essential oils*

Several possible mechanisms have been proposed for antibacterial activity of essential oils. Table 4 shows the mechanisms of action of reported EOs. Essential oils can inhibit enzymes and compounds that are needed for the growth of *MRSA* (Eom, et al. 2014; Burris, et al. 2015). For example, *cinnamaldehyde* in cinnamon oil inhibits *N-3-oxohexanoyl-L-homoserine lactone* (*3-oxo-C6-HSL*) and *AI-2* (Salem 2017) while allicin liquid can inhibit sulfhydryl enzymes, thereby inhibiting DNA and protein synthesis (Cutler, et al 2004; Li, et al. 2011). Some EOs can cause the release of intracellular components (Eom, et al. 2014; Jaradat, et al. 2021), such as brown algae, which lead to the release of intracellular components via phlorofucofuroeckol (PFF) (Eom, et al. 2014). Inhibition of enzymes by EOs can occur through participation in electron transport with the cell components and binding to bacterial adhesions and cell walls (Ifesan, et al. 2009). *Aloysia citriodora* EO can participate in the lipophilic lipids of the mitochondria and cytoplasmic membrane due to their lipophilic ability (Jaradat, et al. 2021). The lipophilic characteristics of EOs make them capable of easily penetrating the bacterial cell (Prastiyanto, et al. 2020). For example, *terpenoids* in mushroom *Pleurotus flabellatus* have this ability and can interfere with protein synthesis and DNA replication (Prastiyanto, et al. 2020). Additionally, some EOs such as EOs derived from *Chuzhou chrysanthemum* and *clove buds* increase the permeability of the cell membrane, resulting in the leakage of intracellular essential substances such as electrolytes, protein, and nucleic acids (Xu, et al. 2016; Cui, et al. 2018). Many EOs such as *carvacrol* are safe to apply in foods as a natural food preservative and are 'Generally Recognized as Safe' (GRAS) by the US Food and Drug Administration (FDA) (Chang, et al. 2017). EOs can have an enhanced effect when they are used at high concentrations (Higginbotham, et al. 2014). Furthermore, if they are applied in processed foods such as hot dogs, chemicals like potassium lactate, sodium lactate, sodium diacetate, and sodium nitrite, they can improve the antimicrobial activity of the Eos (Higginbotham, et al. 2014). Black seed (*Nigella sativa*) is a type of medicinal herb that contains bioactive substances of medical importance. The GC-MS analysis of *N. sativa* shows that it contains five essential compounds, all of which are a unique mix of organic compounds and alkaloids that possess high biological activity, such as *Hep-tanal*, *Benton 2,3-dimethyl, 1-OCTAN-1,1-D2-OL*, and *Pentane, 2-cyclopropyl* (Abdullah, et al. 2021). *Litsea cubeba* essential oil (*LC-EO*) can cause *MRSA* cell rupture, which results in the leakage of cellular content and ultimately

leads to the bacteria's death. LC-EO treatment decreases the activity of four ATPases, including the Na<sup>+</sup>/K<sup>+</sup> ATPase, Ca<sup>2+</sup>/Mg<sup>2+</sup>ATPase, Ca<sup>2+</sup>ATPase, and Mg<sup>2+</sup>ATPase (Hu, et al. 2019). *Chinese Red Propolis* is rich in *pinobanksin* and *pinobanksin-3-acetate*, and its antibacterial activity may be the result of the synergistic effect of polyphenols (Zhang, et al. 2022). *Carum carvi* L. disrupts MRSA biofilm and amino acid metabolism, and it also hinders DNA and RNA synthesis (Liu, et al. 2023). *Psoralea corylifolia* seed ethanol extract (PCEE) is composed of *phenol*, *hydrazine*, *aldehyde*, and *ketone*, which can destroy the cell structure and reduce enzymes, ultimately killing bacteria (Li, et al. 2019). *Backhousia citriodora* Essential Oil (BCEO) contains large amounts of *oxygenated monoterpenes*, which disrupt the microbial cytoplasmic wall, improve cell permeability, and lead to cell death (Lim, et al. 2022). Oregano essential oil (OEO) and cinnamon essential oil (CEO) increase cell permeability and cause leakage of intracellular constituents, leading to the disruption of the cell respiration system and microbial enzyme system (Debiagi, et al. 2020). *L. micromera* and *P. amboinicus* essential oils contain *monoterpenes* such as *carvacrol*, *γ-terpinene*, and *β-cymene*, which are responsible for their antibacterial activity against *Staphylococcus species* including MRSA (Bugayong, et al. 2019). *Elettaria cardamomum* essential oil blurs the surface barrier of the cell wall, altering the structure of the cells, and causing bacterial mortality (Jha, et al. 2022). The combination of EOs can enhance the efficacy of their antibacterial activity. For instance, when *carvacrol* and *thymol* are combined with organic acids, a significant reduction in the number of *S. aureus* is observed on food samples. On one hand, these EOs disrupt the bacterial cell membrane and make the bacteria more susceptible to the acidic environment. On the other hand, organic acids enhance the hydrophobicity of EOs and make the EOs bind better to hydrophobic regions of the membrane proteins (de Oliveira, et al. 2010). Thyme oil, when combined with lytic *S. aureus* phage, is a promising biocontrol agent and antimicrobial alternative in the food industry to control and reduce MRSA or other *antibiotic-resistant S. aureus* contamination in food (Abdallah, et al. 2021). Some plant extracts can increase the effectiveness of antibiotics against MRSA. For instance, *ursolic acid 3-O-α-L-arabinopyranoside* (URS) from the leaves of *Acanthopanax henryi* (Oliv.) can enhance the *anti-MRSA* effect of oxacillin (Zhou, et al. 2017).

## **Bacteriophages**

Bacteriophages encode peptidoglycan hydrolases, known as endolysins or lysins, which lyse bacterial cells by targeting their cell wall, particularly in Gram-positive bacteria, due to their naturally exposed peptidoglycan layer (Murray,

et al. 2021). Bacterial death by endolysins is in accordance with the typical phenomenon of osmotic-mediated cell lysis, which occurs in Gram-positive bacteria following a phage attack (Lu, et al. 2021). For instance, *LysP108* causes disintegration of the *MRSA* cell wall (Lu, et al. 2021). It has been reported that a combination of endolysin *LysSA97* with *carvacrol* can cleave bacterial peptidoglycan layers and destroy the structure of the cell wall (Chang, et al. 2017). Combining endolysins with antibiotics causes better accessibility of antibiotics to *MRSA* cells through initial lysing of the biofilm by endomysia (Linden, et al. 2015). Combining endolysins with bacteriocins can result in a higher sensitivity of *S. aureus* cells to these antibacterials. The mechanism might be attributed to the prevention of peptidoglycan breaks produced by endolysins from contraction (Arumugam, et al. 2019). Moreover, bacteriocins can cause a partial activation of autolysins that allows for better activity of the endolysin (Arumugam, et al. 2019). The combination of synthetic *SAP8 endolysin* and *nisin* can effectively restrain various types of Gram-positive bacteria by creating openings in the bacterial cell membrane and blocking the production of cell walls (Kim, et al. 2022).

### **Bacteriocin**

Bacteriocins can cause damage to the cell wall or induce cell lysis (Lee, et al. 2013). They target the cytoplasmic membrane of bacterial cells and inhibit the proton motive force (PMF), leading to inhibition of protein or nucleic acid production (Lestari, et al. 2019). The *anti-MRSA* activity of bacteriocins is mainly due to the generation of organic acids such as *lactic acid* and *acetic acid*. These acids enter bacterial cells and interfere with essential metabolic processes (AL-Saadi 2016). Bacteriocins against *MRSA* can change the cell surface from smooth to rough. Therefore, the suggested mechanism is related to the bacterial cell membrane (Takagi, et al. 2012). Several bacteriocins have been reported to have *anti-MRSA* activity, leading to the disruption in the integrity and uniformity of *MRSA* (Zhu, et al. 2015; Jiang, et al. 201; Taggar, et al. 2021). Through bioinformatic analysis of *Lactobacillus acidophilus*, a new class III bacteriocin gene called *NX371* was discovered, which demonstrated high antimicrobial activity across a wide range of pH values (3.0-8.0). This bacteriocin was able to disrupt the cell wall of gram-positive bacteria and induce membrane leakage in gram-negative bacteria, leading to separation of the cell wall and membrane (Meng, et al. 2021). Other bacteriocins such as *colicins* and *enterocins* also exhibit antibacterial effect against Gram-positive bacteria, with *colicins* acting as transmembrane proteins that depolarize the cytoplasmic

membrane and kill cells by producing pores or acting as a nuclease to chop up DNA or RNA (Bajlan, et al. 2018). Another example is *plantaricin ZJ217*, a novel bacteriocin produced by *Lactobacillus plantarum ZJ217*, which was inhibitory effect against a variety of gram-positive and gram-negative bacteria by forming pores in cells (Zhu, et al. 2015). Similarly, bacteriocin *KTH0-1S* produced by *Lactococcus lactis KTH0-1S* acted on sensitive cells by forming pores in membranes, leading to cell death due to the loss of essential intracellular substances (Saelao, et al. 2017). *Paracin 54*, a bacteriocin produced by *Lactobacillus paracasei ZFM54*, also formed pores in the cell membrane of *MRSA*, which disrupted the balance of ions inside and outside the membrane and led to the dissipation of proton driving force, inhibiting the synthesis of intracellular ATP and causing the disorder of intracellular energy metabolism (Zhu, et al. 2021). Another bacteriocin, *plantaricin 827*, produced by *Lactobacillus plantarum 163*, had antibacterial effects against *MRSA* by increasing the cell membrane permeability and integrity, resulting in the leakage of K<sup>+</sup> and changes in cell morphology, inhibiting biofilm formation, and interacting with genomic DNA minor groove in AT-rich regions (Zhao, et al. 2022). The combination of *nisin* produced by *Lactococcus lactis subsp. lactis* and *reuterin* produced by *Lactobacillus reuteri* also disrupted membranes by forming pores, inhibiting energy production and biosynthesis of proteins and nucleic acids (Yehia, et al. 2022). Despite the fact that they are proteins, some bacteriocins can remain stable in harsh environmental conditions. For instance, *Paracin 54* retained 93.7% of its activity after treatment with lysozyme, indicating its potential for use in food preservation. Furthermore, *Paracin 54* maintained its inhibitory activity against *MRSA* at different temperatures, suggesting its potential use in pasteurized products (Zhu, et al. 2021). *Plantaricin 827* also exhibited antibacterial activity at pH 7.0, while *plantaricin ZJ217* was stable at pH 2.0 to 6.0 but lost activity at pH 10.0 (Zhu, et al. 2015).

## **Probiotics**

The major effects of probiotics include modulation of the immune system, inhibition of pathogen adhesion to epithelial cells, and generation of antimicrobial compounds (AL-Saadi 2016; Lee, et al. 2021). Antimicrobial compounds produced by probiotics can also demonstrate anti-adhesion ability (Lee, et al. 2021). These antimicrobial components include organic acids, oxygen catabolites, and proteinaceous compounds (Lee, et al. 2021). These components can inhibit the growth of *MRSA* cells in food products (Karska-Wysocki, et al. 2010). For instance, *Lactococcus lactis* can generate antibacte-



rial agents, including *didehydroaminobutyric acid (Dhb)* and *didehydroalanine (Dha)*, *methyllanthionine (MeLan)*, *Lanthionine (Lan)*, and *bacteriocin (Nisin)*. These substances can disrupt the uptake of amino acids by *S. aureus* cells and suppress the production of the cell wall. In addition, some metabolites will be released, leading to cell death (Li, et al. 2011). Generally, *LBA* can cause alkaline phosphatase leakage from *MRSA cells* to the extracellular medium, and in this way, they prevent the formation of biofilms (Kang, et al. 2020). A list of *anti-S. aureus* agents and their modes of action is in Table 5.

Table 5. Mechanisms of action of anti-MRSA EOs, bacteriophages, bacteriocins, and probiotics.

Name	Active Components	Mechanisms	References
<b>Essential oils</b>			
Essential oils: Cinnamon oil, Thyme oil and Lemongrass oil	<i>Cinnamaldehyde, eugenol, Alpha and beta-citral, mycrene</i>	These can inhibit <i>N-3-oxohexanoyl-Lhomoserine lactone (3-oxo-C6-HSL)</i> and <i>AI-2</i> , and certain enzymes needed for the growth of <i>MRSA</i> .	(Salem 2017)
Liposome containing cinnamon oil	NR	The damage of bacterial cell membrane is by their effect on morphology, structure, function, modification in the transport of nutrients, membrane disruption, extensive leakages from the bacterial cells leading to cell death.	(Cui, et al. 2016)
Indian Spices	<i>Syzygium aromaticum (CLV) and Cinnamomum zeylanicum (CIN) and Cuminum cyminum (CMN)</i>	These can affect the synthesis of the peptidoglycan layer of the cell wall and the mode of action of the spice extracts is cell wall related.	(Mandal, et al. 2011)



Name	Active Components	Mechanisms	References
<b>Essential oils</b>			
<i>Camellia sinensis</i> and <i>Azadirachta indica</i> leaves	<i>catechin</i>	The <i>catechin</i> has direct effects on the destruction of the bacterial cell membrane by binding with the lipid bilayer.	(Zihadi, et al. 2019)
<i>Allicin</i>	NR	Inhibit the acetyl coA forming system, to inhibit DNA and protein synthesis, and to target RNA polymerase.	(Cutler, et al 2004)
<i>Cinnamomum osmophloeum</i> leaf essential oils	<i>cinnamaldehyde</i>	NR	(Chang, et al. 2001)
<i>Thyme</i> ( <i>Tymus vulgaris</i> ) and <i>Oregano</i> ( <i>Origanum vulgare</i> ) essential oils	<i>Thymol</i> from <i>Thyme</i> and <i>Carvacrol</i> from <i>Oregano</i>	Phosphate ion leakage.	(Boskovic, et al. 2015)
<i>PFF</i> (phlorofucofuroeckol, a marine-derived polyphenol found in brown algae)	NR	Interfering with cell wall synthesis and the cell membrane and agents change membrane function and permeability, leading to cell damage or death.	(Eom, et al. 2014)

Name	Active Components	Mechanisms	References
<b>Essential oils</b>			
<i>URS (ursolic acid 3-O-<math>\alpha</math>-L arabinopyranoside was isolated from the leaves of A. henryi (Oliv) with oxacillin</i>	Q	Deformation of bacterial cells. Cell membrane disintegration, cell lysis and release of cytoplasmic contents.	(Yan, et al. 2021)
<i>Pink oyster mushroom Pleurotus flabellatus</i>	The terpenoid compound group	These penetrate the bacterial cell and may interfere with protein synthesis and DNA replication.	(Ghosh, et al. 2016)
<i>Amomum villosum Lour</i>	Bornyl acetate	Leakage of intracellular macromolecular substances.	(Tang, et al. 2020)
<i>Bulb Eleutherine Americana</i>	Naphthoquinone	Inhibits electron transport with the cell components. They also can bind to bacterial adhesions and complex with cell wall, thus inactivating enzymes.	(Ifesan, et al. 2009)
<i>Aloysia citriodora essential oils EOs from Baqa al-Gharbiyye and Umm al-Fahm</i>	lipophilic structures like $\alpha$ - citral and $\alpha$ -curcumene	Their lipophilic ability to partition in the lipophilic lipids of the mitochondria and cytoplasmic membrane. They could also disturb the structures, resulting in leakage of bacterial cell contents.	(Aru-mugam, et al. 2019)

Name	Active Components	Mechanisms	References
<b>Essential oils</b>			
<i>Garlic</i>	Allicin (allyl 2-propenethiosulphinate)	1) The primary mechanism of allicin centers on its ability to inhibit sulfhydryl enzymes common for pathogenic bacteria. 2) Inhibiting enzymes associated with DNA and protein synthesis and limiting RNA polymerase and alcohol dehydrogenase activities.	(Prasti-yanto, et al. 2020)
<i>flavonoids from licorice</i>	glabrol, licochalcone A, licochalcone C, and licochalcone E	Disruption of membrane permeability. The binding of these to the cell wall or the cytoplasmic membrane is important for their action on the bacterial membrane.	(Burgos, et al. 2015)
<i>Clove buds</i>	Eugenol	The permeability of bacterial membrane would be increased, which caused the leakage of intracellular ingredient, especially losses of electrolytes including K <sup>+</sup> , Ca <sup>2+</sup> , Na <sup>+</sup> , as well as cell constituents such as protein, nucleic acids, and some essential molecules.	(Xu, et al. 2016)
<i>Chuzhou chrysanthemum</i>	B-Eudesmene, L-Borneol, Camphor	Disruption of the cell membrane and leakage of DNA, protein and ATP to the bulk solution.	(Cui, et al. 2018)

Name	Active Components	Mechanisms	References
<b>Essential oils</b>			
<i>Syzygium antisepticum plant</i>	b-caryophyllene	Membrane-disrupting effect was observed	(Yuan, et al 2018)
<i>Korean soybean fermented product doenjang</i>	Methanolic	Inhibits the respiratory metabolism and protein synthesis of the bacteria and prevents nucleic acid synthesis. Thus, it affects the integrity of the cell wall and membrane.	(Lalouckova, et al. 2021)
<i>Bisdemethoxycurcumin with three antibiotics (gentamicin, ampicillin, and oxacillin)</i>	NR	The polyphenol structure can destroy the cell wall of bacteria and thus increases the efficiency of antibiotics entering the cell.	(Wang, et al. 2020)
<i>Thymol and carvacrol with organic acids (lactic acid)</i>	NR	Phenolic compounds can damage cellular membrane changing their structure and function and causing it to become more susceptible to acid environments. On the other hand, at low pH the molecules of thymol and carvacrol are mostly dissociated, more hydrophobic, and bind better to hydrophobic regions of the membrane proteins resulting in better partition into the lipid phase of the bacterial membrane.	(de Oliveira, et al. 2010)

Name	Active Components	Mechanisms	References
<b>Essential oils</b>			
<i>Litsea cubeba essential oil</i>	$\beta$ - Citral and $\alpha$ -Citral	The LC-EO could lead to the rupture of MRSA cells and the loss of cellular contents and eventually to the death of bacteria.	(Hu, et al. 2019)
<i>Red Propolis</i>	Pinobanksin, Pinobanksin-3-acetate	The mechanism of action of RPE due to loss of membrane integrity.	(Zhang, et al. 2022)
<i>Ethanol Extracts of Psoralea corylifolia Seeds</i>	phenol, hydrazine, aldehyde, and ketone	PCEE could change the membrane integrity of MRSA, releasing nucleic acids and proteins, resulting in bacterial death.	(Li, et al. 2019)
<i>Manuka EO was extracted from manuka leaves</i>	Sesquiterpenes	MIC: 0.233 mg/mL, MBC: 0.466 mg/mL	(Pedonese, et al. 2022)
<i>Essential Oils from Elettaria Cardamomum fruit capsules</i>	Monoterpenes and sesquiterpenes	Elettaria cardamomum EO damages the biofilm barrier, causing the bacteria to lose metabolic activity.	(Jha, et al. 2022)
<b>Bacteriophages</b>			
Phage Endolysin <i>LysP108</i>	NR	<i>LysP108</i> disintegrated the cell wall of MRSA.	(Lu, et al. 2021)

Name	Active Components	Mechanisms	References
<b>Bacteriophages</b>			
Bacteriophage <i>endolysin plygrcs</i>	<i>PlyGRCS</i>	The endolysin <i>plygrcs</i> would provide the initial disturbance to the biofilm structure.	(Linden, et al. 2015)
<i>Carvacrol and lyssa97</i>	NR	<i>LysSA97</i> cleaving bacterial peptidoglycan layers is likely to render the cell wall structure less rigid so that <i>carvacrol</i> may more readily reach the cytoplasmic membrane of <i>S. aureus</i> .	(Chang, et al. 2017)
<i>Phage endolysin lysh5 and nisin</i>	NR	<i>LysH5</i> activity might be increased by the permeabilization of the cytoplasmic membrane by <i>nisin</i> . Also, partial activation of autolysins by <i>nisin</i> may occur and facilitate <i>LysH5</i> activity.	(García, et al. 2010)
<i>SAP8 endolysin</i>	NR	Forms pores in bacterial cytoplasmic membrane and inhibits cell wall synthesis	(Kim, et al. 2022)
<b>Bacteriocins:</b>			
<i>Bovine myeloid antimicrobial peptide (BMAP-28)</i>	NR	1) Cell wall permeation is made by the activity of <i>BMAP-28</i> as it is diffusing inside the bacteria. 2) Bacterial smooth surface somehow changes into a rough surface by the activity of <i>BMAP-28</i> . 3) <i>BMAP-28</i> can break <i>MRSA</i> cell membranes.	(Takagi, et al. 2012)

Name	Active Components	Mechanisms	References
<b>Bacteriocins</b>			
<i>Pediococcus acidilactici</i> strains A11 and C12	NR	The initial bacteriocin reaction is to damage membrane permeability and eliminate proton motive force (PMF) thereby inhibiting energy production and biosynthesis of proteins or nucleic acids. 2) bacteriocin molecules are in direct contact with cell membranes, this contact process is able to disrupt membrane potential in the destabilizing cytoplasmic membranes so that cells become less strong, and membrane instability is capable of producing holes in cell membrane through the process of interference with PMF (Proton Motive Force).	(Lestari, et al. 2019)
Cell-free extract of <i>Bifidobacterium</i> Species of LAB	<i>b1, b2, BL and BI</i>	The acids produced by LAB enter the sensitive bacterial cells and interfere with the necessary metabolic process such as substrate translocation and oxidative phosphorylation, which leads to a decrease in the internal pH of bacterial cells.	(AL-Saadi 2016)

Name	Active Components	Mechanisms	References
<b>Bacteriocins</b>			
bacteriocin produced by <i>Staphylococcus pasteurii</i> RSP-1 ( <i>S. pasteurii</i> RSP-1)	<i>Pasteuricin</i>	<i>Pasteuricin</i> rapidly damaged the membrane of viable cells.	(Hong, et al. 2018)
Bacteriocin isolated from <i>Lactobacillus pentosus</i>	<i>Pentocin JL-1</i>	<i>Pentocin JL-1</i> targets the cell membrane of MRSA GIM 1.771, causing a loss of PMF in only a few minutes, and that has a dramatic impact on the structure and integrity of the MRSA cell and finally leads to cell death.	(Jiang, et al. 2017)
Bacteriocin from <i>Lactococcus lactis</i> KU24	<i>Bacteriocin KU24</i>	The bacteriocin <i>KU24</i> damages the cell wall or induces cell lysis and has an impact on the bacterial cytoplasmic membrane.	(Lee, et al. 2013)
Bacteriocin from <i>Lactobacillus plantarum</i> ZJ217	<i>NR</i>	Bacteriocin produced by <i>Lactobacillus plantarum</i> can cause the formation of pores on bacterial cells and releasing ATP, and bacterial death	(Zhu, et al. 2015)
Bacteriocin isolated from the natural inhabitant of <i>Allium cepa</i>	<i>Peptide-Ba49</i>	Peptide-Ba49 can result in the rupturing and uniformity of MRSA.	(Taggar, et al. 2021)



Name	Active Components	Mechanisms	References
<b>Bacteriocins</b>			
Bacteriocin producing <i>Lactobacillus acidophilus</i>	<i>Bacteriocin gene NX371</i>	The leakage of intracellular ATP, disrupt the cell wall, and induce membrane leakage.	(Meng, et al. 2021)
Bacteriocin produced by <i>Escherichia coli</i> strains and <i>Enterococcus</i> species	<i>Colicins and Enterocin</i>	These depolarize the cytoplasmic membrane, leading to dissipation of cellular energy and killing domain may produce a pore in the target cell membrane, or act as a nuclease to chop up the DNA or RNA of the target cell	(Bajlan, et al. 2018)
Bacteriocin produced by <i>Lactobacillus plantarum</i> ZJ217	<i>Plantaricin ZJ217</i>	The Plantaricin ZJ217 had activity against biofilm cells of MRSA by forming pores to release ATP.	(Zhu, et al. 2015)
Bacteriocin produced of <i>Lactococcus lactis</i> KTH0-1S	<i>Bacteriocin KTH0-1S</i>	The KTH0-1S can have an impact on sensitive cells, causing pores formation in the membrane, resulting in cell death due to loss of essential intracellular substances	(Saelao, et al. 2017)
Bacteriocin produced by <i>Lactobacillus paracasei</i> ZFM54	<i>Bacteriocin Paracin 54</i>	The treatment with Paracin 54 enhanced the permeability of the cell membrane, damaged the cell membrane, and led to electrolyte outflow.	(Zhu, et al. 2021)

Name	Active Components	Mechanisms	References
<b>Bacteriocins</b>			
Bacteriocin produced by <i>Lactobacillus plantarum</i> 163	<i>Plantaricin 827</i>	Its antibacterial mechanism increased the cell membrane permeability and integrity, resulting in the leakage of K <sup>+</sup> and changes in cell morphology.	(Zhao, et al. 2022)
Bacteriocin produced by <i>Lactococcus lactis</i> subsp. <i>lactis</i> . and <i>Lactobacillus reuteri</i>	<i>Nisin and reuterin</i>	The combination of nisin and reuterin may change the permeability of the outer membrane and cause a lethal effect.	(Yehia, et al. 2022)
<b>Probiotics</b>			
<i>Lactobacillus plantarum</i> KU200656	NR	It can inhibit the adherence of pathogens by competing for nutrition and host intestinal cell-binding sites, e.g., receptor exclusion. bolites (e.g. hydrogen peroxide), and proteinaceous compounds.	(Lee, et al. 2021)
<i>Lactobacillus acidophilus</i> and <i>Lactobacillus casei</i>	NR	They produce antimicrobial components that can inhibit the growth and eliminate of the <i>MRSA</i> cells.	(Karska-Wysocki, et al. 2010)

NR: not reported.

## CONCLUSION

According to our review, the most effective EO against *MRSA* was a liposome containing cinnamon oil, which resulted in a significant decrease in *MRSA* populations. Additionally, essential oils from *Cinnamomum zeylanicum*, *Syzygium aromaticum*, *Cuminum cyminum*, allicin, *glabrol*, *clove buds*, and *backhousia citriodora* have shown significant effectiveness against *MRSA*. Another potential solution against *MRSA* is the use of bacteriophages. Based on our review, promising phage compounds include *S. aureus* phage containing *CHAPLysGH15* and *LysGH15* and *phage SA11 endolysin*. Bacteriocins have also shown promise in combatting *MRSA*. Bacteriocins such as *Enterocin AS-48*, *Pentocin JL-1*, bacteriocin-producing *Pseudomonas aeruginosa TA6*, and bacteriocin produced by *S. pasteurii RSP-1* were effective against *S. aureus*. Probiotics have also shown antimicrobial properties against *MRSA*. *Streptomyces griseus*, *Pediococcus acidilactici* strains *A11* and *C12*, *Lactococcus lactis*, and *Lactobionic acid* are among the most effective probiotics against *MRSA*. In the fight against *MRSA*, the combination of above-mentioned antibacterials has also shown promising results. These natural compounds and microorganisms possess unique mechanisms of action that can effectively target and eliminate *MRSA* cells. Furthermore, their use in combination with other antimicrobial agents including chemicals can enhance their efficacy, providing a multi-hurdle approach in combatting antibiotic-resistant bacteria. However, in food matrices, the results might be different from in vitro experiments because natural compounds can interact with food compounds like proteins and lipids, potentially reducing the availability of the natural compound as an antimicrobial agent. Additionally, processing steps can diminish the antimicrobial activity of such compounds. Furthermore, before the application of natural antimicrobials in food products, health and safety risks associated with them should be thoroughly assessed. The impact of EOs on the organoleptic characteristics of food should also be taken into account, as they may have negative effects. Nevertheless, the application of nanotechnology can mitigate these effects.

## ACKNOWLEDGEMENT

We would like to thank Mashhad University of Medical Sciences, Mashhad, Iran for their support.

### Author's Contribution:

Z.A. made contributions to conception and design of the study, was involved in data collection and drafting the manuscript. G.S. revised the manuscript critically and together with Z.A., M.H., and A.A. prepared the final draft of the manuscript etc. All authors read and approved the final manuscript.

### Competing interest

The authors declare that they have no competing interests.

### REFERENCES

1. Abdallah K., Tharwat A., Gharieb R. 2021. High efficacy of a characterized lytic bacteriophage in combination with thyme essential oil against multi-drug-resistant *Staphylococcus aureus* in chicken products. *Iranian Journal of Veterinary Research*, 22, 1, 24. doi: 10.22099/ijvr.2020.38083.5543.
2. Abdullah S.A., Salih T.F.M., Hama A.A., Ali S.I., Hamaamin H.H. 2021. The Antibacterial Property of *Nigella sativa* (Black seed) Oil Against Gram-positive and Gram-negative Bacteria. *Kurdistan Journal of Applied Research*, 6, 2, 156-165. doi: 10.24017/science.2021.2.15.
3. Afshari A., Hashemi M., Tavassoli M., Eraghi V., Noori S.M.A. 2022. Probiotic bacteria from 10 different traditional Iranian cheeses: Isolation, characterization, and investigation of probiotic potential. *Food Science and Nutrition*. doi: 10.1002/fsn3.2817.
4. Afshari A., Taheri S., Hashemi M., Norouzy A., Nematy M., Mohamadi S. 2022. Methicillin- and Vancomycin-Resistant *Staphylococcus aureus* and Vancomycin-Resistant Enterococci Isolated from Hospital Foods: Prevalence and Antimicrobial Resistance Patterns. *Current microbiology*, 79, 11, 326. doi: 10.1007/s00284-022-03022-0.
5. AL-Saadi Z.N. 2016. Estimation of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of cell-free extracts of *Bifidobacterium* species against methicillin-resistant *Staphylococcus aureus* in vitro. *American Journal of Biomedical and Life Sciences*, 4, 5, 75-80. doi: 10.11648/j.ajbls.20160405.12.
6. Ansari M.A., Albetran H.M., Alheshibri M.H., Timoumi A., Algarou N.A., Akhtar S., Slimani Y., Almessiere M.A., Alahmari F.S., Baykal A. 2020. Synthesis of electrospun TiO<sub>2</sub> nanofibers and characterization of their antibacterial and antibiofilm potential against gram-positive and gram-negative bacteria. *Antibiotics*, 9, 9, 572. doi: 10.3390/antibiotics9090572.

7. Arumugam T., Dhanam S., Rameshkumar N., Krishnan M., Kayalvizhi N. 2019. Inhibition of methicillin resistant *Staphylococcus aureus* by bacteriocin producing *Pseudomonas aeruginosa*. *International Journal of Peptide Research and Therapeutics*, 25, 339-348. doi: 10.1007/s10989-018-9676-y.
8. Bajlan J.S., Khudiar M.M., Fakhry S.S., Abbas Z. 2018. Antimicrobial Activity of Colicin and Enterocin on *Staphylococcus aureus* (MRSA) isolated from food. *Current Research in Microbiology and Biotechnology*, 6, 1, 1470-1477.
9. Boskovic M., Zdravkovic N., Ivanovic J., Janjic J., Djordjevic J., Starcevic M. Baltic M.Z. 2015. Antimicrobial activity of thyme (*Tymus vulgaris*) and oregano (*Origanum vulgare*) essential oils against some food-borne microorganisms. *Procedia Food Science*, 5, 18-21. doi: 10.1016/j.profoo.2015.09.005.
10. Bugayong A.M., Cruz P., Padilla P.I. 2019. Antibacterial activity and chemical composition of essential oils from leaves of some aromatic plants of Philippines. *Journal of Essential Oil Bearing Plants*, 22, 4, 932-946. doi: 10.1080/0972060X.2019.1682683.
11. Burgos M.J.G., Aguayo M.C.L., Pulido R.P., Gálvez A., López R.L. 2015. Inactivation of *Staphylococcus aureus* in Oat and Soya Drinks by Enterocin AS-48 in Combination with Other Antimicrobials. *Journal of Food Science*, 80, 9, M2030-M2034. doi: 10.1111/1750-3841.12983.
12. Burris K.P., Higginbotham K.L., Stewart Jr C.N. 2015. Aqueous extracts of yerba mate as bactericidal agents against methicillin-resistant *Staphylococcus aureus* in a microbiological medium and ground beef mixtures. *Food Control*, 50, 748-753. doi:10.1016/j.foodcont.2014.10.021.
13. Catteau L., Reichmann N.T., Olson J., Pinho M.G., Nizet V., Van Bambeke F., Quetin-Leclercq J. 2017. Synergy between ursolic and oleanolic acids from *Vitellaria paradoxa* leaf extract and  $\beta$ -lactams against methicillin-resistant *Staphylococcus aureus*: in vitro and in vivo activity and underlying mechanisms. *Molecules*, 22, 12, 2245. doi: 10.3390/molecules22122245.
14. Chang S.T., Chen P.F., Chang S.C. 2001. Antibacterial activity of leaf essential oils and their constituents from *Cinnamomum osmophloeum*. *Journal of ethnopharmacology*, 77, 1, 123-127. doi: 10.1016/s0378-8741(01)00273-2.
15. Chang Y., Kim M., Ryu S. 2017. Characterization of a novel endolysin Lys-SA11 and its utility as a potent biocontrol agent against *Staphylococcus aureus* on food and utensils. *Food Microbiology*, 68, 112-120. doi: 10.1016/j.fm.2017.07.004.
16. Chang Y., Yoon H., Kang D.-H., Chang P.-S., Ryu S. 2017. Endolysin Lys-SA97 is synergistic with carvacrol in controlling *Staphylococcus aureus* in foods. *International journal of food microbiology*, 244, 19-26. doi: 10.1016/j.ijfoodmicro.2016.12.007.

17. Chauhan A.K., Maheshwari D.K., Bajpai V.K. 2017. Isolation and preliminary characterization of a bacteriocin-producer *Bacillus* strain inhibiting methicillin resistant *Staphylococcus aureus*. *Acta Biologica Hungarica*, 68, 2, 208-219. doi: 10.1556/018.68.2017.2.8.
18. Chen X., Shang F., Meng Y., Li L., Cui Y., Zhang M., Qi K., Xue T. 2015. Ethanol extract of *Sanguisorba officinalis* L. inhibits biofilm formation of methicillin-resistant *Staphylococcus aureus* in an ica-dependent manner. *Journal of Dairy Science*, 98, 12, 8486-8491. doi: 10.3168/jds.2015-9899.
19. Cui H., Bai M., Sun Y., Abdel-Samie M.A.-S., Lin L. 2018. Antibacterial activity and mechanism of Chuzhou chrysanthemum essential oil. *Journal of Functional Foods*, 48, 159-166. doi: 10.1016/j.jff.2018.07.021.
20. Cui H., Li W., Li C., Vittayapadung S., Lin L. 2016. Liposome containing cinnamon oil with antibacterial activity against methicillin-resistant *Staphylococcus aureus* biofilm. *Biofouling*, 32, 2, 215-225. doi: 10.1080/08927014.2015.1134516.
21. Cutler R., Wilson P. 2004. Antibacterial activity of a new, stable, aqueous extract of allicin against methicillin-resistant *Staphylococcus aureus*. *British journal of biomedical science*, 61, 2, 71-74. doi: 10.1080/09674845.2004.11732646.
22. de Oliveira C.E.V., Stamford T.L.M., Neto N.J.G., de Souza E.L. 2010. Inhibition of *Staphylococcus aureus* in broth and meat broth using synergies of phenolics and organic acids. *International journal of food microbiology*, 137, 2-3, 312-316. doi: 10.1016/j.ijfoodmicro.2009.11.019.
23. Debiagi F., Kobayashi R.K., Nakazato G., Panagio L.A., Mali S. 2020. Antimicrobial activity of oregan and clove essential oils against some food-borne pathogens. *Semina: Ciências Biológicas e da Saúde*, 41, 1, 3-12. doi:10.5433/1679-0367.2020v41n1p3.
24. Eom S.-H., Lee D.-S., Jung Y.-J., Park J.-H., Choi J.-I., Yim M.-J., Jeon J.-M., Kim H.-W., Son K.-T., Je J.-Y. 2014. The mechanism of antibacterial activity of phlorofucofuroeckol-A against methicillin-resistant *Staphylococcus aureus*. *Applied microbiology and biotechnology*, 98, 23, 9795-9804. doi: 10.1007/s00253-014-6041-8.
25. García P., Martínez B., Rodríguez L., Rodríguez A. 2010. Synergy between the phage endolysin LysH5 and nisin to kill *Staphylococcus aureus* in pasteurized milk. *International journal of food microbiology*, 141, 3, 151-155. doi: 10.1016/j.ijfoodmicro.2010.04.029.
26. Ghosh A., Ricke S.C., Almeida G., Gibson K.E. 2016. Combined application of essential oil compounds and bacteriophage to inhibit growth of *Staphylococcus aureus* in vitro. *Current Microbiology*, 72, 4, 426-435. doi: 10.1007/s00284-015-0968-6.

27. Gyawali R. Ibrahim, S.A. 2014. Natural products as antimicrobial agents. *Food control*, 46, 412-429. doi: 10.1016/j.foodcont.2014.05.047.
28. Hassan M.U., Nayab H., Rehman T.U., Williamson M.P., Haq K.U., Shafi N. Shafique F. 2020. Characterisation of bacteriocins produced by *Lactobacillus* spp. isolated from the traditional Pakistani yoghurt and their antimicrobial activity against common foodborne pathogens. *Journal of biomedicine and biotechnology*, 8281623. doi: 10.1155/2020/8281623.
29. Hermawati A. H., Aryati, Isnaeni, 2016. Inhibitory Activity of Probiotic Fermented Milk Against *Escherichia coli* ATCC 6538 and *Staphylococcus aureus* ATCC 8739. *Berkala Ilmiah Kimia Farmasi*, 5, 2, 8-10.
30. Higginbotham K.L., Burris K.P., Zivanovic S., Davidson P.M., Stewart Jr C.N. 2014. Aqueous extracts of *Hibiscus sabdariffa* calyces as an antimicrobial rinse on hot dogs against *Listeria monocytogenes* and methicillin-resistant *Staphylococcus aureus*. *Food Control*, 40, 274-277. doi: 10.1016/j.foodcont.2013.12.011.
31. Hong J., Kim J., Quan L.-H., Heu S., Roh E. 2018. Purification and characterization of pasteuricin produced by *Staphylococcus pasteurii* RSP-1 and active against multidrug-resistant *Staphylococcus aureus*. *Journal of Food Protection*, 81, 11, 1768-1775. doi: 10.4315/0362-028X.JFP-18-111.
32. Hu W., Li C., Dai J., Cui H., Lin L. 2019. Antibacterial activity and mechanism of *Litsea cubeba* essential oil against methicillin-resistant *Staphylococcus aureus* (MRSA). *Industrial Crops and Products*, 130, 34-41. doi: 10.1016/j.indcrop.2018.12.078.
33. Ifesan B.O., Hamtasin C., Mahabusarakam W., Voravuthikunchai S.P. 2009. Assessment of antistaphylococcal activity of partially purified fractions and pure compounds from *Eleutherine americana*. *Journal of food protection*, 72, 2, 354-359. doi: 10.4315/0362-028x-72.2.354.
34. Jaradat N., Hawash M., Abualhasan M.N., Qadi M., Ghanim M., Massarwy E., Ammar S.A., Zmero N., Arar M., Hussein F. 2021. Spectral characterization, antioxidant, antimicrobial, cytotoxic, and cyclooxygenase inhibitory activities of *Aloysia citriodora* essential oils collected from two Palestinian regions. *BMC Complementary Medicine and Therapies*, 21, 1, 1-11. doi: 10.1186/s12906-021-03314-1.
35. Jaradat N., Hawash M., Qadi M., Abualhasan M., Odetallah A., Qasim G., Awayssa R., Akkawi A., Abdullah I. Al-Maharik N. 2022. Chemical markers and pharmacological characters of *Pelargonium graveolens* essential oil from Palestine. *Molecules*, 27, 17, 5721. doi: 10.3390/molecules27175721.

36. Jha V., Shaikh D., Bhargava A., Marick A., Khan F., Dhamapurkar V., Jhangiani A., Narvekar S., Shinde R., Nair M. 2022. Characterization of Physio-Chemical Properties and Evaluation of Bioactive Potentials of Essential Oils from *Elettaria Cardamomum*. *Journal of Plant Biology and Crop Research*, 5, 2, 1068.
37. Jiang H., Zou J., Cheng H., Fang J., Huang G. 2017. Purification, characterization, and mode of action of pentocin JL-1, a novel bacteriocin isolated from *Lactobacillus pentosus*, against drug-resistant *Staphylococcus aureus*. *BioMed Research International*, 2017, 7657190. doi: 10.1155/2017/7657190.
38. Kang S., Kong F., Shi X., Han H., Li M., Guan B., Yang M., Cao X., Tao D., Zheng Y., 2020. Antibacterial activity and mechanism of lactobionic acid against *Pseudomonas fluorescens* and Methicillin-resistant *Staphylococcus aureus* and its application on whole milk. *Food Control*, 108, 106876. doi: 10.1016/j.foodcont.2019.106876.
39. Karska-Wysocki B., Bazo M., Smoragiewicz W. 2010. Antibacterial activity of *Lactobacillus acidophilus* and *Lactobacillus casei* against methicillin-resistant *Staphylococcus aureus* (MRSA). *Microbiological research*, 165, 8, 674-686. doi: 10.1016/j.micres.2009.11.008.
40. Keyvan E., Tutun H. 2019. Effects of carvacrol on *Staphylococcus aureus* isolated from bulk tank milk. *Medycyna Weterynaryjna*, 75, 4, 238-241. doi: 10.21521/mw.6211.
41. Kim S.-G., Khan S.A., Lee Y.-D., Park J.-H., Moon G.-S. 2022. Combination Treatment for Inhibition of the Growth of *Staphylococcus aureus* with Recombinant SAP8 Endolysin and Nisin. *Antibiotics*, 11, 9, 1185. doi: 10.3390/antibiotics11091185.
42. Kim S.-G., Lee Y.-D., Park J.-H., Moon G.-S. 2019. Synergistic inhibition by Bacteriocin and Bacteriophage against *Staphylococcus aureus*. *Food science of animal resources*, 39, 6, 1015-1020. doi: 10.5851/kosfa.2019.e95.
43. Lalouckova K., Mala L., Marsik P., Skrivanova E. 2021. In Vitro Antibacterial Effect of the Methanolic Extract of the Korean Soybean Fermented Product Doenjang against *Staphylococcus aureus*. *Animals*, 11, 8, 2319. doi: 10.3390/ani11082319.
44. Lee J.-E., Lee N.-K., Paik H.-D. 2021. Antimicrobial and anti-biofilm effects of probiotic *Lactobacillus plantarum* KU200656 isolated from kimchi. *Food Science and Biotechnology*, 30, 1, 97-106. doi: 10.1007/s10068-020-00837-0.
45. Lee J.-W., Ji Y.-J., Yu M.-H., Bo M.-H.H., Seo H.-J., Lee S.-P., Lee I.-S. 2009. Antimicrobial effect and resistant regulation of *Glycyrrhiza uralensis* on



- methicillin-resistant *Staphylococcus aureus*. *Natural product research*, 23, 2, 101-111. doi: 10.1080/14786410801886757.
46. Lee N.K., Jin Han E., Jun Han K., Paik H.D. 2013. Antimicrobial effect of bacteriocin KU24 produced by *Lactococcus lactis* KU24 against methicillin-resistant *Staphylococcus aureus*. *Journal of Food Science*, 78, 3, M465-M469. doi: 10.1111/1750-3841.12053.
  47. Lestari S., Sadiq A., Safitri W., Dewi S., Prastiyanto M. 2019. The antibacterial activities of bacteriocin *Pediococcus acidilactici* of breast milk isolate to against methicillin-resistant *Staphylococcus aureus*. *Journal of Physics: Conference Series*, IOP Publishing. doi: 10.1088/1742-6596/1374/1/012021.
  48. Li H.-N., Wang C.-Y., Wang C.-L., Chou C.-H., Leu Y.-L., Chen B.-Y. 2019. Antimicrobial effects and mechanisms of ethanol extracts of *Psoralea corylifolia* seeds against *Listeria monocytogenes* and methicillin-resistant *Staphylococcus aureus*. *Foodborne pathogens and disease*, 16, 8, 573-580. doi: 10.1089/fpd.2018.2595.
  49. Li M., Muthaiyan A., O'Bryan C.A, Gustafson J.E., Li Y., Crandall P.G., Ricke S. C. 2011. Use of natural antimicrobials from a food safety perspective for control of *Staphylococcus aureus*. *Current pharmaceutical biotechnology*, 12, 8, 1240-1254. doi: 10.2174/138920111796117283.
  50. Lim A.C., Tang S.G.H., Zin N.M., Maisarah A.M., Ariffin I.A., Ker P.J., Mahlia T.M.I. 2022. Chemical Composition, Antioxidant, Antibacterial, and Antibiofilm Activities of *Backhousia citriodora* Essential Oil. *Molecules* 27(15): 4895. doi: 10.3390/molecules27154895.
  51. Linden S.B., Zhang H., Heselpoth R.D., Shen Y., Schmelcher M., Eichenhofer F., Nelson D.C. 2015. Biochemical and biophysical characterization of PlyGRCS, a bacteriophage endolysin active against methicillin-resistant *Staphylococcus aureus*. *Applied microbiology and biotechnology*, 99,2, 741-752. doi: 10.1007/s00253-014-5930-1.
  52. Liu C., Cheng F., Aisa H.A. Maiwulanjiang M. 2023. Comprehensive Study of Components and Antimicrobial Properties of Essential Oil Extracted from *Carum carvi* L. Seeds. *Antibiotics*, 12, 3, 591. doi: 10.3390/molecules27051693.
  53. Lu Y., Wang Y., Wang J., Zhao Y., Zhong Q., Li G., Fu Z., Lu S. 2021. Phage endolysin LysP108 showed promising antibacterial potential against methicillin-resistant *Staphylococcus aureus*. *Frontiers in cellular and infection microbiology*, 11, 668430. doi: 10.3389/fcimb.2021.668430.
  54. Mandal S., DebMandal M., Saha K., Pal N.K. 2011. In vitro antibacterial activity of three Indian spices against methicillin-resistant *Staphylococcus aureus*. *Oman Medical Journal*, 26, 5, 319. doi: 10.5001/omj.2011.80.

55. Meng F., Zhu X., Zhao H., Nie T., Lu F., Lu Z., Lu Y. 2021. A class III bacteriocin with broad-spectrum antibacterial activity from *Lactobacillus acidophilus* NX2-6 and its preservation in milk and cheese. *Food Control*, 121, 107597. doi: 10.1016/j.foodcont.2020.107597.
56. Mohammed-Ali M.N., Jamalludeen N.M. 2015. Isolation and characterization of bacteriophage against methicillin resistant *Staphylococcus aureus*. *Journal of Medical Microbiology and Diagnosis*, 5, 1, 1000213. doi: 10.4172/2161-0703.1000213.
57. Murray E., Draper L.A., Ross R.P., Hill C. 2021. The advantages and challenges of using endolysins in a clinical setting. *Viruses*, 13, 4, 680. doi: 10.3390/v13040680.
58. Pedonese F., Longo E., Torracca B., Najar B., Fratini F., Nuvoloni R. 2022. Antimicrobial and anti-biofilm activity of manuka essential oil against *Listeria monocytogenes* and *Staphylococcus aureus* of food origin. *Italian Journal of Food Safety*, 11, 1. doi: 10.4081/ijfs.2022.10039.
59. Prastiyanto M.E., Azizah I.H., Haqi H.D., Yulianto B.D., Agmala A.B., Radipasari Z.D., Astuti N.A.D., Putri A.R. 2020. In-vitro antibacterial activity of the seed extract of three-member *Artocarpus* towards Methicillin-Resistant *Staphylococcus aureus* (MRSA). *Jurnal Teknologi Laboratorium*, 9, 2, 128-135. doi:10.29238/teknolabjournal.v9i2.237.
60. Prastiyanto M.E., Rukmana R.M., Saraswati D.K., Darmawati S., Maharani E.T.W., Tursinawati Y. 2020. Anticancer potential of methanolic extracts from *Pleurotus* species on raji cells and antibacterial activity against Methicillin-Resistant *Staphylococcus aureus*. *Biodiversitas Journal of Biological Diversity* 21, 12. doi: 10.13057/biodiv/d211221.
61. Redwan E.M., Abd El-Baky N., Al-Hejin A.M., Baeshen M.N., Almehdar H. A., Elsayay A., Gomaa A.-B.M., Al-Masaudi S.B., Al-Fassi F.A., Abu-Zeid I.E. 2016. Significant antibacterial activity and synergistic effects of camel lactoferrin with antibiotics against methicillin-resistant *Staphylococcus aureus* (MRSA). *Research in microbiology*, 167, 6, 480-491. doi: 10.1016/j.resmic.2016.04.006.
62. Saelao S., Maneerat S., Kaewsuwan S., Rabesona H., Choiset Y., Haertlé T., Chobert J.-M. 2017. Inhibition of *Staphylococcus aureus* in vitro by bacteriocinogenic *Lactococcus lactis* KTH0-1S isolated from Thai fermented shrimp (Kung-som) and safety evaluation. *Archives of microbiology*, 199, 551-562. doi: 10.1007/s00203-016-1324-3.
63. Salem A.M. 2017. Efficiency of some essential oils in control of methicillin resistant *Staphylococcus aureus* (MRSA) in Minced Beef. *Benha Veterinary Medical Journal*, 32, 1, 177-183.

64. Taggar R., Jangra M., Dwivedi, A. Bansal K., Patil P.B., Bhattacharyya, M.S. Nandanwar H., Sahoo D.K. 2021. Bacteriocin isolated from the natural inhabitant of *Allium cepa* against *Staphylococcus aureus*. *World Journal of Microbiology and Biotechnology*, 37, 2, 1-16. doi: 10.1007/s11274-020-02989-x.
65. Takagi S., Hayashi S., Takahashi K., Isogai H., Bai L. Yoneyama H., Ando T., Ito K., Isogai E. 2012. Antimicrobial activity of a bovine myeloid antimicrobial peptide (BMAP-28) against methicillin-susceptible and methicillin-resistant *Staphylococcus aureus*. *Animal Science Journal*, 83, 6, 482-486. doi: 10.1111/j.1740-0929.2011.00979.x.
66. Tang C., Chen J., Zhang L., Zhang R., Zhang S., Ye S., Zhao Z., Yang D. 2020. Exploring the antibacterial mechanism of essential oils by membrane permeability, apoptosis and biofilm formation combination with proteomics analysis against methicillin-resistant *Staphylococcus aureus*. *International Journal of Medical Microbiology*, 310, 5, 151435. doi: 10.1016/j.ijmm.2020.151435.
67. Vaiyapuri M., Joseph T.C., Rao B.M., Lalitha K.V., Prasad M.M. 2019. Methicillin-Resistant *Staphylococcus aureus* in Seafood: prevalence, laboratory detection, clonal nature, and control in seafood chain. *Journal of Food Science*, 84, 12, 3341-3351. doi:10.1111/1750-3841.14915.
68. Wang S., Kim M.-C., Kang O.-H., Kwon D.-Y. 2020. The mechanism of bisdemethoxycurcumin enhances conventional antibiotics against methicillin-resistant *Staphylococcus aureus*. *International Journal of Molecular Sciences*, 21, 21, 7945. doi: 10.3390/ijms21217945.
69. Wen H., Yuan L., Ye J.-h., Li Y.-j., Yang Z.-q., Zhou W.-y. 2023. Isolation and characterization of a broad-spectrum phage SapYZU11 and its potential application for biological control of *Staphylococcus aureus*. *Quality Assurance and Safety of Crops and Foods*, 15, 2, 32-48. doi: 10.15586/qas.v15i2.1238.
70. Xu J.-G., Liu T., Hu Q.-P., Cao X.-M. 2016. Chemical composition, antibacterial properties and mechanism of action of essential oil from clove buds against *Staphylococcus aureus*. *Molecules*, 21, 9, 1194. doi: 10.3390/molecules21091194.
71. Yan J., Yang R., Yu S., Zhao W. 2021. The strategy of biopreservation of meat product against MRSA using lytic domain of lysin from *Staphylococcus aureus* bacteriophage. *Food Bioscience*, 41, 100967. doi: /10.1016/j.fbio.2021.100967.

72. Yassin M.T., Mostafa A.A.-F, Al-Askar A.A., Alkhelaif A.S. 2022. In vitro antimicrobial potency of *Elettaria cardamomum* ethanolic extract against multidrug resistant of food poisoning bacterial strains. *Journal of King Saud University-Science*, 34, 6, 102167. doi:10.1016/j.jksus.2022.102167.
73. Yehia H.M., Alkhuriji A.F., Savvaidis I., Al-Masoud A.H. 2022. Bactericidal effect of nisin and reuterin on methicillin-resistant *Staphylococcus aureus* (MRSA) and *S. aureus* ATCC 25937. *Food Science and Technology*, 42. doi: 10.1590/fst.105321.
74. Yuan W., Yuk H.-G. 2018. Antimicrobial efficacy of *Syzygium antisepticum* plant extract against *Staphylococcus aureus* and methicillin-resistant *S. aureus* and its application potential with cooked chicken. *Food microbiology*, 72, 176-184. doi: 10.1016/j.fm.2017.12.002.
75. Yusuf M. 2018. Natural antimicrobial agents for food biopreservation. *Food packaging and preservation*, Elsevier: 409-438. doi:10.1016/B978-0-12-811516-9.00012-9.
76. Zhang W., Margarita G.E., Wu D., Yuan W., Yan S., Qi S., Xue X., Wang K., Wu L. 2022. Antibacterial activity of Chinese red propolis against *Staphylococcus aureus* and MRSA. *Molecules*, 27, 5, 1693. doi: 10.3390/molecules27051693.
77. Zhao D., Wang Q., Lu F., Bie X., Zhao H., Lu Z., Lu Y. 2022. A novel planaricarin 827 effectively inhibits *Staphylococcus aureus* and extends shelf life of skim milk. *LWT*, 154, 112849. doi:10.1016/j.lwt.2021.112849.
78. Zhou T., Li Z., Kang O.H., Mun, S.H., Seo Y.S., Kong R., Shin D.-W., Liu X. Q., Kwon D.Y. 2017. Antimicrobial activity and synergism of ursolic acid 3-O- $\alpha$ -L-arabinopyranoside with oxacillin against methicillin-resistant *Staphylococcus aureus*. *International Journal of Molecular Medicine*, 40, 4, 1285-1293. doi: 10.3892/ijmm.2017.3099.
79. Zhu X., Shen L., Liu J., Zhang C., Gu Q. 2015. Purification of a bacteriocin from *Lactobacillus plantarum* ZJ217 active against methicillin-resistant *Staphylococcus aureus*. *International Journal of Food Engineering*, 11, 1, 51-59. doi: 10.1515/ijfe-2014-0176.
80. Zhu Y., Zhou Q., Li P., Gu Q. 2021. Purification, characterization, and mode of action of Paracin 54, a novel bacteriocin against *Staphylococci*. *Applied Microbiology and Biotechnology*, 105, 18, 6735-6748. doi: 10.1007/s00253-021-11505-6.
81. Zihadi M.A.H., Rahman M., Talukder S., Hasan M.M., Nahar S., Sikder M.H. 2019. Antibacterial efficacy of ethanolic extract of *Camellia sinensis* and *Azadirachta indica* leaves on methicillin-resistant *Staphylococcus aureus* and shiga-toxigenic *Escherichia coli*. *Journal of advanced veterinary and animal research*, 6, 2, 247. doi: 10.5455/javar.2019.f340.

82. Zouhir A., Jridi T., Nefzi A., Ben Hamida J., Sebei K. 2016. Inhibition of methicillin-resistant *Staphylococcus aureus* (MRSA) by antimicrobial peptides (AMPs) and plant essential oils. *Pharmaceutical Biology*, 54, 12, 3136-3150. doi: 10.1080/13880209.2016.1190763.

Received: 27.07.2023.

Accepted: 26.11.2023.



Original research article

UDC 544.723.21

<https://doi.org/10.46784/e-avm.v16i2.322>

## POTENTIAL OF DIFFERENT MYCOTOXIN ADSORBENTS UNDER *IN VITRO* CONDITIONS

Saša Krstović<sup>1\*</sup>, Darko Guljaš<sup>1</sup>, Jelena Krulj<sup>2</sup>, Marko Damjanović<sup>1</sup>, Igor Jajić<sup>1</sup>

<sup>1</sup> University of Novi Sad, Faculty of Agriculture, Department  
of Animal Science, Novi Sad, Republic of Serbia

<sup>2</sup> University of Novi Sad, Institute of Food Technology, Republic of Serbia

### Abstract

Mycotoxins are a large and chemically diverse group of toxic secondary metabolites. Regarding their prevalence in animal feed and the effect on animal health, the biggest problems in terms of safety and economic losses are caused by aflatoxins, fumonisins, ochratoxins, trichothecenes and zearalenone. Adsorbents are substances that are added to food contaminated with mycotoxins, in order to bind them in the gastrointestinal tract and thereby prevent or reduce their effect. The aim of this study was to examine the possibility of using pyrophyllite as a mineral adsorbent, as well as preparations made of ground peach pits of different particle sizes as organic adsorbents, for adsorption of deoxynivalenol and ochratoxin A. Mycotoxin adsorption experiments were performed *in vitro* in electrolyte solutions at pH 3 and 7. The adsorption efficiency of the adsorbent was expressed as adsorption index. Pyrophyllite had adsorption index of 13.47% for ochratoxin A at pH 3, while at pH 7, as well as for deoxynivalenol, the same mycotoxin produced a negligible degree of adsorption. Ground peach stones (of larger diameter,  $d = 0.1$  mm) had considerable adsorption rates for ochratoxin A at pH 3 (34.41%) and deoxynivalenol at pH 7 (18.57%). The values were similar for smaller diameter ( $d < 0.1$  mm) for ochratoxin A at pH 3 (42.71%) and deoxynivalenol at pH 7 (20.11%). The obtained results suggest that the potential of the preparation of ground peach stones for the adsorption of tested mycotoxins is higher compared to the potential of pyrophyllite, but there are differences in their efficiency depending on the pH value of the adsorption environment.

**Key words:** ochratoxin A, deoxynivalenol, adsorbents, pyrophyllite, peach stones

---

<sup>1\*</sup> Corresponding Author: [sasa.krstovic@stocarstvo.edu.rs](mailto:sasa.krstovic@stocarstvo.edu.rs)

## POTENCIJAL RAZLIČITIH ADSORBENATA MIKOTOKSINA U *IN VITRO* USLOVIMA

Saša Krstović<sup>1</sup>, Darko Guljaš<sup>1</sup>, Jelena Krulj<sup>2</sup>, Marko Damjanović<sup>1</sup>, Igor Jajić<sup>1</sup>

<sup>1</sup> Univerzitet u Novom Sadu, Poljoprivredni fakultet,  
Departman za stočarstvo, Novi Sad, Republika Srbija

<sup>2</sup> Univerzitet u Novom Sadu, Naučni institut za prehrambene  
tehnologije, Novi Sad, Republika Srbija

### Kratak sadržaj

Mikotoksini su relativno velika i hemijski raznolika grupa toksičnih sekundarnih metabolita. Uzimajući u obzir prevalencu u hrani za životinje i efekat na zdravlje životinja, najveće bezbednosne i ekonomske probleme predstavljaju aflatoksini, fumonizini, ohratoksini, trihoteceni i zearalenon. Adsorbenti predstavljaju materije koje se dodaju hrani kontaminiranoj mikotoksinima, kako bi ih u gastrointestinalnim traktu vezivali i time sprečili ili umanjili njihovo dejstvo. Cilj ovog rada je da se ispita mogućnost primene pirofilita kao predstavnika mineralnih, kao i preparata mlevenih koštica breskve različitih veličina čestica kao predstavnika organskih adsorbenata za adsorpciju deoksinivalenola i ohratoksina A. Eksperimenti adsorpcije mikotoksina su izvođeni *in vitro* u rastvorima elektrolita na pH 3 i 7. Efikasnost adsorpcije adsorbenta je izražena kao indeks adsorpcije. Rezultati su ukazali da pirofilit ima vrednost indeksa adsorpcije od 13,47% za ohratoksin A pri pH 3, dok je za isti mikotoksin pri pH 7, kao i za deoksinivalenol, utvrđen zanemarljiv nivo adsorpcije. Mlevene koštice breskve većeg dijametra ( $d = 0,1$  mm) su pokazale odgovarajuće indekse adsorpcije za ohratoksin A pri pH 3 (34,41%) i deoksinivalenol pri pH 7 (18,57%), dok su mlevene koštice breskve manjeg dijametra ( $d < 0,1$  mm) pokazale slične vrednosti indeksa adsorpcije za ohratoksin A pri pH 3 (42,71%) i za deoksinivalenol pri pH 7 (20,11%). Iz dobijenih rezultata se može zaključiti da je potencijal preparata mlevenih koštica breskve za adsorpciju ispitanih mikotoksina veći u odnosu na potencijal pirofilita, ali da postoje razlike u njihovoj efikasnosti u zavisnosti od pH vrednosti sredine u kojoj se adsorpcija odvija.

**Ključne reči:** ohratoksin A, deoksinivalenol, adsorbenti, pirofilit, koštice breskve



## INTRODUCTION

Agriculture is becoming increasingly important due to the rise in world population and urbanization. This implies a rapid growth and boost of livestock production, resulting in the safety of animal feed becoming even more significant considering the potential threat of hazards reaching the human food chain. Among the undesirable substances, according to Directive 2002/32/EC (European Commission, 2002), mycotoxins are considered one of the greatest hazards in feed raw materials (Santos Pereira et al., 2019). Among other mycotoxins, deoxynivalenol (DON) and ochratoxin A (OTA) certainly represent the most important causes of diseases in animals. Namely, global economic losses caused by DON are in the range of about one billion dollars per year. The Food and Agriculture Organization and the World Health Organization identified it as one of the most dangerous food contaminants as early as 1973 (Neme and Mohammed, 2017). This mycotoxin mainly contaminates agricultural crops such as corn, wheat, and barley, and has immunogenic, carcinogenic, and teratogenic effects in animals. It is also detected in animal products such as meat, eggs, and milk, and poses a danger to human health (Yao and Long, 2020). OTA causes great economic losses to animal husbandry, as the intake of contaminated feed can significantly impair animal health and safety of animal products (Battacone et al., 2010). It can be found in a wide range of agricultural and livestock products, and in processed foods as well, while human exposure to this mycotoxin is mainly attributed to contaminated grains (Abrunhosa et al., 2010). Juodeikiene et al. (2012) stated three possible solutions for avoiding the harmful effect of mycotoxin contamination of both food and feed. They include the following: prevention of contamination, decontamination of mycotoxin-containing food and feed, and inhibition of mycotoxin absorption into the digestive tract. Nevertheless, if mycotoxin contamination already exists, application of decontamination methods is advised (Jouany, 2007). Various methods for mycotoxin reduction were studied, including the application of irradiation, thermal or microwave heating, ozone, chemical compounds, and microbials (Binder and Binder, 2004; Bullerman and Bianchini, 2007; Herzallah et al., 2008; Garg et al., 2013; Krstović et al., 2021). Moreover, the use of existing feed additives, such as enzymes showed a potential for degradation of some mycotoxins (Jakšić et al., 2022). Finally, measures can be applied for inhibition of mycotoxin absorption in the gastrointestinal tract, e.g., the use of adsorbents to reduce the bioavailability of mycotoxins in the digestive tract of animals (Abdel-Wahhab and Kholif, 2010). The use of adsorbents is one of the most suitable options for treatment of mycotoxins in practice (Li et al., 2018). In general, the adsorption method includes both physical and chemical force,

which can not only reduce the toxic impact of mycotoxins, but also enable the avoidance of toxic residues, thus becoming the most commonly applied method of protecting animals from mycotoxins (Li et al., 2018). Adsorbents can be used as single formulations, but are recently combined for better efficiency, usually as mineral-organic adsorbent mixture (Nešić et al., 2020).

The aim of this study was to examine the possibility of using two types of mycotoxin adsorbents. The first is pyrophyllite, a non-metallic aluminosilicate mineral that has adsorptive properties, primarily for ions of heavy metals and colors from aqueous solutions. The second adsorbent included two preparations of ground peach stones of different particle sizes. This type of adsorbent is organic, its waste biomass of agro-industrial source, and as an economically and ecologically profitable material, it is generally considered cheaper than mineral (inorganic) adsorbents. The adsorptive capacity of these preparations was tested for the adsorption of DON and OTA under *in vitro* conditions.

## MATERIAL AND METHODS

### *Adsorbents*

Adsorption potential test was performed for two preparations. Pyrophyllite, which belongs to the group of non-metallic aluminosilicate minerals, was selected as a potential inorganic adsorbent. Its use is already permitted in animal feed at up to 2% to prevent ruminal acidosis in ruminants (US Food and Drug Administration, 2019; Adamović et al., 2020). Another potential adsorbent is a preparation of ground peach stones (Lopičić et al., 2013). It was prepared in two fractions: larger (particle size  $d = 0.1$  mm) and smaller (particle size  $d < 0.1$  mm) fraction. The preparations were not commercially available. All preparations were prepared by and obtained from the Institute for Technology of Nuclear and Other Mineral Raw Materials, Belgrade, Serbia.

### *Mycotoxin removal procedure in vitro*

To simulate *in vivo* conditions, where mycotoxin adsorption is performed on adsorbents, mycotoxin adsorption experiments were performed *in vitro* in solutions at pH 3 and 7. These pH values are expected in the digestive tract of monogastric animals and humans. The crude extract of DON, produced in house on wet maize kernels after artificial inoculation with toxigenic *Fusarium graminearum* (Krstović et al., 2018), as well as the standard solution of OTA (Sigma, St. Louis, MO, USA) were used for the adsorption experiments. 90 mg

of adsorbent was weighed into glass tubes using Teflon stoppers (volume of 20 cm<sup>3</sup>), and then 10 mL of 0.1 M KH<sub>2</sub>PO<sub>4</sub> (13.609 g KH<sub>2</sub>PO<sub>4</sub> in 1000 mL of water, pH set to pH = 3 and pH = 7) was added. After that, a volume of 100 µL of crude toxin solution (*c* = 300 µg/mL) was added in order to obtain the final concentration of 3 µg/ml (crude toxin to adsorbent ratio was 1:3000). Mixing magnets were added to the tubes and then placed in an incubation system at 37 °C for 120 minutes with continuous mixing. The control was set up in the same way, without adsorbent. After the contact of the adsorbent and the mycotoxin was completed, the solution was filtered through quantitative filter paper for slow filtration and then additionally through nylon micro syringe filters with a porosity of 0.2 µm. The solutions prepared in this way were analyzed for HPLC for the mycotoxins' contents. All experiments were performed in duplicate. The adsorption efficiency of the natural adsorbent is expressed as an adsorption index, where:

*C*<sub>i</sub> – mycotoxin initial concentration,

*C*<sub>eq</sub> – mycotoxin concentration at equilibrium.

Adsorption index, % =  $[(C_i - C_{eq})/C_i] \times 100$

### ***HPLC analysis***

DON and OTA determinations were carried out on a 1260 series HPLC system (Agilent Technologies, Santa Clara, CA, USA) using photodiode (DAD) and fluorescence (FLD) detectors (Agilent Technologies, USA) and a Hypersil ODS (150 x 4.6 mm i.e., particle size 5 µm) column (Agilent Technologies, USA). Stock calibration solutions at a concentration of 0.1 mg/mL were prepared in a mixture of ethyl acetate and methanol (19:1, v/v) for DON (Sigma, St. Louis, MO, USA), and in acetonitrile for OTA (Sigma, St. Louis, MO, USA). Working calibrant solutions were prepared by measuring the appropriate volume of the stock solution, evaporating to dryness under a stream of nitrogen at 50 °C and dissolving in the appropriate volume of the mobile phase. The stock solutions were stored at a temperature of -18 °C, while the working solutions were stored in a refrigerator at a temperature of 4 – 8 °C. HPLC conditions for DON determination were set as proposed by Abramović et al. (2005) and for OTA a method by Sugita-Konishi et al. (2006) was used. All analyses were done in duplicate. A volume of 20 µL of solution obtained after adsorption was injected into a HPLC system. The mobile phase consisted of an isocratic mixture of acetonitrile and water (HPLC grade, Sigma, St. Louis, MO, USA). For the determination of DON, the ratio of the solvents was the following: acetonitrile: water (16:84, v/v), and in the case of OTA, this ratio

acetonitrile: water was (50:50, v/v) and 1% of acetic acid was added (HPLC purity, Fisher Scientific, USA). In both cases, a mobile phase flow rate of 0.8 mL/min was applied. Before use, the mobile phase was filtered through regenerated cellulose membrane filters (0.45  $\mu\text{m}$ ) (Agilent Technologies, USA). DON was detected using a DAD detector at a wavelength of  $\lambda = 220 \text{ nm}$ , for the detection of OTA, FLD detector was used at wavelengths of  $\lambda_{\text{ex}} = 333 \text{ nm}$  and  $\lambda_{\text{em}} = 470 \text{ nm}$ . The identification of DON and OTA was performed by comparing the retention times and spectra of the standards with the retention times and spectra of the samples.

## RESULTS

The results of mycotoxin adsorption using the *in vitro* method are shown in tables 1-3.

Table 1. Results of mycotoxin adsorption using pyrophyllite,  $n = 2$

		DON	OTA
<b>Control</b>	Ci, ng/mL	3012 $\pm$ 15	2986 $\pm$ 10
	Ceq, ng/mL	2996 $\pm$ 11	2981 $\pm$ 13
	A, %	0.53	0.17
<b>pH 3</b>	Ci, ng/mL	2946 $\pm$ 53	2969 $\pm$ 18
	Ceq, ng/mL	2945 $\pm$ 23	2569 $\pm$ 21
	A, %	0.03	13.47
<b>pH 7</b>	Ci, ng/mL	2978 $\pm$ 31	2980 $\pm$ 11
	Ceq, ng/mL	2974 $\pm$ 13	2948 $\pm$ 32
	A, %	0.15	1.1

Ci - mycotoxin initial concentration, Ceq - mycotoxin concentration at equilibrium, A - adsorption index.

Table 2. Results of mycotoxin adsorption using the preparation of ground peach stones (GPS), particle size  $d = 0.1$  mm,  $n = 2$

		<b>DON</b>	<b>OTA</b>
<b>Control</b>	Ci, ng/mL	3012 ± 15	2986 ± 10
	Ceq, ng/mL	2996 ± 11	2981 ± 13
	A, %	0.5	0.2
<b>pH 3</b>	Ci, ng/mL	2946 ± 53	2969 ± 18
	Ceq, ng/mL	2940 ± 56	1948 ± 89
	A, %	0.20	34.41
<b>pH 7</b>	Ci, ng/ml	2978 ± 31	2980 ± 11
	Ceq, ng/ml	2425 ± 38	2972 ± 12
	A, %	18.57	0.29

Ci - mycotoxin initial concentration, Ceq - mycotoxin concentration at equilibrium, A - adsorption index.

Table 3. Results of mycotoxin adsorption using the preparation of ground peach stones (GPS), particle size  $d < 0.1$  mm,  $n = 2$

		<b>DON</b>	<b>OTA</b>
<b>Control</b>	Ci, ng/mL	3012 ± 15	2986 ± 10
	Ceq, ng/mL	2996 ± 11	2981 ± 13
	A, %	0.5	0.2
<b>pH 3</b>	Ci, ng/mL	2946 ± 53	2969 ± 18
	Ceq, ng/mL	2941 ± 28	1701 ± 98
	A, %	0.19	42.71
<b>pH 7</b>	Ci, ng/mL	2978 ± 31	2980 ± 11
	Ceq, ng/mL	2379 ± 89	2897 ± 56
	A, %	20.11	2.80

Ci - mycotoxin initial concentration, Ceq - mycotoxin concentration at equilibrium, A - adsorption index.

The adsorption index of DON was below 1% using pyrophyllite for both pH values, as well as in the case of using the preparation of ground peach stones at pH = 3 (Figure 1). As for the preparation of ground peach stones

at pH = 7, adsorption index values of 18.57% (larger fraction) and 20.11% (smaller fraction) were obtained. This indicates that there is a certain potential of the ground peach stone preparation for DON adsorption at pH = 7, while the adsorption potential of pyrophyllite has not been proven.




Figure 1. Comparative overview of the adsorption index of ground peach stones (GPS) and pyrophyllite for DON adsorption

When it comes to the adsorption index of pyrophyllite for OTA, it was affected by the pH value (Figure 2). Namely, at pH=3, the adsorption index was found to be 13.47%, while at pH = 7, it was as low as 1.1%. However, using the preparation of ground peach stones, these differences in the adsorption index were opposing compared to the application of pyrophyllite, where high values of the adsorption index of 34.41% (larger fraction) and 42.71% (smaller fraction) were found at pH = 3, and low values (0.29% and 2.80%) at pH = 7. These results indicate that the potential of the preparation of ground peach stones for OTA adsorption is higher compared to the potential of pyrophyllite, but there are still differences in their efficiency depending on the pH value of the environment in which the adsorption takes place.




Figure 2. Comparative overview of the adsorption index of ground peach stones (GPS) and pyrophyllite for OTA adsorption

## DISCUSSION

Pyrophyllite is already a recognized adsorbent of various substances such as cationic (due to negative hydrophilic surface sites) and anionic (after the addition of trivalent aluminium cation) dyes (Gücek et al., 2005). It is also known for its ability to bind ions of heavy metals such as cobalt (98.97%), lead (97.53%), nickel (98.87%) and cadmium (98.65%) from aqueous solution (maximum adsorption in optimized conditions) (Panda et al., 2018). Furthermore, in the research conducted by Murtić et al. (2020), it was demonstrated that the application of pyrophyllite, due to its adsorbent and ion exchange capabilities can reduce the use of mineral fertilizers in the production of lettuce without adverse effects on its yield and quality, in the amount of 25% or 50% of the recommended amount of fertilizer. However, despite the results of the aforementioned research, as well as the proven adsorption capacity of numerous other aluminosilicates against mycotoxins, literature data on the adsorption of mycotoxins, specifically by pyrophyllite, is very scarce. In contrast, the potential of peach stones to adsorb mycotoxins has been studied more extensively. Hence, in the research by Adamović et al. (2013) the adsorption of the following six mycotoxins was tested: AFB1, zearalenone, diacetoxyscirpenol (DAS), T-2 toxin, OTA and DON using the *in vitro* method. Similar to our study, the adsorption index was tested at two pH values, pH = 3.0 and 6.9.

Peach stones showed the highest affinity to aflatoxin (80.00% and 73.30%) and the lowest to DAS (0% at both pH values). When it comes to OTA and DON, a higher adsorption capacity was demonstrated in comparison with our research, given that the adsorption index at pH=3.0 and 6.9 were 66.67% and 50% for OTA, and 25% and 50% for DON, respectively. However, there were certain differences in the experimental design that could produce a different result (the ratio of individual mycotoxins and adsorbents in this research was 1:5000 and the particle size of the investigated biomass < 100 µm). Comparable research was conducted by Lopičić et al. (2013), at pH values of 3.0 and 7.0. Similar to the previous study, the best adsorption index of peach stones was obtained for aflatoxin (58.82% at both pH values), the poorest for DAS (0% and 16.67%), while for OTA it was 66.67% and 19.98% and 23.08% and 39.97% for DON, at pH 3.0 and 7.0, respectively. It is interesting to point out that in both studies, in addition to the unmodified, modified peach stones (activated with 1 M HCl) were used, and they achieved a somewhat different, weaker result compared to the unmodified. Furthermore, in the research by Bočarov-Stančić et al. (2011), the adsorption capacities of mineral adsorbents bentonite, diatomite and zeolite against aflatoxin, DAS, OTA, and DON were investigated. Like in the previous research, the highest adsorption index was obtained for aflatoxins (at pH 3.0 and 6.9: bentonite 96.90%; zeolite 95.50% and diatomite 95%) which is slightly higher compared to organic adsorbents, while the weakest was obtained for DAS (0% in all adsorbents). However, it is noted that organic adsorbents were more effective for OTA and DON. With OTA, only diatomite had adsorption properties (66.67%) at pH = 3. On the other hand, at pH = 6.9, as well as for bentonite and zeolite at both pH values, the adsorption index was 0%. Considering DON, mineral adsorbents showed affinity at pH = 3, bentonite and zeolite 50% and diatomite 25%, whereas at pH = 7 they did not display any affinity (0%). These results may lead to a conclusion that mineral adsorbents are more effective when it comes to aflatoxins, while organic adsorbents are more successful for OTA and DON adsorption. This was confirmed by the results of our research, where pyrophyllite was used as a mineral adsorbent. This adsorbent had an effect (13.47%) only for OTA at pH = 3, while it was ineffective in other cases. Ground peach stones were more efficient, as a larger diameter showed the degree of adsorption for OTA at pH = 3 (34.41%) and DON at pH 7 (18.57%), and the smaller diameter similarly, for OTA at pH = 3 (42.71%) and for DON at pH = 7 (20.11%). However, it is certainly necessary to prove this result under *in vivo* conditions.

The obtained results in our and similar research indicate that the degree of binding depends primarily on the type of adsorbent (mineral or organic), and



on individual types within these groups, as well as on the mycotoxin. These characteristics should be considered when creating formulations for use in practice, and certain adsorbents should be used depending on the conditions on the farm and occurrence of certain types of mycotoxins. In the future, formulations containing several types of adsorbents need to be tested, in order to enable action against several types of mycotoxins or use one of them that has the widest spectrum of adsorption capacity when different types of mycotoxins are involved.

## CONCLUSION

The results of this study point to several conclusions. Namely, the potential of the preparation of ground peach stones for the adsorption of DON at pH = 7 was found, while its application at pH=3, the adsorption potential was not confirmed. The adsorption potential of pyrophyllite was not established at any of the pH values to which it was applied. The potential of the preparation of ground peach stones for OTA adsorption is higher compared to the potential of pyrophyllite, but there are differences in their efficiency depending on the pH value of the environment in which the adsorption takes place. Like with other *in vitro* research, this research cannot fully simulate conditions in the gastrointestinal tract of animals, so further *in vivo* experiments are necessary in order to evaluate the effectiveness of these materials as mycotoxin adsorbents.

## ACKNOWLEDGEMENT

This research was funded by the Provincial Secretariat for Higher Education and Scientific Research, Autonomous Province of Vojvodina, Republic of Serbia (Contract Number: 142-451-3148/2022-01/2).

## Author's Contribution:

S.K. basic idea, conception and design; D.G. acquisition of data; J.K. interpretation of results, manuscript revision; M.D. acquisition of data, drafting the manuscript; I.J. conception and design, final approval.

## Competing interest

The author(s) declare that they have no competing interests.

## REFERENCES

1. Abdel-Wahhab M.A. and Kholif A.M. 2010. Mycotoxins in animal feeds and prevention strategies: A review. *Asian Journal of Animal Sciences*, 4, 3, 113-131. doi:10.3923/ajas.2008.7.25.
2. Abramović B., Jajić I., Jurić V., Gaál F.F. 2005. Optimization of determination of deoxynivalenol in corn samples by liquid chromatography and comparison of two clean-up principles. *Journal of Serbian Chemical Society*, 70, 1005-1013. doi:10.2298/JSC0507005A.
3. Abrunhosa L., Paterson R.R.M., Venâncio A. 2010. Biodegradation of ochratoxin A for food and feed decontamination. *Toxins*, 2, 5, 1078-1099. doi:10.3390%2Ftoxins2051078.
4. Adamović M., Stojanović M., Lopičić Z., Milojković J., Lačnjevac Č., Petrović J., Bočarov-Stančić A. 2013. Biosorpcija mikotoksina otpadnom masom. *Zaštita Materijala*, 54, 4, 327-333.
5. Adamović M., Stojanović M.D., Harbinja M.M., Maslovarić D., Bočarov-Stančić A., Pezo L.L. 2020. Efficiency investigation of the use of pyrophyllite in ensiling maize plant. *Food and Feed Research*, 47, 2, 109-118. doi: 10.5937/ffr47-29445.
6. Battacone G., Nudda A., Pulina G. 2010. Effects of ochratoxin A on livestock production. *Toxins*, 2, 7, 1796-1824. doi:10.3390%2Ftoxins2071796.
7. Binder E.M. and Binder J. 2004. Strain of Eubacterium that detoxifies trichothecenes. US Patent no. 6794175. Available at: <https://patentimages.storage.googleapis.com/7f/3e/3c/b78d08e42a8188/US6794175.pdf>. Accessed 08.09.2023.
8. Bočarov-Stančić A., Adamović M., Salma N., Bodroža-Solarov M., Vučković J., Pantić V. 2011. In vitro efficacy of mycotoxins' adsorption by natural mineral adsorbents. *Biotechnology in Animal Husbandry*, 27, 3, 1241-1251. doi: 10.2298/BAH1103241B.
9. Bullerman L.B. and Bianchini A. 2007. Stability of mycotoxins during food processing. *International Journal of Food Microbiology*, 119, 1-2, 140-146. doi:10.1016/j.ijfoodmicro.2007.07.035.
10. European Commission. 2002. Directive 2002/32/EC of the European Parliament and of the Council of 7 May 2002 on undesirable substances in animal feed. *Official Journal of the European Communities*, L140, 10-22. Available at: <https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A32002L0032>. Accessed 08.09.2023.
11. Garg N., Aggarwal M., Javed S., Khandal K.R. 2013. Studies for optimization of conditions for reducing Aflatoxin Contamination in Peanuts using

- Ultraviolet Radiations. *International Journal of Drug Development and Research*, 5, 3, 155–168.
12. Gücek A., Sener S., Bilgen S., Mazmancı M.A. 2005. Adsorption and kinetic studies of cationic and anionic dyes on pyrophyllite from aqueous solutions. *Journal of Colloid and Interface Science*, 286, 53-60. doi: 10.1016/j.jcis.2005.01.012.
  13. Herzallah S., Alshwabkeh K., Fataftah, A.A.L. 2008. Aflatoxin decontamination of artificially contaminated feeds by sunlight,  $\gamma$ -radiation, and microwave heating. *Journal of Applied Poultry Research*, 17, 4, 515–521. doi:10.3382/japr.2007-00107.
  14. Jakšić S., Baloš M.Ž., Popov N., Mihaljev Ž., Zloh B., Polaček V. 2022. In vitro study of the efficacy of mycotoxins degradation by feed enzymes. *Archives of Veterinary Medicine*, 15, 1, 5–17. doi: 10.46784/eavm.v15i1.280.
  15. Jouany J.P. 2007. Methods for preventing, decontaminating and minimizing the toxicity of mycotoxins in feeds. *Animal Feed Science and Technology*, 137, 3–4, 342–362. doi:10.1016/j.anifeeds.2007.06.009.
  16. Juodeikiene G., Basinskiene L., Bartkiene E., Matusevicius P. 2012. Mycotoxin Decontamination Aspects in Food, Feed and Renewables Using Fermentation Processes. In *Structure and Function of Food Engineering*. Eds. A. Eissa, Intech Open, 171–204. doi:10.5772/46184.
  17. Krstović S., Bočarov-Stančić S., Krulj J., Janković S., Guljaš D., Jajić I. 2018. Potential of *Fusarium graminearum* isolate to biosynthesize deoxynivalenol and zearalenone in vitro. In *Proceedings XVIII International Symposium "Feed Technology"*, 23-25.10.2018, University of Novi Sad, Institute of Food Technology, Novi Sad, Serbia, 71-76.
  18. Krstović S., Krulj J., Jakšić S., Bočarov-Stančić A., Jajić I. 2021. Ozone as decontaminating agent for ground corn containing deoxynivalenol, zearalenone, and ochratoxin A. *Cereal Chemistry*, 98, 1, 135-143. doi:10.1002/cche.10289.
  19. Li Y., Tian G., Dong G., Bai S., Han X., Liang J., Meng J., Zhang H. 2018. Research progress on the raw and modified montmorillonites as adsorbents for mycotoxins: A review. *Applied Clay Science*, 163, 299-311. doi: 10.1016/j.clay.2018.07.032.
  20. Lopičić R.Z., Bočarov-Stančić S.A., Stojanović D.M., Milojković V.J., Pantić R.V., Adamović J.M. 2013. In vitro evaluation of the efficacy of peach stones as mycotoxin binders. *Matica Srpska Journal for Natural Sciences*, 124, 287-296. doi:10.2298/ZMSPN1324287L.
  21. Murtić S., Zahirović Ć., Karić L., Jurković J., Čivić H., Sijahović E. 2020. Use of pyrophyllite as soil conditioner in lettuce production. *Nature Environment and Pollution Technology*, 19, 1, 355-359.

22. Neme K. and Mohammed A. 2017. Mycotoxin occurrence in grains and the role of postharvest management as a mitigation strategies: A review. *Food Control*, 78, 412-425. doi:10.1016/j.foodcont.2017.03.012.
23. Nešić K., Jakšić S., Popov N., Živkov-Baloš M., Pajić M., Zloh B., Polaček V. 2020. In vitro assessment of binding capacity of combined adsorbent (bentonite with yeast cell wall extracts) and aflatoxin B1. *Archives of Veterinary Medicine*, 13, 1, 41–52. doi:10.46784/e-avm.v13i1.65.
24. Panda L., Rath S.S., Rao D.S., Nayak B.B., Das B., Misra P.K. 2018. Thorough understanding of the kinetics and mechanism of heavy metal adsorption onto a pyrophyllite mine waste based geopolymer. *Journal of Molecular Liquids*, 263, 428-441. doi:10.1016/j.molliq.2018.05.016.
25. Santos Pereira C., Cunha S.C., Fernandes J.O. 2019. Prevalent mycotoxins in animal feed: Occurrence and analytical methods. *Toxins*, 11, 5, 290. doi:10.3390/toxins11050290.
26. Sugita-Konishi Y., Tanaka T., Nakajima M., Fujita K., Norizuki H., Mochizuki N., Takatori K. 2006. The comparison of two clean-up procedures, multifunctional column and immunoaffinity column, for HPLC determination of ochratoxin A in cereals, raisins and green coffee beans. *Talanta*, 69, 650-655. doi:10.1016/j.talanta.2005.10.036
27. United States Food and Drug Administration. 2019. Part 573 - Food additives permitted in feed and drinking water of animals. *Food and Drugs, Chapter I - Food and drug administration, Department of Health and Human Services, Subchapter E-Animal drugs, feeds, and related products*. US FDA, Silver Spring, MD.
28. Yao Y. and Long M. 2020. The biological detoxification of deoxynivalenol: A review. *Food and Chemical Toxicology*, 145, 11649. doi:10.1016/j.fct.2020.111649.

Received: 17.05.2023.

Accepted: 23.07.2023.

Original research article

UDK 636.29:579.842:[615.281.015.8(849.3)]  
<https://doi.org/10.46784/e-avm.v16i2.317>

## ISOLATION, MOLECULAR IDENTIFICATION AND ANTIBIOTIC SENSITIVITY OF *SALMONELLA* FROM BUFFALO FECES IN SYLHET DISTRICT OF BANGLADESH

Bishwajit Dashgupta<sup>1</sup>, Md. Mahfujur Rahman<sup>1</sup>, Sharmin Akter<sup>2</sup>,  
Ruhen Begum<sup>1</sup>, Md. Shahidur Rahman Chowdhury<sup>1</sup>, Md. Mukter Hossain<sup>1\*</sup>

<sup>1</sup>Department of Medicine, Sylhet Agricultural University, Sylhet, Bangladesh

<sup>2</sup>Department of Epidemiology and Public Health, Sylhet  
Agricultural University, Sylhet, Bangladesh

### Abstract

*Salmonella* is a widely distributed foodborne pathogen affecting humans and animals around the globe. This cross-sectional bacteriological study was aimed at isolation of *Salmonella* from fecal samples of buffalos in Sylhet district (Upazilas Jaintapur and Fenchuganj) of Bangladesh, their molecular confirmation, and learning their antibiotic sensitivity patterns. A total of 334 fecal samples were collected using a simple random sampling technique. Standard conventional bacteriological culture and biochemical tests were done to isolate and confirm *Salmonella*. The isolates were confirmed with polymerase chain reaction (PCR). In this study, *Salmonella* was isolated from 56 samples (16.77%) using bacteriological culture methods and biochemical tests, and all isolates were confirmed in PCR tests. The prevalence of *Salmonella* was estimated to be 17.57% and 13.93% in Jaintapur and Fenchuganj Upazilas, respectively. Buffalo calves under one year of age had a higher prevalence (24.32%) than older animals aged 1 - 2 (18.62%), 2 - 4 (13.25%), and > 4 years (10.67%). Furthermore, the prevalence was substantially higher in diarrheic animals (72.22%) than in their healthy counterparts (13.60%). It did not vary significantly ( $p > 0.05$ ) between animals from Jaintapur and Fenchuganj Upazilas. Likewise, no significant difference ( $p > 0.05$ ) in *Salmonella* isolates was detected between different age groups. The results revealed that the isolation rate of *Salmonella* was significantly ( $p < 0.05$ ) higher in female and diarrheic animals.

---

\* mukter.vetmed@sau.ac.bd

The most effective antibiotics against the majority of *Salmonella* isolates were gentamycin (100%), levofloxacin (100%), and ciprofloxacin (76.67%). On the other hand, *Salmonella* isolates were highly resistant to tetracycline (100%), ampicillin (87.5%), and streptomycin (78.6%). Pathogenic microorganisms in feces are a potential risk to public health due to environmental and animal food contamination. Therefore, infection control and establishing strategic antibiotic therapy should be a priority.

**Key words:** Bangladesh, buffalo feces, *Salmonella*, *invA* gene, antibiotics sensitivity

## IZOLACIJA, MOLEKULARNA IDENTIFIKACIJA I ANTIBIOTSKA OSETLJIVOST *SALMONELLA* IZ BIVOLJEG IZMETA U OKRUGU SILHET, BANGLADEŠ

Bishwajit Dashgupta<sup>1</sup>, Md. Mahfujur Rahman<sup>1</sup>, Sharmin Akter<sup>2</sup>,  
Ruhena Begum<sup>1</sup>, Md. Shahidur Rahman Chowdhury<sup>1</sup>, Md. Mukter Hossain<sup>1</sup>

<sup>1</sup>Departman za medicinu, Univerzitet za poljoprivredu u Silhetu, Silhet, Bangladeš

<sup>2</sup>Departman za epidemiologiju i javno zdravlje, Univerzitet  
za poljoprivredu u Silhetu, Silhet – 3100, Bangladeš

### Kratak sadržaj

*Salmonella* je široko rasprostranjen patogen koji se prenosi hranom i pogađa ljude i životinje širom sveta. Ova bakteriološka studija poprečnog preseka imala je za cilj izolaciju *Salmonella* iz uzoraka fecesa bivola u okrugu Silhet (distrikti Jaintapur i Fenchuganj) u Bangladešu, njihovu molekularnu potvrdu i osetljivost na antibiotike. Ukupno 334 uzorka fecesa prikupljena su jednostavnom tehnikom slučajnog uzorkovanja. Standardne konvencionalne bakteriološke metode i biohemijski testovi su urađeni da bi se izolovala i potvrdila *Salmonella*. Izolati su potvrđeni lančanom reakcijom polimeraze (PCR). U ovoj studiji *Salmonella* je izolovana iz 56 uzoraka (16,77%) metodom kultivacije i biohemijskim testovima, a svi izolati su potvrđeni i PCR testovima. Prevalencija *Salmonella* je iznosila 17,57% i 13,93% u Jaintapuru i Fenchuganj distriktu. Mladunčad bivola mlađih od jedne godine imala

su veću prevalenciju (24,32%) od starijih životinja uzrasta 1 - 2 (18,62%), 2 - 4 godine (13,25%) i > 4 godine (10,67%). Osim toga, prevalencija je bila znatno veća kod životinja sa dijarejom (72,22%) nego kod zdravih životinja (13,60%). Prevalencija nije značajno varirala ( $p > 0,05$ ) između životinja iz Jaintapura i Fenchuganj distrikta. Isto tako, nije otkrivena značajna razlika ( $p > 0,05$ ) u izolatima *Salmonella* između različitih starosnih grupa. Rezultati su otkrili da je stopa izolacije *Salmonella* značajno ( $p < 0,05$ ) veća kod ženki i životinja sa dijarejom. Najefikasniji antibiotici protiv većine izolata *Salmonella* bili su gentamicin (100%), levofloksacin (100%) i ciprofloksacin (76,67%). S druge strane, izolati *Salmonella* su bili visoko otporni na tetraciklin (100%), ampicilin (87,5%) i streptomycin (78,6%). Patogeni mikroorganizmi u fecesu predstavljaju potencijalni rizik za javno zdravlje zbog kontaminacije životne sredine i hrane za životinje. Stoga, kontrola infekcije i uspostavljanje strateške antibiotske terapije treba da budu prioritet.

**Ključne reči:** Bangladeš, bivolji feces, *Salmonella*, *invA* gen, antibiotska osetljivost

## INTRODUCTION

*Salmonella*, a genus of the family *Enterobacteriaceae*, is a major cause of foodborne disease of public health significance both in developed and developing countries (Gebeyehu et al., 2022). All across the world, pathogens have been isolated from the feces of animals (Sabur et al., 2021). Salmonellosis, the clinical form of *Salmonella* infection, is a costly disease to livestock producers on account of mortality, treatment expenses, reduced milk yield, and weight loss/decreased weight gain within the herd (Callaway et al., 2005). By producing high-quality milk, meat, and farmyard waste, buffalo ranching contributes significantly to the agriculture and cattle sectors in many Asian nations (Khongsai, 2020). Bangladesh has only 1.485 million indigenous buffaloes, with a more significant concentration (40%) in coastal areas and certain buffalo pockets. Smallholder farmers in Bangladesh raise a small number of imported Nili-Ravi and Murrah buffaloes and their crosses on a few fields (Samad, 2020). Pathogens that infect buffaloes and their offspring or are transferred via their products are significant because they impact milk production and total livestock performance. In buffaloes, *Salmonella* is a major pathogen causing calf diarrhea (Khongsai, 2020; Ribeiro et al., 2000), leading to early-age

calf mortality (Rana et al., 2012) and a foremost pathogen transmitted through animal products. *Salmonella enterica* subsp. *enterica* can cause infections with a variety of clinical signs, as well as systemic infections characterized by diarrhea and septicemia, and, in extreme cases, death.

Antimicrobial resistance (AMR) is now recognized as one of the most serious global threats to human health in the 21<sup>st</sup> century (Morehead and Scarborough, 2018; Tacconelli et al., 2018a; Tacconelli et al., 2018b) and a decline in the rate of new antibiotic development (Luepke and Mohr, 2017). It causes a considerable risk of death and economic hardship all over the world. However, impoverished nations are more harmed due to extensive antibiotic abuse, non-human antibiotic usage, poor medication quality, and insufficient surveillance (Ayukekbong et al., 2017; Van Boeckel et al., 2019). Bangladesh, a Southeast Asian developing country with a high level of AMR, poses a regional and global concern. Several studies have found irrational antibiotic prescribing by doctors and veterinarians, a patient habit of self-medication, and indiscriminate antibiotic usage in agriculture and farming in various sections of the nation (Biswas et al., 2014; Sutradhar, 2014).

*Salmonella* species with single and multidrug resistance are becoming more common (Liu et al., 2010). Salmonellosis is treated with a variety of antibiotics. Fluoroquinolones and third generation cephalosporins are the most often prescribed antibiotics to treat salmonellosis. Chloramphenicol, Ampicillin, Amoxicillin, and trimethoprim-sulfamethoxazole are some of the older antibiotics occasionally used as alternatives (Ayukekbong et al., 2017). Antimicrobial resistance in *Salmonella* has been observed to be on the rise in several developing and developed nations (Schmidt et al., 2018).

In some upazilas of the Sylhet region, the farmers depend upon the buffaloes primarily for draught and meat purposes, an integral part of the farming system in this area. Buffalo is economically significant in this region and could be considered a “small tractor” for farmers, and its meat and milk are nutritionally rich. Despite their great contribution to the socio-economy, they are still undervalued. Diseases are one of the most significant constraints for buffalo production, which decrease milk and meat production and reduce farmer’s income. In addition, the status of *Salmonella* in buffalo populations in Sylhet district is unknown. Therefore, this study aimed to isolate and identify *Salmonella* from buffalo feces by conventional bacteriological, biochemical, and molecular methods and to determine the antibiotic sensitivity of *Salmonella* isolates.



## MATERIAL AND METHODS

### *Study Area and Sample Collection*

For this study, Fenchuganj and Jaintapur Upazilas of Sylhet District of Bangladesh were purposively selected due to their relativeness of larger buffalo population and milk production. The sampling units for the study were buffalo of different ages. A total of 334 fecal samples of buffaloes (112 from Fenchuganj and 222 from Jaintapur) of Sylhet District constituted the study population, which was selected by using a simple random sampling method. The study was conducted for a period of one year (July 2021 to June 2022). Feces samples were collected directly from the rectum and freshly voided feces from buffalo. The samples were placed in a labeled clean plastic container and immediately transferred to the laboratory for further analysis.

### *Isolation and identification of Salmonella*

Conventional bacteriological methods were used to isolate the *Salmonella* from feces samples. The samples were inoculated into buffered peptone water (BPW), incubated at 37°C for 24 hours, and 0.5 mL was transferred to 10 mL Tetrathionate Broth (Merck) and incubated at 37°C for 24 hours. Following enrichment, a loopful of samples were streaked on xylose-lysine deoxycholate (XLD) agar and *Salmonella* – *Shigella* (SS) agar plates and incubated at 37 °C for 24 h. Biochemical confirmation of *Salmonella* was performed using TSI agar, Urea agar, Simmon's citrate agar, methyl red, and Voges Proskauer broth.

### *Bacterial genomic DNA Extraction and PCR assay*

The DNA extraction was performed according to the manufacturer's instructions using the Addprep genomic DNA extraction kit (Addbio Inc. Ltd., Korea). These eluted DNA samples were stored at -80 °C until further analysis. The PCR analysis was performed to detect the *Salmonella* invasion gene (*invA* gene) according to the manufacturer's instructions (Addbio Inc. Ltd., Korea). PCR assay performed in the thermal cycler TC1000G PCR System\* (DLAB Scientific Inc., USA) with a heated lid. The cycling conditions included 50 °C for 3 minutes (UDG Reaction), 95 °C for 10 minutes (Initial Denaturation), 35 cycles of 95 °C for 30 seconds (denaturation), 68 °C for 45 seconds (annealing), and 72 °C for 5 minutes for final extension (Khan et al., 2021). For the detection of *Salmonella*, the primers of *invS*-F (5'-TAA TGCCAGACGAAA-GAGCGT-3') and *invS*-R (5'-GATATTGGTGTTTATGGG GTCGTT-3') were

used (Khan et al., 2021). All reaction mixtures, including the negative control and *Salmonella* positive DNA, were tested in duplicate in the same run of PCR assay. PCR products were analyzed on 1.8% agarose gels stained with RedSafe™ (iNtRON Biotechnology, Korea) Nucleic Acid Staining Solution (20,000×), photographed, and stored as a digital image.

### ***Determination of Antibiotic sensitivity patterns***

The *in vitro* antibiotic sensitivity test was determined by the standard disc diffusion method according to the Clinical and Laboratory Standard Institute (CLSI, 2020). The antibiotic discs used in the present study were Ampicillin (AMP, 10 µg), Amoxicillin/Clavulanic Acid (AMC, 30 µg), Gentamycin (CN, 10 µg), Streptomycin (S, 10 µg), Cefixime (CFM, 5 µg), Ceftriaxone (CRO, 30 µg), Azithromycin (AZM, 15 µg), Ciprofloxacin (CIP, 5 µg), Levofloxacin (LEV, 5 µg), Colistin sulfate (CT, 10 µg), Tetracycline (TE, 10 µg), Sulfamethoxazole-trimethoprim (SXT, 25 µg) all from Oxoid company, UK. After incubation, each disc's diameter of the clear zones produced by antibacterial inhibition of bacterial growth was measured to the nearest millimeter and then classified as resistant, intermediate, or susceptible using a published interpretive chart of Clinical and Laboratory Standards Institute (CLSI,2020).

### ***Statistical analysis***

Microsoft Excel Office 2010 was used for descriptive statistics. Chi-square tests were used to assess the significance of differences in prevalence between age, sex, and health status of the animals. P values less than 0.05 were considered significant using Chi-square tests (SPSS Inc., Chicago, IL, USA).

## **RESULTS**

*Salmonella* was isolated from 56 (16.77%) out of 334 examined samples, of which 39 (17.57%) and 17 (13.93%) were from feces of Jaintapur and Fenchuganj upazila, respectively (Table 1). The prevalence of *Salmonella* was higher in buffalo calves aged less than one year (24.32%); although the difference was not statistically significant ( $p = 0.11$ ) (Table 2). Furthermore, the isolation rate was relatively higher in animals aged 1 - 2 years (18.62%) than in the groups of 4 years and above four years (Table 2).

Table 1: Overall prevalence of *Salmonella* in buffalo feces and its association with study area

Study area	Number of samples tested	Tests name					
		Culture positive	Prevalence	Biochemical Test positive	Prevalence	PCR positive	Prevalence
Jaintapur	222	45	20.27%	39	17.57%	39	17.57%
Fenchuganj	122	19	15.57%	17	13.93%	17	13.93%
Total	334	64	19.16%	56	16.77%	56	16.77%

Table 2: Association of the prevalence of *Salmonella* with age of buffalo populations

Age of animals	No. of animals examined	No. of positive fecal samples	Prevalence	P-value
Up to 1 year	74	18	24.32%	0.11
1 - 2 years	102	19	18.62%	
2 - 4 years	83	11	13.25%	
> 4 years	75	8	10.67%	
Total	334	56	16.77%	

Level of significance  $p < 0.05$

It was observed that out of the total 334 feces samples collected from two different upazilas, the female buffaloes showed a higher prevalence (21.56%) of *Salmonella* in their fecal samples (Table 3). All suspected *Salmonella* colonies underwent specific biochemical tests such as indole formation, methyl red and Voges Proskauer reaction, citrate utilization, and triple sugar iron agar due to their cultural and morphological characteristics. Sixty-four of the suspected *Salmonella* colonies had 56 confirmed colonies by biochemical test results. Most of the *Salmonella* isolates showed fermentation of glucose, gas

production from glucose, H<sub>2</sub>S formation, but none of the isolates showed either lactose or sucrose. The results showed that the prevalence rate of *Salmonella* was statistically significant ( $p = 0.01$ ). In this study, the *Salmonella* isolation rate was categorized based on the health condition of buffalo populations. The isolation rate of *Salmonella* was higher in diarrheic buffalo fecal samples (72.22%) compared with apparently healthy animals (13.60%). The result revealed statistically significant differences ( $p = 0.01$ ) (Table 4).

Table 3: Association of *Salmonella* isolation rate with the sex of animals

Sex of animals	No. of animals examined	No. of positive fecal samples	Prevalence	$p$ -value
Male	153	17	11.11%	
Female	181	39	21.55%	0.01
Total	334	56	16.77%	

Level of significance  $p < 0.05$

Table 4: The association of *Salmonella* isolation rate with the health status of buffalo populations

Health status of animals	No. of animals examined	No. of positive fecal samples	Prevalence	$p$ -value
Apparently healthy	316	43	13.60%	
Diarrheic	18	13	72.22%	< 0.01
Total	334	56	16.77%	

Level of significance  $p < 0.05$

A total of 56 isolates of *Salmonella* were tested for commonly used 12 antibiotics from 8 groups. All the *Salmonella* isolates were found resistant to one or more antibiotics used. This antibiotic susceptibility study revealed that *Salmonella* isolates were 100%, 93.33%, and 76.67% sensitive to Gentamycin, Levofloxacin, Colistin sulfate, and Ciprofloxacin. On the other hand, isolates were 100%, 87.5%, and 78.6% resistant to Tetracycline, Ampicillin, and Streptomycin, respectively (Table 5.). All of the biochemically positive *Salmonella* isolates

(n = 56) were submitted to a PCR test using a particular primer set to identify the *invA* gene of *Salmonella*. After agarose gel electrophoresis under UV transilluminator, all the biochemically identified 56 isolates were confirmed positive for *Salmonella* and revealed an *invA* gene-specific band at 100bp (Figure 1.).

Table 5. Antibiotic susceptibility profile of *Salmonella* isolated (n = 56) from buffalo feces

Antibiotic tested	Susceptible (%)	Intermedi- ate (%)	Resist- ance (%)
<b>Penicillin</b>			
Ampicillin (AMP, 10 µg)	-	7 (12.5)	49 (87.5)
Amoxicillin/clavulanic Acid (AMC, 30 µg)	30 (53.33)	15 (26.67)	11 (20)
<b>Aminoglycosides</b>			
Gentamicin (CN, 10 µg)	56 (100)	-	-
Streptomycin (S, 10 µg)	-	12 (21.4)	44 (78.6)
<b>Cephalosporins</b>			
Cefixime (CFM, 5 µg)	41 (73.21)	4 (7.14)	11 (20)
Ceftriaxone (CRO, 30 µg)	39 (70)	4 (7.14)	13 (23.21)
<b>Macrolides</b>			
Azithromycin (AZM, 15 µg)	39 (70)	-	17 (30)
<b>Fluoroquinolones</b>			
Ciprofloxacin (CIP, 5 µg)	43 (76.67)	13 (23.21)	-
<b>Levofloxacin (LEV, 5 µg)</b>	56 (100)	-	-
<b>Polymyxins</b>			
Colistin Sulphate (CT, 10 µg)	52 (92.86)	-	4 (7.14)
<b>Tetracyclines</b>			
Tetracycline (TE, 10 µg)	-	-	56 (100)
<b>Folate Pathway Inhibitors</b>			
Sulfamethoxazole -Tri- methoprim (SXT, 25 µg)	35 (62.5)	-	21 (37.5)




Figure 1. PCR amplification of biochemically identified *Salmonella*

## DISCUSSION

In the present study, 334 buffalo fecal samples were collected from Jain-tapur (222) and Fenchuganj (112) Upazilas of Sylhet district. Bacteriological examination revealed the *Salmonella* organisms from 56 of 334 buffalo fecal samples with a prevalence of 16.77% (Table 1), which is close to 11.2% (Zahran and Elbehiry, 2014). *Salmonella* in the buffalo population is a health risk for people who consume the products (meat, milk), as it has been reported that 25% of meat samples are contaminated with *Salmonella* (Abd-Elghany et al., 2022). The prevalence of *Salmonella* was higher in young (up to 1 year) and sick (diarrheic) animals, estimated to be 24.32% and 72.22%, respectively. The age-related result of the present study is consistent with the findings of other researchers (Saha et al., 2013; Mahmood et al., 2014). The findings also coincide with the results of Hunduma et al. (2010), who stated that diarrhea is a major problem in animals with a higher prevalence.

For detection of *Salmonella* genus using PCR, it was found that all PCR products, including positive control, resulted in 100 bp amplified fragment. Figure 1 revealed no amplified DNA fragments obtained from the non-*Salmonella* genus. *Salmonella* isolates produced a white band at the level of marker DNA (Figure 1). The PCR method is recommended for detecting *Salmonella* in feces samples because it is faster than culture methods (Stone et al., 1994; van der Zee and Huis in 't Veld, 2000).

According to Vella and Cuschieri (1995), *Salmonella* isolates were most frequently resistant to trimethoprim. *Salmonella* isolated from feces of dairy cattle were resistant to ampicillin (100%), streptomycin (66.7%), and tetracycline (55.56%) but susceptible to gentamicin (100%) and ciprofloxacin (91.7%) as reported by others (Khan et al., 2021). According to Wieczorek and Osek (2013), sulfamethizole resistance was found in various strains of *S. Dublin* and *S. Enteritidis*. *Salmonella* isolates are resistant to multiple antibiotics (ampicillin, streptomycin, tetracycline, and sulfamethizole). The isolates were susceptible to gentamicin (100%), levofloxacin (100%), and ciprofloxacin (76.67%) but have shown higher resistance to tetracycline, ampicillin, and streptomycin (100%, 87.5%, and 78.6%, respectively). According to Esaki et al. (2004), many *Salmonella* isolates from both healthy and ill animals were resistant to two or more antimicrobials. These microorganisms are disseminated in the environment and spread through the excrement of animals that appear to be in good health. According to reports, *S. Typhimurium* was released in a pig farm (Tanaka et al., 2014). The release was relatively high for several days following vaccination; therefore, the animals appeared to be in good health. As a result, herd infection could come even from the excrement of clinically healthy animals. Furthermore, a range of serotypes of antibiotic-resistant bacteria may exist. *Salmonella* isolates were shown to be resistant to numerous drugs in the current investigation. Tetracycline resistance was found in all *Salmonella* isolates. The results of this study revealed that *Salmonella*-infected buffalo could be effectively treated with gentamicin, Levofloxacin, and Ciprofloxacin.

## CONCLUSION

It could be concluded that *Salmonella* is a significant cause of diarrhea in buffaloes with salmonellosis in Bangladesh. Therefore, a rapid and proper diagnosis could prevent harm inflicted on the livestock industry. The molecular basis of *Salmonella* identification techniques, such as using the *invA* gene-specific PCR method, could be helpful in diagnostic and research laboratories. This study suggests the strategic use of antibiotics to control *Salmonella* infections in animals.

## ACKNOWLEDGEMENT

This project was funded by the Ministry of Science & Technology, Bangladesh. The authors also express their gratitude to Sylhet Agricultural University Research System (SAURES) for their support in completing this research successfully.

### Author's Contribution:

MMH and MMR: Supervised and contributed to study design; BDG and RB: Carried out the laboratory experiments; SA and MSRC: Performed statistical analysis; and BDG and MMH: Wrote the manuscript. All authors read and approved the final manuscript.

### Competing interest

The authors declare that they have no competing interests.

### REFERENCES

1. Abd-Elghany S.M., Fathy T.M., Zakaria A.I., Imre K., Morar A., Herman V., Paşcalau R., Şmuleac L., Morar D., Imre M., Sallam K.I. 2022. Prevalence of Multidrug-Resistant *Salmonella enterica* Serovars in Buffalo Meat in Egypt. *Foods*, 11, 18, 2924. doi: 10.3390/foods11182924.
2. Ayukekbong J.A., Ntemgwa M., Atabe, A.N. 2017. The threat of antimicrobial resistance in developing countries: Causes and control strategies. *Antimicrobial Resistance and Infection Control*, 6, 1, 1–8. doi: 10.1186/s13756-017-0208-x.
3. Biswas M., Roy M.N. Manik M.I.N., Hossain M.S., Tapu S.T.A., Moniruzzaman M. Sultana S. 2014. Self medicated antibiotics in Bangladesh: A cross-sectional health survey conducted in the Rajshahi City. *BMC Public Health*, 14, 1, 1–7. doi: 10.1186/1471-2458-14-847.
4. Callaway T.R., Keen J.E., Edrington T.S., Baumgard L.H., Spicer L., Fonda E.S., Griswold K.E., Overton T.R., Van Amburg M.E., Anderson R.C., Genovese K.J., Poole T.L., Harvey R.B., Nisbet D.J. 2005. Fecal prevalence and diversity of *Salmonella* species in lactating dairy cattle in four states. *Journal of Dairy Science*, 88, 3603–3608. doi: 10.3168/jds.S0022-0302(05)73045-9.
5. Clinical and Laboratory Standards Institute (CLSI) M100 Performance Standards for Antimicrobial Susceptibility Testing, 2020.
6. Esaki H., Morioka A., Ishihara K., Kojima A., Shiroki S., Tamura Y., Takahashi T. 2004. Antimicrobial susceptibility of *Salmonella* isolated from cattle, swine and poultry (2001–2002): Report from the Japanese Veterinary antimicrobial resistance monitoring program. *Journal of Antimicrobial Chemotherapy*, 53, 266–270. doi: 10.1093/jac/dkh081.
7. Gebeyehu A., Taye M., Abebe R. 2022. Isolation, molecular detection and antimicrobial susceptibility profile of *Salmonella* from raw cow milk



- collected from dairy farms and households in southern Ethiopia. *BMC Microbiology*, 22, 84. doi: 10.1186/s12866-022-02504-2.
8. Hunduma D., Tigre W., Wagari M., Regassa F. 2010. Preliminary study on major health problems of the newly introduced boer goat breed in Ethiopia. *World Applied Sciences Journal*, 11, 803-807.
  9. Khan M.N.K., Das M.R., Sabur M.A., Rahman M.M., Uddin M.B., Cho H.S., Hossain M.M. 2021. Isolation, identification, molecular detection and sensitivity to antibiotics of *Salmonella* from cattle feces. *Bulgarian Journal of Veterinary Medicine*, 24, 57-66. doi: 10.15547/bjvm.2019-0061.
  10. Khongsai L. 2020. Growth and Development of Dairy Industry in India. *International Journal of Recent Technology and Engineering*, 8, 5, 1566-1571. doi: 10.35940/ijrte.D4239.018520.
  11. Liu W.B., Chen J., Huang Y.Y., Liu B., Shi X.M. 2010. Serotype, genotype, and antimicrobial susceptibility profiles of *Salmonella* from chicken farms in Shanghai. *Journal of Food Protection*, 73, 3, 562-567. doi: 10.4315/0362-028x-73.3.562.
  12. Luepke K.H. and Mohr J.F. 2017. The antibiotic pipeline: reviving research and development and speeding drugs to market. *Expert Review of Anti-infective Therapy*, 15, 5, 425-433. doi: 10.1080/14787210.2017.1308251.
  13. Mahmood A.K., Khan M.S., Khan M.A., Khan M.A., Bilal M. 2014. Prevalence of *Salmonella* in diarrheic adult goats in field conditions. *The Journal of Animal and Plant Sciences*, 24, 1, 98-102.
  14. Morehead M.S. and Scarbrough C. 2018. Emergence of Global Antibiotic Resistance. *Prime Care*, 45, 3, 467-484. doi: 10.1016/j.pop.2018.05.006.
  15. Rana N., Raut A.A., Khurana S.K., Manuja A., Saini A. 2012. Isolation and biotyping of *Salmonella* and *Escherichia coli* associated with neonatal buffalo calves. *The Indian Journal of Animal Science*, 82, 7, 676-678.
  16. Ribeiro M.G., Langoni H., Jerez J.A., da Silva Leite D., Ferreira F.E.R., Gennari S.M. 2000. Identification of enteropathogens from buffalo calves with and without diarrhoea in the Ribeira Valley, State of São Paulo, Brazil. *Brazilian Journal of Veterinary Research and Animal Science*, 37, 2, 159-165. doi: 10.1590/S1413-95962000000200013.
  17. Sabur M.A., Das M.R., Uddin M.B., Rahman M.M., Islam M.R., Chowdhury M.S.R., Hossain M.M. 2021. Molecular Detection and Antibiotic Sensitivity of *Salmonella* Species Isolated from Goat Feces in Sylhet District of Bangladesh. *World Veterinary Journal*, 11, 3, 395-401. doi: 10.54203/scil.2021.wvj51.
  18. Saha G.K., Paul A.K., Abdussamad A., Islam M.A., Khan M.S.R. 2013. Epidemiological investigation and antibiotic sensitivity of salmonellosis in goats at the selected areas of Bangladesh. *Journal of Animal Reproduction and Biotechnology*, 28: 337-342.

19. Samad M.A. 2020. A systematic review of research findings on buffalo health and production published during the last six decades in Bangladesh. *Journal of Veterinary Medicine and One Health Research*, 2, 1, 01-62. doi: 10.36111/jvmohr.2020.2(1).0016.
20. Schmidt V.M., Pinchbeck G., McIntyre K.M., Nuttall T., McEwan N., Dawson S. Williams N.J. 2018. Routine antibiotic therapy in dogs increases the detection of antimicrobial-resistant faecal *Escherichia coli*. *Journal of Antimicrobial Chemotherapy*, 73, 12, 3305-3316. doi: 10.1093/jac/dky352.
21. Stone G.G., Oberst R.D., Hays M.P., McVey D.S., Chengappa M.M. 1994. Detection of *Salmonella* serovars from clinical samples by enrichment broth cultivation-PCR procedure. *Journal of Clinical Microbiology*, 32, 7, 1742-1749. doi: 10.1128/jcm.32.7.1742-1749.1994.
22. Sutradhar K.B, Saha A., Huda N.H., Uddin R. 2014. Irrational Use of Antibiotics and Antibiotic Resistance in Southern Rural Bangladesh: Perspectives from Both the Physicians and Patients. *Annual Research and Review in Biology*, 4, 9, 1421-1430. doi: 10.9734/ARRB/2014/8184.
23. Tacconelli E., Carrara E., Savoldi A., Harbarth S., Mendelson M., Monnet D.L., Pulcini C., Kahlmeter G., Kluytmans J., Carmeli Y., Ouellette M., Outtersson K., Patel J., Cavalieri M., Cox E.M., Houchens C.R., Grayson M.L., Hansen P., Singh N., Theuretzbacher U., Magrini N., WHO Pathogens Priority List Working Group. 2018a. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infectious Diseases*, 18, 3, 318-327. doi: 10.1016/S1473-3099(17)30753-3.
24. Tacconelli E., Sifakis F., Harbarth S., Schrijver R., van Mourik M., Voss A., Sharland M., Rajendran N.B., Rodríguez-Baño J., EPI-Net COMBAC-TE-MAGNET Group. 2018b. Surveillance for control of antimicrobial resistance. *Lancet Infectious Diseases*, 18, 3, e99-e106. doi: 10.1016/S1473-3099(17)30485-1.
25. Tanaka T., Imai Y., Kumagae N., Sasaki T., Ochiaial N. Uruno K., Kitazawa H., Saito T., Sato S. 2014. Quantitative microbiological evaluation of *Salmonella* Typhimurium shed in diarrhea, loose, and normal stools of infected pigs. *Open Journal of Veterinary Medicine*, 4, 58-66. doi: 10.4236/ojvm.2014.44007.
26. Van Boeckel T.P., Pires J., Silvester R., Zhao C., Song J., Criscuolo N.G., Gilbert M., Bonhoeffer S., Laxminarayan R. 2019. Global trends in antimicrobial resistance in animals in low- And middle-income countries. *Science*, 365, 6459, 1251. doi: 10.1126/science.aaw1944.

27. van der Zee H. and Huis in't Veld J.H.J. 2000. Method for the rapid detection of *Salmonella*. In *Salmonella in Domestic Animals*. Eds. C. Wray and A. Wray, CABI Publishing, Wallingford, UK, 373–391.
28. Vella L. and Cuschieri P. 1995. *Salmonella* excretion in adult cattle on the Maltese island of Gozo. *Revue Scientifique et Technique*, 14, 3, 777-787. doi: 10.20506/rst.14.3.871.
29. Wiczorek K. and Osek J. 2013. Prevalence and characterisation of *Salmonella* in slaughtered cattle and beef in Poland. *Bulletin of the Veterinary Institute Pulawy*, 57, 4, 607-611. doi: 10.2478/bvip-2013-0103.
30. Zahran R. and Elbehiry A. 2014. Prevalence, molecular identification and virulence attributes of *Salmonella* serovars isolated from feces of diarrheic cow and buffalo calves. *International Journal of Current Microbiology and Applied Sciences*, 3, 9–27.

Received: 16.06.2023.

Accepted: 09.10.2023.



Original research article

UDK 636.7.09:616.993.161:577.21  
<https://doi.org/10.46784/e-avm.v16i2.327>

## EVALUATION OF PHYSIOLOGICAL BIOMARKERS AS POSSIBLE PREDICTIVE FACTORS AND PROGNOSIS MARKERS OF KIDNEY INJURY IN DOGS NATURALLY INFECTED WITH *LEISHMANIA INFANTUM*

Felipe Muniz dos Santos<sup>1</sup>, Julio César Cambraia Veado<sup>1</sup>,  
Vitor Márcio Ribeiro<sup>2</sup>, Adriane Pimenta da Costa-Val<sup>1\*</sup>

<sup>1</sup> Veterinary Hospital, Clinical and Surgery Department, Veterinary School, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil

<sup>2</sup> Santo Agostinho Hospital Veterinário, Belo Horizonte, Minas Gerais, Brazil

### Abstract

Impaired renal function is one of the main characteristics of dogs infected with *Leishmania infantum*. Early diagnosis of kidney injury is essential for improving patient's prognosis. This study aims to evaluate physiological biomarkers as predictors of kidney injury and prognostic markers. Medical records of fifty-nine dogs of different breed, age, and sex, naturally infected with *L. infantum*, were analyzed. Red blood cells, leucocytes, platelets count, hematocrit, total plasma proteins, plasma globulin, plasma albumin, serum creatinine, serum urea, serum phosphorus, serum symmetrical dimethyl arginine, urine analysis, urinary density, urinary protein creatinine ratio, urinary creatinine, urinary protein, and systemic blood pressure were examined in trial 0. Six months after trial 0, twenty-four dogs returned for clinical and laboratory examination. The second medical record analysis was identified as trial 1. The twenty-four dogs were examined using the same tests performed in trial 0. The physiological biomarker such as platelets and leukocyte count, hematocrit, serum phosphorus, urinary density, and systemic blood pressure, showed a significant correlation as prognostic and predictive factors of kidney injury in dogs. The platelet count was used as the physiological biomarker to show the value as a predictive factor and prognostic marker related to biomarkers of kidney injury in dogs naturally infected with *L. infantum*.

**Key words:** acute kidney injury, CanL, survival

---

<sup>1\*</sup> Corresponding Author: [adriane@ufmg.br](mailto:adriane@ufmg.br)

## EVALUACIJA FIZIOLOŠKIH BIOMARKERA KAO MOGUĆIH PREDIKTIVNIH FAKTORA I PROGNOŠTIČKIH MARKERA OŠTEĆENJA BUBREGA KOD PASA PRIRODNO INFICIRANIH SA LEISHMANIA INFANTUM

Felipe Muniz dos Santos<sup>1</sup>, Húlio Sezar Kambraja Veado<sup>1</sup>,  
Vitor Markio Ribeiro<sup>2</sup>, Adrijan Pimenta da Costa-Val<sup>1\*</sup>

<sup>1</sup> Veterinarska bolnica, kliničko i hirurško odeljenje, Veterinarska škola, Federalni univerzitet Minas Žerais (UFMG), Belo Horizonte, Minas Žerais, Brazil

<sup>2</sup> Veterinarska bolnica Santo Agostinjo, Belo Horizonte, Minas Žerais, Brazil

### Kratak sadržaj

Oštećena bubrežna funkcija je jedna od glavnih karakteristika pasa zaraženih sa *Leishmania infantum*. Rana dijagnostika oštećenja bubrega je od suštinskog značaja za bolju prognozu stanja pacijenta. Ova studija ima za cilj da proceni fiziološke biomarkere kao prediktore oštećenja bubrega i prognostičke markere. Izvršena je analiza medicinske dokumentacije za pedeset i devet pasa različitih rasa, starosti i pola, prirodno zaraženih sa *L. infantum*. Crvena krvna zrnca, leukociti, broj trombocita, hematokrit, ukupni proteini plazme, globulini u plazmi, albumin u plazmi, serumski kreatinin, serumski urea, serumski fosfor, serumski simetrični dimetil arginin, analiza urina, gustina urina, odnos urinarnog proteina i kreatinina, kreatinin u urinu, urinarni protein, i sistemski krvni pritisak ispitivani su kao parametri nultog ispitivanja. Šest meseci nakon nultog ispitivanja, dvadeset i četiri psa su se vratila na klinički i laboratorijski pregled. Podaci od drugog pregleda su označeni kao ispitivanje 1. Dvadeset četiri psa su pregledana korišćenjem istih testova izvršenih u ogledu „0“ (nultog ispitivanja). Fiziološki biomarkeri kao što su broj trombocita i leukocita, hematokrit, fosfor u serumu, gustina urina i sistemski krvni pritisak, pokazali su značajnu korelaciju kao prognostički i prediktivni faktori oštećenja bubrega kod pasa. Broj trombocita je korišćen kao fiziološki biomarker da pokaže vrednost kao prediktivni faktor i prognostički marker koji se odnosi na biomarkere oštećenja bubrega kod pasa prirodno inficiranih *L. infantum*.

**Ključne reči:** akutno oštećenje bubrega, lajšmanioza pasa, preživljavanje

## INTRODUCTION

Visceral leishmaniasis (VL) is an infectious, systemic, and zoonotic disease caused by the protozoan *Leishmania infantum* and is transmitted by infected female sandflies, *Lutzomyia longipalpis*, and its main vector is in Brazil (Dantas-Torres and Brandão-Filho, 2006). It is estimated that there are millions of infected dogs in South America, especially in Brazil, where there are high rates of infection (Marcondes and Day, 2019)

Infected dogs can develop canine leishmaniosis (CanL), which can affect several organs and therefore exhibit several clinical characteristics, ranging from apparently healthy to severe illness and death, depending on the immune response triggered by the patient (Soares et al., 2005; Freitas et al., 2012)

Renal function impairment is quite frequent among the clinical changes observed in infected animals (Braga et al., 2015). The formation and deposition of immune complexes secondary to CanL can cause glomerulonephritis and tubulointerstitial lesions (De Oliveira Frazilio et al., 2018). Some authors believe that tubulointerstitial lesions occur secondary to glomerulopathy (Pardo-Marín et al., 2017; De Oliveira Frazilio et al., 2018). Renal proteinuria, which is a reflection of increased glomerular capillary permeability, is associated with the production of immune complexes and may be evidence of kidney injury (D'Amico and Bazzi, 2003; Soares et al., 2005; Freitas et al., 2012; Brown et al., 2013; IRIS 2023). Treatments for CanL in Brazil are based on miltefosine for leishmanicidal action, immunomodulatory medications such as domperidone, and immunotherapy, which consists of three double doses of the Leishtec<sup>®</sup> vaccine with intervals of twenty-one days between applications. Subsequently, a six-monthly booster should be administered with the application of a double dose. Immunotherapy was a good and efficient protocol for reducing clinical manifestations and controlling CanL relapses compared to other treatments (Santos et al., 2007; Ribeiro et al., 2013; Araujo and Gondim, 2020).

This study aims to evaluate physiological biomarkers as predictive and prognostic markers of the evolution of infection, renal injury, and renal failure in dogs naturally infected with *L. infantum*, assisting in the determination of treatment procedures, managing possible alterations identified, and in the prognosis of patients.

## MATERIAL AND METHODS

For the retrospective data collection, no ethical approval was required as no identifying information was included, and no dogs were actively recruited.

Medical records of fifty-nine dogs of different breeds and ages naturally infected with *L. infantum* were examined. Out of the fifty-nine dogs studied, twenty-six were female dogs, while thirty-three were males. The dogs were classified and divided into stages as suggested by Solano-Gallego et al. (2011). The clinical staging of canine visceral leishmaniasis is classified in four stages based on serological status, clinical symptoms and laboratory findings. Dogs in Stage I - Negative to low positive antibody levels; Dogs with mild clinical symptoms such as peripheral lymphadenomegaly, or papular dermatitis. Usually, no clinicopathological abnormalities were observed. Normal renal profile was the following: creatinine <1.4 mg/dl; non-proteinuric: UPC < 0.5. Stage II - Low to high positive antibody levels; Dogs, which apart from the signs listed in stage I, may exhibit the following symptoms: diffuse or symmetrical cutaneous lesions such as exfoliative dermatitis / onychogryphosis, ulcerations (planum nasale, footpads, bony prominences, mucocutaneous junctions), anorexia, weight loss, fever, and epistaxis; Clinicopathological abnormalities such as mild non-regenerative anemia, hyperglobulinemia, hypoalbuminemia, serum hyperviscosity syndrome. Substages: a) Normal renal profile: creatinine < 1.4 mg/dl; non-proteinuric: UPC < 0.5 b) Creatinine <1.4 mg/dl; UPC = 0.5-1,0. Stage III - Medium to high positive antibody levels; Dogs, which apart from the symptoms listed in stages I and II, may show the signs originating from immune-complex lesions: vasculitis, arthritis, uveitis, and glomerulonephritis. Clinicopathological abnormalities listed in IRIS stage II of chronic kidney disease (CKD), creatinine 1.4-2,8 mg/dl, or stage I with UPC > 1. Stage IV - Medium to high positive antibody levels; Dogs with clinical symptoms listed in stage III. Pulmonary thromboembolism, or nephrotic syndrome (marked proteinuria UPC > 5) and final stage renal disease; Clinicopathological abnormalities listed in IRIS stage II CKD, stage III (creatinine 2,9-5mg/dl) and stage IV (creatinine >5 mg/dl).

The dogs from stage II and those undergoing treatment with immunotherapy (do Nascimento et al, 2018; Gouveia et al, 2021) as suggested by Brasileish (2019) were included. Medical records should also present parasitological examinations for *Leishmania sp.* identification by direct or molecular identification or titration above 1:160 in the indirect Fluorescent Antibody Test (IFAT) or sample value four times higher than the cut-off point in the Enzyme-Linked Immunosorbent Assay (ELISA) (Brasileish, 2019; Solano-Gallego et al., 2011; Laia et al., 2011) at trial 0 (T0). Eighteen (30.5%) dogs were classified as stage IIa (Normal renal profile: creatinine < 1.4 mg/dl; non-proteinuric: UPC < 0.5), fifteen (25.4%) as stage IIb (Creatinine <1.4 mg/dl; UPC = 0.5-1), twenty-three (39%) in stage III, and three (5.1%) dogs were classified as stage IV (Solano-Gallego, et al., 2011).



Also, medical records should present complete blood count tests: red blood cell count (RBC), hematocrit (HC), leucocytes (LE) and platelets (PL), total plasma proteins (PROT), plasma globulin (GL), plasma albumin (AL), serum creatinine (CR), serum urea (UR), serum phosphorus (PH), serum symmetrical dimethyl arginine (SDMA), urine analysis, urinary density (UR. D), urinary protein creatinine ratio (UPC), urinary creatinine (CR. U) and urinary protein (UR PTN), all performed in the exact consultation, in the same laboratory. Systemic blood pressure (SBP) was measured using vascular doppler or through the oscillometer method with the animal positioned in lateral decubitus, in line with criteria for cuff size and minimum stress. Three to seven measurements were performed, and the first measurement was discarded to obtain an average of the other measurements, considering the patient's SBP value.

Animals that showed signs of dehydration, episodes of vomiting, diarrhea, inappetence, or lower urinary tract disease were excluded from the study. This first moment is identified as T0. Six months after T0, twenty-four dogs were returned for clinical and laboratory evaluation. The second medical record analysis was identified as trial 1 (T1). These twenty-four dogs were clinically healthy and evaluated through the same exams performed in the same laboratory in T0. Thirty-five dogs were not returned for evaluation or returned for more than six months and were therefore excluded from the study.

### ***Statistical Analysis***

Principal component analysis (multivariate analysis) was performed using numerical variables. This analysis evaluated all numerical variables, considering their correlation, and was performed using Spearman's correlation matrix. Moderate, strong, and robust correlations were reported, with confidence intervals above 95%. Statistical analyses were performed using the R software version ("The R Project for Statistical Computing," 2019).

## **RESULTS**

### ***T0***

The distribution of the dogs evaluated in this study is shown in Figure 1. The arrows facing the same direction indicate biomarkers that are positively correlated with each other. The points in the two quadrants on the right showed higher values for CR, UR, SDMA, PH, UPC, and UR. PTN. In these

quadrants there were higher concentration of dogs classified in stages III and IV, whereas those in the two left quadrants, mostly dogs classified in stages IIa and IIb, had higher values mainly for CR, U, HC, AL, and UR. D. The points in the two upper quadrants had higher PL counts. On the other hand, the points in the two lower quadrants had higher values, mainly for PROT and GL. There was a relative separation in the group IIa, with animals concentrated on the left side of the graph, and group IV, with animals focused on the right side. The chart shows the dispersion and evolution of dogs from T0 to T1. The dogs classified as stage IIa or IIb were in the left quadrant. The dogs in stages III and IV were in the right quadrant, with high levels of CR, UR, SDMA, PH, and UPC, demonstrating that patients classified in the final stages have a greater impairment of the glomerular filtration rate.




Figure 1: Dispersion of dogs considering the staging and the values obtained in the analytes studied at T0 and T1. The points in the two quadrants on the right showed higher values for CR, UR, SDMA, PH, UPC, and UR. PTN, whereas those in the two left quadrants showed higher values mainly for CR, UR, HC, AL, and UR. D. The points in the two upper quadrants had higher PL counts, while the points in the two lower quadrants had higher values, mainly for PROT and GL.

Anemia was found in twenty-one (35%) dogs out of fifty-nine analyzed in the study. Two (11%) of the dogs were classified as stage IIa, five (33%) as stage IIb, 11 (47%) in stage III, and three (100%) in stage IV present anemia.

Thrombocytopenia was present in seventeen (28%) dogs out of fifty-nine evaluated in the study. Three (16%) of the dogs classified as stage IIa, four (26%) in stage IIb, seven (30%) in stage III, and three (100%) in stage IV had thrombocytopenia.

Out of the thirty-three dogs at T0, classified by Solano-Gallego et al. (2011) IIa and IIb stages evaluated in this study, in thirteen (39%), UPC was the first biomarker to assess kidney injury to have the values higher than reference values. SDMA was the first evaluated biomarker with values higher than reference values in two dogs (6%). SDMA and UPC levels increased simultaneously in two dogs (6 %) classified by Solano-Gallego et al. (2011) IIa and IIb stages.

SDMA had the values above the reference ( $> 18 \mu\text{g/dL}$  IRIS, 2023) in one (5%) dog classified as stage IIa and in four (26%) dogs classified as stage IIb. In stage III, there was an increase in SDMA in eight (34%) dogs, and in stage IV in three (100%) dogs.

Analyzing correlations at T0, they were found to be moderate with values varying between 0.4 and 0.69, and strong between 0.70 and 0.89. SDMA had a moderate positive correlation with UR and CREAT and a moderate negative correlation with HC. UR levels had a strong positive correlation with serum CR levels and a moderate positive correlation with PH levels. PH showed a reasonable positive correlation with UPC and a moderate negative correlation with RBC and HC. PROT levels showed a moderate negative correlation with the PL count. AL levels had a moderate positive correlation with HC and RBC, which was negatively correlated with UPC and UR. PTN levels. UR. D showed a moderate correlation with CR.U.

### ***Comparisons between T0 X T1***

The correlation of biomarkers evaluated at T0 and T1 is shown in Table 1. When correlations were evaluated at T0 and T1, PL (T0) had a negative correlation with UPC and UR. PTN levels at T1. There was no correlation between PL and UPC in T0. The UR. D (T0) and UPC (T1) showed a strong negative correlation. LE (T0) had a moderate correlation with UR (T1). PH (T0) had a moderate correlation with UR. PTN.

In the analysis of the correlation between the variables in T0 and the variables of dogs with CR lower than 1.4 mg/L in T1 is shown in Table 2. UR D (T0) had a negative correlation with the UPC (T1) and the GL (T1). SDMA

(T0) was correlated with CR. U level (T1). PL (T0) correlated with UR and PH levels (T1). UR. PTN (T0) levels are associated with PROT levels (T1). PH and SBP (T0) were correlated with LE (T1). It was not possible to perform the analysis for animals with serum CR equal to or greater than 1.4 mg/L, as due to an insufficient number of dogs, it is not possible to get a basis for interpretable analysis.

Table 1: Correlations between the biomarkers studied at T0 and T1 that were statistically significant.

BIOMARKER	TRIAL 0	BIOMARKER	TRIAL 1	CORRELATION	P
CR.U	T0	UR.D	T1	0.73	0.003
GL	T0	LE	T1	0.48	0.019
CR.U	T0	UR. PTN	T1	-0.71	0.023
PL	T0	UPC	T1	-0.69	0.023
PL	T0	UR. PTN	T1	-0.69	0.026
PROT	T0	GL	T1	0.45	0.027
UR. D	T0	UPC	T1	-0.69	0.027
SDMA	T0	CR. U	T1	0.68	0.029
CR. U	T0	UPC	T1	-0.68	0.03
LE	T0	UR	T1	-0.44	0.031
PROT	T0	LE	T1	0.43	0.031
PL	T0	LE	T1	-0.43	0.036
PH	T0	UR. PTN	T1	0.66	0.036
HC	T0	PTOT	T1	-0.42	0.043
UR. PTN	T0	UPC	T1	0.65	0.043
PL	T0	PH	T1	-0.41	0.048
SBP	T0	LE	T1	0.41	0.049

Hematocrit (HC), leucocytes (LE) and platelets (PL), total plasma proteins (PROT), serum globulin (GL), serum urea (UR), serum phosphorus (PH), serum symmetrical dimethyl arginine (SDMA), urine analysis, urinary density (UR. D), urinary protein creatinine ratio (UPC), urinary creatinine (CR. U), urinary protein (UR PTN) and systemic blood pressure (SBP).

Table 2: Correlation of the variables in T0 together with the variables of dogs that present creatinine lower than 1.4 mg/L at T1 that presented statistically significant.

BIOMARKER	TRIAL 0	BIOMARKER	TRIAL 1	CORRELATION	P
UR. D	T0	UPC	T1	-0.92	0.001
SDMA	T0	CR. U	T1	0.92	0.001
PL	T0	UR	T1	-0.59	0.013
UR. D	T0	GL	T1	0.57	0.016
SBP	T0	LE	T1	0.56	0.018
PL	T0	PH	T1	-0.55	0.022
PH	T0	LE	T1	0.53	0.03
UR. PTN	T0	PROT	T1	0.5	0.042

Hematocrit (HC), leucocytes (LE) and platelets (PL), total plasma proteins (PROT), serum globulin (GL), serum urea (UR), serum phosphorus (PH), serum symmetrical dimethyl arginine (SDMA), urine analysis, urinary density (UR. D), urinary protein creatinine ratio (UPC), urinary creatinine (CR. U) and urinary protein (UR PTN) and Systemic blood pressure (SBP).

## DISCUSSION

The importance of evaluating coinfections in dogs infected with *L. infantum* is well known. Infections with *Babesia canis*, *Anaplasma platys*, *Hepatozoon canis* and *Ehrlichia canis* cause hematological alterations such as anemia, pancytopenia, and thrombocytopenia (Thrall, 2007; Vilela et al., 2013), which may change the values of laboratory tests in the studied dogs. The lack of this evaluation presents a limitation of this study.

Changes in the erythrogram of dogs infected with *L. infantum* were observed in this study, in the form of mild to moderate anemia and thrombocytopenia. However, the pathogenesis of anemia in CanL includes additional mechanisms such as reduced erythropoietin synthesis due to renal failure (Paltinieri et al., 2016). Anemia may also result from the parasite's invasion of the bone marrow, which induces inflammation that may contribute to a decrease in erythrocyte production (Da Costa-Val et al., 2007). Anemia is usually present in normocytic and normochromic forms with a non-regenerative character (Freitas et al., 2012). Thrombocytopenia is a common finding in dogs with CanL and occurs due to vasculitis caused by circulating immune complexes,

thrombocytopoiesis disorders, and PL destruction (Solano-Gallego L., et al., 2009; De Carvalho Nicolato et al., 2013).

Hyperproteinemia is caused by hyperglobulinemia, which is associated with the activation of B lymphocytes and high antibody production (Freitas et al., 2012; Paltrinieri et al., 2016; Maia and Campino, 2018). A decrease in the production or renal loss of AL was also observed in this study, but the increase in GL levels was very expressive, causing the levels of PROT to increase significantly during CanL (Giunchetti et al., 2008; Solano-Gallego, et al., 2009). As for urinalysis, in the present study, proteinuria was the most frequent alteration in animals with CanL to both mild or severe degrees, as described by Amusategui et al. (2003) and Bonfanti and Zatelli (2004).

Glomerulonephritis, tubulointerstitial nephritis, and nephropathy are common in CanL (De Oliveira Frazilio et al., 2018). Initially, glomerulonephritis may manifest as asymptomatic proteinuria (Koutinas and Koutinas, 2014; Paltrinieri et al., 2016), but with its progression, excretion dysfunction can occur in the presence of an increase or decrease in the glomerular filtration rate (GFR) and systemic hypertension (Plevraki et al., 2006; Cortadellas et al., 2008). An increase in GFR associated with hypertension can amplify glomerulopathy, resulting in the progression of CKD (Koutinas and Koutinas, 2014). End-stage CKD is a severe manifestation of disease progression and the leading cause of death in CanL. The two main parameters used to classify the degree of kidney disease in CanL, according to (Solano-Gallego et al., 2011; Laia et al., 2011), are UPC, used as a marker of glomerular pathology, and serum CR level, used as a marker of renal excretion (Torrent et al., 2018).

In 2019, IRIS included SDMA levels in the CKD staging of chronic kidney disease. SDMA is methylated arginine produced by cellular catabolism correlated with CREAT and GFR (Nabity et al., 2015). Several studies have demonstrated that SDMA levels are elevated in dogs with CKD (Hall et al., 2014; Nabity et al., 2015). Studies have suggested that SDMA levels also increase earlier than serum CR levels (Hall et al., 2014; Nabity et al., 2015) because its production is not influenced by the loss of muscle mass. SDMA showed a moderate correlation with UR and PH in T0. An increase in SDMA, UR, PH, and CR and a reduction in UR is expected as there is a worsening of renal excretion and a decrease in TGF.

There is a paucity of data on the behavior of SDMA in dogs naturally infected with *Leishmania* sp., with only four studies reported to date (Pardo-Marín et al., 2017; De Oliveira Frazilio et al., 2018; Torrent et al., 2018; Giapitzoglou et al., 2020). The serum concentration of SDMA is elevated mainly in azotemic dogs with severe proteinuria and decreased UR. D (Giapitzoglou et

al., 2020). SDMA correlated with CR and UR. D, a result like that obtained by (Giapitzoglou et al., 2020). A study carried out by (Torrent et al., 2018) found different results, without observing a correlation between SDMA and CR.

SDMA was also inversely correlated with the red RBC and HC. Kidneys perform numerous metabolic functions, including their contribution to erythropoiesis. Several factors contribute to anemia in patients with reduced GFR and CanL. The reduction of erythropoietin of renal origin is an important cause, but other mechanisms, such as anemia of inflammatory origin, the influence of uremic toxins on the survival time of the erythroid lineage, cofactor deficiency, blood loss due to various bleeding events, and parasitic destruction (Babitt and Lin, 2012; Fiocchi et al., 2017; Lippi et al., 2021).

There was a significant and progressive increase in the number of dogs with SDMA levels above the reference values (IRIS, 2023) as the stage progressed. The expected result of disease progression between stages demonstrated that SDMA could be used to classify CanL severity (Giapitzoglou et al., 2020). A different result was found by Torrent et al. (2018), who found no significant difference in the comparison between the stages (Solano-Gallego et al., 2011).

In this study, two dogs classified in stage IIa (non-proteinuric and non-azotemic) with elevated SDMA levels were observed. (Cortadellas et al., 2008) pointed out that dogs with CanL and UPC levels between 0.2 and 0.5 may have a decrease in GFR. Dogs with CanL may have some renal perfusion impairment secondary to hypovolemia, which could cause an increase in SDMA concentration without an association with proteinuria or renal azotemia. Torrent et al. (2018) suggested that dogs with CanL and changes in SDMA concentration without proteinuria should be carefully examined for pre-renal causes of impaired renal perfusion.

UPC was shown to be an earlier diagnostic sign of acute kidney injury (AKI) concerning SDMA in dogs naturally infected with *L. infantum* observed in this study, which is in line with other studies (Pardo-Marín et al., 2017; Torrent et al., 2018; Giapitzoglou et al., 2020). Glomerulonephritis is the main pathological event of nephropathy in CanL, and proteinuria is the primary laboratory alteration. However, glomerular pathology can cause a reduction in GFR and an increase in the serum concentrations of SDMA and CR (Koutinas and Koutinas, 2014; Paltrinieri et al., 2016)

When evaluated as prognostic markers and predictors of kidney injury and kidney failure, the UPC and SDMA levels did not show a statistically significant correlation. Pardo-Marín et al. (2017) identified a reduction in the concentration of UPC, however, they did not observe a decrease in the SDMA levels in dogs after leishmanicidal treatment. In this study, we observed a cor-



relation between SDMA (T0) and CR. U (T1) levels; however, as the dogs examined in this study underwent a treatment with immunotherapy, an improvement in GFR may have occurred after the reduction of the injury caused by CanL. Gouveia et al, 2021 found that immunotherapy with vaccines was the most effective treatment for negative serology in the ELISA and IFAT tests after the treatments compared to other treatments in the study. The decrease in the result in the serology may suggest a reduction in the production of antigen-antibody complexes influencing the GFR.

An increase in PROT and GL levels, associated with a decrease in AL levels, has been observed in several studies (Artan et al., 2006; Sales et al., 2017). This increase in PROT and the presence of hyperglobulinemia are considered to be among the most common alterations in CanL and may be associated with increased levels of anti-*Leishmania* antibodies, especially in severe stages of the disease (Castro et al., 2012; Freitas et al., 2012). However, hypoalbuminemia observed in animals may be due to the migration of albumin to the extravascular environment, with the formation of edema, a widespread clinical change in CanL (Silva, 2007; Freitas et al., 2012) and/or associated with an inflammatory process and/or albuminuria (Pierantozzi et al., 2013; Proverbio et al., 2016). Given the processes that occur during CanL due to the association of GL with the stimulation of B lymphocytes (Vieira et al., 2021), we can explain why the serum concentration of GL and PROT (T0) had a significant correlation with LE (T1). AL levels did not significantly correlate with any of the biomarkers.

The development of glomerulopathies not only leads to complications resulting from the accumulation of uremic toxins and fluid and electrolyte imbalances, but also causes systemic arterial hypertension, aggravating the clinical picture of patients and possibly compromising other organs, such as the heart (Schiffrin et al., 2007). In this study, seventeen (28%) dogs were identified with SBP above 160 mmHg. Out of these, seven (41%) were non-azotemic and non-proteinuric. Cortadellas et al. (2008) observed that 49.5% (52 / 105) of the dogs had some degree of renal disease, and 61.5% (32 / 52) of these dogs were diagnosed with systemic hypertension (SH). Moreover, SH also was diagnosed in 2% of dogs without renal disease. Braga et al. (2015) found that all dogs with hypertension had histopathological and laboratory evidence of glomerular disease. However, there was no statistically significant correlation between elevated BP and the severity of glomerular lesions.

This study found that SBP (T0) correlated with LE count (T1). CanL glomerulonephritis can form large antigen-antibody complexes, inciting inflammation and overloading of glomerular capillaries, resulting in obstruction that can further elevate glomerular pressure (Harrison et al., 2012). There is also



evidence that inflammatory cells accumulate in the perivascular region of the kidney (Theuer et al., 2002) also contributing to hypertension.

Unlike SBP, data in the literature cite the destruction of LE in uremic patients (Minnaganti and Cunha, 2001; Cohen and Hörl, 2012; Pahl et al., 2010). In this study, predictive factors of LE (T0) and HC (T1) concerning UR were observed through an inverse correlation. Uremia is associated with hematological abnormalities such as hemostatic, granulocytic, lymphocytic, and PL disorders, mainly caused by chemotaxis, phagocytosis, and oxidative abnormalities. Some diseases related to antigen presentation have also been reported in uremic patients (Minnaganti and Cunha, 2001; Cohen and Hörl, 2012) demonstrated that patients with renal failure had impaired body defense. Pahl et al. (2010) reported that the number of B lymphocytes and their ability to produce antibodies was reduced in patients with uremia. A study conducted on dogs infected with *Leishmania sp.*, showed more intense hematological alterations, such as profound anemia, thrombocytopenia, and leukopenia, characterizing pancytopenia associated with bone marrow hypoplasia or aplasia as a result of the invasion of the microorganism and immune-mediated processes (Paltrinieri et al., 2016). Hyperplasia and peripheral cytopenia can partially be attributed to the increased destruction of mature blood cells in the periphery. There are also morphologic features indicative of differentiation blockage and dyserythropoietic changes in the erythroid precursors (Poulaki et al., 2021)

HC (T0) also showed an inverse correlation with serum PROT (T1). Thus, the presence of leukopenia and anemia may indicate an initial process of immunosuppression and an increase in parasite load, which may lead to a change in hyperglobulinemia, an initial process of renal injury, and disease progression.

PH concentrations were also moderately correlated with UR and PTN levels. A study demonstrated an essential relationship between PH and proteinuria. When analyzing the renal protective response, it was found that for a reduction in proteinuria, a reduction in protein intake was not necessary, but a reduction in PH, either in its urinary excretion or serum concentration. Patients with low PH levels had the most significant decrease in proteinuria, regardless of UR excretion (a factor used to estimate protein intake) (Di Iorio et al., 2013).

Based on all findings and discussion it can be concluded that the most associated parameters are PL and SBP. In order to interpret the results and analyze the predictive factors and prognostic markers, we analyzed Figure 1 and isolated four patients who presented a negative evolution, starting from classification in stage IIa at T0 to stage IV at T1. Two patients developed thrombo-

cytopenia and systemic arterial hypertension at T0. Neither of the patients had proteinuria, azotemia, or hyperglobulinemia and had SDMA < 14µg/dL. The authors pointed out the importance of evaluating systemic hypertension and thrombocytopenia in dogs with *L. infantum* infection. The other two patients exhibited no changes in laboratory test results at T0. New studies should be carried out in order to evaluate PL and SBP as predictive factors and prognostic markers.

## CONCLUSIONS

PL was the primary physiological biomarker to demonstrate value as a predictive factor and prognostic marker being related to biomarkers of kidney injury as PH and UPC. It has been shown that SBP, LE, HC, PH and UR. D are predictive or prognostic markers in dogs infected with *L. infantum*. There was no advantage of SDMA over UPC for assessing kidney injury in dogs infected with *L. infantum* at the time of the study. SDMA and UPC didn't show significance as predictive or prognostic markers in dogs infected with *L. infantum*. It is concluded that the evaluation of thrombocytopenia is important in the evaluation of CanL, and its reversal corresponds to an improvement in the prognosis.

## Author's Contributions

FSM and APCV: data collection, analysis and experimental design. They conducted the gathered the necessary data and performed statistical analysis on the results; assisted in data interpretation and manuscript preparation. They contributed equally to the interpretation of the experimental results, helped in drafting the manuscript, and critically reviewed the content for accuracy and clarity. JCCV and VMR contributed to the theoretical framework and literature review.

## Competing interest

The author(s) declare that they have no competing interests.

## REFERENCES

1. Amusatogui I., Sainz A., Rodríguez F., Tesouro M.A. Distribution and relationships between clinical and biopathological parameters in ca-

- nine leishmaniasis. *Eur J Epidemiol* 18, 147–156 (2003). <https://doi.org/10.1023/A:1023090929302>
2. Araujo A.K.L. and Gondim A.L. de C.L. 2020. Use of Immunotherapy in the Treatment of Canine Visceral Leishmaniasis. *Acta Scientiae Veterinariae*, 48, 1–7. doi:10.22456/1679-9216.105438.
  3. Artan R., Yilmaz A., Akçam M., Aksoy N.H. 2006. Liver biopsy in the diagnosis of visceral leishmaniasis. *Journal of Gastroenterology and Hepatology*, 21, 1 Pt 2, 299–302. doi: 10.1111/j.1440-1746.2006.04172. x.
  4. Babitt J.L. and Lin H.Y. 2012. Mechanisms of anemia in CKD. *Journal of the American Society of Nephrology*, 23, 10, 1631–4. doi: 10.1681/ASN.2011111078.
  5. Bonfanti U., Zatelli A. Evaluation of proteinuria in leishmaniotic patient. In: *International Congress on Canine Leishmaniasis. Abstract book of the International congress on canine leishmaniasis.* p. 13-18, 2004.
  6. Braga E.T., Leite J.H.A. de C., Rosa F.A., Tivelli P., Araújo A.M., de Almeida B.F.M., Ferrari H.F., Ciarlini P.C., Machado G.F., Marcondes M. 2015. Hypertension and its correlation with renal lesions in dogs with leishmaniasis. *Revista Brasileira de Parasitologia Veterinária*, 24, 1, 45–51. doi: 10.1590/S1984-29612015007.
  7. Brasileish. 2019. Diretrizes para o diagnóstico, estadiamento, tratamento e prevenção da leishmaniose visceral canina. Available at <http://www.brasileish.com.br> . Accessed 15.12.2022.
  8. Brown S., Elliott J., Francey T., Polzin D., Vaden S. 2013. Consensus recommendations for standard therapy of glomerular disease in dogs. *Journal of Veterinary Internal Medicine*, 27 Suppl 1, S27–43. doi :10.1111/jvim.12230.
  9. de Carvalho Nicolato R., de Abreu R.T., Roatt B.M., de Oliveira Aguiar-Soares R.D., Reis L.E.S., Carvalho M das G, Carneiro C.M., Giunchetti R.C., Bouillet L.E.M., Lemos D.S., Coura-Vital W., Reis A.B. 2013. Clinical Forms of Canine Visceral Leishmaniasis in Naturally Leishmania infantum-Infected Dogs and Related Myelogram and Hemogram Changes. *PLoS One*, 8, 12, e82947. doi: 10.1371/journal.pone.0082947. eCollection 2013.
  10. Castro I.P., de Sousa M.V.C., Magalhães G.M., Mundim A.V., Noleto P.G., de Paula M.B.C., de Albuquerque Pajuaba Neto A., Medeiros A.A. 2012. Perfil hepático e protéico em cães com leishmaniose visceral. *Bioscience Journal*, 28,5, 799–804.
  11. Cohen G. and Hörl W.H. 2012. Immune Dysfunction in Uremia—An Update. *Toxins*, 2012, 4, 11, 962–90. doi: 10.3390/toxins4110962.

12. Cortadellas O., Fernández del Palacio M.J., Talavera J., Bayón A. 2008. Glomerular filtration rate in dogs with leishmaniasis and chronic kidney disease. *Journal of Veterinary Internal Medicine*, 22, 2, 293–300. doi: 10.1111/j.1939-1676.2008.0062. x.
13. da Costa-Val A.P., Cavalcanti R.R., de Figueiredo Gontijo N., Michalick M.S.M., Alexander B., Williams P., Melo M.N. 2007. Canine visceral leishmaniasis: relationships between clinical status, humoral immune response, haematology and *Lutzomyia (Lutzomyia) longipalpis* infectivity. *Veterinary Journal*, 174, 3, 636–43. doi: 10.1016/j.tvjl.2006.11.006. Epub 2007 Jan 16.
14. D'Amico G. and Bazzi C. 2003. Pathophysiology of proteinuria. *Kidney International*, 63, 3, 809–25. doi:10.1046/j.1523-1755.2003.00840. x.
15. Dantas-Torres F., Brandão-Filho S.P. 2006. Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control. *Revista do Instituto de Medicina Tropical de São Paulo*, 48, 3, 151–6. doi: 10.1590/S0036-46652006000300007.
16. Di Iorio B.R., Bellizzi V., Bellasi A., Torraca S., D'Arrigo G., Tripepi G., Zoccali C. Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients. *Nephrology Dialysis Transplantation*, Volume 28, Issue 3, March 2013, 632–640, <https://doi.org/10.1093/ndt/gfs477>
17. Fiocchi E.H., Cowgill L.D., Brown D.C., Markovich J.E., Tucker S., Labato M.A., Callan M.B. 2017. The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs. *Journal of Veterinary Internal Medicine*, 31, 2, 476–85. doi: 10.1111/jvim.14681. Epub 2017 Mar 3.
18. Freitas J.C.C de, Nunes-Pinheiro D.C.S., Lopes Neto B.E., Santos G.J.L., Abreu C.R.A. de, Braga R.R., Campos R. de M., Oliveira L.F. de. 2012. Clinical and laboratory alterations in dogs naturally infected by *Leishmania chagasi*. *Revista da Sociedade Brasileira de Medicina Tropical*, 45, 1, 24–9. doi: 10.1590/S0037-86822012000100006.
19. Giapitzoglou S., Saridomichelakis M.N., Leontides L.S., Kasabalis D., Chatzis M., Apostolidis K., Theodorou K., Roumpeas E., Mylonakis M.E. 2020. Evaluation of serum symmetric dimethylarginine as a biomarker of kidney disease in canine leishmaniosis due to *Leishmania infantum*. *Veterinary Parasitology*, 277, 109015. doi: 10.1016/j.vetpar.2019.109015. Epub 2019 Dec 18.
20. Giunchetti R.C., Mayrink W., Carneiro C.M., Corrêa-Oliveira R., Martins-Filho O.A., Marques M.J., Tafuri W.L., Reis A.B. 2008. Histopathological and immunohistochemical investigations of the hepatic compar-

- tment associated with parasitism and serum biochemical changes in canine visceral leishmaniasis. *Research in Veterinary Science*, 84, 2, 269–77. doi:10.1016/j.rvsc.2007.04.020. Epub 2007 Jun 29.
21. Gouveia E. M. M. F., da Fonseca A. L.S., Noe P., Onselen V. J. V. Evaluation of the effectiveness of three therapeutic protocols used in the treatment of visceral canine leishmaniosis. *International Journal for Innovation Education and Research*, 9, 3, 129–39. doi: 10.31686/ijer.vol9.iss3.2980.
  22. Hall J.A., Yerramilli M., Obare E., Yerramilli M., Jewell D.E. 2014. Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease. *Journal of Veterinary Internal Medicine*, 28, 6, 1676–83. doi: 10.1111/jvim.12445. Epub 2014 Sep 17.
  23. Harrison D.G., Marvar P.J., Titze J.M. 2012. Vascular inflammatory cells in hypertension. *Frontiers in Physiology*, 3, 128. doi: 10.3389/fphys.2012.00128.
  24. IRIS. 2023. International Renal Interest Society-IRIS staging of CKD, Available at <http://www.iris-kidney.com/guidelines/staging.html>. Accessed: 06.08.2023.
  25. Koutinas A.F. and Koutinas C.K. 2014. Pathologic Mechanisms Underlying the Clinical Findings in Canine Leishmaniosis due to *Leishmania infantum/chagasi*. *Veterinary Pathology*, 51, 2, 527–38. doi:10.1177/0300985814521248. Epub 2014 Feb 7.
  26. Lippi I., Perondi F., Lubas G., Gori E., Pierini A., D'Addetta A., Marchetti V. 2021. Erythrogram Patterns in Dogs with Chronic Kidney Disease. *Veterinary Sciences*, 8, 7, 123. doi: 10.3390/vetsci8070123.
  27. Maia C. and Campino L. 2018. Biomarkers Associated with *Leishmania infantum* Exposure, Infection, and Disease in Dogs. *Frontiers in Cellular and Infection Microbiology*, 8, 302. doi: 10.3389/fcimb.2018.00302.
  28. Marcondes M. and Day M.J. 2019. Current status and management of canine leishmaniasis in Latin America. *Research in Veterinary Science*, 123, 261–72. doi: 10.1016/j.rvsc.2019.01.022. Epub 2019 Jan 23.
  29. Minnaganti V.R. and Cunha B.A. 2001. Infections associated with uremia and dialysis. *Infectious Disease Clinics of North America*, 15, 2, 385–406. doi: 10.1016/s0891-5520(05)70152-5.
  30. Nabity M.B., Lees G.E., Boggess M.M., Yerramilli M., Obare E., Yerramilli M., Rakitin A., Aguiar J., Relford R. 2015. Symmetric Dimethylarginine Assay Validation, Stability, and Evaluation as a Marker for the Early Detection of Chronic Kidney Disease in Dogs. *Journal of Veterinary Internal Medicine*, 29, 4, 1036–44. doi: 10.1111/jvim.12835. Epub 2015 Jun 16.

31. do Nascimento L.F.M., de Moura L.D., Lima R.T., do Socorro Pires e Cruz M. 2018. Novos adjuvantes vacinais: importante ferramenta para imunoterapia da leishmaniose visceral. *Hu revista*, 44, 3, 401–10. doi: 10.34019/1982-8047.2018.v44.14123.
32. de Oliveira Frazilio F, de Almeida Borges F, de Souza A.I., Palumbo M.I.P., do Nascimento Ramos C.A., Freire D.H., Galvão A.L.B., de Freitas M.G., Barbosa F.B. 2018. Biomarkers and renal arterial resistive index in dogs naturally infected with *Leishmania infantum*. *Parasitology Research*, 117, 11, 3399–405. doi: 10.1007/s00436-018-6032-2. Epub 2018 Aug 1.
33. Pahl M.V., Gollapudi S., Sepassi L., Gollapudi P., Elahimehr R., Vaziri N.D. 2010. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. *Nephrology Dialysis Transplantation*, 25, 1, 205–12. doi: 10.1093/ndt/gfp397. Epub 2009 Aug 14.
34. Paltrinieri S., Gradoni L., Roura X., Zatelli A., Zini E. 2016. Laboratory tests for diagnosing and monitoring canine leishmaniasis. *Veterinary Clinical Pathology*, 45, 4, 552–78. doi: 10.1111/vcp.12413. Epub 2016 Nov 2.
35. Pardo-Marín L., Martínez-Subiela S., Pastor J., Tvarijonavičiute A., Garcia-Martinez J.D., Segarra S., Cerón J.J. 2017. Evaluation of various biomarkers for kidney monitoring during canine leishmaniosis treatment. *BMC Veterinary Research*, 13, 1, 31. doi: 10.1186/s12917-017-0956-0.
36. Pierantozzi M., Roura X., Paltrinieri S., Poggi M., Zatelli A. 2013. Variation of proteinuria in dogs with leishmaniasis treated with meglumine antimoniate and allopurinol: a retrospective study. *Journal of the American Animal Hospital Association*, 49, 4, 231–6. doi: 10.5326/JAAHA-MS-5840. Epub 2013 May 20.
37. Plevraki K., Koutinas A.F., Kaldrymidou H., Roumpies N., Papazoglou L.G., Saridomichelakis M.N., Savvas I., Leondides L. 2006. Effects of allopurinol treatment on the progression of chronic nephritis in Canine leishmaniosis (*Leishmania infantum*). *Journal of Veterinary Internal Medicine*, 20, 2, 228–33. doi: 10.1892/0891-6640(2006)20[228:eoatot]2.0.co;2.
38. Poulaki A., Piperaki E-T., Voulgarelis M. 2021. Effects of Visceralising *Leishmania* on the Spleen, Liver, and Bone Marrow: A Pathophysiological Perspective. *Microorganisms*, 9, 4. doi: 10.3390/microorganisms9040759.
39. Proverbio D., Spada E., de Giorgi G.B., Perego A.R. 2016. Proteinuria reduction after treatment with miltefosine and allopurinol in dogs naturally infected with leishmaniasis. *Veterinary World*, 9, 8, 904–8. doi: 10.14202/vetworld.2016.904-908. Epub 2016 Aug 26.
40. Ribeiro V.M., Bahia E.M., Teles P.P.A. 2013. Evaluation of immunotherapy assessment Leishtec R associated with allopurinol in dogs naturally infec-

- ted by *Leishmania infantum*-Preliminary Studies. In *Fifth world congress on leishmaniasis*, Porto de Galinhas, Pernambuco, Brasil.
41. Sales E.T., de Almeida G.K.G., de Oliveira A.R.F., Ferreira T.M.V., Freitas J.C.C., Nunes-Pinheiro D.C.S. 2017. Neutrofilia e hipoalbuminemia em sangue periférico de cães naturalmente infectados por *Leishmania infantum*. *Ciência Animal*, 27, 1 64-74.
  42. Santos F.N., Borja-Cabrera G.P., Miyashiro L.M., Grechi J., Reis A.B., Moreira M.A.B., Martins Filho O.A., Luvizotto M.C.R., Menz I., Pessôa L.M., Gonçalves P.R., Palatnik M., Palatnik-de-Sousa C.B. 2007. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine. *Vaccine*, 25, 33, 6176-90. doi: 10.1016/j.vaccine.2007.06.005. Epub 2007 Jun 21.
  43. Schiffrin E.L., Lipman M.L., Mann J.F.E. 2007. Chronic kidney disease: effects on the cardiovascular system. *Circulation*, 116, 1, 85-97. doi: 10.1161/CIRCULATIONAHA.106.678342.
  44. Soares M.J.V., Moraes J.R.E., Palmeira Borges V., Miyazato L.G., Moraes F.R. 2005. Renal involvement in visceral leishmaniasis dogs. *Journal of Venomous Animals and Toxins including Tropical Diseases*, 11, 4, 579-93. doi: 10.1590/S1678-91992005000400014.
  45. Solano-Gallego L., Koutinas A., Miró G., Cardoso L., Pennisi M.G., Ferrer L., Bourdeau P., Oliva G., Baneth G. 2009. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. *Veterinary Parasitology*, 165, 1-2, 1-18. doi: 10.1016/j.vetpar.2009.05.022. Epub 2009 Jun 6.
  46. Solano-Gallego L., Miró G., Koutinas A., Cardoso L., Pennisi M.G., Ferrer L., Bourdeau P., Oliva G., Baneth G., The LeishVet Group. 2011. LeishVet guidelines for the practical management of canine leishmaniosis. *Parasites & Vectors*, 4, 86. doi: 10.1186/1756-3305-4-86.
  47. Thrall M. A. 2007. *Hematologia e bioquímica clínica veterinária*, Editora Roca, ISBN 8572416684.
  48. Vilela J. A. R., Sandes Pires M., da Silva C.B., Peixoto M.P., Falqueto A., Santos H.A., Sanavria A., Massard C.L., Faccini J.L.H. 2013. Alterações clínico-hematológicas da infecção por *Babesia canis vogeli* em cães do município de Seropédica. *Revista Brasileira de Medicina Veterinária*, 35,1, 63-68.
  49. Theuer J., Dechend R., Muller D.N., Park J-K., Fiebeler A., Barta P., Ganten D., Haller H., Dietz R., Luft F.C. 2002. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. *BMC Cardiovascular Disorders*, 2, 3. doi: 10.1186/1471-2261-2-3.



50. The R Project for Statistical Computing. 2019. Available at <https://www.r-project.org/>. Accessed 15.12.2022.
51. Torrent E., Planellas M., Ordeix L., Pastor J., Rodon J., Solano-Gallego L. 2018. Serum Symmetric Dimethylarginine as an Early Marker of Excretory Dysfunction in Canine Leishmaniosis (*L. infantum*) Induced Nephropathy. *Veterinary Medicine International*. doi: 10.1155/2018/7517359.
52. Vieira M.S., Marcondes N.A., Spindler B.M., Olivo L.D., Fernandes F.B. 2021. Diagnóstico de leishmaniose visceral em Medula óssea a partir de suspeita de neoplasia maligna: relato de caso. *Hematology, Transfusion and Cell Therapy*, 43, S425. doi: 10.1016/j.htct.2021.10.729.

Received: 03.06.2023.

Accepted: 20.11.2023.



Original research article

UDK 598.112:616.98

<https://doi.org/10.46784/e-avm.v16i2.350>

## INFECTIOUS STOMATITIS IN CAPTIVE *SALVATOR MERIANAE* LIZARDS

Olga Luz Sánchez-Loria<sup>1\*</sup>, Fernando Horacio Campos-Casal<sup>1</sup>

<sup>1</sup>Universidad Nacional de Tucumán, Facultad de Agronomía, Zootecnia y Veterinaria. Cátedra de Biología del Desarrollo, Tucumán, Argentina.

### Abstract

Infectious stomatitis is a common ailment in captive reptiles, it arises from a combination of predisposing factors such as poor nutritional conditions, habitat issues or stress, where normal oral flora microorganisms act as pathogens, facilitating the disease development. This study aims to describe infectious stomatitis in a captive population of adult *Salvator merianae* lizards and to propose prophylactic measures for their maintenance in captivity. Within a population of 57 animals, a morbidity rate of 19.2% and a mortality rate of 7% were estimated. Microbiological analysis of oral mucosa revealed *Pseudomonas aeruginosa* susceptible to ceftazidime, ciprofloxacin, gentamicin, and amikacin. Symptoms ranged from asymptomatic to animals with mild oral cavity lesions or severe stomatitis, with some cases exhibiting respiratory complications. Histopathological examination of lung samples was consistent with caseous pneumonia. Intramuscular ceftazidime treatment and oral disinfection yielded excellent results for lizards with stomatitis, although a favorable response was not observed in animals with pneumonia.

**Key words:** Black and white tegu, caseous pneumonia, oral diseases, *Pseudomonas aeruginosa*, reptiles

---

<sup>1\*</sup> Corresponding Author: [olga.sanchezloria@faz.unt.edu.ar](mailto:olga.sanchezloria@faz.unt.edu.ar)

## INFEKTIVNI STOMATITIS KOD GUŠTERA VRSTE *SALVATOR MERIANAE* KOJI SE DRŽE U ZATOČENIŠTVU

Olga Luz Sánchez-Loria<sup>1\*</sup>, Fernando Horacio Campos-Casal<sup>1</sup>

<sup>1</sup> Nacionalni Univerzitet Tucumán, Fakultet za poljoprivredu, zootehniku  
i veterinu, Katedra za razvojnu biologiju, Tucumán, Argentina.

### Kratak sadržaj

Infektivni stomatitis je česta bolest kod gmizavaca koji se drže u zatočeništvu. Uzrokuje ga kombinacija predisponirajućih faktora kao što su loša ishrana, problemi sa staništem ili stres, gde normalni mikroorganizmi oralne flore deluju kao patogeni, što potpomaže razvoj bolesti. Ova studija ima za cilj da opiše infektivni stomatitis u populaciji odraslih guštera *Salvator merianae* koji se drže u zatočeništvu i da izloži predloge profilaktičkih mera za njihovo držanje u zatočeništvu. U okviru populacije od 57 životinja utvrđena je stopa morbiditeta od 19,2% i mortaliteta od 7%. Mikrobiološka analiza oralne sluzokože pokazala je prisustvo *Pseudomonas aeruginosa* koji je osetljiv na ceftazidim, ciprofloksacin, gentamicin i amikacin. Simptomi su bili raznoliki - od asimptomatskih životinja do onih koje su ispoljile simptome teškog stomatitisa, blage lezije usne duplje, a neke su imale i respiratorne komplikacije. Histopatološki pregled uzoraka pluća ukazao je na kazeoznu pneumoniju. Intramuskularni tretman ceftazidimom i oralna dezinfekcija dali su odlične rezultate za guštere sa stomatitisom. Međutim, nije primećen povoljan odgovor kod životinja sa pneumonijom.

**Cljučne reči:** Crni i beli tegu, kazeozna pneumonija, oralne bolesti, *Pseudomonas aeruginosa*, reptili

### INTRODUCTION

Adequate zootechnical management stands out as the most crucial factor for maintaining healthy reptiles bred in captivity. Inappropriate breeding conditions, such as overcrowding, nutritional deficiencies, infections, and parasitosis lead to stress-induced immunosuppression (Cobos and Ribas 1987; Meredith and Redrobe, 2012; Zhou et al., 2020; Tian et al., 2022). Numerous microorganisms constitute oral microbiota in reptiles. Nevertheless, disrup-

tions in the homeostasis of the immune response caused by the captive environment transform the commensal oral microbiota into opportunistic pathogens (Grego et al., 2017; Vega-Manriquez et al., 2018).

Infectious stomatitis, or “mouth rots,” is a common oral mucosa infection in reptiles bred in captivity. While this disease has been predominantly described in snakes (Peñuela Gomez and Brieva Rico, 2007; Rojas-Sereno et al., 2015; Martins et al., 2021), it also affects turtles and some lizard species (Herrera Ramírez, 2008; Pereira et al., 2021). Symptoms of this pathology include sialorrhea, petechiae, plaques around the lips and mouth, facial malformations, gingival abscesses, and teeth loss. In cases that are not promptly controlled, the exudate from ulcerative stomatitis may be swallowed or aspirated, leading to gastroenteritis or bacterial pneumonia. In severe cases, the pathogen may also enter the general circulation, causing septicemia and death (Cobos and Ribas 1987; Mader, 2006; Meredith and Redrobe, 2012; Rodríguez Molano, 2015; Pereira et al., 2021; Rojas-Sereno et al., 2015; Doneley et al., 2018).

In saurians, pathological processes tend to be multifactorial, slow-progressing, and challenging to diagnose due to their inherent resistance and ability to mask symptoms. For this reason, in most cases, diseases are detected at advanced stages, which complicates the success of treatment and, in the case of captive populations, epidemiological control (Mader, 2006; Meredith and Redrobe, 2012).

This study provides a detailed report on the clinical manifestations, lesions, and treatment in a captive population of *Salvator merianae* lizards with infectious stomatitis.

## MATERIALS AND METHODS

### *Animals*

The study included 57 adult individuals from the *Salvator merianae* lizard breeding facility at the Facultad de Agronomía, Zootecnia y Veterinaria of the Universidad Nacional de Tucumán, province of Tucumán, Argentina (26° 51'S and 65° 17'W). The animals were housed in open-air enclosures with masonry fences, equipped with shelters containing dry grass and shade. For the welfare of adult *Salvator merianae* individuals, the minimum living space of 2 m<sup>2</sup>, was provided (Manes, 2016). Ad-libitum feeding consisted of a diet specifically designed for this captive-bred species (Vega Parry and Manes, 2000). For individual health monitoring, radiofrequency identification devices (micro transponder ID-100, Trovan Electronic Identification, Rosenbusch, Buenos Aires, Argentina) were used.

All experiments, including all animal handling protocols, were carried out in accordance with the Principles of Laboratory Animal Care (National Institutes of Health, publication N° 85- 23, revised 1985), as well as specific national laws. All experiments were carried out and approved by the Ethics Committee of Consejo de Investigaciones de Universidad Nacional de Tucumán (CIUNT).

### ***Characterization of pathogens***

The samples from the buccal and gingival mucosa of animals exhibiting signs of advanced stomatitis were collected using swabs and transported and preserved in Stuart medium. Bacteriological culture and antibiogram testing were conducted using the agar diffusion method (Kirby-Bauer test).

### ***Histopathology***

Histopathological analysis of lung biopsies from recently deceased animals was performed using standard procedures, including fixation with 10% neutral buffered formalin, embedding, sectioning, and hematoxylin and eosin staining (Suvarna et al., 2018).

## **RESULTS**

### ***Epidemiology and clinical signs***

The disease affected both males and females. Out of a total number of 57 adult animals that were examined, 4 exhibited symptoms of advanced stomatitis, 7 showed signs of mild stomatitis, and another 4 were cases with respiratory and/or systemic complications. The remaining 42 animals did not show any lesions in the oral mucosa indicative of clinical stomatitis. As population indicators, the morbidity rate of stomatitis with clinical signs was estimated at 19.2%, with a mortality rate of 7%.

The 4 individuals with the signs of advanced stomatitis had petechiae and ecchymosis in the oral mucosa, periodontitis, they experienced loss of dental pieces, and granulomatous plaques in the oral and lingual mucosa. In some cases, these signs were accompanied by oral, ocular, or nasal discharge (Figure 1A).

The seven animals that manifested mild signs of stomatitis, had inflammation of the oral and gingival mucosa, but without hemorrhagic lesions or any type of plaques.

The 4 animals with severe stomatitis and caseous necrosis in the mouth and tongue died due to respiratory and systemic complications. Only two of them showed evident signs of respiratory distress with dyspnea, white foamy excretions, and loss of appetite. The other 2 did not show evident signs of respiratory complications, and the diagnosis was confirmed through post-mortem lesions (Figure 1B).




Figure 1. A. Adult female *S. merianae* lizard with stomatitis; arrow indicates granulomatous plaque on oral mucosa, asterisk indicates inflamed, congested, and ecchymotic area at oral commissure. B. Adult male *S. merianae* lizard with severe stomatitis; asterisk indicates apical region of the tongue and oral mucosa with caseous necrosis, arrow indicates granulomatous plaque on the body of the tongue.

### ***Macroscopic findings***

The necropsy of the recently deceased lizards revealed that the most affected organs were the lungs, although some macroscopic lesions were also found in the mouth, the fat bodies, and the liver. The fat bodies were notably congested and friable, with hemorrhagic lesions. Additionally, the friable liver had changed in its color. The lungs were the most affected organs, significantly hyperemic, and hemorrhagic with numerous pinpoint granulomatous plaques similar to those found in the oral cavity (Figure 2).




Figure 2. Lungs with numerous small granulomatous lesions (arrow).

### ***Histopathology findings***

In the submesothelial layer of the visceral serous tunic and the stroma of type III trabeculae in both lungs, inflammatory hyperplasia, characterized by the profusion of collagen fibers, was evident. Moreover, in the lumen of the pulmonary venules, there was a notable abundance of lymphocytes (Figure 3A). Necrotic lesions with infiltration of the pulmonary parenchyma and eosinophilic areas centrally located to the granulomatous lesion, composed of distinctive amorphous tissue of caseous necrosis, were also prominent (Figures 3B and 3C).






Figure 3. A. Detailed view of foveolar epithelium with marked hypertrophy of type III trabeculae (asterisks). Note the abundance of lymphocytes (arrow). NI, type I pneumocytes; NII, type II pneumocytes; E, erythrocytes. Scale bar 10 µm. B. Detailed view of visceral serous layer of the lung. Note the abundance of collagen fibers in the submesothelial layer (asterisks). Scale bar 10 µm. C. Lung section with granulomatous lesion (asterisk). Scale bar 50 µm. The insert shows characteristic necrotic tissue with absence of cellular boundaries and pyknotic nuclei. Scale bar 10 µm.

### ***Culturing and antibiogram***

Bacteriological culture of the oral mucosa of animals with the clinical disease revealed few Gram-positive cocci and few Gram-negative bacilli, as well as polymorphic nuclear cells. *Pseudomonas aeruginosa*, sensitive to antibiotics such as ceftazidime, ciprofloxacin, gentamicin, and amikacin, was isolated.

### ***Treatment and evolution of animals with clinical signs***

Based on the antibiogram results, intrinsic characteristics of each antibiotic (therapeutic margin, toxicity, duration of action, ease of application), and cost analysis, ceftazidime antibiotic therapy was chosen.

Animals with the signs of stomatitis with evident oral mucosa plaques and lesions underwent the following treatment: cleaning of wounds with 10 vol. hydrogen peroxide or 0.05% chlorhexidine and manual removal of oral plaques. Simultaneously, they were supplemented with 5000 IU of oral vitamin A once a week.

Depending on the characteristics of each patient and the severity of the clinical picture, between 3 and 6 applications of intramuscular ceftazidime at 30 mg/kg were performed every 72 hours until the reversal of symptoms.

In cases of mild or advanced stomatitis without respiratory complications, the treatment was highly effective, and the patient's evolution was favorable (Figure 4). However, in animals with clinical signs of pneumonia, the treatment was not effective.





Figure 4. Evolution of a stomatitis case: A and B. Initial state of oral wounds, left and right profiles, respectively. C. Oral wounds at 2 weeks after the start of treatment. Arrows indicate granulomatous plaques at both commissures, asterisk indicates petechiae. D. Resolution of oral wounds and patient's discharge 6 weeks after treatment initiation.

### ***Population Management Measures***

For metaphylactic treatment, the entire breeding stock received a single dose of 30 mg/kg of intramuscular ceftazidime. Weekly controls of the oral mucosa and body condition of 10 randomly selected animals were conducted for a month. When an individual showed any signs or suspected symptoms of stomatitis, it was isolated to start antibiotic treatment, vitamin A supplementation, and cleaning and disinfecting of the oral mucosa.

After a month, and in order to avoid stress from manipulation, inspections consisted of visual examination of animals in the corral, and only if suspicious, the animal was restrained for mucous membrane inspection. An animal was considered suspicious if it exhibited at least one of the following symptoms:

oral, ocular, or nasal discharge of any type, weight loss of body condition, or dehydration.

Sick or suspected animals were separated from the rest in an isolation area with the same shade, shelter, water, and ration conditions as the rest of the enclosures. Feeders, drinkers, and shelters throughout the breeding facility were disinfected with 0.1% sodium hypochlorite, and the substrate in all shelters was renewed.

## DISCUSSION

The oral and intestinal microbiota varies significantly among different groups of reptiles and is influenced by their habitat, physiology, and nutrition. Generally, the oral flora in saurians is primarily composed of Gram-negative bacteria, such as *Escherichia coli*, *Salmonella*, *Pseudomonas*, *Proteus*, and *Aeromonas* (Meredith and Redrobe, 2012; Tian et al., 2020, 2022). These bacteria can be isolated from both healthy and diseased animals. It is known that healthy reptiles can transmit *Salmonella* or *P. aeruginosa*, representing a major zoonotic risk associated with keeping reptiles (Meredith and Redrobe, 2012; Martins et al., 2021). This is the first study reporting *P. aeruginosa* as a potential opportunistic pathogen causing infectious stomatitis in *S. merianae*.

The clinical signs observed in our animals coincided with those reported for stomatitis in other captive reptiles (Cobos and Ribas 1987; Mader, 2006; Meredith and Redrobe, 2012; Rojas-Sereno, 2015; Hedley, 2016; Doneley et al., 2018; Pereira, 2021). The lesions found in the oral cavity of diseased animals were similar to those described for *Boa constrictor amarali* with caseous stomatitis caused by *P. aeruginosa* (Martins et al., 2021). In reptiles, pneumonia signs often appear late, when the infection is chronic with significant respiratory involvement (Mader, 2006; Rodríguez Molano, 2015). In most cases observed in this study, the condition was limited to oral infection. However, in animals with pneumonia, macroscopic and histopathological lesions were consistent with chronic inflammatory processes, characterized by a marked increase in collagen fibers and notable lymphocytic infiltration. Timely treatment with intramuscular ceftazidime every 72 hours and oral antiseptics proved to be the appropriate combination for treating stomatitis in *S. merianae*. The combination of clinical examination, oral culture and antibiogram, histopathology, and favorable response to treatment, enabled us to confirm the diagnosis without the need for more expensive complementary tests.

The incidence of bacterial diseases in captive lizards is often associated with a compromised immune system resulting from overcrowding, trauma, nutritional deficiencies, infections, and excessively low temperatures that can

predispose normal microbial flora to act as opportunistic pathogens (Mader, 2006; Hedley, 2016; Van Zanten and Simpson, 2021). Regarding predisposing factors, overcrowding and poor management as promoters of stomatitis were ruled out. Indeed, we have optimized the zootechnical management of captive *S. merianae*, as well as the breeding conditions in which these lizards are kept and reproduced. This includes spacious enclosures with over 2 m<sup>2</sup>/animal, shelters resembling their natural habitat, dirt floors for digging, and other elements of environmental enrichment (Manes, 2016; Van Zanten and Simpson, 2021). Although the animals are fed a diet specifically designed for this species (Vega Parry and Manes, 2000), maintaining a sustained mono diet for approximately 20 years, it is likely that they require supplementation of vitamins A, D, and E. Vitamin A deficiencies have been linked to stomatitis and inflammation of the upper respiratory tract (Herrera Ramírez, 2008; Rodríguez Molano, 2015). In this study, oral administration of vitamin A was chosen to coincide with the oral inspection of each patient, avoiding additional intramuscular injections that could be painful and stressful for the animal. Stress from increased frequency or duration of handling, including health management, predisposes the animals to illness and complicates the healing process (Doneley et al., 2018).

The immune response of reptiles is subjected to seasonal temperature-dependent alterations, with a maximum response observed when they are maintained near their preferred optimal body temperature (Mader, 2006; Doneley et al., 2018). Prolonged maintenance of reptiles at temperatures ranging from 15 °C to 21 °C predisposes them to opportunistic diseases. The innate and adaptive arms of the reptilian immune system are accepted to function optimally at the preferred body temperature of the animal. Many reptiles are kept at suboptimal temperatures, and simply warming them up can lead to significant improvements in their immunological defenses (Doneley et al., 2018). The monthly average temperature recorded in the region, where the breeding facility is located during the brumation period (May to September), was of 14.8 °C between 2018 and 2022 (EEAOC, 2023). This temperature would be at the limit of the suggested optimum for normal brumation (3.8 °C to 15 °C). Our results suggest that untimely winters with inappropriate temperatures for proper brumation may be a predisposing factor for stomatitis in captive *S. merianae*.

There is little knowledge about the immune system of reptiles. Some agents of reptiles are more or less infectious, but for most of them, the level of infectivity is unknown (Doneley et al., 2018). In our study, it is likely that *P. aeruginosa* acted as an opportunistic agent, and the great diversity of clinical

manifestations observed in our population may be attributed to the intrinsic immunity of each animal. The physiological state of each individual can impact susceptibility to diseases, even under similar captive conditions. Gravid females, males during breeding season, dominance of food sources, or other resources by enclosure mates, together with the effects of hierarchical stress, may predispose to illness (Meredith and Redrobe, 2012; Doneley et al., 2018).

## CONCLUSIONS

This article provides a detailed report of clinical manifestations and macroscopic and histopathological findings in a captive population of *S. merianae* lizards with stomatitis. Identification of each individual facilitated precise treatment monitoring and the evolution of each patient. Furthermore, periodic follow-ups within the population have allowed us to suggest sanitary management measures to reduce the prevalence of this disease in captive animals.

## ACKNOWLEDGEMENTS

This paper was funded by Secretaría de Ciencia, Arte e Innovación Tecnológica (SCAIT) of the Universidad Nacional de Tucumán. We are especially grateful to the technicians Roque Carranza and Juan Oliver for their help in the field work.

## Author's Contributions

OLSL: Animal management, diagnosis and treatment of patients, drafting the manuscript. FHCC: Histopathological analysis, drafting the manuscript.

## Competing interests

The author(s) declare that they have no competing interests.

## REFERENCES

1. Cobos R.M., Ribas R. 1987. Reptiles: tortugas, serpientes, lagartos. Revista de AVEPA, 7, 3, 133–150.
2. Doneley B., Monks D., Johnson, R., Carmel, B. 2018. Reptile medicine and surgery in clinical practice. John Wiley & Sons Ltd, UK, ISBN:9781118977675. doi: 10.1002/9781118977705.

3. EEAOC. 2023. Estación Experimental Agroindustrial Obispo Colombres. Available at: <https://www.eeaoc.gob.ar/servicios/> Accessed: 12 09. 2023.
4. Grego K.F., Carvalho M.P.N., Cunha M.P.V., Knöbl T., Pogliani F.C., Catão-Dias J. L., Sant'Anna, S.S., Ribeiro M.S., Sellera, F.P. 2017. Antimicrobial photodynamic therapy for infectious stomatitis in snakes: Clinical views and microbiological findings. Photodiagnosis and photodynamic therapy, 20, 196–200. doi:10.1016/j.pdpdt.2017.10.004.
5. Hedley J. 2016. Anatomy and Disorders of the Oral Cavity of Reptiles and Amphibians. The veterinary clinics of North America. Exotic animal practice, 19, 3, 689–706. doi:10.1016/j.cvex.2016.04.002.
6. Herrera Ramírez J. R. 2008. Estudio patológico retrospectivo de mortalidad en reptiles del zoológico Jaime Duque entre el año 1991 y el 2006. Thesis. Universidad de La Salle, Ciencia Unisalle. Medicina Veterinaria, Facultad de Ciencias Agropecuarias.
7. Mader D.R. 2006. Reptile Medicine and Surgery, Elsevier, St. Louis, Mo., 2nd ed., ISBN 9780721693279. doi: 10.1016/B0-7216-9327-X/X5001-9.
8. Manes M.E. 2016. Lagartos Tejú: fundamentos de la crianza productiva. Universidad Nacional de Tucumán. Tucumán, Argentina, Facultad de Agronomía y Zootecnia. 1st ed., ISBN 978-987-754-034-5.
9. Meredith A., Redrobe S. 2012. Manual de animales exóticos, Lexus Editores, Argentina, 4th ed, ISBN: 9788487736636.
10. Martins N., Arthur L., Ferreira R., Queiroz C., Buiatte A., Monteiro A., Rocha de Souza R., Oliveira W.J., Santos A. 2021. Caseous stomatitis caused by *Pseudomonas aeruginosa* in *Boa constrictor amarali*. Acta Scientiae Veterinariae, 49, 1, 615. doi:10.22456/1679-9216.105257.
11. Peñuela Gomez S.M., Brieva Rico C.A. 2007. Review of ulcerative stomatitis in snakes. Revista de la Facultad de Medicina Veterinaria y de Zootecnia, 54, 1, 43-49.
12. Pereira L.M., Prazeres Junior F.R., de Oliviera Curgel J.V., Santana V.S., Mayer L.L., da Silva Pereira A.W., de Medeiros M.O., Freitas C.I.A. 2021. Ozonized water used as complementary therapy for stomatitis in *Salvator merianae* – case report. Research, Society and Development. 10, 11, e280101119550. doi: 10.33448/rsd-v10i11.19550.
13. Rodríguez Molano H.R. 2015. Manual de diagnóstico y tratamiento de neumonías en saurios y quelonios, mantenidos como mascotas no convencionales. Thesis, Universidad de La Salle Ciencia Unisalle, Medicina Veterinaria, Facultad de Ciencias.

14. Rojas-Sereno Z., Gómez-Acosta X., Brieva-Rico C. 2015. Estomatitis ulcerativa infecciosa como consecuencia de un traumatismo en una Boa constrictor con desarrollo de neumonía bacteriana y septicemia. Memorias de la conferencia interna en medicina y aprovechamiento de fauna silvestre, Exótica Y No Convencional, 11, 2, 32–43.
15. Suvarna K.S., Layton C., Bancroft J.D. 2018. Bancroft's theory and practice of histological techniques. Elsevier, China, 8 ed., ISBN 9780702068645.
16. Tian Z., Gou D., Wu Y., Guo P. 2020. Gut and oral bacterial diversity of the lizard *Diploderma splendidum* investigated using metagenomic analysis. doi: 10.21203/rs.3.rs-128688/v1.
17. Tian Z., Pu H., Cai D., Luo G., Zhao L., Li K., Zou J., Zhao X., Yu M., Wu, Y., Yang, T., Guo, P., Hu, X. 2022. Characterization of the bacterial microbiota in different gut and oral compartments of splendid japalure (*Japalura sensu lato*). BMC veterinary research, 18, 1, 205. doi:10.1186/s12917-022-03300-w.
18. Van Zanten T.C., Simpson S.C. 2021. Managing the Health of Captive Groups of Reptiles and Amphibians. The veterinary clinics of North America. Exotic animal practice, 24, 3, 609–645. doi: 10.1016/j.cvex.2021.05.005.
19. Vega-Manriquez D.X., Dávila-Arellano R.P., Eslava-Campos C.A., Salazar Jiménez E., Negrete-Philipp, A.C., Raigoza-Figueras R. Muñoz-Tenería, F.A. 2018. Identification of bacteria present in ulcerative stomatitis lesions of captive sea turtles *Chelonia mydas*. Veterinary research communications, 42, 3, 251–254. doi: 10.1007/s11259-018-9728-y.
20. Vega Parry H.E., Manes M.E. 2000. Alimentación de lagartos overos *Tupinambis merianae* con subproductos avícolas. Revista Argentina de Producción Animal, 20, 2, 135–143.
21. Zhou J., Zhao Y.T., Dai Y.Y., Jiang Y.J., Lin L.H., Li H., Li P., Qu Y.F., Ji X. 2020. Captivity affects diversity, abundance, and functional pathways of gut microbiota in the northern grass lizard *Takydromus septentrionalis*. Microbiology Open, 9, 9, e1095. doi:10.1002/mbo3.1095.

Received: 27. 09.2023.

Accepted: 27.11.2023.



Case report

UDK 636.8:618.2

<https://doi.org/10.46784/e-avm.v16i2.329>

## ECTOPIC PRIMARY ABDOMINAL PREGNANCY IN A PERSIAN CAT

Ashraf M. Abu-Seida<sup>1\*</sup>

<sup>1</sup> Department of Surgery, Anesthesiology and Radiology, Faculty  
of Veterinary Medicine, Cairo University, Giza, Egypt

### Abstract

Ectopic pregnancies are common in human medicine, while they are rarely recorded in animals. This report describes a case of 2.5-year-old ectopic primary abdominal pregnancy in a 7-year-old Persian cat. The cat was admitted to the surgery clinic for routine ovariohysterectomy with no characteristic clinical symptoms. During surgery, ovaries, uterus and ligaments were normal, like in a non-pregnant cat. Four intra-abdominal fetuses of different developmental stages were found and carefully removed. Three fetuses were found free in the abdomen inside their gestational sacs. The fourth fetus was covered with omentum and had no gestational sac. The gestational sacs had different sizes (2-8 cm in diameter). Two of the fetuses were fully-haired with normal position of limbs. No complications were recorded during the surgery and 10 months post-operative. This case report adds to the database of ectopic pregnancies in cats and further illustrates their incidental nature.

**Key words:** Abdominal pregnancy, cat, ectopic pregnancy, fetuses, ovariohysterectomy.

---

<sup>1\*</sup> Corresponding Author: [ashrafseida@cu.edu.eg](mailto:ashrafseida@cu.edu.eg)

## VANMATERIČNI PRIMARNI ABDOMINALNI GRAVIDITET KOD PERSIJSKE MAČKE

Ashraf M. Abu-Seida<sup>1</sup>

<sup>1</sup>Departman za hirurgiju, anesteziologiju i radiologiju, Fakultet veterinarske Medicine, Univerzitet Kairo, Giza, Egipat

### Kratak sadržaj

Vanmaterične trudnoće su česte u humanoj medicini, dok se retko beleže kod životinja. Ovaj izveštaj opisuje slučaj 2,5-godišnjeg vanmateričnog primarnog abdominalnog graviditeta kod 7-godišnje persijske mačke. Mačka je primljena na Kliniku za hirurgiju radi rutinske ovariohisterektomije bez karakterističnih kliničkih simptoma. Tokom operacije jajnici, maternica i ligamenti bili su normalni, kao kod mačke koja nije gravidna. Pronađena su i pažljivo izvađena četiri intraabdominalna fetusa različitih razvojnih stadijuma. Tri fetusa pronadena su slobodna u abdomenu unutar svojih gestacijskih vrećica. Četvrti fetus bio je prekriven omentumom i nije imao gestacijsku vreću. Gestacijske vreće bile su različite veličine (2-8 cm u promeru). Dva fetusa su bila sa potpuno formiranim dlačnim pokrivačem s normalnim položajem udova. Tokom operacije i 10 meseci nakon operacije nisu zabeležene komplikacije. Ovaj prikaz slučaja predstavlja dodatni podatak za bazu podataka o vanmateričnom graviditetu kod mačaka i dodatno ilustruje njihovu slučajnu prirodu.

**Cljučne reči:** Abdominalni graviditet, mačka, vanmaterični graviditet, fetusi, ovariohisterektomija

### INTRODUCTION

Ectopic pregnancy refers to a pregnancy occurring outside of the cavity of the uterus. While this disorder is common in humans, it is rarely recorded in animals (Vidiastuti et al., 2022). Ectopic pregnancies are classified according to the site of implantation and they can be abdominal and tubal pregnancies. The etiology and pathogenesis of ectopic pregnancy are not always clearly defined (Chong, 2017; Zheng et al., 2018; Jiasan et al., 2019).

Abdominal pregnancies are also subdivided into primary and secondary



forms. The primary form occurs when fertilized oocytes are released into the abdomen and implanted on the abdomen (Osenko and Tarello, 2014; Zheng et al., 2018; Vidiastuti et al., 2022). Secondary form occurs when a pregnant uterus is ruptured due to trauma or wounds and the fetuses are released into the abdominal cavity where they continue their development (Tirgari, 1986; Findik et al., 1998; Ivanova et al., 2019). Differentiation between primary and secondary extra-uterine pregnancies is controversial due to the presence of an intact (Dzięcioł et al., 2012), altered (Kumru et al., 2007) or partially missing reproductive system (Johnston et al., 1983). Consequently, the absence of signs of uterine rupture is one of the most important inclusion criteria for the diagnosis of primary extra-uterine pregnancies in cats (Osenko and Tarello, 2014).

Diagnosis of ectopic pregnancy is based mainly using X-ray (Johnston et al., 1983; Osenko and Tarello, 2014; Mirsepehr et al., 2015), ultrasound (Findik et al., 1998; Mirsepehr et al., 2015; Vidiastuti et al., 2022) and exploratory laparotomy (Bodle, 1979; Tirgari, 1986). Nevertheless, several cases of ectopic pregnancies were recorded in cats as an accidental finding during routine clinical examination or radiography (Mirsepehr et al., 2015; Chong, 2017; Ivanova et al., 2019). Moreover, the histological examination of the ectopic fetuses did not definitively prove their extra-uterine development (Rosset et al., 2011).

Death of the abdominal fetuses is a typical outcome of recorded ectopic pregnancies in cats due to insufficient nutrition resulting from a lack of adequate blood supply inside the abdomen (Mirsepehr et al., 2015; Chong, 2017; Zheng et al., 2018). Therefore, laparotomy, removal of the ectopic fetuses and ovariohysterectomy are usually performed for treatment and prevention of recurrence of ectopic pregnancies in cats (Mirsepehr et al., 2015; Chong, 2017; Zheng et al., 2018; Ivanova et al., 2019). Nevertheless, spontaneous resolution of early ectopic pregnancies may occur, suggesting that many diagnosed cases in early stages require no treatment at all (Mirsepehr et al., 2015; Chong, 2017).

Ectopic pregnancy in cats has been recorded in the veterinary literature. However, it is quite uncommon, as shown in Table 1. Therefore, this case report adds to the available database of ectopic pregnancies in cats and further explains their accidental nature.

Table 1. Types of ectopic pregnancies recorded in different breeds of cats and characters of the ectopic fetuses

<b>Age/Breed</b>	<b>Type of ectopic pregnancy</b>	<b>Characters of the fetuses</b>	<b>Reference</b>
A 3-year-old Persian cat	Primary abdominal pregnancy	One mummified fetus, 7.25 x 4.74 cm	Vidiastuti et al. (2022)
Two European shorthair cats	Secondary abdominal pregnancies	Three fetuses, 3 cm in diameter Two, 6 x 3.5 cm and 5 x 4.5 cm	Ivanova et al. (2019)
A British shorthair	Tubal pregnancy	One fetus, not identified	Jiasan et al. (2019)
Unidentified cat	Primary abdominal pregnancy	One calcified fetus, 4 cm in diameter	Zheng et al. (2018)
A British shorthair cat	Tubal pregnancy	One immature fetus, unidentified size	
A domestic, short-haired cat	Secondary abdominal pregnancy	Two fetuses, 10 cm from crown to rump	Chong (2017)
A domestic short-haired cat	Secondary abdominal pregnancy	Three fetuses, fully developed	Mirsepehr et al. (2015)
A domestic short haired spayed cat	Primary abdominal pregnancy	Three calcified fetuses, 4-5 cm in size	Osenko and Tarello (2014)
A domestic shorthair	Secondary abdominal pregnancies	Two fetuses, different stages of development	Dzięcioł et al. (2012)
Unidentified cat		One outside the uterus and one inside, 30-35 days pregnancy	
A 1.5-year-old domestic short-haired cat	Secondary abdominal pregnancies	One mummified fetus, 7 cm in length	Rosset et al. (2011)
A 2-year-old crossbreed free-roaming cat	Secondary abdominal pregnancies	One dead fetus at 55 days' gestation	Kumru et al. (2007)
Angora cat	Secondary abdominal pregnancy	One fetus, 6 x 2.5 cm	Findik et al. (1998)
A 2.5-year-old short-haired cat	Secondary abdominal pregnancy	One encapsulated fetus, 7 x 4 x 4 cm and one embedded in the omentum, 7.5 x 3 cm	Tirgari (1986)

<b>Age/Breed</b>	<b>Type of ectopic pregnancy</b>	<b>Characters of the fetuses</b>	<b>Reference</b>
A 2.5- year-old domestic short-haired cat	Secondary abdominal pregnancy	Two necrotic fetuses, 7 x 4 cm	Johnston et al. (1983)
Unidentified cat	Primary abdominal pregnancy	Three mummified fetuses, 2,3 and 6 cm in diameter	Bodle (1979)

## CASE PRESENTATION

This study was approved by the ethical committee at Faculty of Veterinary Medicine, Cairo University, Egypt. The cat was treated in accordance with guidelines established by the international and institutional Animal Care and Use Committees.

A seven-year-old Persian cat was brought to the veterinary clinic for routine ovariohysterectomy. The owner adopted the cat when it was 2.5 years old from the street. The cat showed normal sings of regular estrous cycles. Detailed history of previous pregnancies could not be obtained. During the preoperative examination, two large intra-abdominal hard masses were palpated in the middle abdomen and no other abnormalities were detected. The masses were freely mobile inside the abdominal cavity.

The cat was given general anesthetic for ovariohysterectomy and exploratory laparotomy. During surgery, three freely movable encapsulated intra-abdominal masses were found and easily removed. A fourth mass covered with omentum was also removed by careful blunt dissection. The ovaries, uterus and ligaments had normal appearance without any abnormalities. Ovariohysterectomy was carried out according to a standard procedure. Prior to closing, the abdominal cavity was thoroughly examined and washed with sterile warm normal saline solution. The cat was monitored for 10 months after surgery. A successful recovery without any complications was reported.

The dimensions of the removed masses were 8 x 5 x 4 cm, 6 x 5 x 3cm, 4 x 2 x 2 cm and 1.5 x 1 x 0.5 cm as shown in Figure 1. Three of these masses were covered with calcified sacs while the fourth mass was covered with omentum and had no sac. After opening the sacs of the three masses and removal of the omental tissue from the fourth mass, four mummified and calcified fetuses were found. Two fetuses were well-developed, fully haired and had normal positions of limbs (Figure 2). One of the well-developed fetuses had a normal body, while the second one had open abdomen without viscera as shown in Figure 2.




Figure 1. Four masses of different sizes were removed from the abdominal cavity of the cat. Note that three of them were encapsulated by gestational sacs and one embedded in the omentum.



Figure 2. Four ectopic fetuses at different stages of development were identified after opening the gestational sacs and removal of the omentum.

## DISCUSSION

While ectopic pregnancy is a common pathology in humans, it is still rarely recorded in veterinary literature. No detailed epidemiological studies on ectopic pregnancy have been conducted on animals, particularly cats. Cats are less likely to have ectopic pregnancy due to a difference in their endotheliochorial placentation (Zheng et al., 2018). This report describes a rare case of long-standing (> 2.5 years) ectopic primary abdominal pregnancy in a Persian cat.

Diagnosis of this case depended on the case history and findings of the clinical examination as well as laparotomy. In addition, abdominal ectopic pregnancy is truly primary when placentation presents onto a peritoneal or omental surface (Zheng et al., 2018; Vidiastuti et al., 2022), as in the current case. The differences between this case and other recorded ectopic pregnancy cases in cats are the number (N = 4) and different developmental stages of the ectopic fetuses as shown in Table 1.

Regarding the cat breed, domestic short-haired cats were the most commonly affected breed with ectopic pregnancies as shown in Table 1. However, the reported cat in this case study is a Persian cat. Similarly, a Persian cat with ectopic pregnancy was recently diagnosed by Vidiastuti et al. (2022).

Similar to the current cat, cats with ectopic pregnancy generally exhibit no clear clinical signs due to the aseptic condition of the ectopic fetuses which can remain within the animal's body for months or even years without complications (> 2.5 years). This is in agreement with the previously reported results by other authors (Dzięcioł et al., 2012; Zheng et al., 2018). Nevertheless, some cats with ectopic pregnancies, particularly secondary abdominal ectopic pregnancies, show various clinical signs such as loss of appetite, fever, vomiting, vaginal bleeding and peritonitis (Rosset et al., 2011; Dzięcioł et al., 2012; Mirsepehr et al., 2015). In other cases, particularly in primary abdominal ectopic pregnancies, cats have no clinical signs and they are detected during abdominal radiography or routine spaying as in the current case. Similar findings have been recorded before (Osenko and Tarello, 2014; Ivanova et al., 2019; Vidiastuti et al., 2022). Therefore, ectopic pregnancy may be detected as an incidental finding during clinical examination prior to ovariohysterectomy, like in the present case. The lack of associated clinical signs appears to demonstrate that such pregnancy is compatible with a normal healthy life in cats. Similar finding was confirmed by other authors (Chong, 2017; Zheng et al., 2018; Ivanova et al., 2019).

In the present case, only two of the four fetuses were palpable prior to the surgery. This could be attributed to the small size of the other two fetuses. This

finding is similar to the findings of other recorded cases of ectopic pregnancies in cats (Dzięcioł et al., 2012; Osenko and Tarello, 2014; Zheng et al., 2018; Ivanova et al., 2019). Therefore, radiography and ultrasonography examinations are useful tools for diagnosis of this problem in cats (Osenko and Tarello, 2014; Zheng et al., 2018). The main limitation in the present case report is the lack of radiography and ultrasonography examinations due to their unavailability at the time of examination.

During surgery, the uterus, ovaries and ligaments were normal in the present case. Therefore, it was diagnosed as primary abdominal pregnancy. Similar findings were recorded by other authors (Zheng et al., 2018; Ivanova et al., 2019). Unlike in these findings, ectopic abdominal fetuses secondary to trauma were observed in cats with multiple uterine abnormalities (Johnston et al., 1983; Dzięcioł et al., 2012; Chong, 2017). Moreover, Zheng et al. (2018) and Jiasan et al. (2019) diagnosed tubal ectopic pregnancy in the fallopian tubes of cats, and Osenko and Tarello (2014) recorded a case of ectopic pregnancy in a spayed cat at necropsy.

In the current case, laparotomy, removal of the ectopic fetuses and ovariohysterectomy were performed for treatment and prevention of recurrence of ectopic pregnancy. The surgeries were simple and without any early or late complications. This can be explained by the lack of attachment of the fetuses to any of the internal organs. These findings are in accordance with the findings of other authors (Mirsepehr et al., 2015; Chong, 2017; Zheng et al., 2018; Ivanova et al., 2019).

The number of extra-uterine fetuses ranged between one and three as shown in Table 1. The cat had four extra-uterine fetuses. According to the available literature, this is the largest number of extra-uterine fetuses recorded in cats to this day. In addition, the removed fetuses here were grown to different stages of development. The difference in developmental stages of the removed fetuses can be explained by the difference in the time of death of each fetus. Therefore, there was a variation in the size of the removed ectopic fetuses. Development of abdominal fetuses to advanced stages without an elaborated placentation has been recorded previously in cats (Mirsepehr et al., 2015).

According to Knospe (2002), the removed ectopic fetuses died between three and eight weeks of gestation. At 60 days of gestation, pigmentation can occur on the skin, hair, and nails, the brain and bones ossification also are present at this time. Signs of fetal mummification and calcification were observed in all ectopic fetuses. This is the common end of all recorded cases of ectopic pregnancies in cats due to malnutrition of the ectopic fetuses (Mirsepehr et al., 2015).



## CONCLUSION

This is an interesting rare case of long-lasting ectopic primary abdominal pregnancy in a Persian cat. Four extra-uterine fetuses at different stages of development were present inside the abdomen for more than 2.5 years without any clinical signs or complications.

## Competing interest

The author declares no conflicts of interest affecting the work reported in this paper. This research received no external funding.

## REFERENCES

1. Bodle T.J. 1979. Ectopic pregnancy in a cat. *New Zealand Veterinary Journal*, 27, 279. doi:10.1080/00480169.1979.34673.
2. Chong A. 2017. A case of feline ectopic abdominal fetuses secondary to trauma. *The Canadian Veterinary Journal*, 58, 4, 400-402.
3. Dzięcioł M., Nizański W., Ochota M., Błasiak K., Kozdrowski R., Stanczyk E., Twardon J. 2012. Two separate cases of extrauterine pregnancy in queens. *Electronic Journal of Polish Agricultural Universities. Series Veterinary Medicine*, 15: 2.
4. Findik M., Vural O., Beşal T.Y., Gülbahar M. 1998. Secondary ectopic pregnancy in an Angora cat: A case report. *Ankara Üniversitesi Veteriner Fakültesi Dergisi*, 45, 239-241. doi:10.1501/Vetfak\_0000000600.
5. Ivanova M., Ivanova C., Marinkov T., Georgiev P. 2019. Two cases of ectopic abdominal pregnancy in queens. *Tradition and Modernity in Veterinary Medicine*, 4, 2, 21-25. doi:10.5281/zenodo.3066338.svg.
6. Jiasan Z., Tingting Z., Zheng W., Jiaren Z. 2019. Pathological analysis of feline fallopian tubal ectopic pregnancy. *Acta Veterinaria et Zootechnica Sinica*, 50, 9, 1936-1939. doi: 10.11843/j.issn.0366-6964.2019.09.023.
7. Johnston S.D., Harish G., Stevens J.B., Scheffler H.G. 1983. Ectopic pregnancy with uterine horn encapsulation in a cat. *Journal of the American Veterinary Medical Association*, 183, 9, 1001-1002.
8. Knospe C. 2002. Periods and stages of the prenatal development of the domestic cat. *Anatomia, Histologia, Embryologia*, 31, 1, 37-51. doi: 10.1046/j.1439-0264.2002.00360.x.
9. Kumru H., Seyrek-Intas K., Tuna B., Celimli N., Seyrek-Intas D. 2007. Severe abdominal dog bite wounds in a pregnant cat. *Journal of Feline Medicine and Surgery*, 9, 6, 499-502. doi: 10.1016/j.jfms.2007.03.011.

10. Mirsepehr P., Asheghian I., Hajinasrollah M., Javadi S.R., Bashiri A.R., Esmailinejad M.R., Taghipour H., Mojtahedzade S.M. 2015. Accidental finding of ectopic pregnancy in a cat with presence of three fetuses without gestational sac that were attached to the abdominal wall and mesentery (A case report). *International Journal of Advanced Biological and Biomedical Research*, 3, 3, 217-221.
11. Osenko A., Tarello W. 2014. A 7-year-old extrauterine pregnancy in a cat. *Case Reports in Veterinary Medicine*, Article ID: 145064. doi:10.1155/2014/145064.
12. Rosset E., Galet C., Buff S. 2011. A case report of an ectopic fetus in a cat. *Journal of Feline Medicine and Surgery*, 13, 610-613. doi:10.1016/j.jfms.2011.04.003.
13. Tirgari M. 1986. Secondary ectopic pregnancy in a cat: a case report. *Journal of Small Animal Practice*, 27, 6, 383-385. doi:10.1111/j.1748-5827.1986.tb02152.x.
14. Vidiastuti D., Fauzi A., Noviatri A. 2022. Feline extrauterine pregnancy (EUP) in Persian cat with fetal mummification: a case study. *Journal of Experimental Biology and Agricultural Sciences*, 10, 3, 633-637. doi:10.18006/2022.10(3).633.637.
15. Zheng J.S., Wang Z., Zhang J.R., Qiu S., Wei R.Y., Nie J., Zhu T.T. 2018. Ectopic pregnancy in two cats. *Acta Scientiae Veterinariae*, 46, 5. doi:10.22456/1679-9216.85155.

Received: 25.06.2023.

Accepted: 01.10.2023.



## **Note for Contributors**

**ARCHIVES OF VETERINARY MEDICINE (AVM)** is a journal of the Scientific Veterinary Institute “Novi Sad” in Novi Sad. The journal publishes original research papers and review articles, short communications and case reports. The journal is devoted to the advancement and dissemination of scientific knowledge concerning veterinary sciences, biotechnology and related academic disciplines. The journal is published in the English language, with an abstract in English and Serbian language. All manuscripts are sent for a review and evaluation. In the case the reviewer suggests additional changes, the manuscript will be sent to the first author with a kind request to change the manuscript. In the case the author does not want to change, appropriate argumentation should be given. Final decision on accepting the manuscript is given by the Editor in Chief or Deputy Editor.

By submitting a manuscript, Authors warrant that their contribution to the Journal is their original work, that it has not been published before, that it is not under consideration for publication elsewhere, and that its publication has been approved by all co-authors, if any, and tacitly or explicitly by the responsible authorities at the institution where the work was carried out. Authors are exclusively responsible for the contents of their submissions, the validity of the experimental results and must make sure they have permission from all involved parties to make the data public. Authors wishing to include figures or text passages that have already been published elsewhere are required to obtain permission from the copyright holder(s) and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the Authors. Authors must make sure that only contributors who have significantly contributed to the submission are listed as authors and, conversely, that all contributors who have significantly contributed to the submission are listed as authors.

Peer review process is managed electronically. Authors have the possibility to provide the contact details of one or two potential peer reviewers, but the final decision on the choice of reviewers is on Editor decision without any obligation to contact any of the Author-recommended peer reviewers. The Editor nominates peer reviewers (at least two). The submitted manuscripts are sent to the reviewers together with the instructions for reviewers and accompanying reviewers' evaluation form. Acceptance of the manuscript is based on the reviews and on the final decisions of the reviewers regarding the acceptability of the manuscript. A reviewer's decision is one of following: “Accepted as it is”, “Accepted after minor revision”, “Accepted after major compulsory revision” or “Rejected”. If there is marked discrepancy in the decisions between the reviewers, the Editor can send the manuscript to another reviewer for additional comments and further decision, or make the decision based on the existing information.

Names of the reviewers are not transmitted to the author (single blind review). The peer review process is expected, in general, to start within two weeks after the submission of the manuscript. The Corresponding Author must indicate clearly in a separate letter what corrections have been made in response to the reviewers' comments point by point, and giving the relevant new line numbers using *Final show markup* view under Track Changes in MS Word Review ribbon. Corrected manuscripts are expected to be returned within three weeks. Accepted manuscripts are published on <https://niv.ns.ac.rs/e-avm/index.php/e-avm/issue/current> and then selected for a subsequent print issue.

The Journal *Archives of Veterinary Medicine* (AVM) uses open-source software for the management of peer-reviewed academic journals, the *Open Journal System* (OJS), created by the Public Knowledge Project (PKP), released under the GNU General Public License. Instructions for the submission using OJS 3.0 are available on the Open Journal Systems web page (OJS 3.0 User Guide" © by PKP <https://openjournal-systems.com/ojs-3-user-guide/>).

### General notes

The manuscript must be written in clear and concise English, and should be checked by a native-English speaker or certified English instructor with a good understanding of scientific terminology. The complete manuscript must be prepared according to instructions given in this section. Please read all instructions carefully. A manuscript that has not been prepared in accordance with the Journal's instructions for authors will not be considered for review.

All manuscripts submitted to *Archives of Veterinary Medicine*, must be accompanied by a Cover letter (see below). Also, authors are required to submit a scanned copy of the signed original, Competing interests, Authors contribution, and License to Publish which can be downloaded from the Journal homepage (see below).

Approval of the ethics committee must be obtained prior to the start of the study and be available upon request. Authors report this approval in their manuscript in the first paragraph of the Materials and Methods section, including the name of the regulatory group, reference number and date of the approval.

*Examples:*

*Ethical approval:* The research related to animal use complied with all the relevant national regulations and institutional policies for the care and use of animals (name of regulatory group, number and date).

*Ethical approval:* No ethical approval was obtained because this study did not involve laboratory animals and only involved non-invasive procedures (e.g. collection of waste tissue after surgery, fecal samples, voided urine etc.)

Registration and/or Login are required to submit items online and to check the

status of current submissions. Please note that by signing up and submitting your manuscript to *Archives of Veterinary Medicine* you agree to the Journal's terms and conditions. All correspondence, including notification of the Editor's decision and requests for revision, is done by e-mail. The Journal submission system guides you stepwise through the process of entering your article details and uploading your files. Editable files (Microsoft Word, .doc, or .docx format) are required to typeset your article for final publication. The text of the submitted manuscript should be written in good English language. The Editor reserves the right to amend submitted manuscripts to a suitable standard of formal, written English. Manuscripts are pre-evaluated at the Editorial Office in order to check whether they meet the basic publishing requirements and quality standards, and authors will be notified by email upon receiving their submission. Only those contributions which conform to the following instructions can be accepted for peer-review. Otherwise, the manuscripts will be returned to the authors with comments / suggestions.

Online submission (<https://niv.ns.ac.rs/e-avm/index.php/e-avm>)

- If you already have a username and password for Archives of Veterinary Medicine continue to Login Page (<https://niv.ns.ac.rs/e-avm/index.php/e-avm/login>).
- If you are not registered with this site, you need to fill in and submit the form available on Registration Page (<https://niv.ns.ac.rs/e-avm/index.php/e-avm/user/register>).

### **Layout of the manuscript, Style and Form**

The paper should be in Word program, Latin characters, size 12 pt., Times New Roman with justified alignment, double spaced. Left and right margins 20 mm, top and foot margins 30 mm, paper size A4. The journal requires continuous line numbering in submitted manuscripts. Number the pages consecutively with the title page being page 1. If special symbols are used, use font Symbol. The manuscript should be submitted on paper size A4 in electronic form. Pagination on the right side, starting from the title page.

The journal publishes the following types of articles: Original research articles, Review articles, Short communications and Case reports.

**Original research articles** describe the original research, previously unpublished and includes the following sections: Title Page, Abstract with Key words, Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgments, References, Tables/Figures (with legends). The writing style should be concise but clear enough to enable readers to reproduce the experimental methodology as described. The article must present a clear hypothesis and data expressed according to an appropriate experimental design. The Original research article should not contain more than 40 references, and usually have no more than 5000 words.

**Review articles** represent analysed and discussed summaries of different topics in the area of veterinary medicine, biotechnology and related scientific disciplines which are of broad interest to the target audience of *Archives of Veterinary Medicine*. The authors of a Review articles should be experts on the subject of the review, as proven by their own published peer-reviewed papers and by citations of these papers in the submitted review. It is essential that the authors of a review article are cited as authors of at least five other articles, published in Journals from the SCI list, addressing the same subject as the review article submitted. A review contains: Title Page, Abstract with Key words, Main Text, Conclusion, Acknowledgements, References, Tables/Figures/ Illustrations (with legends). The main text in reviews preferably has less than 6000 words.

**Short communications** represent the concise but complete descriptions of limited investigations, which will not be included in a later full research article. A short communication usually contains the following sections: Title Page, Abstract with Key words, Introduction, Materials and Methods, Results and Discussion, Conclusion, Acknowledgments, References, Tables/Figures/Illustrations (with legends). A short communication should not contain more than 15 references and preferably has less than 3000 words.

**Case Reports** are reports describing a novel case (or set of cases) with detailed documentation and diagnostic investigation. Authors are encouraged to describe how the subject of the Case report is novel or unusual in the covering letter that will accompany the submission of the Case report. Case reports usually contain the following sections: Title page, Abstract with Key words, Case presentation, Discussion, Acknowledgements, References, Tables/Figures/Illustrations (with Legends). Case reports usually have no more than 2500 words, and should not contain more than 15 references.

### **Title page**

On the title page the following should be written:

- The title of the paper in capital letters, without underlining and abbreviations
- The names of the authors (first name and surname, followed by a comma).
- Above the surname place a number in superscript (1,2,3) that denotes the institution where the author works (affiliation).
- Full name of the institutions should be given below the list of authors (the following order should be considered: university or organization/institution, department, city, and country for all authors).
- One of the authors must be designated as the Corresponding Author (add an asterisk next to the Author's surname). Full contact details including postal address, and e-mail address for the corresponding author must be provided at the bottom of the Title page.

## **Abstract**

An Abstract not exceeding 300 words must be provided with and three to eight key words. It should contain and summarize the most important facts from the submitted manuscript. For Original research articles, Short Communications and Case reports the material and techniques used must be mentioned without going into methodological detail, and the most important findings must be summarized. An Abstract for a Review paper *should contained* background, key findings and/or conclusions. Citations, tables and specialist abbreviations are not included in any Abstract.

Authors from Serbia must also submit an Abstract and Key words in Serbian, including the title of the paper, list of authors and their affiliations on a separate page after References. Translation of the Abstract and Key words from English to Serbian language will be performed by the Editorial Office for Authors who are not fluent in Serbian.

## **The main Text**

All the text headings should be typed in bold capital letters, and the subheadings, where necessary should be in bold italic with only an initial capital letter. Use short and concise sentences. Name the drugs as their International Nonproprietary Names (so called generic names). If the name of a specific drug is to be stressed, name it together with the producer (in brackets). The names of devices write as used in trade (name of the producer in brackets). When using an abbreviation for the first time, write the words that stand for. Abbreviations cannot be used in the title and summary. Text should not be longer than 8 pages. Avoid long enclosures.

## **Tables and Figures**

Tables and Figures (graphs, images, schemes etc.) must not be integrated into the main text. Instead, they must be submitted as separate, supplementary files. Tables and Figures are numbered consecutively using Arabic numerals (Figure 1, Figure 2, Figure 3, Table 1, Table 2, Table 3, *etc.*). Results which can be described as short statements within the text must not be presented as Figures or Tables. Data must not be replicated in Tables and Figures. The titles and legends help make the tables and figures understandable without the reader having to refer to the main text. However, they must also be concise and are not used to re-describe the methodology. Appropriate numbers and titles for tables and numbers and legends (including titles and explanations of markings) for figures are typed single line spaced using Times New Roman, 12 pt, in the main text and placed next to the relevant text in the article to enable the Editors to place them properly.

*Tables* are submitted as one document, with one table per page. Tables should be submitted as editable text and not as images. Each table is prepared on a separate page

and is appropriately numbered with a short, descriptive table title placed above. Tables can include footnotes, which are placed below the table and explain any abbreviations. Use superscript Arabic numbers (1, 2, 3 etc., in the correct order of reading the table, from top left to bottom right) to link each footnote to the appropriate item in the table requiring explanation.

Each *Figure* (graphs, images, schemes etc.) is submitted as a separate file. Uppercase letters A, B, C, etc. should be used to identify parts of multipart figure. Images must be at resolution 300 dpi or higher and allowable formats – JPG, TIFF. For microphotographs, scale bars with appropriate units must be provided. Symbols, arrows or letters used in photographs should contrast with the background. Legends for figures do not appear in the figures. However, when uploading the figures in the submission procedures, please ensure that the files are appropriately identified as Figure 1, Figure 2, etc. Legends for figures include both the figure number and title and explanations of any symbol, line or marking used in the figure and are placed at the appropriate location within the main text.

## Headings

Headings in the paper are: **INTRODUCTION, MATERIAL and METHODS, RESULTS, DISCUSSION (or RESULTS and DISCUSSION for Short Communications), CONCLUSION and REFERENCES**. For Review articles instead M&M, Results and Discussion section, the Main text section should be subdivided by different subheadings describing topics presented/discussed/analysed. For Case studies this part could be the same or replaced by Case presentation part with or without different subheadings.

**INTRODUCTION** points on the most important, i.e. most recent data regarding the topic with a short presentation of the aims of this research. The essence of the problem and the purpose of the study should be pointed to in this section. The key aspects of the published literature and research should be reviewed. A detailed literature survey or a summary of the results should be avoided. The last part of the Introduction must contain the specific aim(s) of the study.

**MATERIAL and METHODS**. Here describe the conditions in the experiment, name the used methods, material and animals. The Ethical statement (or description why ethical statement is not applicable) should be provided at the beginning of the section. This section includes, as appropriate, a description of study design, experimental animals or data about the samples used, analytical methods and statistical analyses. Identify the methods and procedures in sufficient details to allow others to reproduce the study. If methods are widely known, they are not described, but appropriate references must be cited. For new methods, the detailed protocols for the method should be included. Authors must provide references for established methods including sta-

tistical methods. Specify any general computer program used. Identify all drugs and chemicals used with generic or chemical names, doses and route of administration. For diagnostic kits/reagents and instruments used in the study provide manufacturer, product number, city and country where applicable.

**RESULTS.** Results are presented in a logical order and in parallel with the Methods (for every Method, there should be a Result), using text descriptions and Tables and/or Figures without duplicating the results between these formats. To enhance clarity, this section can be divided into subsections, each with a concise subheading in italics and which provides details of findings that are required to support the conclusions made in the manuscript.

**DISCUSSION.** Here give analyses of the obtained results comparing to the results and opinions of other authors, pointing the importance of this research, without giving a conclusion. The Discussion section is not used to summarize current knowledge. The Discussion should clearly identify the main Conclusions of the study. Authors are to provide a clear explanation of the importance and relevance of these Conclusions. Any new information should be distinguished from the previous findings, and relevant hypotheses can be generated.

**CONCLUSION.** Here the authors gives his final conclusions. This part consists of a short integration of Results that refer directly to the stated aim(s) of the study and a statement on the practical implications of the results. The statements and conclusions not supported by data in the presented research should be avoided. This section should not exceed one short paragraph. Do not summarize the Discussion or current knowledge in this section.

**ACKNOWLEDGEMENT.** The source of funding for the study should be stated in this section. Also, those who have made a substantial contribution to the study in terms of design, execution, analysis or manuscript drafting/revision but do not fit the criteria for authorship should be mentioned in this section. It is the responsibility of the Authors to ensure that those being acknowledged have agreed to being named in this part.

## REFERENCES

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). The author should list the references, preferably the most recent one. Only essential references should be included in the text, and these are restricted to the necessary minimum. Cite in-text references by surname and year in parentheses (e.g. Petrović, 2014). In the case of two authors, use the word “and” (e.g. Petrović and Savić, 2015). The abbreviation “et al.” must be used in all cases where more than two authors are cited (e.g. Lazić et al., 2016). Multiple references within parentheses in the text are cited in chronological order (e.g. Petrović, 2014; Petrović and Savić, 2015;

Lazić et al., 2016). In case the same author has more publications in the same year, additional letters are added next to the year (Savić et al., 2008a; Savić et al., 2008b).

In the list of **REFERENCES**, references should be numbered with Arabic numerals, one under the other, written in alphabetical order (use the A-Z sort tool) according to the surname of the first author. In general, the number of references is not limited, but only essential references should be included in the text, and these are restricted to the necessary minimum.

### **Examples of references:**

#### **Articles in journals:**

1. Stojanović D., Maličević Ž., Ašanin R. 2002. The use a new model for the investigation of sepsis. *Acta Veterinaria*, 52, 2/3, 125-131.
2. Chen J. and McClane B.A. 2015. Characterization of *Clostridium perfringens* TpeL toxin gene carriage, production, cytotoxic contributions, and trypsin sensitivity. *Infection and Immunity*, 83, 2369–2381. doi:10.1128/IAI.03136-14.
3. Williams R.B. 2015. Intercurrent coccidiosis and necrotic enteritis of chickens: rational, integrated disease management by maintenance of gut integrity. *Avian Pathology*, 34, 159-180. doi: 10.1080/03079450500112195.
4. Bailey M.A., Macklin K.S., Krehling J.T. 2013. Use of a multiplex PCR for the detection of toxin-encoding genes *netB* and *tpeL* in strains of *Clostridium perfringens*. *ISRN Veterinary Science*, Article ID 865702, 1-4. doi:10.1155/2013/865702.

#### **Books:**

5. Ficken, M. D. and Wages, D. P. 1997. Necrotic enteritis in Diseases of Poultry, Eds. B.W. Calnek, H.J. Barnes, C.W. Beard, L.R. McDougald and Y.M. Saif, Iowa State University Press, Ames, Iowa, USA, 10th edition, ISBN xxx-xxx-xxxxx-xx-x.

#### **Chapters in books:**

6. Plumb J.A. and Hanson L.A. 2011. Sturgeon viruses. In *Health maintenance and principal microbial diseases of cultured fishes*. Eds. J.A. Plumb, L.A. Hanson, 3rd edition, Blackwell Publishing, 219-225.

#### **Articles in proceedings:**

7. Giangaspero A., Marangi M., Pati S., Cafiero M.A., Camarda C., Sparagano O.A.E. 2011. Investigating the presence of acaricide residues in laying hens naturally infected by the red mite *Dermanyssus gallinae*. In *Book of Abstracts*, The 12th Asian food conference 2011, BITEC Bangna, Bangkok, Thailand, 27.
8. Vidanović D., Petrović T., Šekler M., Debeljak Z., Vasković N., Matović K., Plavšić



- B., Dmitrić M. 2018. Avian influenza in Serbia: epidemiological situation during 2016–2017. In *Programme and Abstract book*, 11th International Congress for Veterinary Virology, 12th Annual Meeting of EPIZONE, 27-30.08.2018, University of Veterinary Medicine Vienna, Vienna, Austria, 118 (p187).
9. Lazić G., Lazić S., Bugarski D., Grubač S., Lupulović D., Samojlović M., Petrović T. 2018. Human enteroviruses in river water and sewage in Vojvodina. In *Book of Abstracts*, International Scientific Conference “Green economy and environment protection”, Belgrade, 23-25. April 2018, edited by Larisa Jovanović, Belgrade, Naučno stručno društvo za zaštitu životne sredine “ECOLOGICA“, 95-96. ISBN 978-86-89061-11-6.

#### **Laws and Regulations:**

10. European Union. 2003. Commission Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition, Official Journal of the European Union, L 268:29. <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2003R1831:20100901:EN:PDF>

#### **Citations with organisations as authors:**

11. European Food Safety Authority. 2016. Peer review of the pesticide risk assessment of the active substance benzoic acid. EFSA Journal, 14(12):4657-n/a. <http://dx.doi.org/10.2903/j.efsa.2016.4657>.

#### **Software:**

12. Statistica (Data Analysis Software System). 2006. v.7.1., StatSoft, Inc., USA ([www.statsoft.com](http://www.statsoft.com)).

#### **Web Links:**

13. OIE: Animal Diseases. Available at: <http://www.oie.int/en/animal-health-in-the-world/information-on-aquatic-and-terrestrial-animal-diseases/>. Accessed 07.08.2019.
14. European Centre for Disease Prevention and Control (ECDC). Historical data by year - West Nile fever seasonal surveillance. Available at: <https://ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/historical> Accessed 31.07.2019.

#### **Cover letter**

All submitted manuscripts must be accompanied by a cover letter which explains why the manuscript is suitable for publication in *Archives of Veterinary Medicine* and declaring that the manuscript has not been submitted or accepted for publication else-

where. Authors should suggest one or two potential unbiased reviewers who are qualified to review the manuscript (reviewers' affiliations with email addresses, and briefly explain why authors think the suggested scientists would be good reviewers). This letter must warrant that all authors have seen and approved the content.

### **Authors' contributions**

In order to give appropriate credit to each author of a paper, the individual contributions of authors to the manuscript are specified by initials in this section. An author is generally considered to be someone who has made significant contribution to a published study. All contributors who do not meet the criteria for authorship should be listed in the Acknowledgements section.

### **Competing interest**

A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with people or organizations. Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.

### **Note**

A paper that is not in accordance to the aforementioned instructions will not be sent for a review and will be returned to the authors for corrections.

### **Copyright**

Once the manuscript is accepted for publication, authors assign a *License to Publish*. Authors retain copyright of the published papers and grant the publisher the right to publish the article, to be cited as its original publisher in case of reuse, and to distribute it in all forms and media. The final proof will be sent to the Corresponding Author, together with a *License to Publish*, which all authors have to sign. When an issue is completed, a hard copy of the issue will be produced as well as electronic copy on the Journal webpage. If the submitted manuscript is not accepted for publication by the journal, all rights to the manuscript will be retained by the author(s).

Articles published in *Archives of Veterinary Medicine* will be Open-Access articles distributed under a **Creative Commons Attribution International License** (CC BY 4.0).

**Address of the journal**

Scientific Veterinary Institute “Novi Sad”,

21000 Novi Sad, Rumenački put 20

Tel. 381 (0)21 4895 321

E-mail: [arhiv@niv.ns.ac.rs](mailto:arhiv@niv.ns.ac.rs)

Web: <https://niv.ns.ac.rs/e-avm/>

Account No: 355-1006444-18 Vojvođanska banka,

ID No.: 08608857,

PIB 100236555

**Privacy Statement**

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.



### List of reviewers:

Sava Lazić, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Tamaš Petrović, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Milica Živkov Baloš, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Dubravka Milanov, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Dr Ljiljana Spalević, Research Fellow	Scientific Veterinary Institute of Serbia, Belgrade (Serbia)
Sara Savić, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Vladimir Polaček, Senior Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Aleksandar Potkonjak, Professor	Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad (Serbia)
Nada Plavša, Professor	Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad (Serbia)
Ljubo Barbić, Professor	Faculty of Veterinary Medicine, University of Zagreb (Croatia)
Ivan Toplak, Assoc. Professor	Faculty of Veterinary Medicine, University of Ljubljana (Slovenia)
Maja Velhner, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Dejan Vidanović, Senior Research Fellow	Veterinary Specialist Institute „Kraljevo“, Kraljevo (Serbia)
Dušan Petrić, Professor	Faculty of Agriculture, University of Novi Sad (Serbia)
Vladimir Petrović, Professor	Faculty of Medicine, University of Novi Sad (Serbia)
Neđeljko Karabasil, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Milorad Mirilović, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Jelena Petrović, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Tamara Ilić, Assoc. Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Igor Stojanov, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Sandra Jakšić, Senior Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)

### List of reviewers:

Jakov Nišavić, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Ksenija Nešić, Senior Research Fellow	Scientific Veterinary Institute of Serbia, Belgrade (Serbia)
Diana Lupulović, Senior Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Nikolina Novakov, Assoc. Professor	Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad (Serbia)
Jasna Prodanov Radulović, Senior Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Vesna Miličević, Research Fellow	Scientific Veterinary Institute of Serbia, Belgrade (Serbia)
Vladimir Radosavljević, Principal Research Fellow	Scientific Veterinary Institute of Serbia, Belgrade (Serbia)
Gospava Lazić, Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Vladimir Ivović, Assoc. Professor	The Faculty of Mathematics, Natural Science and Information Technologies, University of Primorska (Slovenia)
Dragana Ljubojević Pelić, Senior Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Branislav Kureljušić, Senior Research Fellow	Scientific Veterinary Institute of Serbia, Belgrade (Serbia)
Milanko Šekler, Senior Research Fellow	Veterinary Specialist Institute „Kraljevo“, Kraljevo (Serbia)
Sandra Stefan Mikić, Professor	Faculty of Medicine, University of Novi Sad (Serbia)
Ivana Hranjaković Cvjetković, Professor	Faculty of Medicine, University of Novi Sad (Serbia)
Juan Carlos Saiz, Principal Research Fellow	INIA, Madrid (Spain)
Kiril Krstevski, Assoc. Professor	Faculty of Veterinary Medicine, University Ss. Cyril and Methodius, Skopje (North Macedonia)
Vladimir Savić, Principal Research Fellow	Croatian Veterinary Institute, Zagreb (Croatia)
Lorena Jemeršić, Principal Research Fellow	Croatian Veterinary Institute, Zagreb (Croatia)
Aleksandar Mašić, Senior Research Fellow	ZOETIS, Global Bios Research (USA)
Alessio Lorusso, Principal Research Fellow	IZSAM, Teramo (Italy)

### List of reviewers:

Dejan Bugarski, Senior Research Fellow	Scientific Veterinary Institute "Novi Sad" (Serbia)
Tamas Bakonyi, Professor	European Centre for Disease Prevention and Control (ECDC), Solna, (Sweden)
Teufik Goletić, Professor	Faculty of Veterinary Medicine, University of Sarajevo (Bosnia and Herzegovina)
Igor Džadžovski, Assoc. Professor	Faculty of Veterinary Medicine, University Ss. Cyril and Methodius, Skopje (North Macedonia)
João R. Mesquita, Assoc. Professor	Institute of Biomedical Sciences Abel Salazar, University of Porto (Portugal)
Jasna Kureljušić, Research Fellow	Scientific Veterinary Institute of Serbia, Belgrade (Serbia)
Radmila Resanović, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Igor Jajić, Professor	Faculty of Agriculture, University of Novi Sad (Serbia)
Dušan Mišić, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Marija Zgomba, Professor	Faculty of Agriculture, University of Novi Sad (Serbia)
Vera Gusman, Professor	Faculty of Medicine, University of Novi Sad (Serbia)
Dragan Šefer, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Ljiljana Suvajdžić, Professor	Faculty of Medicine, University of Novi Sad (Serbia)
Abdeljelil Ghram, Research Fellow	Pasteur Institute of Tunis, Department of Veterinary Microbiology (Tunis)
Nadir Alloui, Assist. Professor	Veterinary Department, University of Batna (Algeria)
Dragica Stojanović, Professor	Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad (Serbia)
Mirjana Đukić Stojčić, Professor	Faculty of Agriculture, University of Novi Sad (Serbia)
Ljiljana Janković, Assoc. Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Stanimir Simin, Assist. Professor	Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad (Serbia)
Jovan Bojkovski, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)

### List of reviewers:

Nevenka Aleksić, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Marija Lesjak, Assoc. Professor	Faculty of natural science, University of Novi Sad, (Serbia)
Žolt Bečkei, Assist. Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Olivera Bjelić Čabrilo, Professor	Faculty of natural science, University of Novi Sad, (Serbia)
Jelena Nedeljковиć Trailović, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Kazimir Matović, Senior Research Fellow	Veterinary Specialist Institute „Kraljevo“, Kraljevo (Serbia)
Adnan Jažić, Professor	Faculty of Veterinary Medicine, University of Sarajevo (Bosnia and Herzegovina)
Goran Marković, Assoc. Professor	Faculty of Agronomy Čačak, University of Kragujevac (serbia)
Marko Stanković, Assist. Professor	Faculty of Agriculture, University of Belgrade (Serbia)
Peter Hostnik, Professor	Faculty of Veterinary Medicine, University of Ljubljana (Slovenia)
Vladimir Kukolj, Assoc. Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Bojan Toholj, Professor	Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad (Serbia)
Milan Hadži-Milić, Assist. Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Jasmin Omeragić, Professor	Faculty of Veterinary Medicine, University of Sarajevo (Bosnia and Herzegovina)
Aleksandar Jurišić, Assoc. Professor	Faculty of Agriculture, University of Novi Sad (Serbia)
Snežana Medić, Assist. Professor	Faculty of Medicine, University of Novi Sad (Serbia)
Slavica Maris, MD, MSc	Institute of Public Health, Belgrade (Serbia)
Dragiša Trailović, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Jelena Francuski Andrić, Assist. Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Dalibor Todorović, Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Nemanja Zdravković, Research Fellow	Scientific Veterinary Institute of Serbia, Belgrade (Serbia)





## Beleške / Notes

ISSN 1820-9955

UDK 619

Scientific Veterinary Institute „Novi Sad” Novi Sad  
Naučni institut za veterinarstvo „Novi Sad” Novi Sad

# **Archives of Veterinary Medicine**

## **Arhiv veterinarske medicine**

Arch. vet. med.	Vol. 16	No. 2	Pg. 1-144	Novi Sad, 2023.
-----------------	---------	-------	-----------	-----------------

CIP – Каталогизација у публикацији  
Библиотека Матице српске, Нови Сад

619

**Archives of Veterinary Medicine = Arhiv veterinarske medicine** / Editor in Chief Sava Lazić. – Vol. 1, br. 1 (2008) –.- Novi Sad : Scientific Veterinary Institute “Novi Sad”, 2014 –.- 25 cm

Published twice a year.

ISBN 1820-9955

COBISS.SR-ID 235692807

## EDITORIAL TEAM

### Editor in Chief:

**Sava Lazić**, Principal Research Fellow (lazic@niv.ns.ac.rs)  
Scientific Veterinary Institute "Novi Sad" (Serbia)

### Deputy Editor:

**Tamaš Petrović**, Principal Research Fellow, (tomy@niv.ns.ac.rs)  
Scientific Veterinary Institute "Novi Sad" (Serbia)

### Advisory Board Members:

**Neđeljko Karabasil**, Professor, Faculty of Veterinary Medicine, University of Belgrade (Serbia)  
**Milorad Mirilović**, Professor, Faculty of Veterinary Medicine, University of Belgrade (Serbia)  
**Ivan Toplak**, Assoc. Professor, Faculty of Veterinary Medicine, University of Ljubljana (Slovenia)  
**Vladimir Petrović**, Professor, Faculty of Medicine, University of Novi Sad (Serbia)  
**Dušan Petrić**, Professor, Faculty of Agriculture, University of Novi Sad (Serbia)  
**Dejan Vidanović**, Senior Research Fellow, Veterinary Specialist Institute „Kraljevo“, Kraljevo (Serbia)  
**Maja Velhner**, Principal Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Milica Živkov Baloš**, Principal Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Dubravka Milanov**, Principal Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Sara Savić**, Principal Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Vladimir Polaček**, Senior Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Aleksandar Potkonjak**, Professor, Dep. of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad (Serbia)  
**Ljubo Barbić**, Professor, Faculty of Veterinary Medicine, University of Zagreb (Croatia)

### Editorial Board Members

**Jelena Petrović**, Principal Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Igor Stojanov**, Principal Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Sandra Jakšić**, Senior Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Željko Mihaljev**, Senior Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Radimir Ratajac**, Senior Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Diana Lupulović**, Senior Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Jasna Prodanov Radulović**, Senior Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Dejan Bugarski**, Senior Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Dragana Ljubojević Pelić**, Senior Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Gospava Lazić**, Research Fellow, Scientific Veterinary Institute "Novi Sad" (Serbia)  
**Tamara Ilić**, Assoc. Professor, Faculty of Veterinary Medicine, University of Belgrade (Serbia)  
**Jakov Nišavić**, Professor, Faculty of Veterinary Medicine, University of Belgrade (Serbia)  
**Ksenija Nešić**, Senior Research Fellow, Scientific Veterinary Institute of Serbia, Belgrade (Serbia)  
**Vesna Milićević**, Research Fellow, Scientific Veterinary Institute of Serbia, Belgrade (Serbia)  
**Vladimir Radosavljević**, Principal Research Fellow, Scientific Veterinary Institute of Serbia, Belgrade (Serbia)  
**Branislav Kureljušić**, Senior Research Fellow, Scientific Veterinary Institute of Serbia, Belgrade (Serbia)  
**Milanko Šekler**, Senior Research Fellow, Veterinary Specialist Institute „Kraljevo“, Kraljevo (Serbia)  
**Sandra Stefan Mikić**, Professor, Faculty of Medicine, University of Novi Sad (Serbia)  
**Ivana Hranjaković Cvjetković**, Professor, Faculty of Medicine, University of Novi Sad (Serbia)

**Snežana Medić**, Assistant Professor, Faculty of Medicine, University of Novi Sad (Serbia)  
**Drago Nedić**, Professor, Veterinary Institute „Dr Vaso Butozan“, Banja Luka (Bosnia and Herzegovina)  
**Teufik Goletić**, Professor, Faculty of Veterinary Medicine, University of Sarajevo (Bosnia and Herzegovina)  
**Juan Carlos Saiz**, Principal Research Fellow, INIA, Madrid (Spain)  
**Igor Pajović**, Research Fellow, Biotechnical faculty, University of Montenegro, Podgorica (Montenegro)  
**Lazo Pendovski**, Professor, Faculty of Veterinary Medicine, University Ss. Cyril and Methodius, Skopje (North Macedonia)  
**Jovana Stefanovska**, Professor, Faculty of Veterinary Medicine, University Ss. Cyril and Methodius, Skopje (North Macedonia)  
**Kiril Krstevski**, Assoc. Professor, Faculty of Veterinary Medicine, University Ss. Cyril and Methodius, Skopje (North Macedonia)  
**Igor Džadžovski**, Assoc. Professor, Faculty of Veterinary Medicine, University Ss. Cyril and Methodius, Skopje (North Macedonia)  
**João R. Mesquita**, Assoc. Professor, Institute of Biomedical Sciences Abel Salazar, University of Porto (Portugal)  
**Željko Cvetnić**, Academician, Croatian Academy of Sciences and Arts, Zagreb (Croatia)  
**Vladimir Savić**, Principal Research Fellow, Croatian Veterinary Institute, Zagreb (Croatia)  
**Lorena Jemeršić**, Principal Research Fellow, Croatian Veterinary Institute, Zagreb (Croatia)  
**Relja Beck**, Principal Research Fellow, Croatian Veterinary Institute, Zagreb (Croatia)  
**Tatjana Vilbić-Čavlek**, Assoc. Professor, Faculty of Medicine, University of Zagreb (Croatia)  
**Aleksandar Mašić**, Senior Research Fellow, ZOETIS, Global Bios Research (USA)  
**Alessio Lorusso**, Principal Research Fellow, Institute IZSAM, Teramo (Italy)  
**Petra Vasicková**, Senior Research Fellow, Veterinary Research Institute (VUVEL), Brno (Czech Republic)  
**Wim van der Poel**, Professor, Wageningen University, Wageningen (The Netherlands)  
**Tamas Bakonyi**, Professor, European Centre for Disease Prevention and Control (ECDC), Solna, (Sweden)

#### **Technical Editor**

**Jelena Vranešević**, Research Associate, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Miloš Pelić**, Research Associate, Scientific Veterinary Institute “Novi Sad” (Serbia)

#### **English Language Editor**

**Dubravka Klajić**, translator and English language editor  
**Danka Vukašinović**, translator and English language editor

#### **Technical Support and Website Administrator**

**Vladimir Polaček**, Senior Research Fellow, Scientific Veterinary Institute “Novi Sad” (Serbia)  
**Dobrisav Vuković**, ing, Scientific Veterinary Institute “Novi Sad” (Serbia)

**Published twice a year.** Circulation: 100 copies

#### **Address:**

Scientific Veterinary Institute “Novi Sad”,  
21000 Novi Sad, Rumenački put 20  
Tel. 381 (0)21 4895 321  
E-mail: arhiv@niv.ns.ac.rs  
Account No: 355-1006444-18 Vojvodanska banka,  
ID No.: 08608857,  
PIB 100236555

Review article

UDK 579.86:615.33.015.8  
579.67

<https://doi.org/10.46784/e-avm.v16i2.334>

## COMBATTING METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) IN THE FOOD INDUSTRY BY HARNESSING THE POWER OF NATURE: A SYSTEMATIC REVIEW

Zahra Alinezhad<sup>1,2</sup>, Mohammad Hashemi<sup>1,2</sup>,  
Asma Afshari<sup>1,2</sup>, Golshan Shakeri<sup>2\*</sup>

<sup>1</sup> Medical Toxicology Research Center, Mashhad  
University of Medical Sciences, Mashhad, Iran

<sup>2</sup> Department of Nutrition, Faculty of Medicine, Mashhad  
University of Medical Sciences, Mashhad, Iran

### Abstract

Antibiotic resistance is a critical global health concern, with *Methicillin-resistant Staphylococcus aureus* (MRSA) posing a significant challenge due to its resistance to commonly used antibiotics. Recent research has revealed the potential of natural compounds and microorganisms in combatting MRSA and other antibiotic-resistant bacteria. In this systematic review, we studied the effect of essential oils, bacteriophages, bacteriocins, and probiotics on *S. aureus*, including MRSA in particular, in the food industry. Essential oils (EOs) have gained significant attention because of their antimicrobial properties, inhibiting MRSA growth by damaging bacterial cells and inhibiting essential enzymes and compounds. Cinnamon oil liposomes caused the most significant decrease in MRSA populations among our reviewed essential oils. Bacteriophages can lyse the bacterial host. They encode peptidoglycan hydrolases called endolysins that target the bacterial cell wall. In our study, *S. aureus* phage (containing CHAPLysGH15 and LysGH15), and phage SA11 endolysin (LysSA11) were the most effective against *S. aureus*. Bacteriocins, antimicrobial peptides produced by bacteria, also show potential in combatting MRSA, mainly by generating organic acids that interfere with bacterial metabolism. According to our review, the

---

<sup>1\*</sup> Golshan.shakeri@gmail.com

most effective bacteriocins against *S. aureus* were *Enterocin AS-48* with phenolic compounds or with *2NPOH*, Bacteriocin isolated from *Lactobacillus pentosus* - *Pentocin JL-1*, and bacteriocin produced by *S. pasteurii* *RSP-1*, respectively. Probiotics can compete with pathogens by producing antimicrobial compounds that disrupt *MRSA* cell production and ultimately lead to bacterial death. In our review, the most effective probiotics were *Streptomyces griseus*, *Pediococcus acidilactici* strains *A11* and *C12*, *Lactococcus lactis*, and *Lactobionic acid* respectively. A multi-hurdle approach combining these natural agents has shown promising results in targeting and eliminating *MRSA* cells. By harnessing the power of nature, we can potentially overcome the challenges posed by *MRSA* and other antibiotic-resistant bacteria.

**Key words:** *Methicillin-resistant Staphylococcus aureus (MRSA)*, Essential oils, Bacteriophage, Bacteriocin, Probiotic

## **BORBA PROTIV STAPHILOCOCCUS AUREUS-a (MRSA) OTPORNOG NA METICILIN U PREHRAMBENOJ INDUSTRIJI KORIŠĆENJEM SNAGE PRIRODE: SISTEMATSKI PREGLEDNI RAD**

Zahra Alinezhad<sup>1,2</sup>, Mohammad Hashemi<sup>1,2</sup>,  
Asma Afshari<sup>1,2</sup>, Golshan Shakeri<sup>2\*</sup>

<sup>1</sup> Istraživački centar za medicinsku toksikologiju,  
Univerzitet Mashhad, Mashhad, Iran

<sup>2</sup> Katedra za ishranu, Medicinski fakultet, Univerzitet Mashhad, Mashhad, Iran

### **Kratak sadržaj**

Otpornost na antibiotike je globalni zdravstveni problem, a meticilin rezistentan *Staphylococcus aureus* (MRSA) predstavlja značajan izazov zbog otpornosti na antibiotike koji se obično koriste. Skorija istraživanja otkrila su potencijal prirodnih jedinjenja i mikroorganizama u borbi protiv MRSA i drugih bakterija otpornih na antibiotike. U ovom preglednom radu proučavan je efekat eteričnih ulja, bakteriofaga, bakteriocina i probiotika na *S. aureus*, uključujući i izolate MRSA, u prehrambenoj industriji. Eterična ulja (EO) privukla su značajnu pažnju zbog svojih antimikrobnih svojstava, inhibirajući rast MRSA tako što oštećuju bakterijsku ćeliju i inhibiraju njihove esencijalne enzime i jedinjenja. Od svih ispitanih eteričnih ulja, lipo-



zomi ulja cimeta doveli su do najznačajnijeg smanjenja populacije MRSA. Bakteriofagi mogu da liziraju bakteriju koju napadaju. Oni sintetišu enzime peptidoglikan hidrolaze koji su poznati pod nazivom - endolizini, koji oštećuju bakterijski zid. U našoj studiji, *S. aureus* fage (koje sadrže CHAPLisGH15 i LisGH15) i fag SA11 endolizin (LisSA11) bili su najefikasniji protiv *S. aureus*. Bakteriocini, antimikrobni peptidi koje proizvode bakterije, takođe pokazuju potencijal u borbi protiv MRSA, uglavnom stvaranjem organskih kiselina koje ometaju metabolizam bakterija. Na osnovu rezultata našeg preglednog rada, najefikasniji bakteriocini protiv *S. aureus* su bili Enterocin AS-48 sa fenolnim jedinjenjima ili sa 2NPOH, Bacteriocin izolovan iz *Lactobacillus pentosus* - Pentocin JL-1 i bakteriocin proizveden od *S. pasteurii* RSP-1. Probiotici mogu da deluju na patogen tako što proizvode antimikrobna jedinjenja koja ometaju proizvodnju MRSA ćelija i na kraju dovode do smrti bakterija. U našem pregledom radu, najveću efikasnost pokazali su probiotici *Streptomyces griseus*, *Pediococcus acidilactis* sojevi A11 i C12, *Lactococcus lactis* i *Lactobionis acid*. Pristup koji kombinuje ove prirodne agense pokazao je zadovoljavajuće rezultate u prepoznavanju i eliminaciji MRSA ćelija. Koristeći snagu prirode, razvijamo potencijal za prevazilaženje infekcija uzrokovanih sa MRSA-ma i drugim bakterijama koje su otporne na antibiotike.

**Ključne reči:** *Staphylococcus aureus* otporan na meticilin (MRSA), eterična ulja, bakteriofag, bakteriocin, probiotik

## INTRODUCTION

*Staphylococcus aureus* is a gram-positive pathogenic bacterium. The ability of *S. aureus* to adhere to specific host substrates and evade host defenses (Eom, et al. 2014; Lu, et al. 2021), as well as its ability to survive in various environmental conditions while posing different virulence factors (de Oliveira, et al. 2010; Eom, et al. 2014; Burris, et al. 2015; Lu, et al. 2021), makes it highly virulent and capable of causing life-threatening infections in both humans and animals (Zhu, et al. 2015; Catteau, et al. 2017; Lalouckova, et al. 2021). Food-borne diseases caused by *S. aureus* (Lee, et al. 2009; de Oliveira, et al. 2010; Keyvan and Tutun 2019; Prastiyanto, et al. 2020; Lalouckova, et al. 2021) are generally limited to food poisoning and gastroenteritis, resulting from enterotoxins produced by *S. aureus* (Lee, et al. 2009; Zhu, et al. 2015; AL-Saadi 2016; Prastiyanto, et al. 2020).

Antibiotic resistance is one of the most significant health challenges of the

century (Lee, et al. 2009; Chang, et al. 2017; Chang, et al. 2017; Prastiyanto, et al. 2020). Antibiotic-resistant forms of *S. aureus*, such as methicillin-resistant *Staphylococcus aureus* (*MRSA*), are multi-drug-resistant (Eom, et al. 2014; AL-Saadi 2016; Lu, et al. 2021) to  $\beta$ -lactam antibiotics (Eom, et al. 2014; Redwan et al. 2016; Catteau, et al. 2017; Lestari, et al. 2019; Prastiyanto, et al. 2020). Food-borne *MRSA* is a major concern for public health worldwide (Lee, et al. 2013; Redwan, et al. 2016; Kang, et al. 2020; Lu, et al. 2021), because it can enter the food chain as animal based food (Vaiyapuri, et al. 2019; Kang, et al. 2020) or by colonizing in food handlers and transferring from them to food (Eom, et al. 2014). A high rate of morbidity and mortality by *MRSA* have been reported worldwide (Zhu, et al. 2015; Redwan, et al. 2016; Zouhir, et al. 2016; Salem 2017; Zihadi, et al. 2019). *MRSA* has already been isolated from food, indicating that it is present as a contaminant in the food production chain (Ansari, et al. 2020; Afshari, et al. 2022). The presence of *MRSA* has been reported mainly in meat such as pork, beef, lamb, chicken, rabbit, and turkey, as well as in dairy products such as milk and cheese (Mohammed-Ali, et al 2015). This means that the food production chain is a pathway of transmission between resistant microorganisms and humans (Mohammed-Ali, et al 2015). Food safety is an important global concern in the food industry and public health. Many preservatives that are used to control microbial growth in foods not only increase the shelf-life of food products, but they also reduce the incidence of foodborne diseases (Xu, et al. 2016; Chang, et al. 2017). Due to consumer worries regarding safety of chemical preservatives utilized in food, there is an increasing need for natural alternatives that can function as food preservatives. (Gyawali, et al 2014). Therefore, it is critical to use natural agents that control or prevent foodborne pathogens, including *MRSA*, in food (Kang, et al. 2020). By utilizing these natural antimicrobials as food preservatives, the need for excessive physical and chemical food processing can be reduced while ensuring microbial safety and environmental preservation (Yusuf, 2018).

Several natural compounds from plants, animals, and microorganisms have been studied and applied in order to inhibit or control the growth of foodborne microorganisms, including *MRSA*. Plant-derived essential oils are commonly used as flavoring and preservation agents in food and drinks have antimicrobial and antioxidative activity (Cui, et al. 2018; Yuan, et al 2018).

Bacteriophages are viruses that infect bacteria and can exhibit inhibitory activity against *S. aureus*, particularly *MRSA*. Furthermore, since gram-positive bacteria lack an outer membrane, bacteriophages can directly lyse the cell wall from the outside (Lysis from without) (Lu, et al. 2021). Bacteriocins are proteins that exhibit bactericidal effects on a variety of bacteria, including *S. aureus*. They are considered as alternatives to traditional antibiotics (Zhu, et al.

2015; Chauhan, et al. 2017; Lestari, et al. 2019) and an effective approach for use in food against *MRSA* (Arumugam, et al. 2019). Probiotics are living organisms used as food additives to help maintain a healthy microbial balance in the gastrointestinal tract, leading to better health in humans (Lee, et al. 2021).

This review focuses on the effective natural antimicrobials originating from plants and microorganisms against *MRSA*, including essential oils, bacteriophages, bacteriocins, and probiotics. The mechanisms of action, as well as their effectiveness, are also surveyed. Our main aim was to review the efficiency of natural antimicrobial agents in combating *MRSA* in food.

## **MATERIAL AND METHODS**

### ***Study Design***

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were applied to conduct this systematic review. The main objective of this study was to review the literature on natural approaches for controlling *MRSA* in food.

### ***Search Strategy***

In this study, the main databases, including Scopus, PubMed, Google Scholar, and Science Direct, were searched. The literature review was limited to studies published from 2000 to 2023. The search was independently conducted for each database, focusing on controlling *Methicillin-resistant Staphylococcus aureus* OR *MRSA* in any food product worldwide. The keywords used were “*Methicillin-resistant Staphylococcus aureus*” OR “*MRSA*” AND “Dairy” OR “Milk” OR “Meat” OR “Food” AND “Essential Oils” OR “Probiotic” OR “Bacteriophage” OR “Bacteriocin” AND “Control”.

### ***Inclusion and Exclusion Criteria***

This review included articles (n = 83) that reported on the natural types of effective antimicrobials, including essential oils, bacteriophages, bacteriocins, and probiotics, against *MRSA*. The selection for inclusion eligibility was conducted by scanning the titles, abstracts, and full texts of retrieved articles. The focus of our study was on livestock-associated (*LA*) *MRSA*. All review studies, duplicate publications, as well as clinical reports and trials on healthcare-associated (*HA*) *MRSA*, were excluded.




Figure 1. PRISMA flowchart for studies selection

## RESULTS

### *Essential Oils*

Essential oils have shown an antimicrobial effect against *S. aureus* and *MRSA* in particular. For instance, Cinnamon oil, Thyme oil, and Lemongrass oil reduced the *MRSA* population in minced meat by 7.6, 6.53, and 5.94 log CFU/g, respectively, when applied at a concentration of 1.5% (Eom, et al. 2014). Cinnamon oil was bactericidal against the biofilm activity of *MRSA*. A concentration of 1.0 mg/mL of cinnamon oil was sufficient to eliminate *MRSA* biofilm (Cui, et al. 2016). *Syzygium aromaticum* (CLV) and *Cinnamomum zeylanicum* (CIN) exhibited bactericidal activity at a concentration of 200 µg/mL against *S. aureus* and reduced the population of *S. aureus* by 4.50 log<sub>10</sub> CFU/mL and 3.97 log<sub>10</sub> CFU/mL, respectively (Mandal, et al. 2011). *Cuminum cyminum* (CMN) exhibited bactericidal activity at 300 µg/mL and caused a reduction of 0.59 log<sub>10</sub> CFU/mL in *MRSA* after 24 hrs (Mandal, et al. 2011). The MIC concentration of the polyphenolic components of green tea, neem leaves extract, and a combination of green tea and neem were 15.62, 31.25,

and 46.87 mg/mL, respectively (Zihadi, et al. 2019). Allicin liquid was active against *S. aureus* strains, and all *MRSA* strains were inhibited by *allicin* at 32 µg/mL (Cutler, et al 2004). The indigenous cinnamon B leaf oil (*Cinnamomum osmophloeum*) had antibacterial effect against *MRSA* with an MIC of 250 µg/mL (Chang, et al. 2001). The *ethanolic* extract of *Elettaria cardamomum* displayed antibacterial activity against *MRSA*, with a minimum inhibitory concentration (MIC) of 0.25 mg/disk and minimum bactericidal concentration (MBC) of 0.50 mg/disk against *S. aureus* (Yassin, et al. 2022). *Nigella sativa* oil extract was effective against *MRSA*, with inhibition zones of  $7 \pm 1$  mm and  $10 \pm 0.9$  mm observed at concentrations of 400 µl and 800 µl, respectively (Abdullah, et al. 2021). *Litsea cubeba* essential oil (*LC-EO*) contained high percentages of *aldehydes*, primarily  $\beta$ -Citral (39.25%) and  $\alpha$ -Citral (30.89%). *LC-EO* caused a steady decrease in *MRSA* populations, with a 99.99% reduction observed after 2 hours of treatment with 0.25 mg/mL of *LC-EO* (Hu, et al. 2019). *Red propolis* extracts (*RPE*) had an inhibition zone of  $16.5 \pm 0.5$  mm and  $19.3 \pm 0.5$  mm against *S. aureus* and *MRSA*, respectively (Zhang, et al. 2022). The essential oil extracted from *Carum carvi* L. seeds completely prevented *MRSA* biofilm formation at a concentration of 1.28%, with decreasing inhibitory effects observed at lower concentrations (Liu, et al. 2023). The *ethanol* extract from *Psoralea corylifolia* seeds exhibited antibacterial activity against Gram-positive bacteria, with inhibition zones of 14 mm and 16 mm for *S. aureus* and *MRSA*, respectively. *MRSA* cells treated with 1600 µg/mL of the extract were deformed and collapsed (Li, et al. 2019). *Backhousia citriodora* essential oil significantly inhibited 90.01% to 93.39% of *S. aureus* biofilms (Lim, et al. 2022). *Oregano* (*Origanum vulgare*) and clove (*Eugenia caryophyllata*) essential oils were effective against *S. aureus* and *MRSA*, with complete inhibition at concentrations of 0.63 µg/mL and 10 µg/mL, respectively (Debiagi, et al. 2020). Finally, *Lippia micromera* and *Plectranthus amboinicus* exhibited potent antibacterial activity against *MRSA*, with large inhibition zones of 23.7 - 35.7 mm (Bugayong, et al. 2019). The MIC of a combination of *oregano* and *thyme* essential oils was found to be 320 µg/mL (Boskovic et al. 2015). Other studies reporting the effectiveness of essential oils are summarized in Table 1. According to Table 1, the most effective compound against *MRSA* is the *liposome* containing cinnamon oil, with a MIC of 0.25 mg/mL and MBC of 0.25 mg/mL, this compound resulted in a 99.99% decrease in *MRSA* populations after 4 hours and a decrease of 2.83 logs after 24 hours at a concentration of 1.0 mg/mL. Other most effective EOs against *MRSA* are *Cinnamomum zeylanicum*, *Syzygium aromaticum*, *Cuminum cyminum*, respectively. Additionally, *allicin*, *glabrol*, *clove buds*, and *Backhousia citriodora* essential oils  $s < 0$ , have shown significant effectiveness against *MRSA* with low MIC values.

Table 1. Effectiveness of essential oils against MRSA

Essential oils			
Name	Active Components	Effectiveness	References
Cinnamon oil, Thyme oil and Lemongrass oil	<i>Cinnamaldehyde, eugenol, Alpha and beta-citral, mycrene</i>	The initial count of MRSA after inoculation (at zero time) was 10.28(log CFU/g) which at a concentration of 1.5% Cinnamon oil, Thyme oil and Lemongrass oil reduced MRSA population by 7.6, 6.53, 5.94 log CFU/g, respectively.	(Salem 2017)
Liposome containing cinnamon oil	<i>Cinnamon oil</i>	After 4h there was a decrease of around 99.99% in the MRSA populations and after 24 h, the population of MRSA decreased by 2.83 logs using 1.0 mg mL <sup>-1</sup> . MIC (mg/mL): 0.25, MBC (mg/mL): 0.25	(Cui, et al. 2016)
Indian Spices	<i>Syzygium aromaticum (CLV), Cinnamomum zeylanicum (CIN) and Cuminum cyminum (CMN)</i>	After 24 h the CIN and CLV showed bactericidal activity at concentration 200 µg/mL against <i>S. aureus</i> reducing 4.50 log <sub>10</sub> cfu/mL and 3.97 log <sub>10</sub> cfu/mL, respectively; CMN exhibited bactericidal effects at 300 µg/mL, leaving 0.59 log <sub>10</sub> cfu/mL. Effectiveness order: <i>C.zeylanicum</i> > <i>S.aromaticum</i> > <i>C. cyminum</i>	(Mandal, et al. 2011)

Essential oils			
Name	Active Components	Effectiveness	References
Polyphenolic components of <i>Green tea</i> , Neem leaves extract of <i>Camellia sinensis</i> and <i>Azadirachta indica</i> leaves	<i>Catechin</i>	MIC (mg/mL): <i>Green tea</i> : 15.62 <i>Neem</i> : 31.25 <i>Green tea + Neem</i> : 46.87 ( <i>green tea</i> extract is more potent than <i>neem</i> against <i>MRSA</i> )	(Zihadi, et al. 2019)
<i>Allicin</i>	NR	MIC: 32 µg/ML, MBC: 128 µg/mL	(Cutler, et al 2004)
<i>Cinnamomum osmophloeum</i> leaf	<i>Cinnamaldehyde</i>	MIC: 250 µg/mL	(Chang, et al. 2001)
<i>Thyme</i> ( <i>Thymus vulgaris</i> ) and <i>Oregano</i> ( <i>Origanum vulgare</i> )	<i>Thymol</i> from <i>Thyme</i> and <i>Carvacrol</i> from <i>Oregano</i>	MIC of <i>Oregano</i> and <i>Thyme</i> : 320 µg/mL MBC of <i>Oregano</i> : 1280 µg/mL MBC of <i>Thyme</i> : 640 µg/mL	(Boskovic, et al. 2015)
<i>PFF</i> ( <i>phlorofucoxanthin</i> , a marine-derived polyphenol found in brown algae)	NR	MIC: 64 µg/mL	(Eom, et al. 2014)
<i>URS</i> ( <i>ursolic acid 3-O-α-L-arabinopyranoside</i> was isolated from the leaves of <i>A. henryi</i> (Oliv) with <i>oxacillin</i> )	Urso-lic acid 3-O-α-L-arabinopyranoside with (URS) <i>oxacillin</i>	MIC: 6.25 µg/mL After 24 h, treatment with 1/2 MIC OXA and 3/4 MIC URS in combination resulted in combined group bacteria counts that decreased to 3 log <sub>10</sub> .	(Zhou, et al. 2017)

Essential oils			
Name	Active Components	Effectiveness	References
<i>Pink oyster mushroom Pleurotus flabellatus</i>	The terpenoid compound group	MIC: 62.5 mg/mL MBC: 250 mg/mL	(Ghosh, et al. 2016)
<i>Carvacrol</i>	NR	MIC: 0.11 mg/mL	(Keyvan, and Tutun 2019)
<i>Bulb Eleutherine Americana</i>	Naphtho-quinone	MIC: 125-500 g/mL, MBC: 250-1000 g/mL	(Ifesan, et al. 2009)
<i>Aloysia citriodora essential oils from Baqa al-Gharbiyye and Umm al-Fahm</i>	lipophilic structures like $\alpha$ - citral and $\alpha$ -curcumene	MIC: 2.5 $\mu$ g/mL	(Aru-mugam, et al. 2019)
<i>Garlic</i>	Allicin (allyl 2-propenethi- osulphinate)	MIC: 256 g/mL	(Prasti- yanto, et al. 2020)
<i>Cinnamon (Cinnamo- mum verum)</i>	Cinnamal- dehyde, eugenol	Against MSSA: MIC of 250 $\mu$ g/mL Against MRSA: MIC of 250 $\mu$ g/mL	(Prasti- yanto, et al. 2020)
<i>Thyme (Thymus vulgaris L.)</i>	Thymol, carvacrol	MIC of 0.25% (v/v)	(Prastiyanto, et al. 2020)
<i>Clove (Eugenia caryophyllata)</i>	Eugenol, Cariofilene	MIC of 0.25% (v/v)	(Prastiyanto, et al. 2020)
<i>Rosemary (Rosemarinus officinalis)</i>	Borneol, 1, 8-cineole	MIC of 1.0% (v/v) MIC of 0.5% (v/v)	(Prasti- yanto, et al. 2020)
<i>Sage (Salvia officinalis)</i>	Thujone, cin- eol, thymol	MIC of 1.0 (% v/v)	(Prastiyanto, A et al. 2020)
<i>Tea tree (Melaleuca alternifolia)</i>	Terpene	MIC of 0.5% (v/v)	(Prasti- yanto, et al. 2020)



Essential oils			
Name	Active Components	Effectiveness	References
<i>Flavonoids from licorice</i>	glabrol, licochalcone A, licochalcone C, and licochalcone E	After 3 h, at 8 mg/mL killed both MRSA T144 and MSSA ATCC29213 completely and after 1 h, all MRSA T144 and MSSA ATCC29213 cells were killed after exposure to glabrol at 4–16 mg/mL.	(Burgos, et al. 2015)
<i>Clove buds</i>	Eugenol	MIC: 0.62 mg/mL	(Xu, et al. 2016)
<i>Chuzhou chrysanthemum</i>	B-Eudesmene, L-Borneol, Camphor	MIC: 5 mg/mL, MBC: 10 mg/mL	(Cui, et al. 2018)
<i>Syzygium antisepticum plant</i>	b-caryophyllene	MIC: 0.12 mg/mL MBC: 0.5 mg/mL	(Yuan, et al 2018)
<i>Sanguisorba officinalis strains</i>	Ethanol	At the concentration of 10 mg/mL <i>S. officinalis</i> the growth of the MRSA was inhibited. at a low concentration (<2.5 mg/mL), inhibitory effect of <i>S. officinalis</i> on biofilm formation in the MRSA strain was obvious.	(Chen, et al. 2015)
<i>Korean soybean fermented product doenjang</i>	Methanolic	MIC: 2048 µg/mL	(Lalouckova, et al. 2021)

Essential oils			
Name	Active Components	Effectiveness	References
<i>Bisdemethoxycurcumin with three antibiotics (gentamicin, ampicillin and oxacillin)</i>	NR	MIC: 7/8 µg /mL for all <i>S. aureus</i> strains including MRSA. The combination of BDMC with antibiotics caused more than 3 log <sub>10</sub> cfu/mL reductions on all the three <i>S. aureus</i> strains.	(Her-mawati, et al. 2016)
<i>Thymol and carvacrol with organic acids (lactic acid)</i>	NR	Combination of thymol and carvacrol with organic acids results a reduction over two log cycles in initial bacterial after 24 h. Thymol and carvacrol showed MIC of 0.6 and 1.25 µL/mL and MIC of lactic acid was 2.5 µL/mL	(de Oliveira, et al. 2010)
<i>Elettaria cardamomum ethnolic extract</i>	a-terpinyl acetate and 1,8 cineole	MIC: 0.25 mg/disk, MBC: 0.50 mg/disk	(Yassin, et al. 2022)
<i>Nigella sativa (Black seed) Oil</i>	Heptanal, Benton 2,3-dimethyl, 1-OCTAN-1,1-D2-OL and Pentane, 2-cyclopropyl	MIC shows that at the concentration of 400 µl with (7± 1) mm of inhibition zone and 800mL concentration was (10± 0.9) mm	(Abdullah, et al. 2021)
<i>Litsea cubeba essential oil</i>	β-Citral and α-Citral	MIC 0.5 mg/ mL, MBC 1.0 mg/ mL	(Hu, et al. 2019)
<i>Red Propolis</i>	Pinobanksin, pinobanksin-3-acetate	MIC: of 50 µg/mL MBC: 200 µg/mL	(Zhang, et al. 2022)

Essential oils			
Name	Active Components	Effectiveness	References
<i>Essential Oil Extracted from Carum carvi L. seeds (CEO)</i>	Carvone and limonene	MIC: 6.4 µg/mL	(Liu, et al. 2023)
<i>Ethanol Extracts of Psoralea corylifolia Seeds</i>	Phenol, hydrazine, aldehyde, and ketone	MIC: 50 µg/mL MBC: 100 µg/mL	(Li, et al. 2019)
<i>Black seed (Nigella sativa) oil</i>	Heptanal, Benton 2,3-dimethyl, 1-OCTAN-1,1-D2-OL and Pentane, 2-cyclopropyl	MIC: 32.8 mg/mL MBC 42.2 mg/mL	(Abdullah, et al. 2021)
<i>Backhousia citriodora Essential Oil (BCEO) leaves</i>	oxygenated monoterpenes and neral phytochemicals	MIC: 6.25 µL/mL, MBC: 50 µL/mL	(Lim, et al. 2022)
<i>Pelargonium graveolens Oil</i>	citronellol, citronellyl formate	MIC: 1.56 µg/mL.	(Jaradat, et al. 2022)
<i>Origanum-vulgare and Eugenia caryophyllata oil</i>	phenols components	MIC CEO: 10 µg/mL MIC OEO: 0.63 µg/mL	(Debiagi, et al. 2020)
<i>Essential Oils from Leaves of Some Aromatic Plants</i>	Monoterpenes	MIC :2.00 %, MBC>4.00 %	(Bugayong, et al. 2019)

Essential oils			
Name	Active Components	Effectiveness	References
<i>Essential Oils from Elettaria Cardamomum fruit capsules</i>	monoterpenes and sesquiterpenes	MIC: 250 µg/mL.	(Jha, et al. 2022)

NR: not reported

### **Bacteriophage**

A phage endolysin, *LysP108*, was able to decrease viable *MRSA* cells by approximately 2 log units within 30 minutes at an optimal concentration of 250 µg/mL. At an MIC of 100 µg/mL, while the antibiofilm activity of the endolysin resulted in the removal of 66% of *MRSA* biofilm (Lu, et al. 2021). Endolysin *LysSA11*, at a concentration of 450 nM, reduced the optical density of the *S. aureus* culture after 30 minutes. However, the efficacy of *LysSA11* declined by 50% at temperatures of 4 °C or 65 °C (Chang, et al. 2017). Two other endolysins, *CHAPLysGH15* and *LysGH15*, that were isolated from *S. aureus*, showed a rapid antibacterial effect on *MSSA* and *MRSA* strains. Although they became inactive when exposed to heat treatment, *CHAPLysGH15* demonstrated high activity at pH 7.0–10.0, and *LysGH15* was active in high-salt environments. Therefore, they can be used in salty foods, as well as alkaline foods, including raw beef, pork, fish, and chicken, which are prone to contamination with *S. aureus* (Yan, et al. 2021). A well-studied, *S. aureus*-specific bacteriophage, Phage K, demonstrated a good inhibitory effect on *S. aureus* strains, including *MRSA*. Furthermore, when this phage was combined with essential oils, such as *a-pinene*, the inhibitory effect was greater than either the phage or the essential oil alone (Ghosh, et al. 2016). When Phage *SapYZU11* was applied at a multiplicity of infection (MOI) of 100, it resulted in the maximum reduction of *MRSA JCSC 4744* and *S. aureus* cocktail after 4 days, with reductions of 0.33 log CFU/mL and 0.29 log CFU/mL, respectively. These findings suggest that *SapYZU11* could be utilized as a biocontrol agent to effectively combat *S. aureus* contamination in the food industry (Wen, et al. 2023). Good results have been reported for combinations of phages and other antimicrobials, such as bacteriocins. For example, a combination of phage *SAP84* and a bacteriocin from *L. lactis CJNU* demonstrated significantly better *anti-S. aureus* activity

compared to each one alone (Kim, et al. 2019). The synergistic inhibition of the combination of phage SAP84 and bacteriocin against *S. aureus* caused a reduction of more than 5 log in viable counts, while the phage alone led to only about a 2 log cfu/mL reduction in *S. aureus* counts (Kim, et al. 2019). In another study, a lower concentration of endolysin *LysH5* was required in combination with subinhibitory concentrations of nisin to achieve complete inhibition of *S. aureus* Sa9 (Arumugam, et al. 2019). After the treatment with 1  $\mu$ M of recombinant SAP8 endolysin, the initial MRSA count of 5.93 log CFU/mL was reduced to 3.64 log CFU/mL. In addition, the combination of 0.01  $\mu$ M of recombinant SAP8 endolysin and 18 IU/mL of nisin completely prevented the growth of MRSA (Hassan, et al. 2020). Also, the combination of bacteriophage endolysin *LysSA97* with *carvacrol* was found to significantly decrease the number of viable *S. aureus* cells (Chang, et al. 2017). When a combination of *S. aureus* phage (MOI 10) and 1% thyme oil was used, a greater reduction (87.22%) in *S. aureus* was achieved compared to using each treatment alone (Abdallah, et al. 2021). These examples indicate that phages can have a synergistic effect with other antibacterials. The effects of different bacteriophages and endolysins against *S. aureus*, including MRSA, have been reported in studies that are summarized in Table 2. Based on Table 2, the most effective phage compounds are *S. aureus* phage (containing *CHAPLysGH15* and *LysGH15*), phage SA11 endolysin *LysSA11*, endolysin *LysSA97* with *carvacrol*, and phage endolysin *LysH5* and *nisin*, respectively.

Table 2. Effect of bacteriophages and endolysins against MRSA

Bacteriophage			
Name	Active Components	Effectiveness	References
Endolysin <i>LysP108</i>	NR	MIC: 100 $\mu$ g /mL	(Lu, et al. 2021)
Staphylococcus aureus bacteriophage	<i>CHAPLysGH15</i> and <i>LysGH15</i>	MRSA was completely cleaved by 0.4 nmol/cm <sup>2</sup> of <i>CHAPLysGH15</i> . 1.0 Log <sub>10</sub> cfu/cm <sup>2</sup> of MRSA declined after adding 0.4 nmol/cm <sup>2</sup> of <i>LysGH15</i>	(Li, et al. 2011)

Bacteriophage			
Name	Active Components	Effectiveness	References
Endolysin <i>LysSA97</i> (an endolysin encoded by the bacteriophage SA97) with <i>carvacrol</i>	NR	The numbers of <i>S. aureus</i> cells were decreased by $0.8 \pm 0.2$ log cfu/mL and $1.0 \pm 0.0$ log cfu/mL at concentrations of 376 nm and 3.33 mm, respectively.	(Chang, et al. 2017)
EOCs ( <i>a-pinene</i> and <i>3-carene</i> ) combined with two types of <i>S. aureus</i> bacteriophage, <i>phage K</i> (ATCC 19685-B1) and <i>phage 92</i> (ATCC 33741-B1)	NR	Both phage of <i>S. aureus</i> -specific bacteriophage alone and EO ( <i>a-pinene</i> ) alone at 1.5 and 3.28 % yielded similar inhibition trends. However, with <i>phage K</i> and EOC (essential oil compounds) combinations, <i>phage K</i> with 3.28 % <i>a-pinene</i> inhibited <i>S. aureus</i> growth better than other combinations of EOCs and phage depending on the strain.	(Jaradat, et al. 2021)
<i>Phage SA11</i> endolysin <i>LysSA11</i>	NR	The highest dose of <i>Phage SA11 endolysin LysSA11</i> (450 nM of endolysin) yielded a 50% reduction in optical density in less than 20 min and a 70% reduction within 30 min. <i>LysSA11</i> treatment (3.37 $\mu$ M, 1 h) reduced the number of <i>staphylococcal cells</i> in milk by about 2.53 log/mL	(Chang, et al. 2017)
Phage endolysin <i>LysH5</i> and <i>nisin</i>	NR	The MICs of <i>nisin</i> and <i>LysH5</i> were 3 $\mu$ g/mL and 50u/mL, respectively but in the presence of subinhibitory concentrations of <i>nisin</i> , a lower endolysin concentration was needed to fully inhibit <i>S. aureus Sa9</i> . These values implied up to a 64-fold and 16-fold reduction of the <i>nisin</i> and endolysin MICs, respectively, when used in combination.	(Arumugam, et al. 2019)

NR: not reported

## **Bacteriocins**

According to studies, the growth of gram-positive pathogens, including *S. epidermidis*, *S. aureus*, and MRSA, was effectively inhibited by *NX371*, a novel class III bacteriocin gene. When *NX371* was added to milk, it moderately but significantly inhibited the growth of pathogens from day 1 to day 7, with reductions of 3.5 - 4.0 log in milk and 5.0 - 7.0 log in cheese, indicating its effectiveness as a food additive for controlling *S. aureus* in dairy products (Meng, et al. 2021). *Colicin* and *interocin* bacteriocins produced by *Escherichia coli* strains and *Enterococcus* species were found to have bactericidal effect against MRSA and other *Staphylococcal* isolates, with complete bactericidal action achieved after 18-24 hours of incubation (Bajlan, et al. 2018). Bacteriocin produced by *Lactobacillus plantarum* ZJ217 (*plantaricin* ZJ217) was found to significantly decrease the colony forming units (Log<sub>10</sub> CFU) of *S. aureus*, with viable cell counts decreasing from  $6.5 \pm 0.1$  to  $3.7 \pm 0.04$  log CFU/mL within 2 hours of incubation (Zhu, et al. 2015). Bacteriocin *KTH0-1S* produced by *Lactococcus lactis* *KTH0-1S* was found to significantly reduce the viable cell counts of *S. aureus* within 2 hours of incubation, with a higher proportion of dead cells compared to the control treatment (Saelao, et al. 2017). Bacteriocin *Paracin 54* produced by *Lactobacillus paracasei* *ZFM54*, was found to have a strong inhibitory effect on *Staphylococci*, with minimum inhibitory concentration values of 3.00 - 4.50 µg/mL (Zhu, et al. 2021). Bacteriocin producing *Pseudomonas aeruginosa* *TA6*, isolated from soil, was found to decrease the cell density of *S. aureus* rapidly, with cell lysis eventually occurring at concentrations of 100 AU/mL (Arumugam, et al. 2019). *Plantaricin 827*, produced by *Lactobacillus plantarum* *163*, was found to quickly decrease *S. aureus* cells within 150 minutes of treatment with 64 µg/mL, and all *S. aureus* cells were destroyed within 90 minutes of treatment with 128 µg/mL. Moreover, *plantaricin 827* exhibited a certain preservation effect in skimmed milk and significantly extended the shelf life of skimmed milk (Zhao, et al. 2022). Bacteriocins produced by two strains, *Lactobacillus helveticus* (*BLh*) and *Lactobacillus plantarum* (*BLp*), had significant activity against *S. aureus* and MRSA. *L. helveticus* (*BLh*) was the most effective against MRSA after 18 to 24 hours of incubation at 37°C, while *L. plantarum* (*BLp*) had a similar effect against MRSA after 24 to 48 hours of incubation at 37°C under anaerobic conditions. The bacteriocin extracted from *L. plantarum* (*BLp*) was active even after passing through high temperature and pressure during sterilization, but the bacteriocin synthesized by *L. helveticus* (*BLh*) was more labile to heat (Hassan, et al. 2020). *Nisin*, a bacteriocin produced by the *Lactococcus lactis subsp. lactis* bacterium, exhibited

bacteriostatic activity against MRSA alone and had no effect against *S. aureus* ATCC 25937, while some strains of *Lactobacillus reuteri* produced reuterin ( $\beta$ -hydroxypropionaldehyde) under anaerobic conditions, which was considered to have bactericidal effects against MRSA and *S. aureus* ATCC25937. The combination of nisin at a concentration of 25.6 and reuterin at a concentration of 5.2 mg/mL exerted a bactericidal effect on MRSA and *S. aureus* ATCC 25937 (Yehia, et al. 2022). Combinations of bacteriocins with other antimicrobials can increase their antibacterial efficacy. For instance, co-treatment of drinks with enterocin and phenolic compounds (2NPOH) resulted in the eradication of viable staphylococci after 24 hours (Burgos, et al. 2015). The effects of different types of bacteriocins against *S. aureus*, including MRSA, have been reported in studies that are summarized in Table 3. According to Table 3, the most effective bacteriocins against *S. aureus* are Enterocin AS-48 with phenolic compounds or with 2NPOH, Bacteriocin isolated from *Lactobacillus pentosus* – Pentocin JL-1, bacteriocin producing *Pseudomonas aeruginosa* TA6, and bacteriocin produced by *S. pasteurii* RSP-1, respectively.

Table 3. Effect of some bacteriocins against MRSA.

Bacteriocins			
Name	Active Components	Effectiveness	References
Bovine myeloid antimicrobial peptide (BMAP-28)	NR	20 mg/mL of BMAP-28 could inhibit the growth of the two kinds of bacteria (MRSA and MSSA). MIC range (mg/mL): 5–20	(Takagi, et al. 2012)
Cell-free extracts of <i>Bifidobacterium</i>	b1, b2, BL and BI	MIC: 1.0 mg/mL	(AL-Saadi 2016)
Bacteriocin Produced by <i>B. cereus</i> TSH5	NR	MIC: 80 $\mu$ g/mL	(Chauhan, et al. 2017)
Bacteriocin produced by <i>Staphylococcus pasteurii</i> RSP-1 ( <i>S. pasteurii</i> RSP-1)	NR	MIC: 5 AU/mL	(Hong, et al. 2018)



Bacteriocins			
Name	Active Components	Effectiveness	References
Bacteriocin isolated from <i>Lactobacillus pentosus</i>	<i>Pentocin JL-1</i>	MIC: 7.5 µg/mL	(Jiang, et al. 2017)
Enterocin AS-48 with phenolic compounds or with 2NPOH	NR	No viable <i>staphylococci</i> were detected after 24 h incubation with the combination of <i>enterocin AS-48</i> and 2NPOH	(Murray, et al. 2021)
Bacteriocin from <i>Lactococcus lactis KU24</i>	<i>Bacteriocin KU24</i>	<i>S. aureus ATCC 33591</i> was inhibited by <i>bacteriocin KU24</i> at 2 Log cfu/mL after 10 h of incubation. MIC: 400 to 800 AU/mL	(Lee, et al. 2013)
Bacteriocin producing <i>Pseudomonas aeruginosa TA6</i>	NR	MIC: 50 AU/mL the cell density of <i>S. aureus</i> decreased rapidly, and cell lysis occurred at 100 AU/mL concentrations	(Zhou, et al. 2017)
Bacteriocin producing <i>Lactobacillus acidophilus</i>	<i>bacteriocin gene NX371</i>	MIC <sub>90</sub> was ranged from 20 to 160 µg/mL	(Meng, et al. 2021)
Bacteriocins produced by <i>Escherichia coli</i> and <i>Enterococcus species</i>	<i>Colicin and interocin</i>	The incubation times for complete bactericidal action were 18-24h.	(Bajlan, et al. 2018)
Bacteriocin produced of <i>Lactococcus lactis KTH0-1S</i>	<i>Bacteriocin KTH0-1S</i>	The proportion of dead cells was significantly higher since viable cell counts decreased from 6.5±0.1 to 3.7±0.04 log CFU/mL within 2 h of incubation	(Saelao, et al. 2017)
Bacteriocin produced of <i>Lactobacillus paracasei ZFM54</i>	<i>Bacteriocin Paracin 54</i>	MIC: 3.50 µg/mL	(Zhu, et al. 2021)

Bacteriocins			
Name	Active Components	Effectiveness	References
Bacteriocin producing from <i>Pseudomonas aeruginosa</i> TA6	NR	Maximum bacteriocin activity (100AU/mL) was observed at 37 °C in 24 h time duration.	(Arumugam, et al. 2019)
Bacteriocin produced by <i>Lactobacillus plantarum</i> 163	<i>Plantaricin</i> 827	MIC: 64 µg/mL.	(Zhao, et al. 2022)
Bacteriocin produced by <i>Lactobacillus helveticus</i> and <i>Lactobacillus plantarum</i>		<i>L. helveticus</i> showed the activity against MRSA after 18 to 24 hours of incubation at 37°C. In comparison, <i>L. plantarum</i> showed similar activity against MRSA after 24 to 48 hours of incubation at 37°C under anaerobic conditions.	(Hassan, et al. 2020)
Bacteriocin produced by <i>Lactococcus lactis</i> subsp. <i>lactis</i> . and <i>Lactobacillus reuteri</i>	<i>Nisin and reuterin</i>	MIC of nisin: 51.2 mg/ mL, MIC of reuterin: 5.2mg/mL MBC of nisin: 5 mg/mL, MBC for reuterin: 5 mg/mL	(Yehia, et al. 2022)

NR: not reported

## Probiotics

The most common probiotics are *lactic acid bacteria* (LAB) strains, and they are considered safe. LAB can produce bactericidal bioactive peptides and enzymes that have antibacterial and antibiofilm effects (Hermawati, et al. 2016). For instance, *Lactobacillus* can inhibit *Staphylococcal cells*, including MRSA (Hermawati, et al. 2016). Several probiotics such as *Lactobacillus plantarum* (Lee, et al. 2021, Afshari, et al. 2022), *Lactobacillus acidophilus*, *Lactobacillus casei* (Hermawati, et al. 2016), *Streptomyces griseus*, *Lactococcus lactis*, *Streptococcus*, *Leuconostoc*, and *Pediococcus* (Li, et al. 2011) have demonstrated

inhibitory effects on *S. aureus* strains, including MRSA. Table 4 shows the effects of different probiotics on MRSA. According to Table 4, the most effective probiotics were *Streptomyces griseus*, *Pediococcus acidilactici* strains A11 and C12, *Lactococcus lactis*, and *Lactobionic acid*, respectively.

Table 4. Effect of some probiotics against MRSA

Probiotic			
Name	Active Components	Effectiveness	References
<i>Lactobacillus acidophilus</i> and probiotic <i>Lactobacillus casei</i>	NR	MIC: 3.12% for <i>Lactobacillus acidophilus</i> and 2% <i>Lactobacillus casei</i>	(Karska-Wysocki, et al. 2010)
Probiotic <i>Lactobacillus plantarum</i> KU200656	NR	MIC :12.5%	(Lee, et al. 2021)
<i>Pseudomonas fluorescens</i>	<i>Pseudomonic acids</i> and <i>Mupirocin</i>	MIC of 8-256 µg/mL for low level resistance and 512 µg/mL for high level resistance	(Prastiyanto, et al. 2020)
<i>Streptomyces griseus</i>	<i>Treptose</i> , <i>streptidine</i> , and <i>N-methyl- L -glycosamine</i> and <i>Streptomycin</i>	MIC: 1.56-6.25 µg/mL	(Prastiyanto, et al. 2020)
<i>Lactococcus lactis</i>	<i>Lnathionine (Lan)</i> , <i>methyllanthionine (MeLan)</i> , <i>didehydroalanine (Dha)</i> and <i>didehydroaminobutyric acid (Dhb)</i> and <i>Nisin</i>	MIC: 1.5 to > 1.6 mg/L	(Prastiyanto, et al. 2020)
<i>Streptococcus</i> , <i>Leuconostoc</i> , <i>Lactobacillus</i> , and <i>Pediococcus</i>	<i>Diacetyl</i>	MIC: 1.00 µg/mL	(Prastiyanto, et al. 2020)
<i>Pediococcus acidilactici</i> strains A11 and C12	NR	MIC: 25%, MBC: 12.5%	(Lestari, et al. 2019)

NR: not reported

## DISCUSSION

### *Essential oils*

Several possible mechanisms have been proposed for antibacterial activity of essential oils. Table 4 shows the mechanisms of action of reported EOs. Essential oils can inhibit enzymes and compounds that are needed for the growth of *MRSA* (Eom, et al. 2014; Burris, et al. 2015). For example, *cinnamaldehyde* in cinnamon oil inhibits *N-3-oxohexanoyl-L-homoserine lactone* (*3-oxo-C6-HSL*) and *AI-2* (Salem 2017) while allicin liquid can inhibit sulfhydryl enzymes, thereby inhibiting DNA and protein synthesis (Cutler, et al 2004; Li, et al. 2011). Some EOs can cause the release of intracellular components (Eom, et al. 2014; Jaradat, et al. 2021), such as brown algae, which lead to the release of intracellular components via phlorofucofuroeckol (PFF) (Eom, et al. 2014). Inhibition of enzymes by EOs can occur through participation in electron transport with the cell components and binding to bacterial adhesions and cell walls (Ifesan, et al. 2009). *Aloysia citriodora* EO can participate in the lipophilic lipids of the mitochondria and cytoplasmic membrane due to their lipophilic ability (Jaradat, et al. 2021). The lipophilic characteristics of EOs make them capable of easily penetrating the bacterial cell (Prastiyanto, et al. 2020). For example, *terpenoids* in mushroom *Pleurotus flabellatus* have this ability and can interfere with protein synthesis and DNA replication (Prastiyanto, et al. 2020). Additionally, some EOs such as EOs derived from *Chuzhou chrysanthemum* and *clove buds* increase the permeability of the cell membrane, resulting in the leakage of intracellular essential substances such as electrolytes, protein, and nucleic acids (Xu, et al. 2016; Cui, et al. 2018). Many EOs such as *carvacrol* are safe to apply in foods as a natural food preservative and are 'Generally Recognized as Safe' (GRAS) by the US Food and Drug Administration (FDA) (Chang, et al. 2017). EOs can have an enhanced effect when they are used at high concentrations (Higginbotham, et al. 2014). Furthermore, if they are applied in processed foods such as hot dogs, chemicals like potassium lactate, sodium lactate, sodium diacetate, and sodium nitrite, they can improve the antimicrobial activity of the Eos (Higginbotham, et al. 2014). Black seed (*Nigella sativa*) is a type of medicinal herb that contains bioactive substances of medical importance. The GC-MS analysis of *N. sativa* shows that it contains five essential compounds, all of which are a unique mix of organic compounds and alkaloids that possess high biological activity, such as *Hep-tanal*, *Benton 2,3-dimethyl, 1-OCTAN-1,1-D2-OL*, and *Pentane, 2-cyclopropyl* (Abdullah, et al. 2021). *Litsea cubeba* essential oil (*LC-EO*) can cause *MRSA* cell rupture, which results in the leakage of cellular content and ultimately

leads to the bacteria's death. LC-EO treatment decreases the activity of four ATPases, including the Na<sup>+</sup>/K<sup>+</sup> ATPase, Ca<sup>2+</sup>/Mg<sup>2+</sup>ATPase, Ca<sup>2+</sup>ATPase, and Mg<sup>2+</sup>ATPase (Hu, et al. 2019). *Chinese Red Propolis* is rich in *pinobanksin* and *pinobanksin-3-acetate*, and its antibacterial activity may be the result of the synergistic effect of polyphenols (Zhang, et al. 2022). *Carum carvi* L. disrupts MRSA biofilm and amino acid metabolism, and it also hinders DNA and RNA synthesis (Liu, et al. 2023). *Psoralea corylifolia* seed ethanol extract (PCEE) is composed of *phenol*, *hydrazine*, *aldehyde*, and *ketone*, which can destroy the cell structure and reduce enzymes, ultimately killing bacteria (Li, et al. 2019). *Backhousia citriodora* Essential Oil (BCEO) contains large amounts of *oxygenated monoterpenes*, which disrupt the microbial cytoplasmic wall, improve cell permeability, and lead to cell death (Lim, et al. 2022). Oregano essential oil (OEO) and cinnamon essential oil (CEO) increase cell permeability and cause leakage of intracellular constituents, leading to the disruption of the cell respiration system and microbial enzyme system (Debiagi, et al. 2020). *L. micromera* and *P. amboinicus* essential oils contain *monoterpenes* such as *carvacrol*, *γ-terpinene*, and *β-cymene*, which are responsible for their antibacterial activity against *Staphylococcus species* including MRSA (Bugayong, et al. 2019). *Elettaria cardamomum* essential oil blurs the surface barrier of the cell wall, altering the structure of the cells, and causing bacterial mortality (Jha, et al. 2022). The combination of EOs can enhance the efficacy of their antibacterial activity. For instance, when *carvacrol* and *thymol* are combined with organic acids, a significant reduction in the number of *S. aureus* is observed on food samples. On one hand, these EOs disrupt the bacterial cell membrane and make the bacteria more susceptible to the acidic environment. On the other hand, organic acids enhance the hydrophobicity of EOs and make the EOs bind better to hydrophobic regions of the membrane proteins (de Oliveira, et al. 2010). Thyme oil, when combined with lytic *S. aureus* phage, is a promising biocontrol agent and antimicrobial alternative in the food industry to control and reduce MRSA or other *antibiotic-resistant S. aureus* contamination in food (Abdallah, et al. 2021). Some plant extracts can increase the effectiveness of antibiotics against MRSA. For instance, *ursolic acid 3-O-α-L-arabinopyranoside* (URS) from the leaves of *Acanthopanax henryi* (Oliv.) can enhance the *anti-MRSA* effect of oxacillin (Zhou, et al. 2017).

## **Bacteriophages**

Bacteriophages encode peptidoglycan hydrolases, known as endolysins or lysins, which lyse bacterial cells by targeting their cell wall, particularly in Gram-positive bacteria, due to their naturally exposed peptidoglycan layer (Murray,

et al. 2021). Bacterial death by endolysins is in accordance with the typical phenomenon of osmotic-mediated cell lysis, which occurs in Gram-positive bacteria following a phage attack (Lu, et al. 2021). For instance, *LysP108* causes disintegration of the *MRSA* cell wall (Lu, et al. 2021). It has been reported that a combination of endolysin *LysSA97* with *carvacrol* can cleave bacterial peptidoglycan layers and destroy the structure of the cell wall (Chang, et al. 2017). Combining endolysins with antibiotics causes better accessibility of antibiotics to *MRSA* cells through initial lysing of the biofilm by endomysia (Linden, et al. 2015). Combining endolysins with bacteriocins can result in a higher sensitivity of *S. aureus* cells to these antibacterials. The mechanism might be attributed to the prevention of peptidoglycan breaks produced by endolysins from contraction (Arumugam, et al. 2019). Moreover, bacteriocins can cause a partial activation of autolysins that allows for better activity of the endolysin (Arumugam, et al. 2019). The combination of synthetic *SAP8 endolysin* and *nisin* can effectively restrain various types of Gram-positive bacteria by creating openings in the bacterial cell membrane and blocking the production of cell walls (Kim, et al. 2022).

### **Bacteriocin**

Bacteriocins can cause damage to the cell wall or induce cell lysis (Lee, et al. 2013). They target the cytoplasmic membrane of bacterial cells and inhibit the proton motive force (PMF), leading to inhibition of protein or nucleic acid production (Lestari, et al. 2019). The *anti-MRSA* activity of bacteriocins is mainly due to the generation of organic acids such as *lactic acid* and *acetic acid*. These acids enter bacterial cells and interfere with essential metabolic processes (AL-Saadi 2016). Bacteriocins against *MRSA* can change the cell surface from smooth to rough. Therefore, the suggested mechanism is related to the bacterial cell membrane (Takagi, et al. 2012). Several bacteriocins have been reported to have *anti-MRSA* activity, leading to the disruption in the integrity and uniformity of *MRSA* (Zhu, et al. 2015; Jiang, et al. 201; Taggar, et al. 2021). Through bioinformatic analysis of *Lactobacillus acidophilus*, a new class III bacteriocin gene called *NX371* was discovered, which demonstrated high antimicrobial activity across a wide range of pH values (3.0-8.0). This bacteriocin was able to disrupt the cell wall of gram-positive bacteria and induce membrane leakage in gram-negative bacteria, leading to separation of the cell wall and membrane (Meng, et al. 2021). Other bacteriocins such as *colicins* and *enterocins* also exhibit antibacterial effect against Gram-positive bacteria, with *colicins* acting as transmembrane proteins that depolarize the cytoplasmic

membrane and kill cells by producing pores or acting as a nuclease to chop up DNA or RNA (Bajlan, et al. 2018). Another example is *plantaricin ZJ217*, a novel bacteriocin produced by *Lactobacillus plantarum ZJ217*, which was inhibitory effect against a variety of gram-positive and gram-negative bacteria by forming pores in cells (Zhu, et al. 2015). Similarly, bacteriocin *KTH0-1S* produced by *Lactococcus lactis KTH0-1S* acted on sensitive cells by forming pores in membranes, leading to cell death due to the loss of essential intracellular substances (Saelao, et al. 2017). *Paracin 54*, a bacteriocin produced by *Lactobacillus paracasei ZFM54*, also formed pores in the cell membrane of *MRSA*, which disrupted the balance of ions inside and outside the membrane and led to the dissipation of proton driving force, inhibiting the synthesis of intracellular ATP and causing the disorder of intracellular energy metabolism (Zhu, et al. 2021). Another bacteriocin, *plantaricin 827*, produced by *Lactobacillus plantarum 163*, had antibacterial effects against *MRSA* by increasing the cell membrane permeability and integrity, resulting in the leakage of K<sup>+</sup> and changes in cell morphology, inhibiting biofilm formation, and interacting with genomic DNA minor groove in AT-rich regions (Zhao, et al. 2022). The combination of *nisin* produced by *Lactococcus lactis subsp. lactis* and *reuterin* produced by *Lactobacillus reuteri* also disrupted membranes by forming pores, inhibiting energy production and biosynthesis of proteins and nucleic acids (Yehia, et al. 2022). Despite the fact that they are proteins, some bacteriocins can remain stable in harsh environmental conditions. For instance, *Paracin 54* retained 93.7% of its activity after treatment with lysozyme, indicating its potential for use in food preservation. Furthermore, *Paracin 54* maintained its inhibitory activity against *MRSA* at different temperatures, suggesting its potential use in pasteurized products (Zhu, et al. 2021). *Plantaricin 827* also exhibited antibacterial activity at pH 7.0, while *plantaricin ZJ217* was stable at pH 2.0 to 6.0 but lost activity at pH 10.0 (Zhu, et al. 2015).

## **Probiotics**

The major effects of probiotics include modulation of the immune system, inhibition of pathogen adhesion to epithelial cells, and generation of antimicrobial compounds (AL-Saadi 2016; Lee, et al. 2021). Antimicrobial compounds produced by probiotics can also demonstrate anti-adhesion ability (Lee, et al. 2021). These antimicrobial components include organic acids, oxygen catabolites, and proteinaceous compounds (Lee, et al. 2021). These components can inhibit the growth of *MRSA* cells in food products (Karska-Wysocki, et al. 2010). For instance, *Lactococcus lactis* can generate antibacte-



rial agents, including *didehydroaminobutyric acid (Dhb)* and *didehydroalanine (Dha)*, *methyllanthionine (MeLan)*, *Lanthionine (Lan)*, and *bacteriocin (Nisin)*. These substances can disrupt the uptake of amino acids by *S. aureus* cells and suppress the production of the cell wall. In addition, some metabolites will be released, leading to cell death (Li, et al. 2011). Generally, *LBA* can cause alkaline phosphatase leakage from *MRSA cells* to the extracellular medium, and in this way, they prevent the formation of biofilms (Kang, et al. 2020). A list of *anti-S. aureus* agents and their modes of action is in Table 5.

Table 5. Mechanisms of action of anti-MRSA EOs, bacteriophages, bacteriocins, and probiotics.

Name	Active Components	Mechanisms	References
<b>Essential oils</b>			
Essential oils: Cinnamon oil, Thyme oil and Lemongrass oil	<i>Cinnamaldehyde, eugenol, Alpha and beta-citral, mycrene</i>	These can inhibit <i>N-3-oxohexanoyl-Lhomoserine lactone (3-oxo-C6-HSL)</i> and <i>AI-2</i> , and certain enzymes needed for the growth of <i>MRSA</i> .	(Salem 2017)
Liposome containing cinnamon oil	NR	The damage of bacterial cell membrane is by their effect on morphology, structure, function, modification in the transport of nutrients, membrane disruption, extensive leakages from the bacterial cells leading to cell death.	(Cui, et al. 2016)
Indian Spices	<i>Syzygium aromaticum (CLV) and Cinnamomum zeylanicum (CIN) and Cuminum cyminum (CMN)</i>	These can affect the synthesis of the peptidoglycan layer of the cell wall and the mode of action of the spice extracts is cell wall related.	(Mandal, et al. 2011)



Name	Active Components	Mechanisms	References
<b>Essential oils</b>			
<i>Camellia sinensis</i> and <i>Azadirachta indica</i> leaves	<i>catechin</i>	The <i>catechin</i> has direct effects on the destruction of the bacterial cell membrane by binding with the lipid bilayer.	(Zihadi, et al. 2019)
<i>Allicin</i>	NR	Inhibit the acetyl coA forming system, to inhibit DNA and protein synthesis, and to target RNA polymerase.	(Cutler, et al 2004)
<i>Cinnamomum osmophloeum</i> leaf essential oils	<i>cinnamaldehyde</i>	NR	(Chang, et al. 2001)
<i>Thyme</i> ( <i>Tymus vulgaris</i> ) and <i>Oregano</i> ( <i>Origanum vulgare</i> ) essential oils	<i>Thymol</i> from <i>Thyme</i> and <i>Carvacrol</i> from <i>Oregano</i>	Phosphate ion leakage.	(Boskovic, et al. 2015)
<i>PFF</i> (phlorofucofuroeckol, a marine-derived polyphenol found in brown algae)	NR	Interfering with cell wall synthesis and the cell membrane and agents change membrane function and permeability, leading to cell damage or death.	(Eom, et al. 2014)

Name	Active Components	Mechanisms	References
<b>Essential oils</b>			
<i>URS (ursolic acid 3-O-<math>\alpha</math>-L arabinopyranoside was isolated from the leaves of A. henryi (Oliv) with oxacillin</i>	Q	Deformation of bacterial cells. Cell membrane disintegration, cell lysis and release of cytoplasmic contents.	(Yan, et al. 2021)
<i>Pink oyster mushroom Pleurotus flabellatus</i>	The terpenoid compound group	These penetrate the bacterial cell and may interfere with protein synthesis and DNA replication.	(Ghosh, et al. 2016)
<i>Amomum villosum Lour</i>	Bornyl acetate	Leakage of intracellular macromolecular substances.	(Tang, et al. 2020)
<i>Bulb Eleutherine Americana</i>	Naphthoquinone	Inhibits electron transport with the cell components. They also can bind to bacterial adhesions and complex with cell wall, thus inactivating enzymes.	(Ifesan, et al. 2009)
<i>Aloysia citriodora essential oils EOs from Baqa al-Gharbiyye and Umm al-Fahm</i>	lipophilic structures like $\alpha$ - citral and $\alpha$ -curcumene	Their lipophilic ability to partition in the lipophilic lipids of the mitochondria and cytoplasmic membrane. They could also disturb the structures, resulting in leakage of bacterial cell contents.	(Aru-mugam, et al. 2019)

Name	Active Components	Mechanisms	References
<b>Essential oils</b>			
<i>Garlic</i>	Allicin (allyl 2-propenethiosulphinate)	1) The primary mechanism of allicin centers on its ability to inhibit sulfhydryl enzymes common for pathogenic bacteria. 2) Inhibiting enzymes associated with DNA and protein synthesis and limiting RNA polymerase and alcohol dehydrogenase activities.	(Prasti-yanto, et al. 2020)
<i>flavonoids from licorice</i>	glabrol, licochalcone A, licochalcone C, and licochalcone E	Disruption of membrane permeability. The binding of these to the cell wall or the cytoplasmic membrane is important for their action on the bacterial membrane.	(Burgos, et al. 2015)
<i>Clove buds</i>	Eugenol	The permeability of bacterial membrane would be increased, which caused the leakage of intracellular ingredient, especially losses of electrolytes including K <sup>+</sup> , Ca <sup>2+</sup> , Na <sup>+</sup> , as well as cell constituents such as protein, nucleic acids, and some essential molecules.	(Xu, et al. 2016)
<i>Chuzhou chrysanthemum</i>	B-Eudesmene, L-Borneol, Camphor	Disruption of the cell membrane and leakage of DNA, protein and ATP to the bulk solution.	(Cui, et al. 2018)

Name	Active Components	Mechanisms	References
<b>Essential oils</b>			
<i>Syzygium antisepticum plant</i>	b-caryophyllene	Membrane-disrupting effect was observed	(Yuan, et al 2018)
<i>Korean soybean fermented product doenjang</i>	Methanolic	Inhibits the respiratory metabolism and protein synthesis of the bacteria and prevents nucleic acid synthesis. Thus, it affects the integrity of the cell wall and membrane.	(Lalouckova, et al. 2021)
<i>Bisdemethoxycurcumin with three antibiotics (gentamicin, ampicillin, and oxacillin)</i>	NR	The polyphenol structure can destroy the cell wall of bacteria and thus increases the efficiency of antibiotics entering the cell.	(Wang, et al. 2020)
<i>Thymol and carvacrol with organic acids (lactic acid)</i>	NR	Phenolic compounds can damage cellular membrane changing their structure and function and causing it to become more susceptible to acid environments. On the other hand, at low pH the molecules of thymol and carvacrol are mostly dissociated, more hydrophobic, and bind better to hydrophobic regions of the membrane proteins resulting in better partition into the lipid phase of the bacterial membrane.	(de Oliveira, et al. 2010)

Name	Active Components	Mechanisms	References
<b>Essential oils</b>			
<i>Litsea cubeba essential oil</i>	$\beta$ - Citral and $\alpha$ -Citral	The LC-EO could lead to the rupture of MRSA cells and the loss of cellular contents and eventually to the death of bacteria.	(Hu, et al. 2019)
<i>Red Propolis</i>	Pinobanksin, Pinobanksin-3-acetate	The mechanism of action of RPE due to loss of membrane integrity.	(Zhang, et al. 2022)
<i>Ethanol Extracts of Psoralea corylifolia Seeds</i>	phenol, hydrazine, aldehyde, and ketone	PCEE could change the membrane integrity of MRSA, releasing nucleic acids and proteins, resulting in bacterial death.	(Li, et al. 2019)
<i>Manuka EO was extracted from manuka leaves</i>	Sesquiterpenes	MIC: 0.233 mg/mL, MBC: 0.466 mg/mL	(Pedonese, et al. 2022)
<i>Essential Oils from Elettaria Cardamomum fruit capsules</i>	Monoterpenes and sesquiterpenes	Elettaria cardamomum EO damages the biofilm barrier, causing the bacteria to lose metabolic activity.	(Jha, et al. 2022)
<b>Bacteriophages</b>			
Phage Endolysin <i>LysP108</i>	NR	<i>LysP108</i> disintegrated the cell wall of MRSA.	(Lu, et al. 2021)

Name	Active Components	Mechanisms	References
<b>Bacteriophages</b>			
Bacteriophage <i>endolysin plygrcs</i>	<i>PlyGRCS</i>	The endolysin <i>plygrcs</i> would provide the initial disturbance to the biofilm structure.	(Linden, et al. 2015)
<i>Carvacrol and lyssa97</i>	NR	<i>LysSA97</i> cleaving bacterial peptidoglycan layers is likely to render the cell wall structure less rigid so that <i>carvacrol</i> may more readily reach the cytoplasmic membrane of <i>S. aureus</i> .	(Chang, et al. 2017)
<i>Phage endolysin lysh5 and nisin</i>	NR	<i>LysH5</i> activity might be increased by the permeabilization of the cytoplasmic membrane by <i>nisin</i> . Also, partial activation of autolysins by <i>nisin</i> may occur and facilitate <i>LysH5</i> activity.	(García, et al. 2010)
<i>SAP8 endolysin</i>	NR	Forms pores in bacterial cytoplasmic membrane and inhibits cell wall synthesis	(Kim, et al. 2022)
<b>Bacteriocins:</b>			
<i>Bovine myeloid antimicrobial peptide (BMAP-28)</i>	NR	1) Cell wall permeation is made by the activity of <i>BMAP-28</i> as it is diffusing inside the bacteria. 2) Bacterial smooth surface somehow changes into a rough surface by the activity of <i>BMAP-28</i> . 3) <i>BMAP-28</i> can break <i>MRSA</i> cell membranes.	(Takagi, et al. 2012)

Name	Active Components	Mechanisms	References
<b>Bacteriocins</b>			
<i>Pediococcus acidilactici</i> strains A11 and C12	NR	The initial bacteriocin reaction is to damage membrane permeability and eliminate proton motive force (PMF) thereby inhibiting energy production and biosynthesis of proteins or nucleic acids. 2) bacteriocin molecules are in direct contact with cell membranes, this contact process is able to disrupt membrane potential in the destabilizing cytoplasmic membranes so that cells become less strong, and membrane instability is capable of producing holes in cell membrane through the process of interference with PMF (Proton Motive Force).	(Lestari, et al. 2019)
Cell-free extract of <i>Bifidobacterium</i> Species of LAB	<i>b1, b2, BL and BI</i>	The acids produced by LAB enter the sensitive bacterial cells and interfere with the necessary metabolic process such as substrate translocation and oxidative phosphorylation, which leads to a decrease in the internal pH of bacterial cells.	(AL-Saadi 2016)

Name	Active Components	Mechanisms	References
<b>Bacteriocins</b>			
bacteriocin produced by <i>Staphylococcus pasteurii</i> RSP-1 ( <i>S. pasteurii</i> RSP-1)	<i>Pasteuricin</i>	<i>Pasteuricin</i> rapidly damaged the membrane of viable cells.	(Hong, et al. 2018)
Bacteriocin isolated from <i>Lactobacillus pentosus</i>	<i>Pentocin JL-1</i>	<i>Pentocin JL-1</i> targets the cell membrane of <i>MRSA GIM 1.771</i> , causing a loss of PMF in only a few minutes, and that has a dramatic impact on the structure and integrity of the <i>MRSA</i> cell and finally leads to cell death.	(Jiang, et al. 2017)
Bacteriocin from <i>Lactococcus lactis</i> KU24	<i>Bacteriocin KU24</i>	The bacteriocin <i>KU24</i> damages the cell wall or induces cell lysis and has an impact on the bacterial cytoplasmic membrane.	(Lee, et al. 2013)
Bacteriocin from <i>Lactobacillus plantarum</i> ZJ217	<i>NR</i>	Bacteriocin produced by <i>Lactobacillus plantarum</i> can cause the formation of pores on bacterial cells and releasing ATP, and bacterial death	(Zhu, et al. 2015)
Bacteriocin isolated from the natural inhabitant of <i>Allium cepa</i>	<i>Peptide-Ba49</i>	Peptide-Ba49 can result in the rupturing and uniformity of <i>MRSA</i> .	(Taggar, et al. 2021)



Name	Active Components	Mechanisms	References
<b>Bacteriocins</b>			
Bacteriocin producing <i>Lactobacillus acidophilus</i>	<i>Bacteriocin gene NX371</i>	The leakage of intracellular ATP, disrupt the cell wall, and induce membrane leakage.	(Meng, et al. 2021)
Bacteriocin produced by <i>Escherichia coli</i> strains and <i>Enterococcus</i> species	<i>Colicins and Enterocin</i>	These depolarize the cytoplasmic membrane, leading to dissipation of cellular energy and killing domain may produce a pore in the target cell membrane, or act as a nuclease to chop up the DNA or RNA of the target cell	(Bajlan, et al. 2018)
Bacteriocin produced by <i>Lactobacillus plantarum</i> ZJ217	<i>Plantaricin ZJ217</i>	The Plantaricin ZJ217 had activity against biofilm cells of MRSA by forming pores to release ATP.	(Zhu, et al. 2015)
Bacteriocin produced of <i>Lactococcus lactis</i> KTH0-1S	<i>Bacteriocin KTH0-1S</i>	The KTH0-1S can have an impact on sensitive cells, causing pores formation in the membrane, resulting in cell death due to loss of essential intracellular substances	(Saelao, et al. 2017)
Bacteriocin produced by <i>Lactobacillus paracasei</i> ZFM54	<i>Bacteriocin Paracin 54</i>	The treatment with Paracin 54 enhanced the permeability of the cell membrane, damaged the cell membrane, and led to electrolyte outflow.	(Zhu, et al. 2021)

Name	Active Components	Mechanisms	References
<b>Bacteriocins</b>			
Bacteriocin produced by <i>Lactobacillus plantarum</i> 163	<i>Plantaricin 827</i>	Its antibacterial mechanism increased the cell membrane permeability and integrity, resulting in the leakage of K <sup>+</sup> and changes in cell morphology.	(Zhao, et al. 2022)
Bacteriocin produced by <i>Lactococcus lactis</i> subsp. <i>lactis</i> . and <i>Lactobacillus reuteri</i>	<i>Nisin and reuterin</i>	The combination of nisin and reuterin may change the permeability of the outer membrane and cause a lethal effect.	(Yehia, et al. 2022)
<b>Probiotics</b>			
<i>Lactobacillus plantarum</i> KU200656	NR	It can inhibit the adherence of pathogens by competing for nutrition and host intestinal cell-binding sites, e.g., receptor exclusion. bolites (e.g. hydrogen peroxide), and proteinaceous compounds.	(Lee, et al. 2021)
<i>Lactobacillus acidophilus</i> and <i>Lactobacillus casei</i>	NR	They produce antimicrobial components that can inhibit the growth and eliminate of the <i>MRSA</i> cells.	(Karska-Wysocki, et al. 2010)

NR: not reported.

## CONCLUSION

According to our review, the most effective EO against *MRSA* was a liposome containing cinnamon oil, which resulted in a significant decrease in *MRSA* populations. Additionally, essential oils from *Cinnamomum zeylanicum*, *Syzygium aromaticum*, *Cuminum cyminum*, allicin, *glabrol*, *clove buds*, and *backhousia citriodora* have shown significant effectiveness against *MRSA*. Another potential solution against *MRSA* is the use of bacteriophages. Based on our review, promising phage compounds include *S. aureus* phage containing *CHAPLysGH15* and *LysGH15* and *phage SA11 endolysin*. Bacteriocins have also shown promise in combatting *MRSA*. Bacteriocins such as *Enterocin AS-48*, *Pentocin JL-1*, bacteriocin-producing *Pseudomonas aeruginosa TA6*, and bacteriocin produced by *S. pasteurii RSP-1* were effective against *S. aureus*. Probiotics have also shown antimicrobial properties against *MRSA*. *Streptomyces griseus*, *Pediococcus acidilactici* strains *A11* and *C12*, *Lactococcus lactis*, and *Lactobionic acid* are among the most effective probiotics against *MRSA*. In the fight against *MRSA*, the combination of above-mentioned antibacterials has also shown promising results. These natural compounds and microorganisms possess unique mechanisms of action that can effectively target and eliminate *MRSA* cells. Furthermore, their use in combination with other antimicrobial agents including chemicals can enhance their efficacy, providing a multi-hurdle approach in combatting antibiotic-resistant bacteria. However, in food matrices, the results might be different from *in vitro* experiments because natural compounds can interact with food compounds like proteins and lipids, potentially reducing the availability of the natural compound as an antimicrobial agent. Additionally, processing steps can diminish the antimicrobial activity of such compounds. Furthermore, before the application of natural antimicrobials in food products, health and safety risks associated with them should be thoroughly assessed. The impact of EOs on the organoleptic characteristics of food should also be taken into account, as they may have negative effects. Nevertheless, the application of nanotechnology can mitigate these effects.

## ACKNOWLEDGEMENT

We would like to thank Mashhad University of Medical Sciences, Mashhad, Iran for their support.

### Author's Contribution:

Z.A. made contributions to conception and design of the study, was involved in data collection and drafting the manuscript. G.S. revised the manuscript critically and together with Z.A., M.H., and A.A. prepared the final draft of the manuscript etc. All authors read and approved the final manuscript.

### Competing interest

The authors declare that they have no competing interests.

### REFERENCES

1. Abdallah K., Tharwat A., Gharieb R. 2021. High efficacy of a characterized lytic bacteriophage in combination with thyme essential oil against multi-drug-resistant *Staphylococcus aureus* in chicken products. *Iranian Journal of Veterinary Research*, 22, 1, 24. doi: 10.22099/ijvr.2020.38083.5543.
2. Abdullah S.A., Salih T.F.M., Hama A.A., Ali S.I., Hamaamin H.H. 2021. The Antibacterial Property of *Nigella sativa* (Black seed) Oil Against Gram-positive and Gram-negative Bacteria. *Kurdistan Journal of Applied Research*, 6, 2, 156-165. doi: 10.24017/science.2021.2.15.
3. Afshari A., Hashemi M., Tavassoli M., Eraghi V., Noori S.M.A. 2022. Probiotic bacteria from 10 different traditional Iranian cheeses: Isolation, characterization, and investigation of probiotic potential. *Food Science and Nutrition*. doi: 10.1002/fsn3.2817.
4. Afshari A., Taheri S., Hashemi M., Norouzy A., Nematy M., Mohamadi S. 2022. Methicillin- and Vancomycin-Resistant *Staphylococcus aureus* and Vancomycin-Resistant Enterococci Isolated from Hospital Foods: Prevalence and Antimicrobial Resistance Patterns. *Current microbiology*, 79, 11, 326. doi: 10.1007/s00284-022-03022-0.
5. AL-Saadi Z.N. 2016. Estimation of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of cell-free extracts of *Bifidobacterium* species against methicillin-resistant *Staphylococcus aureus* in vitro. *American Journal of Biomedical and Life Sciences*, 4, 5, 75-80. doi: 10.11648/j.ajbls.20160405.12.
6. Ansari M.A., Albetran H.M., Alheshibri M.H., Timoumi A., Algarou N.A., Akhtar S., Slimani Y., Almessiere M.A., Alahmari F.S., Baykal A. 2020. Synthesis of electrospun TiO<sub>2</sub> nanofibers and characterization of their antibacterial and antibiofilm potential against gram-positive and gram-negative bacteria. *Antibiotics*, 9, 9, 572. doi: 10.3390/antibiotics9090572.

7. Arumugam T., Dhanam S., Rameshkumar N., Krishnan M., Kayalvizhi N. 2019. Inhibition of methicillin resistant *Staphylococcus aureus* by bacteriocin producing *Pseudomonas aeruginosa*. *International Journal of Peptide Research and Therapeutics*, 25, 339-348. doi: 10.1007/s10989-018-9676-y.
8. Bajlan J.S., Khudiar M.M., Fakhry S.S., Abbas Z. 2018. Antimicrobial Activity of Colicin and Enterocin on *Staphylococcus aureus* (MRSA) isolated from food. *Current Research in Microbiology and Biotechnology*, 6, 1, 1470-1477.
9. Boskovic M., Zdravkovic N., Ivanovic J., Janjic J., Djordjevic J., Starcevic M. Baltic M.Z. 2015. Antimicrobial activity of thyme (*Tymus vulgaris*) and oregano (*Origanum vulgare*) essential oils against some food-borne microorganisms. *Procedia Food Science*, 5, 18-21. doi: 10.1016/j.profoo.2015.09.005.
10. Bugayong A.M., Cruz P., Padilla P.I. 2019. Antibacterial activity and chemical composition of essential oils from leaves of some aromatic plants of Philippines. *Journal of Essential Oil Bearing Plants*, 22, 4, 932-946. doi: 10.1080/0972060X.2019.1682683.
11. Burgos M.J.G., Aguayo M.C.L., Pulido R.P., Gálvez A., López R.L. 2015. Inactivation of *Staphylococcus aureus* in Oat and Soya Drinks by Enterocin AS-48 in Combination with Other Antimicrobials. *Journal of Food Science*, 80, 9, M2030-M2034. doi: 10.1111/1750-3841.12983.
12. Burris K.P., Higginbotham K.L., Stewart Jr C.N. 2015. Aqueous extracts of yerba mate as bactericidal agents against methicillin-resistant *Staphylococcus aureus* in a microbiological medium and ground beef mixtures. *Food Control*, 50, 748-753. doi:10.1016/j.foodcont.2014.10.021.
13. Catteau L., Reichmann N.T., Olson J., Pinho M.G., Nizet V., Van Bambeke F., Quetin-Leclercq J. 2017. Synergy between ursolic and oleanolic acids from *Vitellaria paradoxa* leaf extract and  $\beta$ -lactams against methicillin-resistant *Staphylococcus aureus*: in vitro and in vivo activity and underlying mechanisms. *Molecules*, 22, 12, 2245. doi: 10.3390/molecules22122245.
14. Chang S.T., Chen P.F., Chang S.C. 2001. Antibacterial activity of leaf essential oils and their constituents from *Cinnamomum osmophloeum*. *Journal of ethnopharmacology*, 77, 1, 123-127. doi: 10.1016/s0378-8741(01)00273-2.
15. Chang Y., Kim M., Ryu S. 2017. Characterization of a novel endolysin Lys-SA11 and its utility as a potent biocontrol agent against *Staphylococcus aureus* on food and utensils. *Food Microbiology*, 68, 112-120. doi: 10.1016/j.fm.2017.07.004.
16. Chang Y., Yoon H., Kang D.-H., Chang P.-S., Ryu S. 2017. Endolysin Lys-SA97 is synergistic with carvacrol in controlling *Staphylococcus aureus* in foods. *International journal of food microbiology*, 244, 19-26. doi: 10.1016/j.ijfoodmicro.2016.12.007.

17. Chauhan A.K., Maheshwari D.K., Bajpai V.K. 2017. Isolation and preliminary characterization of a bacteriocin-producer *Bacillus* strain inhibiting methicillin resistant *Staphylococcus aureus*. *Acta Biologica Hungarica*, 68, 2, 208-219. doi: 10.1556/018.68.2017.2.8.
18. Chen X., Shang F., Meng Y., Li L., Cui Y., Zhang M., Qi K., Xue T. 2015. Ethanol extract of *Sanguisorba officinalis* L. inhibits biofilm formation of methicillin-resistant *Staphylococcus aureus* in an ica-dependent manner. *Journal of Dairy Science*, 98, 12, 8486-8491. doi: 10.3168/jds.2015-9899.
19. Cui H., Bai M., Sun Y., Abdel-Samie M.A.-S., Lin L. 2018. Antibacterial activity and mechanism of Chuzhou chrysanthemum essential oil. *Journal of Functional Foods*, 48, 159-166. doi: 10.1016/j.jff.2018.07.021.
20. Cui H., Li W., Li C., Vittayapadung S., Lin L. 2016. Liposome containing cinnamon oil with antibacterial activity against methicillin-resistant *Staphylococcus aureus* biofilm. *Biofouling*, 32, 2, 215-225. doi: 10.1080/08927014.2015.1134516.
21. Cutler R., Wilson P. 2004. Antibacterial activity of a new, stable, aqueous extract of allicin against methicillin-resistant *Staphylococcus aureus*. *British journal of biomedical science*, 61, 2, 71-74. doi: 10.1080/09674845.2004.11732646.
22. de Oliveira C.E.V., Stamford T.L.M., Neto N.J.G., de Souza E.L. 2010. Inhibition of *Staphylococcus aureus* in broth and meat broth using synergies of phenolics and organic acids. *International journal of food microbiology*, 137, 2-3, 312-316. doi: 10.1016/j.ijfoodmicro.2009.11.019.
23. Debiagi F., Kobayashi R.K., Nakazato G., Panagio L.A., Mali S. 2020. Antimicrobial activity of oregan and clove essential oils against some food-borne pathogens. *Semina: Ciências Biológicas e da Saúde*, 41, 1, 3-12. doi:10.5433/1679-0367.2020v41n1p3.
24. Eom S.-H., Lee D.-S., Jung Y.-J., Park J.-H., Choi J.-I., Yim M.-J., Jeon J.-M., Kim H.-W., Son K.-T., Je J.-Y. 2014. The mechanism of antibacterial activity of phlorofucofuroeckol-A against methicillin-resistant *Staphylococcus aureus*. *Applied microbiology and biotechnology*, 98, 23, 9795-9804. doi: 10.1007/s00253-014-6041-8.
25. García P., Martínez B., Rodríguez L., Rodríguez A. 2010. Synergy between the phage endolysin LysH5 and nisin to kill *Staphylococcus aureus* in pasteurized milk. *International journal of food microbiology*, 141, 3, 151-155. doi: 10.1016/j.ijfoodmicro.2010.04.029.
26. Ghosh A., Ricke S.C., Almeida G., Gibson K.E. 2016. Combined application of essential oil compounds and bacteriophage to inhibit growth of *Staphylococcus aureus* in vitro. *Current Microbiology*, 72, 4, 426-435. doi: 10.1007/s00284-015-0968-6.

27. Gyawali R. Ibrahim, S.A. 2014. Natural products as antimicrobial agents. *Food control*, 46, 412-429. doi: 10.1016/j.foodcont.2014.05.047.
28. Hassan M.U., Nayab H., Rehman T.U., Williamson M.P, Haq K.U., Shafi N. Shafique F. 2020. Characterisation of bacteriocins produced by *Lactobacillus* spp. isolated from the traditional Pakistani yoghurt and their antimicrobial activity against common foodborne pathogens. *Journal of biomedicine and biotechnology*, 8281623. doi: 10.1155/2020/8281623.
29. Hermawati A. H., Aryati, Isnaeni, 2016. Inhibitory Activity of Probiotic Fermented Milk Against *Escherichia coli* ATCC 6538 and *Staphylococcus aureus* ATCC 8739. *Berkala Ilmiah Kimia Farmasi*, 5, 2, 8-10.
30. Higginbotham K.L., Burris K.P., Zivanovic S., Davidson P.M., Stewart Jr C.N. 2014. Aqueous extracts of *Hibiscus sabdariffa* calyces as an antimicrobial rinse on hot dogs against *Listeria monocytogenes* and methicillin-resistant *Staphylococcus aureus*. *Food Control*, 40, 274-277. doi: 10.1016/j.foodcont.2013.12.011.
31. Hong J., Kim J., Quan L.-H., Heu S., Roh E. 2018. Purification and characterization of pasteuricin produced by *Staphylococcus pasteurii* RSP-1 and active against multidrug-resistant *Staphylococcus aureus*. *Journal of Food Protection*, 81, 11, 1768-1775. doi: 10.4315/0362-028X.JFP-18-111.
32. Hu W., Li C., Dai J., Cui H., Lin L. 2019. Antibacterial activity and mechanism of *Litsea cubeba* essential oil against methicillin-resistant *Staphylococcus aureus* (MRSA). *Industrial Crops and Products*, 130, 34-41. doi: 10.1016/j.indcrop.2018.12.078.
33. Ifesan B.O., Hamtasin C., Mahabusarakam W., Voravuthikunchai S.P. 2009. Assessment of antistaphylococcal activity of partially purified fractions and pure compounds from *Eleutherine americana*. *Journal of food protection*, 72, 2, 354-359. doi: 10.4315/0362-028x-72.2.354.
34. Jaradat N., Hawash M., Abualhasan M.N., Qadi M., Ghanim M., Massarwy E., Ammar S.A., Zmero N., Arar M., Hussein F. 2021. Spectral characterization, antioxidant, antimicrobial, cytotoxic, and cyclooxygenase inhibitory activities of *Aloysia citriodora* essential oils collected from two Palestinian regions. *BMC Complementary Medicine and Therapies*, 21, 1, 1-11. doi: 10.1186/s12906-021-03314-1.
35. Jaradat N., Hawash M., Qadi M., Abualhasan M., Odetallah A., Qasim G., Awayssa R., Akkawi A., Abdullah I. Al-Maharik N. 2022. Chemical markers and pharmacological characters of *Pelargonium graveolens* essential oil from Palestine. *Molecules*, 27, 17, 5721. doi: 10.3390/molecules27175721.

36. Jha V., Shaikh D., Bhargava A., Marick A., Khan F., Dhamapurkar V., Jhangiani A., Narvekar S., Shinde R., Nair M. 2022. Characterization of Physio-Chemical Properties and Evaluation of Bioactive Potentials of Essential Oils from *Elettaria Cardamomum*. *Journal of Plant Biology and Crop Research*, 5, 2, 1068.
37. Jiang H., Zou J., Cheng H., Fang J., Huang G. 2017. Purification, characterization, and mode of action of pentocin JL-1, a novel bacteriocin isolated from *Lactobacillus pentosus*, against drug-resistant *Staphylococcus aureus*. *BioMed Research International*, 2017, 7657190. doi: 10.1155/2017/7657190.
38. Kang S., Kong F., Shi X., Han H., Li M., Guan B., Yang M., Cao X., Tao D., Zheng Y., 2020. Antibacterial activity and mechanism of lactobionic acid against *Pseudomonas fluorescens* and Methicillin-resistant *Staphylococcus aureus* and its application on whole milk. *Food Control*, 108, 106876. doi: 10.1016/j.foodcont.2019.106876.
39. Karska-Wysocki B., Bazo M., Smoragiewicz W. 2010. Antibacterial activity of *Lactobacillus acidophilus* and *Lactobacillus casei* against methicillin-resistant *Staphylococcus aureus* (MRSA). *Microbiological research*, 165, 8, 674-686. doi: 10.1016/j.micres.2009.11.008.
40. Keyvan E., Tutun H. 2019. Effects of carvacrol on *Staphylococcus aureus* isolated from bulk tank milk. *Medycyna Weterynaryjna*, 75, 4, 238-241. doi: 10.21521/mw.6211.
41. Kim S.-G., Khan S.A., Lee Y.-D., Park J.-H., Moon G.-S. 2022. Combination Treatment for Inhibition of the Growth of *Staphylococcus aureus* with Recombinant SAP8 Endolysin and Nisin. *Antibiotics*, 11, 9, 1185. doi: 10.3390/antibiotics11091185.
42. Kim S.-G., Lee Y.-D., Park J.-H., Moon G.-S. 2019. Synergistic inhibition by Bacteriocin and Bacteriophage against *Staphylococcus aureus*. *Food science of animal resources*, 39, 6, 1015-1020. doi: 10.5851/kosfa.2019.e95.
43. Lalouckova K., Mala L., Marsik P., Skrivanova E. 2021. In Vitro Antibacterial Effect of the Methanolic Extract of the Korean Soybean Fermented Product Doenjang against *Staphylococcus aureus*. *Animals*, 11, 8, 2319. doi: 10.3390/ani11082319.
44. Lee J.-E., Lee N.-K., Paik H.-D. 2021. Antimicrobial and anti-biofilm effects of probiotic *Lactobacillus plantarum* KU200656 isolated from kimchi. *Food Science and Biotechnology*, 30, 1, 97-106. doi: 10.1007/s10068-020-00837-0.
45. Lee J.-W., Ji Y.-J., Yu M.-H., Bo M.-H.H., Seo H.-J., Lee S.-P., Lee I.-S. 2009. Antimicrobial effect and resistant regulation of *Glycyrrhiza uralensis* on



- methicillin-resistant *Staphylococcus aureus*. *Natural product research*, 23, 2, 101-111. doi: 10.1080/14786410801886757.
46. Lee N.K., Jin Han E., Jun Han K., Paik H.D. 2013. Antimicrobial effect of bacteriocin KU24 produced by *Lactococcus lactis* KU24 against methicillin-resistant *Staphylococcus aureus*. *Journal of Food Science*, 78, 3, M465-M469. doi: 10.1111/1750-3841.12053.
  47. Lestari S., Sadiq A., Safitri W., Dewi S., Prastiyanto M. 2019. The antibacterial activities of bacteriocin *Pediococcus acidilactici* of breast milk isolate to against methicillin-resistant *Staphylococcus aureus*. *Journal of Physics: Conference Series*, IOP Publishing. doi: 10.1088/1742-6596/1374/1/012021.
  48. Li H.-N., Wang C.-Y., Wang C.-L., Chou C.-H., Leu Y.-L., Chen B.-Y. 2019. Antimicrobial effects and mechanisms of ethanol extracts of *Psoralea corylifolia* seeds against *Listeria monocytogenes* and methicillin-resistant *Staphylococcus aureus*. *Foodborne pathogens and disease*, 16, 8, 573-580. doi: 10.1089/fpd.2018.2595.
  49. Li M., Muthaiyan A., O'Bryan C.A, Gustafson J.E., Li Y., Crandall P.G., Ricke S. C. 2011. Use of natural antimicrobials from a food safety perspective for control of *Staphylococcus aureus*. *Current pharmaceutical biotechnology*, 12, 8, 1240-1254. doi: 10.2174/138920111796117283.
  50. Lim A.C., Tang S.G.H., Zin N.M., Maisarah A.M., Ariffin I.A., Ker P.J., Mahlia T.M.I. 2022. Chemical Composition, Antioxidant, Antibacterial, and Antibiofilm Activities of *Backhousia citriodora* Essential Oil. *Molecules* 27(15): 4895. doi: 10.3390/molecules27154895.
  51. Linden S.B., Zhang H., Heselpoth R.D., Shen Y., Schmelcher M., Eichen-seher F., Nelson D.C. 2015. Biochemical and biophysical characterization of PlyGRCS, a bacteriophage endolysin active against methicillin-resistant *Staphylococcus aureus*. *Applied microbiology and biotechnology*, 99,2, 741-752. doi: 10.1007/s00253-014-5930-1.
  52. Liu C., Cheng F., Aisa H.A. Maiwulanjiang M. 2023. Comprehensive Study of Components and Antimicrobial Properties of Essential Oil Extracted from *Carum carvi* L. Seeds. *Antibiotics*, 12, 3, 591. doi: 10.3390/molecules27051693.
  53. Lu Y., Wang Y., Wang J., Zhao Y., Zhong Q., Li G., Fu Z., Lu S. 2021. Phage endolysin LysP108 showed promising antibacterial potential against methicillin-resistant *Staphylococcus aureus*. *Frontiers in cellular and infection microbiology*, 11, 668430. doi: 10.3389/fcimb.2021.668430.
  54. Mandal S., DebMandal M., Saha K., Pal N.K. 2011. In vitro antibacterial activity of three Indian spices against methicillin-resistant *Staphylococcus aureus*. *Oman Medical Journal*, 26, 5, 319. doi: 10.5001/omj.2011.80.

55. Meng F., Zhu X., Zhao H., Nie T., Lu F., Lu Z., Lu Y. 2021. A class III bacteriocin with broad-spectrum antibacterial activity from *Lactobacillus acidophilus* NX2-6 and its preservation in milk and cheese. *Food Control*, 121, 107597. doi: 10.1016/j.foodcont.2020.107597.
56. Mohammed-Ali M.N., Jamalludeen N.M. 2015. Isolation and characterization of bacteriophage against methicillin resistant *Staphylococcus aureus*. *Journal of Medical Microbiology and Diagnosis*, 5, 1, 1000213. doi: 10.4172/2161-0703.1000213.
57. Murray E., Draper L.A., Ross R.P., Hill C. 2021. The advantages and challenges of using endolysins in a clinical setting. *Viruses*, 13, 4, 680. doi: 10.3390/v13040680.
58. Pedonese F., Longo E., Torracca B., Najar B., Fratini F., Nuvoloni R. 2022. Antimicrobial and anti-biofilm activity of manuka essential oil against *Listeria monocytogenes* and *Staphylococcus aureus* of food origin. *Italian Journal of Food Safety*, 11, 1. doi: 10.4081/ijfs.2022.10039.
59. Prastiyanto M.E., Azizah I.H., Haqi H.D., Yulianto B.D., Agmala A.B., Radipasari Z.D., Astuti N.A.D., Putri A.R. 2020. In-vitro antibacterial activity of the seed extract of three-member *Artocarpus* towards Methicillin-Resistant *Staphylococcus aureus* (MRSA). *Jurnal Teknologi Laboratorium*, 9, 2, 128-135. doi:10.29238/teknolabjournal.v9i2.237.
60. Prastiyanto M.E., Rukmana R.M., Saraswati D.K., Darmawati S., Maharani E.T.W., Tursinawati Y. 2020. Anticancer potential of methanolic extracts from *Pleurotus* species on raji cells and antibacterial activity against Methicillin-Resistant *Staphylococcus aureus*. *Biodiversitas Journal of Biological Diversity* 21, 12. doi: 10.13057/biodiv/d211221.
61. Redwan E.M., Abd El-Baky N., Al-Hejin A.M., Baeshen M.N., Almehdar H. A., Elsayay A., Gomaa A.-B.M., Al-Masaudi S.B., Al-Fassi F.A., Abu-Zeid I.E. 2016. Significant antibacterial activity and synergistic effects of camel lactoferrin with antibiotics against methicillin-resistant *Staphylococcus aureus* (MRSA). *Research in microbiology*, 167, 6, 480-491. doi: 10.1016/j.resmic.2016.04.006.
62. Saelao S., Maneerat S., Kaewsuwan S., Rabesona H., Choiset Y., Haertlé T., Chobert J.-M. 2017. Inhibition of *Staphylococcus aureus* in vitro by bacteriocinogenic *Lactococcus lactis* KTH0-1S isolated from Thai fermented shrimp (Kung-som) and safety evaluation. *Archives of microbiology*, 199, 551-562. doi: 10.1007/s00203-016-1324-3.
63. Salem A.M. 2017. Efficiency of some essential oils in control of methicillin resistant *Staphylococcus aureus* (MRSA) in Minced Beef. *Benha Veterinary Medical Journal*, 32, 1, 177-183.

64. Taggar R., Jangra M., Dwivedi, A. Bansal K., Patil P.B., Bhattacharyya, M.S. Nandanwar H., Sahoo D.K. 2021. Bacteriocin isolated from the natural inhabitant of *Allium cepa* against *Staphylococcus aureus*. *World Journal of Microbiology and Biotechnology*, 37, 2, 1-16. doi: 10.1007/s11274-020-02989-x.
65. Takagi S., Hayashi S., Takahashi K., Isogai H., Bai L. Yoneyama H., Ando T., Ito K., Isogai E. 2012. Antimicrobial activity of a bovine myeloid antimicrobial peptide (BMAP-28) against methicillin-susceptible and methicillin-resistant *Staphylococcus aureus*. *Animal Science Journal*, 83, 6, 482-486. doi: 10.1111/j.1740-0929.2011.00979.x.
66. Tang C., Chen J., Zhang L., Zhang R., Zhang S., Ye S., Zhao Z., Yang D. 2020. Exploring the antibacterial mechanism of essential oils by membrane permeability, apoptosis and biofilm formation combination with proteomics analysis against methicillin-resistant *Staphylococcus aureus*. *International Journal of Medical Microbiology*, 310, 5, 151435. doi: 10.1016/j.ijmm.2020.151435.
67. Vaiyapuri M., Joseph T.C., Rao B.M., Lalitha K.V., Prasad M.M. 2019. Methicillin-Resistant *Staphylococcus aureus* in Seafood: prevalence, laboratory detection, clonal nature, and control in seafood chain. *Journal of Food Science*, 84, 12, 3341-3351. doi:10.1111/1750-3841.14915.
68. Wang S., Kim M.-C., Kang O.-H., Kwon D.-Y. 2020. The mechanism of bisdemethoxycurcumin enhances conventional antibiotics against methicillin-resistant *Staphylococcus aureus*. *International Journal of Molecular Sciences*, 21, 21, 7945. doi: 10.3390/ijms21217945.
69. Wen H., Yuan L., Ye J.-h., Li Y.-j., Yang Z.-q., Zhou W.-y. 2023. Isolation and characterization of a broad-spectrum phage SapYZU11 and its potential application for biological control of *Staphylococcus aureus*. *Quality Assurance and Safety of Crops and Foods*, 15, 2, 32-48. doi: 10.15586/qas.v15i2.1238.
70. Xu J.-G., Liu T., Hu Q.-P., Cao X.-M. 2016. Chemical composition, antibacterial properties and mechanism of action of essential oil from clove buds against *Staphylococcus aureus*. *Molecules*, 21, 9, 1194. doi: 10.3390/molecules21091194.
71. Yan J., Yang R., Yu S., Zhao W. 2021. The strategy of biopreservation of meat product against MRSA using lytic domain of lysin from *Staphylococcus aureus* bacteriophage. *Food Bioscience*, 41, 100967. doi: /10.1016/j.fbio.2021.100967.

72. Yassin M.T., Mostafa A.A.-F, Al-Askar A.A., Alkhelaif A.S. 2022. In vitro antimicrobial potency of *Elettaria cardamomum* ethanolic extract against multidrug resistant of food poisoning bacterial strains. *Journal of King Saud University-Science*, 34, 6, 102167. doi:10.1016/j.jksus.2022.102167.
73. Yehia H.M., Alkhuriji A.F., Savvaidis I., Al-Masoud A.H. 2022. Bactericidal effect of nisin and reuterin on methicillin-resistant *Staphylococcus aureus* (MRSA) and *S. aureus* ATCC 25937. *Food Science and Technology*, 42. doi: 10.1590/fst.105321.
74. Yuan W., Yuk H.-G. 2018. Antimicrobial efficacy of *Syzygium antisepticum* plant extract against *Staphylococcus aureus* and methicillin-resistant *S. aureus* and its application potential with cooked chicken. *Food microbiology*, 72, 176-184. doi: 10.1016/j.fm.2017.12.002.
75. Yusuf M. 2018. Natural antimicrobial agents for food biopreservation. *Food packaging and preservation*, Elsevier: 409-438. doi:10.1016/B978-0-12-811516-9.00012-9.
76. Zhang W., Margarita G.E., Wu D., Yuan W., Yan S., Qi S., Xue X., Wang K., Wu L. 2022. Antibacterial activity of Chinese red propolis against *Staphylococcus aureus* and MRSA. *Molecules*, 27, 5, 1693. doi: 10.3390/molecules27051693.
77. Zhao D., Wang Q., Lu F., Bie X., Zhao H., Lu Z., Lu Y. 2022. A novel planaricarin 827 effectively inhibits *Staphylococcus aureus* and extends shelf life of skim milk. *LWT*, 154, 112849. doi:10.1016/j.lwt.2021.112849.
78. Zhou T., Li Z., Kang O.H., Mun, S.H., Seo Y.S., Kong R., Shin D.-W., Liu X. Q., Kwon D.Y. 2017. Antimicrobial activity and synergism of ursolic acid 3-O- $\alpha$ -L-arabinopyranoside with oxacillin against methicillin-resistant *Staphylococcus aureus*. *International Journal of Molecular Medicine*, 40, 4, 1285-1293. doi: 10.3892/ijmm.2017.3099.
79. Zhu X., Shen L., Liu J., Zhang C., Gu Q. 2015. Purification of a bacteriocin from *Lactobacillus plantarum* ZJ217 active against methicillin-resistant *Staphylococcus aureus*. *International Journal of Food Engineering*, 11, 1, 51-59. doi: 10.1515/ijfe-2014-0176.
80. Zhu Y., Zhou Q., Li P., Gu Q. 2021. Purification, characterization, and mode of action of Paracin 54, a novel bacteriocin against *Staphylococci*. *Applied Microbiology and Biotechnology*, 105, 18, 6735-6748. doi: 10.1007/s00253-021-11505-6.
81. Zihadi M.A.H., Rahman M., Talukder S., Hasan M.M., Nahar S., Sikder M.H. 2019. Antibacterial efficacy of ethanolic extract of *Camellia sinensis* and *Azadirachta indica* leaves on methicillin-resistant *Staphylococcus aureus* and shiga-toxigenic *Escherichia coli*. *Journal of advanced veterinary and animal research*, 6, 2, 247. doi: 10.5455/javar.2019.f340.

82. Zouhir A., Jridi T., Nefzi A., Ben Hamida J., Sebei K. 2016. Inhibition of methicillin-resistant *Staphylococcus aureus* (MRSA) by antimicrobial peptides (AMPs) and plant essential oils. *Pharmaceutical Biology*, 54, 12, 3136-3150. doi: 10.1080/13880209.2016.1190763.

Received: 27.07.2023.

Accepted: 26.11.2023.



Original research article

UDC 544.723.21

<https://doi.org/10.46784/e-avm.v16i2.322>

## POTENTIAL OF DIFFERENT MYCOTOXIN ADSORBENTS UNDER *IN VITRO* CONDITIONS

Saša Krstović<sup>1\*</sup>, Darko Guljaš<sup>1</sup>, Jelena Krulj<sup>2</sup>, Marko Damjanović<sup>1</sup>, Igor Jajić<sup>1</sup>

<sup>1</sup> University of Novi Sad, Faculty of Agriculture, Department  
of Animal Science, Novi Sad, Republic of Serbia

<sup>2</sup> University of Novi Sad, Institute of Food Technology, Republic of Serbia

### Abstract

Mycotoxins are a large and chemically diverse group of toxic secondary metabolites. Regarding their prevalence in animal feed and the effect on animal health, the biggest problems in terms of safety and economic losses are caused by aflatoxins, fumonisins, ochratoxins, trichothecenes and zearalenone. Adsorbents are substances that are added to food contaminated with mycotoxins, in order to bind them in the gastrointestinal tract and thereby prevent or reduce their effect. The aim of this study was to examine the possibility of using pyrophyllite as a mineral adsorbent, as well as preparations made of ground peach pits of different particle sizes as organic adsorbents, for adsorption of deoxynivalenol and ochratoxin A. Mycotoxin adsorption experiments were performed *in vitro* in electrolyte solutions at pH 3 and 7. The adsorption efficiency of the adsorbent was expressed as adsorption index. Pyrophyllite had adsorption index of 13.47% for ochratoxin A at pH 3, while at pH 7, as well as for deoxynivalenol, the same mycotoxin produced a negligible degree of adsorption. Ground peach stones (of larger diameter,  $d = 0.1$  mm) had considerable adsorption rates for ochratoxin A at pH 3 (34.41%) and deoxynivalenol at pH 7 (18.57%). The values were similar for smaller diameter ( $d < 0.1$  mm) for ochratoxin A at pH 3 (42.71%) and deoxynivalenol at pH 7 (20.11%). The obtained results suggest that the potential of the preparation of ground peach stones for the adsorption of tested mycotoxins is higher compared to the potential of pyrophyllite, but there are differences in their efficiency depending on the pH value of the adsorption environment.

**Key words:** ochratoxin A, deoxynivalenol, adsorbents, pyrophyllite, peach stones

---

<sup>1\*</sup> Corresponding Author: [sasa.krstovic@stocarstvo.edu.rs](mailto:sasa.krstovic@stocarstvo.edu.rs)

## POTENCIJAL RAZLIČITIH ADSORBENATA MIKOTOKSINA U *IN VITRO* USLOVIMA

Saša Krstović<sup>1</sup>, Darko Guljaš<sup>1</sup>, Jelena Krulj<sup>2</sup>, Marko Damjanović<sup>1</sup>, Igor Jajić<sup>1</sup>

<sup>1</sup> Univerzitet u Novom Sadu, Poljoprivredni fakultet,  
Departman za stočarstvo, Novi Sad, Republika Srbija

<sup>2</sup> Univerzitet u Novom Sadu, Naučni institut za prehrambene  
tehnologije, Novi Sad, Republika Srbija

### Kratak sadržaj

Mikotoksini su relativno velika i hemijski raznolika grupa toksičnih sekundarnih metabolita. Uzimajući u obzir prevalencu u hrani za životinje i efekat na zdravlje životinja, najveće bezbednosne i ekonomske probleme predstavljaju aflatoksini, fumonizini, ohratoksini, trihoteceni i zearalenon. Adsorbenti predstavljaju materije koje se dodaju hrani kontaminiranoj mikotoksinima, kako bi ih u gastrointestinalnim traktu vezivali i time sprečili ili umanjili njihovo dejstvo. Cilj ovog rada je da se ispita mogućnost primene pirofilita kao predstavnika mineralnih, kao i preparata mlevenih koštica breskve različitih veličina čestica kao predstavnika organskih adsorbenata za adsorpciju deoksinivalenola i ohratoksina A. Eksperimenti adsorpcije mikotoksina su izvođeni *in vitro* u rastvorima elektrolita na pH 3 i 7. Efikasnost adsorpcije adsorbenta je izražena kao indeks adsorpcije. Rezultati su ukazali da pirofilit ima vrednost indeksa adsorpcije od 13,47% za ohratoksin A pri pH 3, dok je za isti mikotoksin pri pH 7, kao i za deoksinivalenol, utvrđen zanemarljiv nivo adsorpcije. Mlevene koštice breskve većeg dijametra ( $d = 0,1$  mm) su pokazale odgovarajuće indekse adsorpcije za ohratoksin A pri pH 3 (34,41%) i deoksinivalenol pri pH 7 (18,57%), dok su mlevene koštice breskve manjeg dijametra ( $d < 0,1$  mm) pokazale slične vrednosti indeksa adsorpcije za ohratoksin A pri pH 3 (42,71%) i za deoksinivalenol pri pH 7 (20,11%). Iz dobijenih rezultata se može zaključiti da je potencijal preparata mlevenih koštica breskve za adsorpciju ispitanih mikotoksina veći u odnosu na potencijal pirofilita, ali da postoje razlike u njihovoj efikasnosti u zavisnosti od pH vrednosti sredine u kojoj se adsorpcija odvija.

**Ključne reči:** ohratoksin A, deoksinivalenol, adsorbenti, pirofilit, koštice breskve



## INTRODUCTION

Agriculture is becoming increasingly important due to the rise in world population and urbanization. This implies a rapid growth and boost of livestock production, resulting in the safety of animal feed becoming even more significant considering the potential threat of hazards reaching the human food chain. Among the undesirable substances, according to Directive 2002/32/EC (European Commission, 2002), mycotoxins are considered one of the greatest hazards in feed raw materials (Santos Pereira et al., 2019). Among other mycotoxins, deoxynivalenol (DON) and ochratoxin A (OTA) certainly represent the most important causes of diseases in animals. Namely, global economic losses caused by DON are in the range of about one billion dollars per year. The Food and Agriculture Organization and the World Health Organization identified it as one of the most dangerous food contaminants as early as 1973 (Neme and Mohammed, 2017). This mycotoxin mainly contaminates agricultural crops such as corn, wheat, and barley, and has immunogenic, carcinogenic, and teratogenic effects in animals. It is also detected in animal products such as meat, eggs, and milk, and poses a danger to human health (Yao and Long, 2020). OTA causes great economic losses to animal husbandry, as the intake of contaminated feed can significantly impair animal health and safety of animal products (Battacone et al., 2010). It can be found in a wide range of agricultural and livestock products, and in processed foods as well, while human exposure to this mycotoxin is mainly attributed to contaminated grains (Abrunhosa et al., 2010). Juodeikiene et al. (2012) stated three possible solutions for avoiding the harmful effect of mycotoxin contamination of both food and feed. They include the following: prevention of contamination, decontamination of mycotoxin-containing food and feed, and inhibition of mycotoxin absorption into the digestive tract. Nevertheless, if mycotoxin contamination already exists, application of decontamination methods is advised (Jouany, 2007). Various methods for mycotoxin reduction were studied, including the application of irradiation, thermal or microwave heating, ozone, chemical compounds, and microbials (Binder and Binder, 2004; Bullerman and Bianchini, 2007; Herzallah et al., 2008; Garg et al., 2013; Krstović et al., 2021). Moreover, the use of existing feed additives, such as enzymes showed a potential for degradation of some mycotoxins (Jakšić et al., 2022). Finally, measures can be applied for inhibition of mycotoxin absorption in the gastrointestinal tract, e.g., the use of adsorbents to reduce the bioavailability of mycotoxins in the digestive tract of animals (Abdel-Wahhab and Kholif, 2010). The use of adsorbents is one of the most suitable options for treatment of mycotoxins in practice (Li et al., 2018). In general, the adsorption method includes both physical and chemical force,

which can not only reduce the toxic impact of mycotoxins, but also enable the avoidance of toxic residues, thus becoming the most commonly applied method of protecting animals from mycotoxins (Li et al., 2018). Adsorbents can be used as single formulations, but are recently combined for better efficiency, usually as mineral-organic adsorbent mixture (Nešić et al., 2020).

The aim of this study was to examine the possibility of using two types of mycotoxin adsorbents. The first is pyrophyllite, a non-metallic aluminosilicate mineral that has adsorptive properties, primarily for ions of heavy metals and colors from aqueous solutions. The second adsorbent included two preparations of ground peach stones of different particle sizes. This type of adsorbent is organic, its waste biomass of agro-industrial source, and as an economically and ecologically profitable material, it is generally considered cheaper than mineral (inorganic) adsorbents. The adsorptive capacity of these preparations was tested for the adsorption of DON and OTA under *in vitro* conditions.

## MATERIAL AND METHODS

### *Adsorbents*

Adsorption potential test was performed for two preparations. Pyrophyllite, which belongs to the group of non-metallic aluminosilicate minerals, was selected as a potential inorganic adsorbent. Its use is already permitted in animal feed at up to 2% to prevent ruminal acidosis in ruminants (US Food and Drug Administration, 2019; Adamović et al., 2020). Another potential adsorbent is a preparation of ground peach stones (Lopičić et al., 2013). It was prepared in two fractions: larger (particle size  $d = 0.1$  mm) and smaller (particle size  $d < 0.1$  mm) fraction. The preparations were not commercially available. All preparations were prepared by and obtained from the Institute for Technology of Nuclear and Other Mineral Raw Materials, Belgrade, Serbia.

### *Mycotoxin removal procedure in vitro*

To simulate *in vivo* conditions, where mycotoxin adsorption is performed on adsorbents, mycotoxin adsorption experiments were performed *in vitro* in solutions at pH 3 and 7. These pH values are expected in the digestive tract of monogastric animals and humans. The crude extract of DON, produced in house on wet maize kernels after artificial inoculation with toxigenic *Fusarium graminearum* (Krstović et al., 2018), as well as the standard solution of OTA (Sigma, St. Louis, MO, USA) were used for the adsorption experiments. 90 mg

of adsorbent was weighed into glass tubes using Teflon stoppers (volume of 20 cm<sup>3</sup>), and then 10 mL of 0.1 M KH<sub>2</sub>PO<sub>4</sub> (13.609 g KH<sub>2</sub>PO<sub>4</sub> in 1000 mL of water, pH set to pH = 3 and pH = 7) was added. After that, a volume of 100 µL of crude toxin solution (*c* = 300 µg/mL) was added in order to obtain the final concentration of 3 µg/ml (crude toxin to adsorbent ratio was 1:3000). Mixing magnets were added to the tubes and then placed in an incubation system at 37 °C for 120 minutes with continuous mixing. The control was set up in the same way, without adsorbent. After the contact of the adsorbent and the mycotoxin was completed, the solution was filtered through quantitative filter paper for slow filtration and then additionally through nylon micro syringe filters with a porosity of 0.2 µm. The solutions prepared in this way were analyzed for HPLC for the mycotoxins' contents. All experiments were performed in duplicate. The adsorption efficiency of the natural adsorbent is expressed as an adsorption index, where:

*C*<sub>i</sub> – mycotoxin initial concentration,

*C*<sub>eq</sub> – mycotoxin concentration at equilibrium.

Adsorption index, % =  $[(C_i - C_{eq})/C_i] \times 100$

### ***HPLC analysis***

DON and OTA determinations were carried out on a 1260 series HPLC system (Agilent Technologies, Santa Clara, CA, USA) using photodiode (DAD) and fluorescence (FLD) detectors (Agilent Technologies, USA) and a Hypersil ODS (150 x 4.6 mm i.e., particle size 5 µm) column (Agilent Technologies, USA). Stock calibration solutions at a concentration of 0.1 mg/mL were prepared in a mixture of ethyl acetate and methanol (19:1, v/v) for DON (Sigma, St. Louis, MO, USA), and in acetonitrile for OTA (Sigma, St. Louis, MO, USA). Working calibrant solutions were prepared by measuring the appropriate volume of the stock solution, evaporating to dryness under a stream of nitrogen at 50 °C and dissolving in the appropriate volume of the mobile phase. The stock solutions were stored at a temperature of -18 °C, while the working solutions were stored in a refrigerator at a temperature of 4 – 8 °C. HPLC conditions for DON determination were set as proposed by Abramović et al. (2005) and for OTA a method by Sugita-Konishi et al. (2006) was used. All analyses were done in duplicate. A volume of 20 µL of solution obtained after adsorption was injected into a HPLC system. The mobile phase consisted of an isocratic mixture of acetonitrile and water (HPLC grade, Sigma, St. Louis, MO, USA). For the determination of DON, the ratio of the solvents was the following: acetonitrile: water (16:84, v/v), and in the case of OTA, this ratio

acetonitrile: water was (50:50, v/v) and 1% of acetic acid was added (HPLC purity, Fisher Scientific, USA). In both cases, a mobile phase flow rate of 0.8 mL/min was applied. Before use, the mobile phase was filtered through regenerated cellulose membrane filters (0.45  $\mu\text{m}$ ) (Agilent Technologies, USA). DON was detected using a DAD detector at a wavelength of  $\lambda = 220 \text{ nm}$ , for the detection of OTA, FLD detector was used at wavelengths of  $\lambda_{\text{ex}} = 333 \text{ nm}$  and  $\lambda_{\text{em}} = 470 \text{ nm}$ . The identification of DON and OTA was performed by comparing the retention times and spectra of the standards with the retention times and spectra of the samples.

## RESULTS

The results of mycotoxin adsorption using the *in vitro* method are shown in tables 1-3.

Table 1. Results of mycotoxin adsorption using pyrophyllite,  $n = 2$

		DON	OTA
<b>Control</b>	Ci, ng/mL	3012 $\pm$ 15	2986 $\pm$ 10
	Ceq, ng/mL	2996 $\pm$ 11	2981 $\pm$ 13
	A, %	0.53	0.17
<b>pH 3</b>	Ci, ng/mL	2946 $\pm$ 53	2969 $\pm$ 18
	Ceq, ng/mL	2945 $\pm$ 23	2569 $\pm$ 21
	A, %	0.03	13.47
<b>pH 7</b>	Ci, ng/mL	2978 $\pm$ 31	2980 $\pm$ 11
	Ceq, ng/mL	2974 $\pm$ 13	2948 $\pm$ 32
	A, %	0.15	1.1

Ci - mycotoxin initial concentration, Ceq - mycotoxin concentration at equilibrium, A - adsorption index.

Table 2. Results of mycotoxin adsorption using the preparation of ground peach stones (GPS), particle size  $d = 0.1$  mm,  $n = 2$

		<b>DON</b>	<b>OTA</b>
<b>Control</b>	Ci, ng/mL	3012 ± 15	2986 ± 10
	Ceq, ng/mL	2996 ± 11	2981 ± 13
	A, %	0.5	0.2
<b>pH 3</b>	Ci, ng/mL	2946 ± 53	2969 ± 18
	Ceq, ng/mL	2940 ± 56	1948 ± 89
	A, %	0.20	34.41
<b>pH 7</b>	Ci, ng/ml	2978 ± 31	2980 ± 11
	Ceq, ng/ml	2425 ± 38	2972 ± 12
	A, %	18.57	0.29

Ci - mycotoxin initial concentration, Ceq - mycotoxin concentration at equilibrium, A - adsorption index.

Table 3. Results of mycotoxin adsorption using the preparation of ground peach stones (GPS), particle size  $d < 0.1$  mm,  $n = 2$

		<b>DON</b>	<b>OTA</b>
<b>Control</b>	Ci, ng/mL	3012 ± 15	2986 ± 10
	Ceq, ng/mL	2996 ± 11	2981 ± 13
	A, %	0.5	0.2
<b>pH 3</b>	Ci, ng/mL	2946 ± 53	2969 ± 18
	Ceq, ng/mL	2941 ± 28	1701 ± 98
	A, %	0.19	42.71
<b>pH 7</b>	Ci, ng/mL	2978 ± 31	2980 ± 11
	Ceq, ng/mL	2379 ± 89	2897 ± 56
	A, %	20.11	2.80

Ci - mycotoxin initial concentration, Ceq - mycotoxin concentration at equilibrium, A - adsorption index.

The adsorption index of DON was below 1% using pyrophyllite for both pH values, as well as in the case of using the preparation of ground peach stones at pH = 3 (Figure 1). As for the preparation of ground peach stones

at pH = 7, adsorption index values of 18.57% (larger fraction) and 20.11% (smaller fraction) were obtained. This indicates that there is a certain potential of the ground peach stone preparation for DON adsorption at pH = 7, while the adsorption potential of pyrophyllite has not been proven.




Figure 1. Comparative overview of the adsorption index of ground peach stones (GPS) and pyrophyllite for DON adsorption

When it comes to the adsorption index of pyrophyllite for OTA, it was affected by the pH value (Figure 2). Namely, at pH=3, the adsorption index was found to be 13.47%, while at pH = 7, it was as low as 1.1%. However, using the preparation of ground peach stones, these differences in the adsorption index were opposing compared to the application of pyrophyllite, where high values of the adsorption index of 34.41% (larger fraction) and 42.71% (smaller fraction) were found at pH = 3, and low values (0.29% and 2.80%) at pH = 7. These results indicate that the potential of the preparation of ground peach stones for OTA adsorption is higher compared to the potential of pyrophyllite, but there are still differences in their efficiency depending on the pH value of the environment in which the adsorption takes place.




Figure 2. Comparative overview of the adsorption index of ground peach stones (GPS) and pyrophyllite for OTA adsorption

## DISCUSSION

Pyrophyllite is already a recognized adsorbent of various substances such as cationic (due to negative hydrophilic surface sites) and anionic (after the addition of trivalent aluminium cation) dyes (Gücek et al., 2005). It is also known for its ability to bind ions of heavy metals such as cobalt (98.97%), lead (97.53%), nickel (98.87%) and cadmium (98.65%) from aqueous solution (maximum adsorption in optimized conditions) (Panda et al., 2018). Furthermore, in the research conducted by Murtić et al. (2020), it was demonstrated that the application of pyrophyllite, due to its adsorbent and ion exchange capabilities can reduce the use of mineral fertilizers in the production of lettuce without adverse effects on its yield and quality, in the amount of 25% or 50% of the recommended amount of fertilizer. However, despite the results of the aforementioned research, as well as the proven adsorption capacity of numerous other aluminosilicates against mycotoxins, literature data on the adsorption of mycotoxins, specifically by pyrophyllite, is very scarce. In contrast, the potential of peach stones to adsorb mycotoxins has been studied more extensively. Hence, in the research by Adamović et al. (2013) the adsorption of the following six mycotoxins was tested: AFB1, zearalenone, diacetoxyscirpenol (DAS), T-2 toxin, OTA and DON using the *in vitro* method. Similar to our study, the adsorption index was tested at two pH values, pH = 3.0 and 6.9.

Peach stones showed the highest affinity to aflatoxin (80.00% and 73.30%) and the lowest to DAS (0% at both pH values). When it comes to OTA and DON, a higher adsorption capacity was demonstrated in comparison with our research, given that the adsorption index at pH=3.0 and 6.9 were 66.67% and 50% for OTA, and 25% and 50% for DON, respectively. However, there were certain differences in the experimental design that could produce a different result (the ratio of individual mycotoxins and adsorbents in this research was 1:5000 and the particle size of the investigated biomass < 100 µm). Comparable research was conducted by Lopičić et al. (2013), at pH values of 3.0 and 7.0. Similar to the previous study, the best adsorption index of peach stones was obtained for aflatoxin (58.82% at both pH values), the poorest for DAS (0% and 16.67%), while for OTA it was 66.67% and 19.98% and 23.08% and 39.97% for DON, at pH 3.0 and 7.0, respectively. It is interesting to point out that in both studies, in addition to the unmodified, modified peach stones (activated with 1 M HCl) were used, and they achieved a somewhat different, weaker result compared to the unmodified. Furthermore, in the research by Bočarov-Stančić et al. (2011), the adsorption capacities of mineral adsorbents bentonite, diatomite and zeolite against aflatoxin, DAS, OTA, and DON were investigated. Like in the previous research, the highest adsorption index was obtained for aflatoxins (at pH 3.0 and 6.9: bentonite 96.90%; zeolite 95.50% and diatomite 95%) which is slightly higher compared to organic adsorbents, while the weakest was obtained for DAS (0% in all adsorbents). However, it is noted that organic adsorbents were more effective for OTA and DON. With OTA, only diatomite had adsorption properties (66.67%) at pH = 3. On the other hand, at pH = 6.9, as well as for bentonite and zeolite at both pH values, the adsorption index was 0%. Considering DON, mineral adsorbents showed affinity at pH = 3, bentonite and zeolite 50% and diatomite 25%, whereas at pH = 7 they did not display any affinity (0%). These results may lead to a conclusion that mineral adsorbents are more effective when it comes to aflatoxins, while organic adsorbents are more successful for OTA and DON adsorption. This was confirmed by the results of our research, where pyrophyllite was used as a mineral adsorbent. This adsorbent had an effect (13.47%) only for OTA at pH = 3, while it was ineffective in other cases. Ground peach stones were more efficient, as a larger diameter showed the degree of adsorption for OTA at pH = 3 (34.41%) and DON at pH 7 (18.57%), and the smaller diameter similarly, for OTA at pH = 3 (42.71%) and for DON at pH = 7 (20.11%). However, it is certainly necessary to prove this result under *in vivo* conditions.

The obtained results in our and similar research indicate that the degree of binding depends primarily on the type of adsorbent (mineral or organic), and



on individual types within these groups, as well as on the mycotoxin. These characteristics should be considered when creating formulations for use in practice, and certain adsorbents should be used depending on the conditions on the farm and occurrence of certain types of mycotoxins. In the future, formulations containing several types of adsorbents need to be tested, in order to enable action against several types of mycotoxins or use one of them that has the widest spectrum of adsorption capacity when different types of mycotoxins are involved.

## CONCLUSION

The results of this study point to several conclusions. Namely, the potential of the preparation of ground peach stones for the adsorption of DON at pH = 7 was found, while its application at pH=3, the adsorption potential was not confirmed. The adsorption potential of pyrophyllite was not established at any of the pH values to which it was applied. The potential of the preparation of ground peach stones for OTA adsorption is higher compared to the potential of pyrophyllite, but there are differences in their efficiency depending on the pH value of the environment in which the adsorption takes place. Like with other *in vitro* research, this research cannot fully simulate conditions in the gastrointestinal tract of animals, so further *in vivo* experiments are necessary in order to evaluate the effectiveness of these materials as mycotoxin adsorbents.

## ACKNOWLEDGEMENT

This research was funded by the Provincial Secretariat for Higher Education and Scientific Research, Autonomous Province of Vojvodina, Republic of Serbia (Contract Number: 142-451-3148/2022-01/2).

## Author's Contribution:

S.K. basic idea, conception and design; D.G. acquisition of data; J.K. interpretation of results, manuscript revision; M.D. acquisition of data, drafting the manuscript; I.J. conception and design, final approval.

## Competing interest

The author(s) declare that they have no competing interests.

## REFERENCES

1. Abdel-Wahhab M.A. and Kholif A.M. 2010. Mycotoxins in animal feeds and prevention strategies: A review. *Asian Journal of Animal Sciences*, 4, 3, 113-131. doi:10.3923/ajas.2008.7.25.
2. Abramović B., Jajić I., Jurić V., Gaál F.F. 2005. Optimization of determination of deoxynivalenol in corn samples by liquid chromatography and comparison of two clean-up principles. *Journal of Serbian Chemical Society*, 70, 1005-1013. doi:10.2298/JSC0507005A.
3. Abrunhosa L., Paterson R.R.M., Venâncio A. 2010. Biodegradation of ochratoxin A for food and feed decontamination. *Toxins*, 2, 5, 1078-1099. doi:10.3390%2Ftoxins2051078.
4. Adamović M., Stojanović M., Lopičić Z., Milojković J., Lačnjevac Č., Petrović J., Bočarov-Stančić A. 2013. Biosorpcija mikotoksina otpadnom masom. *Zaštita Materijala*, 54, 4, 327-333.
5. Adamović M., Stojanović M.D., Harbinja M.M., Maslovarić D., Bočarov-Stančić A., Pezo L.L. 2020. Efficiency investigation of the use of pyrophyllite in ensiling maize plant. *Food and Feed Research*, 47, 2, 109-118. doi: 10.5937/ffr47-29445.
6. Battacone G., Nudda A., Pulina G. 2010. Effects of ochratoxin A on livestock production. *Toxins*, 2, 7, 1796-1824. doi:10.3390%2Ftoxins2071796.
7. Binder E.M. and Binder J. 2004. Strain of Eubacterium that detoxifies trichothecenes. US Patent no. 6794175. Available at: <https://patentimages.storage.googleapis.com/7f/3e/3c/b78d08e42a8188/US6794175.pdf>. Accessed 08.09.2023.
8. Bočarov-Stančić A., Adamović M., Salma N., Bodroža-Solarov M., Vučković J., Pantić V. 2011. In vitro efficacy of mycotoxins' adsorption by natural mineral adsorbents. *Biotechnology in Animal Husbandry*, 27, 3, 1241-1251. doi: 10.2298/BAH1103241B.
9. Bullerman L.B. and Bianchini A. 2007. Stability of mycotoxins during food processing. *International Journal of Food Microbiology*, 119, 1-2, 140-146. doi:10.1016/j.ijfoodmicro.2007.07.035.
10. European Commission. 2002. Directive 2002/32/EC of the European Parliament and of the Council of 7 May 2002 on undesirable substances in animal feed. *Official Journal of the European Communities*, L140, 10-22. Available at: <https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A32002L0032>. Accessed 08.09.2023.
11. Garg N., Aggarwal M., Javed S., Khandal K.R. 2013. Studies for optimization of conditions for reducing Aflatoxin Contamination in Peanuts using

- Ultraviolet Radiations. *International Journal of Drug Development and Research*, 5, 3, 155–168.
12. Gücek A., Sener S., Bilgen S., Mazmancı M.A. 2005. Adsorption and kinetic studies of cationic and anionic dyes on pyrophyllite from aqueous solutions. *Journal of Colloid and Interface Science*, 286, 53-60. doi: 10.1016/j.jcis.2005.01.012.
  13. Herzallah S., Alshawabkeh K., Fataftah, A.A.L. 2008. Aflatoxin decontamination of artificially contaminated feeds by sunlight,  $\gamma$ -radiation, and microwave heating. *Journal of Applied Poultry Research*, 17, 4, 515–521. doi:10.3382/japr.2007-00107.
  14. Jakšić S., Baloš M.Ž., Popov N., Mihaljev Ž., Zloh B., Polaček V. 2022. In vitro study of the efficacy of mycotoxins degradation by feed enzymes. *Archives of Veterinary Medicine*, 15, 1, 5–17. doi: 10.46784/eavm.v15i1.280.
  15. Jouany J.P. 2007. Methods for preventing, decontaminating and minimizing the toxicity of mycotoxins in feeds. *Animal Feed Science and Technology*, 137, 3–4, 342–362. doi:10.1016/j.anifeedsci.2007.06.009.
  16. Juodeikiene G., Basinskiene L., Bartkiene E., Matusevicius P. 2012. Mycotoxin Decontamination Aspects in Food, Feed and Renewables Using Fermentation Processes. In *Structure and Function of Food Engineering*. Eds. A. Eissa, Intech Open, 171–204. doi:10.5772/46184.
  17. Krstović S., Bočarov-Stančić S., Krulj J., Janković S., Guljaš D., Jajić I. 2018. Potential of *Fusarium graminearum* isolate to biosynthesize deoxynivalenol and zearalenone in vitro. In *Proceedings XVIII International Symposium "Feed Technology"*, 23-25.10.2018, University of Novi Sad, Institute of Food Technology, Novi Sad, Serbia, 71-76.
  18. Krstović S., Krulj J., Jakšić S., Bočarov-Stančić A., Jajić I. 2021. Ozone as decontaminating agent for ground corn containing deoxynivalenol, zearalenone, and ochratoxin A. *Cereal Chemistry*, 98, 1, 135-143. doi:10.1002/cche.10289.
  19. Li Y., Tian G., Dong G., Bai S., Han X., Liang J., Meng J., Zhang H. 2018. Research progress on the raw and modified montmorillonites as adsorbents for mycotoxins: A review. *Applied Clay Science*, 163, 299-311. doi: 10.1016/j.clay.2018.07.032.
  20. Lopičić R.Z., Bočarov-Stančić S.A., Stojanović D.M., Milojković V.J., Pantić R.V., Adamović J.M. 2013. In vitro evaluation of the efficacy of peach stones as mycotoxin binders. *Matica Srpska Journal for Natural Sciences*, 124, 287-296. doi:10.2298/ZMSPN1324287L.
  21. Murtić S., Zahirović Ć., Karić L., Jurković J., Čivić H., Sijahović E. 2020. Use of pyrophyllite as soil conditioner in lettuce production. *Nature Environment and Pollution Technology*, 19, 1, 355-359.

22. Neme K. and Mohammed A. 2017. Mycotoxin occurrence in grains and the role of postharvest management as a mitigation strategies: A review. *Food Control*, 78, 412-425. doi:10.1016/j.foodcont.2017.03.012.
23. Nešić K., Jakšić S., Popov N., Živkov-Baloš M., Pajić M., Zloh B., Polaček V. 2020. In vitro assessment of binding capacity of combined adsorbent (bentonite with yeast cell wall extracts) and aflatoxin B1. *Archives of Veterinary Medicine*, 13, 1, 41–52. doi:10.46784/e-avm.v13i1.65.
24. Panda L., Rath S.S., Rao D.S., Nayak B.B., Das B., Misra P.K. 2018. Thorough understanding of the kinetics and mechanism of heavy metal adsorption onto a pyrophyllite mine waste based geopolymer. *Journal of Molecular Liquids*, 263, 428-441. doi:10.1016/j.molliq.2018.05.016.
25. Santos Pereira C., Cunha S.C., Fernandes J.O. 2019. Prevalent mycotoxins in animal feed: Occurrence and analytical methods. *Toxins*, 11, 5, 290. doi:10.3390/toxins11050290.
26. Sugita-Konishi Y., Tanaka T., Nakajima M., Fujita K., Norizuki H., Mochizuki N., Takatori K. 2006. The comparison of two clean-up procedures, multifunctional column and immunoaffinity column, for HPLC determination of ochratoxin A in cereals, raisins and green coffee beans. *Talanta*, 69, 650-655. doi:10.1016/j.talanta.2005.10.036
27. United States Food and Drug Administration. 2019. Part 573 - Food additives permitted in feed and drinking water of animals. *Food and Drugs, Chapter I - Food and drug administration, Department of Health and Human Services, Subchapter E-Animal drugs, feeds, and related products*. US FDA, Silver Spring, MD.
28. Yao Y. and Long M. 2020. The biological detoxification of deoxynivalenol: A review. *Food and Chemical Toxicology*, 145, 11649. doi:10.1016/j.fct.2020.111649.

Received: 17.05.2023.

Accepted: 23.07.2023.

Original research article

UDK 636.29:579.842:[615.281.015.8(849.3)]  
<https://doi.org/10.46784/e-avm.v16i2.317>

## ISOLATION, MOLECULAR IDENTIFICATION AND ANTIBIOTIC SENSITIVITY OF *SALMONELLA* FROM BUFFALO FECES IN SYLHET DISTRICT OF BANGLADESH

Bishwajit Dashgupta<sup>1</sup>, Md. Mahfujur Rahman<sup>1</sup>, Sharmin Akter<sup>2</sup>,  
Ruhen Begum<sup>1</sup>, Md. Shahidur Rahman Chowdhury<sup>1</sup>, Md. Mukter Hossain<sup>1\*</sup>

<sup>1</sup>Department of Medicine, Sylhet Agricultural University, Sylhet, Bangladesh

<sup>2</sup>Department of Epidemiology and Public Health, Sylhet  
Agricultural University, Sylhet, Bangladesh

### Abstract

*Salmonella* is a widely distributed foodborne pathogen affecting humans and animals around the globe. This cross-sectional bacteriological study was aimed at isolation of *Salmonella* from fecal samples of buffalos in Sylhet district (Upazilas Jaintapur and Fenchuganj) of Bangladesh, their molecular confirmation, and learning their antibiotic sensitivity patterns. A total of 334 fecal samples were collected using a simple random sampling technique. Standard conventional bacteriological culture and biochemical tests were done to isolate and confirm *Salmonella*. The isolates were confirmed with polymerase chain reaction (PCR). In this study, *Salmonella* was isolated from 56 samples (16.77%) using bacteriological culture methods and biochemical tests, and all isolates were confirmed in PCR tests. The prevalence of *Salmonella* was estimated to be 17.57% and 13.93% in Jaintapur and Fenchuganj Upazilas, respectively. Buffalo calves under one year of age had a higher prevalence (24.32%) than older animals aged 1 - 2 (18.62%), 2 - 4 (13.25%), and > 4 years (10.67%). Furthermore, the prevalence was substantially higher in diarrheic animals (72.22%) than in their healthy counterparts (13.60%). It did not vary significantly ( $p > 0.05$ ) between animals from Jaintapur and Fenchuganj Upazilas. Likewise, no significant difference ( $p > 0.05$ ) in *Salmonella* isolates was detected between different age groups. The results revealed that the isolation rate of *Salmonella* was significantly ( $p < 0.05$ ) higher in female and diarrheic animals.

---

\* mukter.vetmed@sau.ac.bd

The most effective antibiotics against the majority of *Salmonella* isolates were gentamycin (100%), levofloxacin (100%), and ciprofloxacin (76.67%). On the other hand, *Salmonella* isolates were highly resistant to tetracycline (100%), ampicillin (87.5%), and streptomycin (78.6%). Pathogenic microorganisms in feces are a potential risk to public health due to environmental and animal food contamination. Therefore, infection control and establishing strategic antibiotic therapy should be a priority.

**Key words:** Bangladesh, buffalo feces, *Salmonella*, *invA* gene, antibiotics sensitivity

## IZOLACIJA, MOLEKULARNA IDENTIFIKACIJA I ANTIBIOTSKA OSETLJIVOST *SALMONELLA* IZ BIVOLJEG IZMETA U OKRUGU SILHET, BANGLADEŠ

Bishwajit Dashgupta<sup>1</sup>, Md. Mahfujur Rahman<sup>1</sup>, Sharmin Akter<sup>2</sup>,  
Ruhena Begum<sup>1</sup>, Md. Shahidur Rahman Chowdhury<sup>1</sup>, Md. Mukter Hossain<sup>1</sup>

<sup>1</sup>Departman za medicinu, Univerzitet za poljoprivredu u Silhetu, Silhet, Bangladeš

<sup>2</sup>Departman za epidemiologiju i javno zdravlje, Univerzitet  
za poljoprivredu u Silhetu, Silhet – 3100, Bangladeš

### Kratak sadržaj

*Salmonella* je široko rasprostranjen patogen koji se prenosi hranom i pogađa ljude i životinje širom sveta. Ova bakteriološka studija poprečnog preseka imala je za cilj izolaciju *Salmonella* iz uzoraka fecesa bivola u okrugu Silhet (distrikti Jaintapur i Fenchuganj) u Bangladešu, njihovu molekularnu potvrdu i osetljivost na antibiotike. Ukupno 334 uzorka fecesa prikupljena su jednostavnom tehnikom slučajnog uzorkovanja. Standardne konvencionalne bakteriološke metode i biohemijski testovi su urađeni da bi se izolovala i potvrdila *Salmonella*. Izolati su potvrđeni lančanom reakcijom polimeraze (PCR). U ovoj studiji *Salmonella* je izolovana iz 56 uzoraka (16,77%) metodom kultivacije i biohemijskim testovima, a svi izolati su potvrđeni i PCR testovima. Prevalencija *Salmonella* je iznosila 17,57% i 13,93% u Jaintapuru i Fenchuganj distriktu. Mladunčad bivola mlađih od jedne godine imala

su veću prevalenciju (24,32%) od starijih životinja uzrasta 1 - 2 (18,62%), 2 - 4 godine (13,25%) i > 4 godine (10,67%). Osim toga, prevalencija je bila znatno veća kod životinja sa dijarejom (72,22%) nego kod zdravih životinja (13,60%). Prevalencija nije značajno varirala ( $p > 0,05$ ) između životinja iz Jaintapura i Fenchuganj distrikta. Isto tako, nije otkrivena značajna razlika ( $p > 0,05$ ) u izolatima *Salmonella* između različitih starosnih grupa. Rezultati su otkrili da je stopa izolacije *Salmonella* značajno ( $p < 0,05$ ) veća kod ženki i životinja sa dijarejom. Najefikasniji antibiotici protiv većine izolata *Salmonella* bili su gentamicin (100%), levofloksacin (100%) i ciprofloksacin (76,67%). S druge strane, izolati *Salmonella* su bili visoko otporni na tetraciklin (100%), ampicilin (87,5%) i streptomycin (78,6%). Patogeni mikroorganizmi u fecesu predstavljaju potencijalni rizik za javno zdravlje zbog kontaminacije životne sredine i hrane za životinje. Stoga, kontrola infekcije i uspostavljanje strateške antibiotske terapije treba da budu prioritet.

**Ključne reči:** Bangladeš, bivolji feces, *Salmonella*, *invA* gen, antibiotska osetljivost

## INTRODUCTION

*Salmonella*, a genus of the family *Enterobacteriaceae*, is a major cause of foodborne disease of public health significance both in developed and developing countries (Gebeyehu et al., 2022). All across the world, pathogens have been isolated from the feces of animals (Sabur et al., 2021). Salmonellosis, the clinical form of *Salmonella* infection, is a costly disease to livestock producers on account of mortality, treatment expenses, reduced milk yield, and weight loss/decreased weight gain within the herd (Callaway et al., 2005). By producing high-quality milk, meat, and farmyard waste, buffalo ranching contributes significantly to the agriculture and cattle sectors in many Asian nations (Khongsai, 2020). Bangladesh has only 1.485 million indigenous buffaloes, with a more significant concentration (40%) in coastal areas and certain buffalo pockets. Smallholder farmers in Bangladesh raise a small number of imported Nili-Ravi and Murrah buffaloes and their crosses on a few fields (Samad, 2020). Pathogens that infect buffaloes and their offspring or are transferred via their products are significant because they impact milk production and total livestock performance. In buffaloes, *Salmonella* is a major pathogen causing calf diarrhea (Khongsai, 2020; Ribeiro et al., 2000), leading to early-age

calf mortality (Rana et al., 2012) and a foremost pathogen transmitted through animal products. *Salmonella enterica* subsp. *enterica* can cause infections with a variety of clinical signs, as well as systemic infections characterized by diarrhea and septicemia, and, in extreme cases, death.

Antimicrobial resistance (AMR) is now recognized as one of the most serious global threats to human health in the 21<sup>st</sup> century (Morehead and Scarborough, 2018; Tacconelli et al., 2018a; Tacconelli et al., 2018b) and a decline in the rate of new antibiotic development (Luepke and Mohr, 2017). It causes a considerable risk of death and economic hardship all over the world. However, impoverished nations are more harmed due to extensive antibiotic abuse, non-human antibiotic usage, poor medication quality, and insufficient surveillance (Ayukekbong et al., 2017; Van Boeckel et al., 2019). Bangladesh, a Southeast Asian developing country with a high level of AMR, poses a regional and global concern. Several studies have found irrational antibiotic prescribing by doctors and veterinarians, a patient habit of self-medication, and indiscriminate antibiotic usage in agriculture and farming in various sections of the nation (Biswas et al., 2014; Sutradhar, 2014).

*Salmonella* species with single and multidrug resistance are becoming more common (Liu et al., 2010). Salmonellosis is treated with a variety of antibiotics. Fluoroquinolones and third generation cephalosporins are the most often prescribed antibiotics to treat salmonellosis. Chloramphenicol, Ampicillin, Amoxicillin, and trimethoprim-sulfamethoxazole are some of the older antibiotics occasionally used as alternatives (Ayukekbong et al., 2017). Antimicrobial resistance in *Salmonella* has been observed to be on the rise in several developing and developed nations (Schmidt et al., 2018).

In some upazilas of the Sylhet region, the farmers depend upon the buffaloes primarily for draught and meat purposes, an integral part of the farming system in this area. Buffalo is economically significant in this region and could be considered a “small tractor” for farmers, and its meat and milk are nutritionally rich. Despite their great contribution to the socio-economy, they are still undervalued. Diseases are one of the most significant constraints for buffalo production, which decrease milk and meat production and reduce farmer’s income. In addition, the status of *Salmonella* in buffalo populations in Sylhet district is unknown. Therefore, this study aimed to isolate and identify *Salmonella* from buffalo feces by conventional bacteriological, biochemical, and molecular methods and to determine the antibiotic sensitivity of *Salmonella* isolates.



## MATERIAL AND METHODS

### *Study Area and Sample Collection*

For this study, Fenchuganj and Jaintapur Upazilas of Sylhet District of Bangladesh were purposively selected due to their relativeness of larger buffalo population and milk production. The sampling units for the study were buffalo of different ages. A total of 334 fecal samples of buffaloes (112 from Fenchuganj and 222 from Jaintapur) of Sylhet District constituted the study population, which was selected by using a simple random sampling method. The study was conducted for a period of one year (July 2021 to June 2022). Feces samples were collected directly from the rectum and freshly voided feces from buffalo. The samples were placed in a labeled clean plastic container and immediately transferred to the laboratory for further analysis.

### *Isolation and identification of Salmonella*

Conventional bacteriological methods were used to isolate the *Salmonella* from feces samples. The samples were inoculated into buffered peptone water (BPW), incubated at 37°C for 24 hours, and 0.5 mL was transferred to 10 mL Tetrathionate Broth (Merck) and incubated at 37°C for 24 hours. Following enrichment, a loopful of samples were streaked on xylose-lysine deoxycholate (XLD) agar and *Salmonella* – *Shigella* (SS) agar plates and incubated at 37 °C for 24 h. Biochemical confirmation of *Salmonella* was performed using TSI agar, Urea agar, Simmon's citrate agar, methyl red, and Voges Proskauer broth.

### *Bacterial genomic DNA Extraction and PCR assay*

The DNA extraction was performed according to the manufacturer's instructions using the Addprep genomic DNA extraction kit (Addbio Inc. Ltd., Korea). These eluted DNA samples were stored at -80 °C until further analysis. The PCR analysis was performed to detect the *Salmonella* invasion gene (*invA* gene) according to the manufacturer's instructions (Addbio Inc. Ltd., Korea). PCR assay performed in the thermal cycler TC1000G PCR System\* (DLAB Scientific Inc., USA) with a heated lid. The cycling conditions included 50 °C for 3 minutes (UDG Reaction), 95 °C for 10 minutes (Initial Denaturation), 35 cycles of 95 °C for 30 seconds (denaturation), 68 °C for 45 seconds (annealing), and 72 °C for 5 minutes for final extension (Khan et al., 2021). For the detection of *Salmonella*, the primers of *invS*-F (5'-TAA TGCCAGACGAAA-GAGCGT-3') and *invS*-R (5'-GATATTGGTGTTTATGGG GTCGTT-3') were

used (Khan et al., 2021). All reaction mixtures, including the negative control and *Salmonella* positive DNA, were tested in duplicate in the same run of PCR assay. PCR products were analyzed on 1.8% agarose gels stained with RedSafe™ (iNtRON Biotechnology, Korea) Nucleic Acid Staining Solution (20,000×), photographed, and stored as a digital image.

### ***Determination of Antibiotic sensitivity patterns***

The *in vitro* antibiotic sensitivity test was determined by the standard disc diffusion method according to the Clinical and Laboratory Standard Institute (CLSI, 2020). The antibiotic discs used in the present study were Ampicillin (AMP, 10 µg), Amoxicillin/Clavulanic Acid (AMC, 30 µg), Gentamycin (CN, 10 µg), Streptomycin (S, 10 µg), Cefixime (CFM, 5 µg), Ceftriaxone (CRO, 30 µg), Azithromycin (AZM, 15 µg), Ciprofloxacin (CIP, 5 µg), Levofloxacin (LEV, 5 µg), Colistin sulfate (CT, 10 µg), Tetracycline (TE, 10 µg), Sulfamethoxazole-trimethoprim (SXT, 25 µg) all from Oxoid company, UK. After incubation, each disc's diameter of the clear zones produced by antibacterial inhibition of bacterial growth was measured to the nearest millimeter and then classified as resistant, intermediate, or susceptible using a published interpretive chart of Clinical and Laboratory Standards Institute (CLSI,2020).

### ***Statistical analysis***

Microsoft Excel Office 2010 was used for descriptive statistics. Chi-square tests were used to assess the significance of differences in prevalence between age, sex, and health status of the animals. P values less than 0.05 were considered significant using Chi-square tests (SPSS Inc., Chicago, IL, USA).

## **RESULTS**

*Salmonella* was isolated from 56 (16.77%) out of 334 examined samples, of which 39 (17.57%) and 17 (13.93%) were from feces of Jaintapur and Fenchuganj upazila, respectively (Table 1). The prevalence of *Salmonella* was higher in buffalo calves aged less than one year (24.32%); although the difference was not statistically significant ( $p = 0.11$ ) (Table 2). Furthermore, the isolation rate was relatively higher in animals aged 1 - 2 years (18.62%) than in the groups of 4 years and above four years (Table 2).

Table 1: Overall prevalence of *Salmonella* in buffalo feces and its association with study area

Study area	Number of samples tested	Tests name					
		Culture positive	Prevalence	Biochemical Test positive	Prevalence	PCR positive	Prevalence
Jaintapur	222	45	20.27%	39	17.57%	39	17.57%
Fenchuganj	122	19	15.57%	17	13.93%	17	13.93%
Total	334	64	19.16%	56	16.77%	56	16.77%

Table 2: Association of the prevalence of *Salmonella* with age of buffalo populations

Age of animals	No. of animals examined	No. of positive fecal samples	Prevalence	P-value
Up to 1 year	74	18	24.32%	0.11
1 - 2 years	102	19	18.62%	
2 - 4 years	83	11	13.25%	
> 4 years	75	8	10.67%	
Total	334	56	16.77%	

Level of significance  $p < 0.05$

It was observed that out of the total 334 feces samples collected from two different upazilas, the female buffaloes showed a higher prevalence (21.56%) of *Salmonella* in their fecal samples (Table 3). All suspected *Salmonella* colonies underwent specific biochemical tests such as indole formation, methyl red and Voges Proskauer reaction, citrate utilization, and triple sugar iron agar due to their cultural and morphological characteristics. Sixty-four of the suspected *Salmonella* colonies had 56 confirmed colonies by biochemical test results. Most of the *Salmonella* isolates showed fermentation of glucose, gas

production from glucose, H<sub>2</sub>S formation, but none of the isolates showed either lactose or sucrose. The results showed that the prevalence rate of *Salmonella* was statistically significant ( $p = 0.01$ ). In this study, the *Salmonella* isolation rate was categorized based on the health condition of buffalo populations. The isolation rate of *Salmonella* was higher in diarrheic buffalo fecal samples (72.22%) compared with apparently healthy animals (13.60%). The result revealed statistically significant differences ( $p = 0.01$ ) (Table 4).

Table 3: Association of *Salmonella* isolation rate with the sex of animals

Sex of animals	No. of animals examined	No. of positive fecal samples	Prevalence	$p$ -value
Male	153	17	11.11%	
Female	181	39	21.55%	0.01
Total	334	56	16.77%	

Level of significance  $p < 0.05$

Table 4: The association of *Salmonella* isolation rate with the health status of buffalo populations

Health status of animals	No. of animals examined	No. of positive fecal samples	Prevalence	$p$ -value
Apparently healthy	316	43	13.60%	
Diarrheic	18	13	72.22%	< 0.01
Total	334	56	16.77%	

Level of significance  $p < 0.05$

A total of 56 isolates of *Salmonella* were tested for commonly used 12 antibiotics from 8 groups. All the *Salmonella* isolates were found resistant to one or more antibiotics used. This antibiotic susceptibility study revealed that *Salmonella* isolates were 100%, 93.33%, and 76.67% sensitive to Gentamycin, Levofloxacin, Colistin sulfate, and Ciprofloxacin. On the other hand, isolates were 100%, 87.5%, and 78.6% resistant to Tetracycline, Ampicillin, and Streptomycin, respectively (Table 5.). All of the biochemically positive *Salmonella* isolates

(n = 56) were submitted to a PCR test using a particular primer set to identify the *invA* gene of *Salmonella*. After agarose gel electrophoresis under UV transilluminator, all the biochemically identified 56 isolates were confirmed positive for *Salmonella* and revealed an *invA* gene-specific band at 100bp (Figure 1.).

Table 5. Antibiotic susceptibility profile of *Salmonella* isolated (n = 56) from buffalo feces

Antibiotic tested	Susceptible (%)	Intermedi- ate (%)	Resist- ance (%)
<b>Penicillin</b>			
Ampicillin (AMP, 10 µg)	-	7 (12.5)	49 (87.5)
Amoxicillin/clavulanic Acid (AMC, 30 µg)	30 (53.33)	15 (26.67)	11 (20)
<b>Aminoglycosides</b>			
Gentamicin (CN, 10 µg)	56 (100)	-	-
Streptomycin (S, 10 µg)	-	12 (21.4)	44 (78.6)
<b>Cephalosporins</b>			
Cefixime (CFM, 5 µg)	41 (73.21)	4 (7.14)	11 (20)
Ceftriaxone (CRO, 30 µg)	39 (70)	4 (7.14)	13 (23.21)
<b>Macrolides</b>			
Azithromycin (AZM, 15 µg)	39 (70)	-	17 (30)
<b>Fluoroquinolones</b>			
Ciprofloxacin (CIP, 5 µg)	43 (76.67)	13 (23.21)	-
Levofloxacin (LEV, 5 µg)	56 (100)	-	-
<b>Polymyxins</b>			
Colistin Sulphate (CT, 10 µg)	52 (92.86)	-	4 (7.14)
<b>Tetracyclines</b>			
Tetracycline (TE, 10 µg)	-	-	56 (100)
<b>Folate Pathway Inhibitors</b>			
Sulfamethoxazole -Tri- methoprim (SXT, 25 µg)	35 (62.5)	-	21 (37.5)




Figure 1. PCR amplification of biochemically identified *Salmonella*

## DISCUSSION

In the present study, 334 buffalo fecal samples were collected from Jain-tapur (222) and Fenchuganj (112) Upazilas of Sylhet district. Bacteriological examination revealed the *Salmonella* organisms from 56 of 334 buffalo fecal samples with a prevalence of 16.77% (Table 1), which is close to 11.2% (Zahran and Elbehiry, 2014). *Salmonella* in the buffalo population is a health risk for people who consume the products (meat, milk), as it has been reported that 25% of meat samples are contaminated with *Salmonella* (Abd-Elghany et al., 2022). The prevalence of *Salmonella* was higher in young (up to 1 year) and sick (diarrheic) animals, estimated to be 24.32% and 72.22%, respectively. The age-related result of the present study is consistent with the findings of other researchers (Saha et al., 2013; Mahmood et al., 2014). The findings also coincide with the results of Hunduma et al. (2010), who stated that diarrhea is a major problem in animals with a higher prevalence.

For detection of *Salmonella* genus using PCR, it was found that all PCR products, including positive control, resulted in 100 bp amplified fragment. Figure 1 revealed no amplified DNA fragments obtained from the non-*Salmonella* genus. *Salmonella* isolates produced a white band at the level of marker DNA (Figure 1). The PCR method is recommended for detecting *Salmonella* in feces samples because it is faster than culture methods (Stone et al., 1994; van der Zee and Huis in 't Veld, 2000).

According to Vella and Cuschieri (1995), *Salmonella* isolates were most frequently resistant to trimethoprim. *Salmonella* isolated from feces of dairy cattle were resistant to ampicillin (100%), streptomycin (66.7%), and tetracycline (55.56%) but susceptible to gentamicin (100%) and ciprofloxacin (91.7%) as reported by others (Khan et al., 2021). According to Wieczorek and Osek (2013), sulfamethizole resistance was found in various strains of *S. Dublin* and *S. Enteritidis*. *Salmonella* isolates are resistant to multiple antibiotics (ampicillin, streptomycin, tetracycline, and sulfamethizole). The isolates were susceptible to gentamicin (100%), levofloxacin (100%), and ciprofloxacin (76.67%) but have shown higher resistance to tetracycline, ampicillin, and streptomycin (100%, 87.5%, and 78.6%, respectively). According to Esaki et al. (2004), many *Salmonella* isolates from both healthy and ill animals were resistant to two or more antimicrobials. These microorganisms are disseminated in the environment and spread through the excrement of animals that appear to be in good health. According to reports, *S. Typhimurium* was released in a pig farm (Tanaka et al., 2014). The release was relatively high for several days following vaccination; therefore, the animals appeared to be in good health. As a result, herd infection could come even from the excrement of clinically healthy animals. Furthermore, a range of serotypes of antibiotic-resistant bacteria may exist. *Salmonella* isolates were shown to be resistant to numerous drugs in the current investigation. Tetracycline resistance was found in all *Salmonella* isolates. The results of this study revealed that *Salmonella*-infected buffalo could be effectively treated with gentamicin, Levofloxacin, and Ciprofloxacin.

## CONCLUSION

It could be concluded that *Salmonella* is a significant cause of diarrhea in buffaloes with salmonellosis in Bangladesh. Therefore, a rapid and proper diagnosis could prevent harm inflicted on the livestock industry. The molecular basis of *Salmonella* identification techniques, such as using the *invA* gene-specific PCR method, could be helpful in diagnostic and research laboratories. This study suggests the strategic use of antibiotics to control *Salmonella* infections in animals.

## ACKNOWLEDGEMENT

This project was funded by the Ministry of Science & Technology, Bangladesh. The authors also express their gratitude to Sylhet Agricultural University Research System (SAURES) for their support in completing this research successfully.

### Author's Contribution:

MMH and MMR: Supervised and contributed to study design; BDG and RB: Carried out the laboratory experiments; SA and MSRC: Performed statistical analysis; and BDG and MMH: Wrote the manuscript. All authors read and approved the final manuscript.

### Competing interest

The authors declare that they have no competing interests.

### REFERENCES

1. Abd-Elghany S.M., Fathy T.M., Zakaria A.I., Imre K., Morar A., Herman V., Paşcalau R., Şmuleac L., Morar D., Imre M., Sallam K.I. 2022. Prevalence of Multidrug-Resistant *Salmonella enterica* Serovars in Buffalo Meat in Egypt. *Foods*, 11, 18, 2924. doi: 10.3390/foods11182924.
2. Ayukekbong J.A., Ntemgwa M., Atabe, A.N. 2017. The threat of antimicrobial resistance in developing countries: Causes and control strategies. *Antimicrobial Resistance and Infection Control*, 6, 1, 1–8. doi: 10.1186/s13756-017-0208-x.
3. Biswas M., Roy M.N. Manik M.I.N., Hossain M.S., Tapu S.T.A., Moniruzzaman M. Sultana S. 2014. Self medicated antibiotics in Bangladesh: A cross-sectional health survey conducted in the Rajshahi City. *BMC Public Health*, 14, 1, 1–7. doi: 10.1186/1471-2458-14-847.
4. Callaway T.R., Keen J.E., Edrington T.S., Baumgard L.H., Spicer L., Fonda E.S., Griswold K.E., Overton T.R., Van Amburg M.E., Anderson R.C., Genovese K.J., Poole T.L., Harvey R.B., Nisbet D.J. 2005. Fecal prevalence and diversity of *Salmonella* species in lactating dairy cattle in four states. *Journal of Dairy Science*, 88, 3603–3608. doi: 10.3168/jds.S0022-0302(05)73045-9.
5. Clinical and Laboratory Standards Institute (CLSI) M100 Performance Standards for Antimicrobial Susceptibility Testing, 2020.
6. Esaki H., Morioka A., Ishihara K., Kojima A., Shiroki S., Tamura Y., Takahashi T. 2004. Antimicrobial susceptibility of *Salmonella* isolated from cattle, swine and poultry (2001–2002): Report from the Japanese Veterinary antimicrobial resistance monitoring program. *Journal of Antimicrobial Chemotherapy*, 53, 266–270. doi: 10.1093/jac/dkh081.
7. Gebeyehu A., Taye M., Abebe R. 2022. Isolation, molecular detection and antimicrobial susceptibility profile of *Salmonella* from raw cow milk



- collected from dairy farms and households in southern Ethiopia. *BMC Microbiology*, 22, 84. doi: 10.1186/s12866-022-02504-2.
8. Hunduma D., Tigre W., Wagari M., Regassa F. 2010. Preliminary study on major health problems of the newly introduced boer goat breed in Ethiopia. *World Applied Sciences Journal*, 11, 803-807.
  9. Khan M.N.K., Das M.R., Sabur M.A., Rahman M.M., Uddin M.B., Cho H.S., Hossain M.M. 2021. Isolation, identification, molecular detection and sensitivity to antibiotics of *Salmonella* from cattle feces. *Bulgarian Journal of Veterinary Medicine*, 24, 57-66. doi: 10.15547/bjvm.2019-0061.
  10. Khongsai L. 2020. Growth and Development of Dairy Industry in India. *International Journal of Recent Technology and Engineering*, 8, 5, 1566-1571. doi: 10.35940/ijrte.D4239.018520.
  11. Liu W.B., Chen J., Huang Y.Y., Liu B., Shi X.M. 2010. Serotype, genotype, and antimicrobial susceptibility profiles of *Salmonella* from chicken farms in Shanghai. *Journal of Food Protection*, 73, 3, 562-567. doi: 10.4315/0362-028x-73.3.562.
  12. Luepke K.H. and Mohr J.F. 2017. The antibiotic pipeline: reviving research and development and speeding drugs to market. *Expert Review of Anti-infective Therapy*, 15, 5, 425-433. doi: 10.1080/14787210.2017.1308251.
  13. Mahmood A.K., Khan M.S., Khan M.A., Khan M.A., Bilal M. 2014. Prevalence of *Salmonella* in diarrheic adult goats in field conditions. *The Journal of Animal and Plant Sciences*, 24, 1, 98-102.
  14. Morehead M.S. and Scarbrough C. 2018. Emergence of Global Antibiotic Resistance. *Prime Care*, 45, 3, 467-484. doi: 10.1016/j.pop.2018.05.006.
  15. Rana N., Raut A.A., Khurana S.K., Manuja A., Saini A. 2012. Isolation and biotyping of *Salmonella* and *Escherichia coli* associated with neonatal buffalo calves. *The Indian Journal of Animal Science*, 82, 7, 676-678.
  16. Ribeiro M.G., Langoni H., Jerez J.A., da Silva Leite D., Ferreira F.E.R., Gennari S.M. 2000. Identification of enteropathogens from buffalo calves with and without diarrhoea in the Ribeira Valley, State of São Paulo, Brazil. *Brazilian Journal of Veterinary Research and Animal Science*, 37, 2, 159-165. doi: 10.1590/S1413-95962000000200013.
  17. Sabur M.A., Das M.R., Uddin M.B., Rahman M.M., Islam M.R., Chowdhury M.S.R., Hossain M.M. 2021. Molecular Detection and Antibiotic Sensitivity of *Salmonella* Species Isolated from Goat Feces in Sylhet District of Bangladesh. *World Veterinary Journal*, 11, 3, 395-401. doi: 10.54203/scil.2021.wvj51.
  18. Saha G.K., Paul A.K., Abdussamad A., Islam M.A., Khan M.S.R. 2013. Epidemiological investigation and antibiotic sensitivity of salmonellosis in goats at the selected areas of Bangladesh. *Journal of Animal Reproduction and Biotechnology*, 28: 337-342.

19. Samad M.A. 2020. A systematic review of research findings on buffalo health and production published during the last six decades in Bangladesh. *Journal of Veterinary Medicine and One Health Research*, 2, 1, 01-62. doi: 10.36111/jvmohr.2020.2(1).0016.
20. Schmidt V.M., Pinchbeck G., McIntyre K.M., Nuttall T., McEwan N., Dawson S. Williams N.J. 2018. Routine antibiotic therapy in dogs increases the detection of antimicrobial-resistant faecal *Escherichia coli*. *Journal of Antimicrobial Chemotherapy*, 73, 12, 3305-3316. doi: 10.1093/jac/dky352.
21. Stone G.G., Oberst R.D., Hays M.P., McVey D.S., Chengappa M.M. 1994. Detection of *Salmonella* serovars from clinical samples by enrichment broth cultivation-PCR procedure. *Journal of Clinical Microbiology*, 32, 7, 1742-1749. doi: 10.1128/jcm.32.7.1742-1749.1994.
22. Sutradhar K.B, Saha A., Huda N.H., Uddin R. 2014. Irrational Use of Antibiotics and Antibiotic Resistance in Southern Rural Bangladesh: Perspectives from Both the Physicians and Patients. *Annual Research and Review in Biology*, 4, 9, 1421-1430. doi: 10.9734/ARRB/2014/8184.
23. Tacconelli E., Carrara E., Savoldi A., Harbarth S., Mendelson M., Monnet D.L., Pulcini C., Kahlmeter G., Kluytmans J., Carmeli Y., Ouellette M., Outtersson K., Patel J., Cavalieri M., Cox E.M., Houchens C.R., Grayson M.L., Hansen P., Singh N., Theuretzbacher U., Magrini N., WHO Pathogens Priority List Working Group. 2018a. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infectious Diseases*, 18, 3, 318-327. doi: 10.1016/S1473-3099(17)30753-3.
24. Tacconelli E., Sifakis F., Harbarth S., Schrijver R., van Mourik M., Voss A., Sharland M., Rajendran N.B., Rodríguez-Baño J., EPI-Net COMBAC-TE-MAGNET Group. 2018b. Surveillance for control of antimicrobial resistance. *Lancet Infectious Diseases*, 18, 3, e99-e106. doi: 10.1016/S1473-3099(17)30485-1.
25. Tanaka T., Imai Y., Kumagae N., Sasaki T., Ochiaial N. Uruno K., Kitazawa H., Saito T., Sato S. 2014. Quantitative microbiological evaluation of *Salmonella* Typhimurium shed in diarrhea, loose, and normal stools of infected pigs. *Open Journal of Veterinary Medicine*, 4, 58-66. doi: 10.4236/ojvm.2014.44007.
26. Van Boeckel T.P., Pires J., Silvester R., Zhao C., Song J., Criscuolo N.G., Gilbert M., Bonhoeffer S., Laxminarayan R. 2019. Global trends in antimicrobial resistance in animals in low- And middle-income countries. *Science*, 365, 6459, 1251. doi: 10.1126/science.aaw1944.

27. van der Zee H. and Huis in't Veld J.H.J. 2000. Method for the rapid detection of *Salmonella*. In *Salmonella in Domestic Animals*. Eds. C. Wray and A. Wray, CABI Publishing, Wallingford, UK, 373–391.
28. Vella L. and Cuschieri P. 1995. *Salmonella* excretion in adult cattle on the Maltese island of Gozo. *Revue Scientifique et Technique*, 14, 3, 777-787. doi: 10.20506/rst.14.3.871.
29. Wiczorek K. and Osek J. 2013. Prevalence and characterisation of *Salmonella* in slaughtered cattle and beef in Poland. *Bulletin of the Veterinary Institute Pulawy*, 57, 4, 607-611. doi: 10.2478/bvip-2013-0103.
30. Zahran R. and Elbehiry A. 2014. Prevalence, molecular identification and virulence attributes of *Salmonella* serovars isolated from feces of diarrheic cow and buffalo calves. *International Journal of Current Microbiology and Applied Sciences*, 3, 9–27.

Received: 16.06.2023.

Accepted: 09.10.2023.



## **EVALUATION OF PHYSIOLOGICAL BIOMARKERS AS POSSIBLE PREDICTIVE FACTORS AND PROGNOSIS MARKERS OF KIDNEY INJURY IN DOGS NATURALLY INFECTED WITH *LEISHMANIA INFANTUM***

Felipe Muniz dos Santos<sup>1</sup>, Julio César Cambraia Veado<sup>1</sup>,  
Vitor Márcio Ribeiro<sup>2</sup>, Adriane Pimenta da Costa-Val<sup>1\*</sup>

<sup>1</sup> Veterinary Hospital, Clinical and Surgery Department, Veterinary School, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil

<sup>2</sup> Santo Agostinho Hospital Veterinário, Belo Horizonte, Minas Gerais, Brazil

### **Abstract**

Impaired renal function is one of the main characteristics of dogs infected with *Leishmania infantum*. Early diagnosis of kidney injury is essential for improving patient's prognosis. This study aims to evaluate physiological biomarkers as predictors of kidney injury and prognostic markers. Medical records of fifty-nine dogs of different breed, age, and sex, naturally infected with *L. infantum*, were analyzed. Red blood cells, leucocytes, platelets count, hematocrit, total plasma proteins, plasma globulin, plasma albumin, serum creatinine, serum urea, serum phosphorus, serum symmetrical dimethyl arginine, urine analysis, urinary density, urinary protein creatinine ratio, urinary creatinine, urinary protein, and systemic blood pressure were examined in trial 0. Six months after trial 0, twenty-four dogs returned for clinical and laboratory examination. The second medical record analysis was identified as trial 1. The twenty-four dogs were examined using the same tests performed in trial 0. The physiological biomarker such as platelets and leukocyte count, hematocrit, serum phosphorus, urinary density, and systemic blood pressure, showed a significant correlation as prognostic and predictive factors of kidney injury in dogs. The platelet count was used as the physiological biomarker to show the value as a predictive factor and prognostic marker related to biomarkers of kidney injury in dogs naturally infected with *L. infantum*.

**Key words:** acute kidney injury, CanL, survival

---

<sup>1\*</sup> Corresponding Author: adriane@ufmg.br

## EVALUACIJA FIZIOLOŠKIH BIOMARKERA KAO MOGUĆIH PREDIKTIVNIH FAKTORA I PROGNOŠTIČKIH MARKERA OŠTEĆENJA BUBREGA KOD PASA PRIRODNO INFICIRANIH SA LEISHMANIA INFANTUM

Felipe Muniz dos Santos<sup>1</sup>, Húlio Sezar Kambraja Veado<sup>1</sup>,  
Vitor Markio Ribeiro<sup>2</sup>, Adrijan Pimenta da Costa-Val<sup>1\*</sup>

<sup>1</sup> Veterinarska bolnica, kliničko i hirurško odeljenje, Veterinarska škola, Federalni univerzitet Minas Žerais (UFMG), Belo Horizonte, Minas Žerais, Brazil

<sup>2</sup> Veterinarska bolnica Santo Agostinjo, Belo Horizonte, Minas Žerais, Brazil

### Kratak sadržaj

Oštećena bubrežna funkcija je jedna od glavnih karakteristika pasa zaraženih sa *Leishmania infantum*. Rana dijagnostika oštećenja bubrega je od suštinskog značaja za bolju prognozu stanja pacijenta. Ova studija ima za cilj da proceni fiziološke biomarkere kao prediktore oštećenja bubrega i prognostičke markere. Izvršena je analiza medicinske dokumentacije za pedeset i devet pasa različitih rasa, starosti i pola, prirodno zaraženih sa *L. infantum*. Crvena krvna zrnca, leukociti, broj trombocita, hematokrit, ukupni proteini plazme, globulini u plazmi, albumin u plazmi, serumski kreatinin, serumska urea, serumski fosfor, serumski simetrični dimetil arginin, analiza urina, gustina urina, odnos urinarnog proteina i kreatinina, kreatinin u urinu, urinarni protein, i sistemski krvni pritisak ispitivani su kao parametri nultog ispitivanja. Šest meseci nakon nultog ispitivanja, dvadeset i četiri psa su se vratila na klinički i laboratorijski pregled. Podaci od drugog pregleda su označeni kao ispitivanje 1. Dvadeset četiri psa su pregledana korišćenjem istih testova izvršenih u ogledu „0“ (nultog ispitivanja). Fiziološki biomarkeri kao što su broj trombocita i leukocita, hematokrit, fosfor u serumu, gustina urina i sistemski krvni pritisak, pokazali su značajnu korelaciju kao prognostički i prediktivni faktori oštećenja bubrega kod pasa. Broj trombocita je korišćen kao fiziološki biomarker da pokaže vrednost kao prediktivni faktor i prognostički marker koji se odnosi na biomarkere oštećenja bubrega kod pasa prirodno inficiranih *L. infantum*.

**Ključne reči:** akutno oštećenje bubrega, lajšmanioza pasa, preživljavanje

## INTRODUCTION

Visceral leishmaniasis (VL) is an infectious, systemic, and zoonotic disease caused by the protozoan *Leishmania infantum* and is transmitted by infected female sandflies, *Lutzomyia longipalpis*, and its main vector is in Brazil (Dantas-Torres and Brandão-Filho, 2006). It is estimated that there are millions of infected dogs in South America, especially in Brazil, where there are high rates of infection (Marcondes and Day, 2019)

Infected dogs can develop canine leishmaniosis (CanL), which can affect several organs and therefore exhibit several clinical characteristics, ranging from apparently healthy to severe illness and death, depending on the immune response triggered by the patient (Soares et al., 2005; Freitas et al., 2012)

Renal function impairment is quite frequent among the clinical changes observed in infected animals (Braga et al., 2015). The formation and deposition of immune complexes secondary to CanL can cause glomerulonephritis and tubulointerstitial lesions (De Oliveira Frazilio et al., 2018). Some authors believe that tubulointerstitial lesions occur secondary to glomerulopathy (Pardo-Marín et al., 2017; De Oliveira Frazilio et al., 2018). Renal proteinuria, which is a reflection of increased glomerular capillary permeability, is associated with the production of immune complexes and may be evidence of kidney injury (D'Amico and Bazzi, 2003; Soares et al., 2005; Freitas et al., 2012; Brown et al., 2013; IRIS 2023). Treatments for CanL in Brazil are based on miltefosine for leishmanicidal action, immunomodulatory medications such as domperidone, and immunotherapy, which consists of three double doses of the Leishtec<sup>®</sup> vaccine with intervals of twenty-one days between applications. Subsequently, a six-monthly booster should be administered with the application of a double dose. Immunotherapy was a good and efficient protocol for reducing clinical manifestations and controlling CanL relapses compared to other treatments (Santos et al., 2007; Ribeiro et al., 2013; Araujo and Gondim, 2020).

This study aims to evaluate physiological biomarkers as predictive and prognostic markers of the evolution of infection, renal injury, and renal failure in dogs naturally infected with *L. infantum*, assisting in the determination of treatment procedures, managing possible alterations identified, and in the prognosis of patients.

## MATERIAL AND METHODS

For the retrospective data collection, no ethical approval was required as no identifying information was included, and no dogs were actively recruited.

Medical records of fifty-nine dogs of different breeds and ages naturally infected with *L. infantum* were examined. Out of the fifty-nine dogs studied, twenty-six were female dogs, while thirty-three were males. The dogs were classified and divided into stages as suggested by Solano-Gallego et al. (2011). The clinical staging of canine visceral leishmaniasis is classified in four stages based on serological status, clinical symptoms and laboratory findings. Dogs in Stage I - Negative to low positive antibody levels; Dogs with mild clinical symptoms such as peripheral lymphadenomegaly, or papular dermatitis. Usually, no clinicopathological abnormalities were observed. Normal renal profile was the following: creatinine <1.4 mg/dl; non-proteinuric: UPC < 0.5. Stage II - Low to high positive antibody levels; Dogs, which apart from the signs listed in stage I, may exhibit the following symptoms: diffuse or symmetrical cutaneous lesions such as exfoliative dermatitis / onychogryphosis, ulcerations (planum nasale, footpads, bony prominences, mucocutaneous junctions), anorexia, weight loss, fever, and epistaxis; Clinicopathological abnormalities such as mild non-regenerative anemia, hyperglobulinemia, hypoalbuminemia, serum hyperviscosity syndrome. Substages: a) Normal renal profile: creatinine < 1.4 mg/dl; non-proteinuric: UPC < 0.5 b) Creatinine <1.4 mg/dl; UPC = 0.5-1,0. Stage III - Medium to high positive antibody levels; Dogs, which apart from the symptoms listed in stages I and II, may show the signs originating from immune-complex lesions: vasculitis, arthritis, uveitis, and glomerulonephritis. Clinicopathological abnormalities listed in IRIS stage II of chronic kidney disease (CKD), creatinine 1.4-2,8 mg/dl, or stage I with UPC > 1. Stage IV - Medium to high positive antibody levels; Dogs with clinical symptoms listed in stage III. Pulmonary thromboembolism, or nephrotic syndrome (marked proteinuria UPC > 5) and final stage renal disease; Clinicopathological abnormalities listed in IRIS stage II CKD, stage III (creatinine 2,9-5mg/dl) and stage IV (creatinine >5 mg/dl).

The dogs from stage II and those undergoing treatment with immunotherapy (do Nascimento et al, 2018; Gouveia et al, 2021) as suggested by Brasileish (2019) were included. Medical records should also present parasitological examinations for *Leishmania sp.* identification by direct or molecular identification or titration above 1:160 in the indirect Fluorescent Antibody Test (IFAT) or sample value four times higher than the cut-off point in the Enzyme-Linked Immunosorbent Assay (ELISA) (Brasileish, 2019; Solano-Gallego et al., 2011; Laia et al., 2011) at trial 0 (T0). Eighteen (30.5%) dogs were classified as stage IIa (Normal renal profile: creatinine < 1.4 mg/dl; non-proteinuric: UPC < 0.5), fifteen (25.4%) as stage IIb (Creatinine <1.4 mg/dl; UPC = 0.5-1), twenty-three (39%) in stage III, and three (5.1%) dogs were classified as stage IV (Solano-Gallego, et al., 2011).



Also, medical records should present complete blood count tests: red blood cell count (RBC), hematocrit (HC), leucocytes (LE) and platelets (PL), total plasma proteins (PROT), plasma globulin (GL), plasma albumin (AL), serum creatinine (CR), serum urea (UR), serum phosphorus (PH), serum symmetrical dimethyl arginine (SDMA), urine analysis, urinary density (UR. D), urinary protein creatinine ratio (UPC), urinary creatinine (CR. U) and urinary protein (UR PTN), all performed in the exact consultation, in the same laboratory. Systemic blood pressure (SBP) was measured using vascular doppler or through the oscillometer method with the animal positioned in lateral decubitus, in line with criteria for cuff size and minimum stress. Three to seven measurements were performed, and the first measurement was discarded to obtain an average of the other measurements, considering the patient's SBP value.

Animals that showed signs of dehydration, episodes of vomiting, diarrhea, inappetence, or lower urinary tract disease were excluded from the study. This first moment is identified as T0. Six months after T0, twenty-four dogs were returned for clinical and laboratory evaluation. The second medical record analysis was identified as trial 1 (T1). These twenty-four dogs were clinically healthy and evaluated through the same exams performed in the same laboratory in T0. Thirty-five dogs were not returned for evaluation or returned for more than six months and were therefore excluded from the study.

### ***Statistical Analysis***

Principal component analysis (multivariate analysis) was performed using numerical variables. This analysis evaluated all numerical variables, considering their correlation, and was performed using Spearman's correlation matrix. Moderate, strong, and robust correlations were reported, with confidence intervals above 95%. Statistical analyses were performed using the R software version ("The R Project for Statistical Computing," 2019).

## **RESULTS**

### ***T0***

The distribution of the dogs evaluated in this study is shown in Figure 1. The arrows facing the same direction indicate biomarkers that are positively correlated with each other. The points in the two quadrants on the right showed higher values for CR, UR, SDMA, PH, UPC, and UR. PTN. In these

quadrants there were higher concentration of dogs classified in stages III and IV, whereas those in the two left quadrants, mostly dogs classified in stages IIa and IIb, had higher values mainly for CR, U, HC, AL, and UR. D. The points in the two upper quadrants had higher PL counts. On the other hand, the points in the two lower quadrants had higher values, mainly for PROT and GL. There was a relative separation in the group IIa, with animals concentrated on the left side of the graph, and group IV, with animals focused on the right side. The chart shows the dispersion and evolution of dogs from T0 to T1. The dogs classified as stage IIa or IIb were in the left quadrant. The dogs in stages III and IV were in the right quadrant, with high levels of CR, UR, SDMA, PH, and UPC, demonstrating that patients classified in the final stages have a greater impairment of the glomerular filtration rate.




Figure 1: Dispersion of dogs considering the staging and the values obtained in the analytes studied at T0 and T1. The points in the two quadrants on the right showed higher values for CR, UR, SDMA, PH, UPC, and UR. PTN, whereas those in the two left quadrants showed higher values mainly for CR, UR, HC, AL, and UR. D. The points in the two upper quadrants had higher PL counts, while the points in the two lower quadrants had higher values, mainly for PROT and GL.

Anemia was found in twenty-one (35%) dogs out of fifty-nine analyzed in the study. Two (11%) of the dogs were classified as stage IIa, five (33%) as stage IIb, 11 (47%) in stage III, and three (100%) in stage IV present anemia.

Thrombocytopenia was present in seventeen (28%) dogs out of fifty-nine evaluated in the study. Three (16%) of the dogs classified as stage IIa, four (26%) in stage IIb, seven (30%) in stage III, and three (100%) in stage IV had thrombocytopenia.

Out of the thirty-three dogs at T0, classified by Solano-Gallego et al. (2011) IIa and IIb stages evaluated in this study, in thirteen (39%), UPC was the first biomarker to assess kidney injury to have the values higher than reference values. SDMA was the first evaluated biomarker with values higher than reference values in two dogs (6%). SDMA and UPC levels increased simultaneously in two dogs (6 %) classified by Solano-Gallego et al. (2011) IIa and IIb stages.

SDMA had the values above the reference ( $> 18 \mu\text{g/dL}$  IRIS, 2023) in one (5%) dog classified as stage IIa and in four (26%) dogs classified as stage IIb. In stage III, there was an increase in SDMA in eight (34%) dogs, and in stage IV in three (100%) dogs.

Analyzing correlations at T0, they were found to be moderate with values varying between 0.4 and 0.69, and strong between 0.70 and 0.89. SDMA had a moderate positive correlation with UR and CREAT and a moderate negative correlation with HC. UR levels had a strong positive correlation with serum CR levels and a moderate positive correlation with PH levels. PH showed a reasonable positive correlation with UPC and a moderate negative correlation with RBC and HC. PROT levels showed a moderate negative correlation with the PL count. AL levels had a moderate positive correlation with HC and RBC, which was negatively correlated with UPC and UR. PTN levels. UR. D showed a moderate correlation with CR.U.

### ***Comparisons between T0 X T1***

The correlation of biomarkers evaluated at T0 and T1 is shown in Table 1. When correlations were evaluated at T0 and T1, PL (T0) had a negative correlation with UPC and UR. PTN levels at T1. There was no correlation between PL and UPC in T0. The UR. D (T0) and UPC (T1) showed a strong negative correlation. LE (T0) had a moderate correlation with UR (T1). PH (T0) had a moderate correlation with UR. PTN.

In the analysis of the correlation between the variables in T0 and the variables of dogs with CR lower than 1.4 mg/L in T1 is shown in Table 2. UR D (T0) had a negative correlation with the UPC (T1) and the GL (T1). SDMA

(T0) was correlated with CR. U level (T1). PL (T0) correlated with UR and PH levels (T1). UR. PTN (T0) levels are associated with PROT levels (T1). PH and SBP (T0) were correlated with LE (T1). It was not possible to perform the analysis for animals with serum CR equal to or greater than 1.4 mg/L, as due to an insufficient number of dogs, it is not possible to ger a basis for interpret-able analysis.

Table 1: Correlations between the biomarkers studied at T0 and T1 that were statisti-cally significant.

BIOMARKER	TRIAL 0	BIOMARKER	TRIAL 1	CORRELATION	P
CR.U	T0	UR.D	T1	0.73	0.003
GL	T0	LE	T1	0.48	0.019
CR.U	T0	UR. PTN	T1	-0.71	0.023
PL	T0	UPC	T1	-0.69	0.023
PL	T0	UR. PTN	T1	-0.69	0.026
PROT	T0	GL	T1	0.45	0.027
UR. D	T0	UPC	T1	-0.69	0.027
SDMA	T0	CR. U	T1	0.68	0.029
CR. U	T0	UPC	T1	-0.68	0.03
LE	T0	UR	T1	-0.44	0.031
PROT	T0	LE	T1	0.43	0.031
PL	T0	LE	T1	-0.43	0.036
PH	T0	UR. PTN	T1	0.66	0.036
HC	T0	PTOT	T1	-0.42	0.043
UR. PTN	T0	UPC	T1	0.65	0.043
PL	T0	PH	T1	-0.41	0.048
SBP	T0	LE	T1	0.41	0.049

Hematocrit (HC), leucocytes (LE) and platelets (PL), total plasma proteins (PROT), serum globulin (GL), serum urea (UR), serum phosphorus (PH), serum symmetrical dimethyl arginine (SDMA), urine analysis, urinary density (UR. D), urinary protein creatinine ratio (UPC), urinary creatinine (CR. U), urinary protein (UR PTN) and systemic blood pressure (SBP).

Table 2: Correlation of the variables in T0 together with the variables of dogs that present creatinine lower than 1.4 mg/L at T1 that presented statistically significant.

BIOMARKER	TRIAL 0	BIOMARKER	TRIAL 1	CORRELATION	P
UR. D	T0	UPC	T1	-0.92	0.001
SDMA	T0	CR. U	T1	0.92	0.001
PL	T0	UR	T1	-0.59	0.013
UR. D	T0	GL	T1	0.57	0.016
SBP	T0	LE	T1	0.56	0.018
PL	T0	PH	T1	-0.55	0.022
PH	T0	LE	T1	0.53	0.03
UR. PTN	T0	PROT	T1	0.5	0.042

Hematocrit (HC), leucocytes (LE) and platelets (PL), total plasma proteins (PROT), serum globulin (GL), serum urea (UR), serum phosphorus (PH), serum symmetrical dimethyl arginine (SDMA), urine analysis, urinary density (UR. D), urinary protein creatinine ratio (UPC), urinary creatinine (CR. U) and urinary protein (UR PTN) and Systemic blood pressure (SBP).

## DISCUSSION

The importance of evaluating coinfections in dogs infected with *L. infantum* is well known. Infections with *Babesia canis*, *Anaplasma platys*, *Hepatozoon canis* and *Ehrlichia canis* cause hematological alterations such as anemia, pancytopenia, and thrombocytopenia (Thrall, 2007; Vilela et al., 2013), which may change the values of laboratory tests in the studied dogs. The lack of this evaluation presents a limitation of this study.

Changes in the erythrogram of dogs infected with *L. infantum* were observed in this study, in the form of mild to moderate anemia and thrombocytopenia. However, the pathogenesis of anemia in CanL includes additional mechanisms such as reduced erythropoietin synthesis due to renal failure (Paltrinieri et al., 2016). Anemia may also result from the parasite's invasion of the bone marrow, which induces inflammation that may contribute to a decrease in erythrocyte production (Da Costa-Val et al., 2007). Anemia is usually present in normocytic and normochromic forms with a non-regenerative character (Freitas et al., 2012). Thrombocytopenia is a common finding in dogs with CanL and occurs due to vasculitis caused by circulating immune complexes,

thrombocytopoiesis disorders, and PL destruction (Solano-Gallego L., et al., 2009; De Carvalho Nicolato et al., 2013).

Hyperproteinemia is caused by hyperglobulinemia, which is associated with the activation of B lymphocytes and high antibody production (Freitas et al., 2012; Paltrinieri et al., 2016; Maia and Campino, 2018). A decrease in the production or renal loss of AL was also observed in this study, but the increase in GL levels was very expressive, causing the levels of PROT to increase significantly during CanL (Giunchetti et al., 2008; Solano-Gallego, et al., 2009). As for urinalysis, in the present study, proteinuria was the most frequent alteration in animals with CanL to both mild or severe degrees, as described by Amusategui et al. (2003) and Bonfanti and Zatelli (2004).

Glomerulonephritis, tubulointerstitial nephritis, and nephropathy are common in CanL (De Oliveira Frazilio et al., 2018). Initially, glomerulonephritis may manifest as asymptomatic proteinuria (Koutinas and Koutinas, 2014; Paltrinieri et al., 2016), but with its progression, excretion dysfunction can occur in the presence of an increase or decrease in the glomerular filtration rate (GFR) and systemic hypertension (Plevraki et al., 2006; Cortadellas et al., 2008). An increase in GFR associated with hypertension can amplify glomerulopathy, resulting in the progression of CKD (Koutinas and Koutinas, 2014). End-stage CKD is a severe manifestation of disease progression and the leading cause of death in CanL. The two main parameters used to classify the degree of kidney disease in CanL, according to (Solano-Gallego et al., 2011; Laia et al., 2011), are UPC, used as a marker of glomerular pathology, and serum CR level, used as a marker of renal excretion (Torrent et al., 2018).

In 2019, IRIS included SDMA levels in the CKD staging of chronic kidney disease. SDMA is methylated arginine produced by cellular catabolism correlated with CREAT and GFR (Nabity et al., 2015). Several studies have demonstrated that SDMA levels are elevated in dogs with CKD (Hall et al., 2014; Nabity et al., 2015). Studies have suggested that SDMA levels also increase earlier than serum CR levels (Hall et al., 2014; Nabity et al., 2015) because its production is not influenced by the loss of muscle mass. SDMA showed a moderate correlation with UR and PH in T0. An increase in SDMA, UR, PH, and CR and a reduction in UR is expected as there is a worsening of renal excretion and a decrease in TGF.

There is a paucity of data on the behavior of SDMA in dogs naturally infected with *Leishmania* sp., with only four studies reported to date (Pardo-Marín et al., 2017; De Oliveira Frazilio et al., 2018; Torrent et al., 2018; Giapitzoglou et al., 2020). The serum concentration of SDMA is elevated mainly in azotemic dogs with severe proteinuria and decreased UR. D (Giapitzoglou et

al., 2020). SDMA correlated with CR and UR. D, a result like that obtained by (Giapitzoglou et al., 2020). A study carried out by (Torrent et al., 2018) found different results, without observing a correlation between SDMA and CR.

SDMA was also inversely correlated with the red RBC and HC. Kidneys perform numerous metabolic functions, including their contribution to erythropoiesis. Several factors contribute to anemia in patients with reduced GFR and CanL. The reduction of erythropoietin of renal origin is an important cause, but other mechanisms, such as anemia of inflammatory origin, the influence of uremic toxins on the survival time of the erythroid lineage, cofactor deficiency, blood loss due to various bleeding events, and parasitic destruction (Babitt and Lin, 2012; Fiocchi et al., 2017; Lippi et al., 2021).

There was a significant and progressive increase in the number of dogs with SDMA levels above the reference values (IRIS, 2023) as the stage progressed. The expected result of disease progression between stages demonstrated that SDMA could be used to classify CanL severity (Giapitzoglou et al., 2020). A different result was found by Torrent et al. (2018), who found no significant difference in the comparison between the stages (Solano-Gallego et al., 2011).

In this study, two dogs classified in stage IIa (non-proteinuric and non-azotemic) with elevated SDMA levels were observed. (Cortadellas et al., 2008) pointed out that dogs with CanL and UPC levels between 0.2 and 0.5 may have a decrease in GFR. Dogs with CanL may have some renal perfusion impairment secondary to hypovolemia, which could cause an increase in SDMA concentration without an association with proteinuria or renal azotemia. Torrent et al. (2018) suggested that dogs with CanL and changes in SDMA concentration without proteinuria should be carefully examined for pre-renal causes of impaired renal perfusion.

UPC was shown to be an earlier diagnostic sign of acute kidney injury (AKI) concerning SDMA in dogs naturally infected with *L. infantum* observed in this study, which is in line with other studies (Pardo-Marín et al., 2017; Torrent et al., 2018; Giapitzoglou et al., 2020). Glomerulonephritis is the main pathological event of nephropathy in CanL, and proteinuria is the primary laboratory alteration. However, glomerular pathology can cause a reduction in GFR and an increase in the serum concentrations of SDMA and CR (Koutinas and Koutinas, 2014; Paltrinieri et al., 2016)

When evaluated as prognostic markers and predictors of kidney injury and kidney failure, the UPC and SDMA levels did not show a statistically significant correlation. Pardo-Marín et al. (2017) identified a reduction in the concentration of UPC, however, they did not observe a decrease in the SDMA levels in dogs after leishmanicidal treatment. In this study, we observed a cor-



relation between SDMA (T0) and CR. U (T1) levels; however, as the dogs examined in this study underwent a treatment with immunotherapy, an improvement in GFR may have occurred after the reduction of the injury caused by CanL. Gouveia et al, 2021 found that immunotherapy with vaccines was the most effective treatment for negative serology in the ELISA and IFAT tests after the treatments compared to other treatments in the study. The decrease in the result in the serology may suggest a reduction in the production of antigen-antibody complexes influencing the GFR.

An increase in PROT and GL levels, associated with a decrease in AL levels, has been observed in several studies (Artan et al., 2006; Sales et al., 2017). This increase in PROT and the presence of hyperglobulinemia are considered to be among the most common alterations in CanL and may be associated with increased levels of anti-*Leishmania* antibodies, especially in severe stages of the disease (Castro et al., 2012; Freitas et al., 2012). However, hypoalbuminemia observed in animals may be due to the migration of albumin to the extravascular environment, with the formation of edema, a widespread clinical change in CanL (Silva, 2007; Freitas et al., 2012) and/or associated with an inflammatory process and/or albuminuria (Pierantozzi et al., 2013; Proverbio et al., 2016). Given the processes that occur during CanL due to the association of GL with the stimulation of B lymphocytes (Vieira et al., 2021), we can explain why the serum concentration of GL and PROT (T0) had a significant correlation with LE (T1). AL levels did not significantly correlate with any of the biomarkers.

The development of glomerulopathies not only leads to complications resulting from the accumulation of uremic toxins and fluid and electrolyte imbalances, but also causes systemic arterial hypertension, aggravating the clinical picture of patients and possibly compromising other organs, such as the heart (Schiffrin et al., 2007). In this study, seventeen (28%) dogs were identified with SBP above 160 mmHg. Out of these, seven (41%) were non-azotemic and non-proteinuric. Cortadellas et al. (2008) observed that 49.5% (52 / 105) of the dogs had some degree of renal disease, and 61.5% (32 / 52) of these dogs were diagnosed with systemic hypertension (SH). Moreover, SH also was diagnosed in 2% of dogs without renal disease. Braga et al. (2015) found that all dogs with hypertension had histopathological and laboratory evidence of glomerular disease. However, there was no statistically significant correlation between elevated BP and the severity of glomerular lesions.

This study found that SBP (T0) correlated with LE count (T1). CanL glomerulonephritis can form large antigen-antibody complexes, inciting inflammation and overloading of glomerular capillaries, resulting in obstruction that can further elevate glomerular pressure (Harrison et al., 2012). There is also



evidence that inflammatory cells accumulate in the perivascular region of the kidney (Theuer et al., 2002) also contributing to hypertension.

Unlike SBP, data in the literature cite the destruction of LE in uremic patients (Minnaganti and Cunha, 2001; Cohen and Hörl, 2012; Pahl et al., 2010). In this study, predictive factors of LE (T0) and HC (T1) concerning UR were observed through an inverse correlation. Uremia is associated with hematological abnormalities such as hemostatic, granulocytic, lymphocytic, and PL disorders, mainly caused by chemotaxis, phagocytosis, and oxidative abnormalities. Some diseases related to antigen presentation have also been reported in uremic patients (Minnaganti and Cunha, 2001; Cohen and Hörl, 2012) demonstrated that patients with renal failure had impaired body defense. Pahl et al. (2010) reported that the number of B lymphocytes and their ability to produce antibodies was reduced in patients with uremia. A study conducted on dogs infected with *Leishmania sp.*, showed more intense hematological alterations, such as profound anemia, thrombocytopenia, and leukopenia, characterizing pancytopenia associated with bone marrow hypoplasia or aplasia as a result of the invasion of the microorganism and immune-mediated processes (Paltrinieri et al., 2016). Hyperplasia and peripheral cytopenia can partially be attributed to the increased destruction of mature blood cells in the periphery. There are also morphologic features indicative of differentiation blockage and dyserythropoietic changes in the erythroid precursors (Poulaki et al., 2021)

HC (T0) also showed an inverse correlation with serum PROT (T1). Thus, the presence of leukopenia and anemia may indicate an initial process of immunosuppression and an increase in parasite load, which may lead to a change in hyperglobulinemia, an initial process of renal injury, and disease progression.

PH concentrations were also moderately correlated with UR and PTN levels. A study demonstrated an essential relationship between PH and proteinuria. When analyzing the renal protective response, it was found that for a reduction in proteinuria, a reduction in protein intake was not necessary, but a reduction in PH, either in its urinary excretion or serum concentration. Patients with low PH levels had the most significant decrease in proteinuria, regardless of UR excretion (a factor used to estimate protein intake) (Di Iorio et al., 2013).

Based on all findings and discussion it can be concluded that the most associated parameters are PL and SBP. In order to interpret the results and analyze the predictive factors and prognostic markers, we analyzed Figure 1 and isolated four patients who presented a negative evolution, starting from classification in stage IIa at T0 to stage IV at T1. Two patients developed thrombo-

cytopenia and systemic arterial hypertension at T0. Neither of the patients had proteinuria, azotemia, or hyperglobulinemia and had SDMA < 14µg/dL. The authors pointed out the importance of evaluating systemic hypertension and thrombocytopenia in dogs with *L. infantum* infection. The other two patients exhibited no changes in laboratory test results at T0. New studies should be carried out in order to evaluate PL and SBP as predictive factors and prognostic markers.

## CONCLUSIONS

PL was the primary physiological biomarker to demonstrate value as a predictive factor and prognostic marker being related to biomarkers of kidney injury as PH and UPC. It has been shown that SBP, LE, HC, PH and UR. D are predictive or prognostic markers in dogs infected with *L. infantum*. There was no advantage of SDMA over UPC for assessing kidney injury in dogs infected with *L. infantum* at the time of the study. SDMA and UPC didn't show significance as predictive or prognostic markers in dogs infected with *L. infantum*. It is concluded that the evaluation of thrombocytopenia is important in the evaluation of CanL, and its reversal corresponds to an improvement in the prognosis.

## Author's Contributions

FSM and APCV: data collection, analysis and experimental design. They conducted the gathered the necessary data and performed statistical analysis on the results; assisted in data interpretation and manuscript preparation. They contributed equally to the interpretation of the experimental results, helped in drafting the manuscript, and critically reviewed the content for accuracy and clarity. JCCV and VMR contributed to the theoretical framework and literature review.

## Competing interest

The author(s) declare that they have no competing interests.

## REFERENCES

1. Amusatogui I., Sainz A., Rodríguez F., Tesouro M.A. Distribution and relationships between clinical and biopathological parameters in ca-

- nine leishmaniasis. *Eur J Epidemiol* 18, 147–156 (2003). <https://doi.org/10.1023/A:1023090929302>
2. Araujo A.K.L. and Gondim A.L. de C.L. 2020. Use of Immunotherapy in the Treatment of Canine Visceral Leishmaniasis. *Acta Scientiae Veterinariae*, 48, 1–7. doi:10.22456/1679-9216.105438.
  3. Artan R., Yilmaz A., Akçam M., Aksoy N.H. 2006. Liver biopsy in the diagnosis of visceral leishmaniasis. *Journal of Gastroenterology and Hepatology*, 21, 1 Pt 2, 299–302. doi: 10.1111/j.1440-1746.2006.04172. x.
  4. Babitt J.L. and Lin H.Y. 2012. Mechanisms of anemia in CKD. *Journal of the American Society of Nephrology*, 23, 10, 1631–4. doi: 10.1681/ASN.2011111078.
  5. Bonfanti U., Zatelli A. Evaluation of proteinuria in leishmaniotic patient. In: *International Congress on Canine Leishmaniasis. Abstract book of the International congress on canine leishmaniasis.* p. 13-18, 2004.
  6. Braga E.T., Leite J.H.A. de C., Rosa F.A., Tivelli P., Araújo A.M., de Almeida B.F.M., Ferrari H.F., Ciarlini P.C., Machado G.F., Marcondes M. 2015. Hypertension and its correlation with renal lesions in dogs with leishmaniasis. *Revista Brasileira de Parasitologia Veterinária*, 24, 1, 45–51. doi: 10.1590/S1984-29612015007.
  7. Brasileish. 2019. Diretrizes para o diagnóstico, estadiamento, tratamento e prevenção da leishmaniose visceral canina. Available at <http://www.brasileish.com.br>. Accessed 15.12.2022.
  8. Brown S., Elliott J., Francey T., Polzin D., Vaden S. 2013. Consensus recommendations for standard therapy of glomerular disease in dogs. *Journal of Veterinary Internal Medicine*, 27 Suppl 1, S27–43. doi :10.1111/jvim.12230.
  9. de Carvalho Nicolato R., de Abreu R.T., Roatt B.M., de Oliveira Aguiar-Soares R.D., Reis L.E.S., Carvalho M das G, Carneiro C.M., Giunchetti R.C., Bouillet L.E.M., Lemos D.S., Coura-Vital W., Reis A.B. 2013. Clinical Forms of Canine Visceral Leishmaniasis in Naturally Leishmania infantum–Infected Dogs and Related Myelogram and Hemogram Changes. *PLoS One*, 8, 12, e82947. doi: 10.1371/journal.pone.0082947. eCollection 2013.
  10. Castro I.P., de Sousa M.V.C., Magalhães G.M., Mundim A.V., Noleto P.G., de Paula M.B.C., de Albuquerque Pajuaba Neto A., Medeiros A.A. 2012. Perfil hepático e protéico em cães com leishmaniose visceral. *Bioscience Journal*, 28,5, 799–804.
  11. Cohen G. and Hörl W.H. 2012. Immune Dysfunction in Uremia—An Update. *Toxins*, 2012, 4, 11, 962–90. doi: 10.3390/toxins4110962.

12. Cortadellas O., Fernández del Palacio M.J., Talavera J., Bayón A. 2008. Glomerular filtration rate in dogs with leishmaniasis and chronic kidney disease. *Journal of Veterinary Internal Medicine*, 22, 2, 293–300. doi: 10.1111/j.1939-1676.2008.0062. x.
13. da Costa-Val A.P., Cavalcanti R.R., de Figueiredo Gontijo N., Michalick M.S.M., Alexander B., Williams P., Melo M.N. 2007. Canine visceral leishmaniasis: relationships between clinical status, humoral immune response, haematology and *Lutzomyia (Lutzomyia) longipalpis* infectivity. *Veterinary Journal*, 174, 3, 636–43. doi: 10.1016/j.tvjl.2006.11.006. Epub 2007 Jan 16.
14. D'Amico G. and Bazzi C. 2003. Pathophysiology of proteinuria. *Kidney International*, 63, 3, 809–25. doi:10.1046/j.1523-1755.2003.00840. x.
15. Dantas-Torres F., Brandão-Filho S.P. 2006. Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control. *Revista do Instituto de Medicina Tropical de São Paulo*, 48, 3, 151–6. doi: 10.1590/S0036-46652006000300007.
16. Di Iorio B.R., Bellizzi V., Bellasi A., Torraca S., D'Arrigo G., Tripepi G., Zoccali C. Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients. *Nephrology Dialysis Transplantation*, Volume 28, Issue 3, March 2013, 632–640, <https://doi.org/10.1093/ndt/gfs477>
17. Fiocchi E.H., Cowgill L.D., Brown D.C., Markovich J.E., Tucker S., Labato M.A., Callan M.B. 2017. The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs. *Journal of Veterinary Internal Medicine*, 31, 2, 476–85. doi: 10.1111/jvim.14681. Epub 2017 Mar 3.
18. Freitas J.C.C de, Nunes-Pinheiro D.C.S., Lopes Neto B.E., Santos G.J.L., Abreu C.R.A. de, Braga R.R., Campos R. de M., Oliveira L.F. de. 2012. Clinical and laboratory alterations in dogs naturally infected by *Leishmania chagasi*. *Revista da Sociedade Brasileira de Medicina Tropical*, 45, 1, 24–9. doi: 10.1590/S0037-86822012000100006.
19. Giapitzoglou S., Saridomichelakis M.N., Leontides L.S., Kasabalis D., Chatzis M., Apostolidis K., Theodorou K., Roumpeas E., Mylonakis M.E. 2020. Evaluation of serum symmetric dimethylarginine as a biomarker of kidney disease in canine leishmaniosis due to *Leishmania infantum*. *Veterinary Parasitology*, 277, 109015. doi: 10.1016/j.vetpar.2019.109015. Epub 2019 Dec 18.
20. Giunchetti R.C., Mayrink W., Carneiro C.M., Corrêa-Oliveira R., Martins-Filho O.A., Marques M.J., Tafuri W.L., Reis A.B. 2008. Histopathological and immunohistochemical investigations of the hepatic compar-

- tment associated with parasitism and serum biochemical changes in canine visceral leishmaniasis. *Research in Veterinary Science*, 84, 2, 269–77. doi:10.1016/j.rvsc.2007.04.020. Epub 2007 Jun 29.
21. Gouveia E. M. M. F., da Fonseca A. L.S., Noe P., Onselen V. J. V. Evaluation of the effectiveness of three therapeutic protocols used in the treatment of visceral canine leishmaniosis. *International Journal for Innovation Education and Research*, 9, 3, 129–39. doi: 10.31686/ijer.vol9.iss3.2980.
  22. Hall J.A., Yerramilli M., Obare E., Yerramilli M., Jewell D.E. 2014. Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease. *Journal of Veterinary Internal Medicine*, 28, 6, 1676–83. doi: 10.1111/jvim.12445. Epub 2014 Sep 17.
  23. Harrison D.G., Marvar P.J., Titze J.M. 2012. Vascular inflammatory cells in hypertension. *Frontiers in Physiology*, 3, 128. doi: 10.3389/fphys.2012.00128.
  24. IRIS. 2023. International Renal Interest Society-IRIS staging of CKD, Available at <http://www.iris-kidney.com/guidelines/staging.html>. Accessed: 06.08.2023.
  25. Koutinas A.F. and Koutinas C.K. 2014. Pathologic Mechanisms Underlying the Clinical Findings in Canine Leishmaniosis due to *Leishmania infantum*/chagasi. *Veterinary Pathology*, 51, 2, 527–38. doi:10.1177/0300985814521248. Epub 2014 Feb 7.
  26. Lippi I., Perondi F., Lubas G., Gori E., Pierini A., D'Addetta A., Marchetti V. 2021. Erythrogram Patterns in Dogs with Chronic Kidney Disease. *Veterinary Sciences*, 8, 7, 123. doi: 10.3390/vetsci8070123.
  27. Maia C. and Campino L. 2018. Biomarkers Associated with *Leishmania infantum* Exposure, Infection, and Disease in Dogs. *Frontiers in Cellular and Infection Microbiology*, 8, 302. doi: 10.3389/fcimb.2018.00302.
  28. Marcondes M. and Day M.J. 2019. Current status and management of canine leishmaniasis in Latin America. *Research in Veterinary Science*, 123, 261–72. doi: 10.1016/j.rvsc.2019.01.022. Epub 2019 Jan 23.
  29. Minnaganti V.R. and Cunha B.A. 2001. Infections associated with uremia and dialysis. *Infectious Disease Clinics of North America*, 15, 2, 385–406. doi: 10.1016/s0891-5520(05)70152-5.
  30. Nabity M.B., Lees G.E., Boggess M.M., Yerramilli M., Obare E., Yerramilli M., Rakitin A., Aguiar J., Relford R. 2015. Symmetric Dimethylarginine Assay Validation, Stability, and Evaluation as a Marker for the Early Detection of Chronic Kidney Disease in Dogs. *Journal of Veterinary Internal Medicine*, 29, 4, 1036–44. doi: 10.1111/jvim.12835. Epub 2015 Jun 16.

31. do Nascimento L.F.M., de Moura L.D., Lima R.T., do Socorro Pires e Cruz M. 2018. Novos adjuvantes vacinais: importante ferramenta para imunoterapia da leishmaniose visceral. *Hu revista*, 44, 3, 401–10. doi: 10.34019/1982-8047.2018.v44.14123.
32. de Oliveira Frazilio F, de Almeida Borges F, de Souza A.I., Palumbo M.I.P., do Nascimento Ramos C.A., Freire D.H., Galvão A.L.B., de Freitas M.G., Barbosa F.B. 2018. Biomarkers and renal arterial resistive index in dogs naturally infected with *Leishmania infantum*. *Parasitology Research*, 117, 11, 3399–405. doi: 10.1007/s00436-018-6032-2. Epub 2018 Aug 1.
33. Pahl M.V., Gollapudi S., Sepassi L., Gollapudi P., Elahimehr R., Vaziri N.D. 2010. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. *Nephrology Dialysis Transplantation*, 25, 1, 205–12. doi: 10.1093/ndt/gfp397. Epub 2009 Aug 14.
34. Paltrinieri S., Gradoni L., Roura X., Zatelli A., Zini E. 2016. Laboratory tests for diagnosing and monitoring canine leishmaniasis. *Veterinary Clinical Pathology*, 45, 4, 552–78. doi: 10.1111/vcp.12413. Epub 2016 Nov 2.
35. Pardo-Marín L., Martínez-Subiela S., Pastor J., Tvarijonavičiute A., Garcia-Martinez J.D., Segarra S., Cerón J.J. 2017. Evaluation of various biomarkers for kidney monitoring during canine leishmaniosis treatment. *BMC Veterinary Research*, 13, 1, 31. doi: 10.1186/s12917-017-0956-0.
36. Pierantozzi M., Roura X., Paltrinieri S., Poggi M., Zatelli A. 2013. Variation of proteinuria in dogs with leishmaniasis treated with meglumine antimoniate and allopurinol: a retrospective study. *Journal of the American Animal Hospital Association*, 49, 4, 231–6. doi: 10.5326/JAAHA-MS-5840. Epub 2013 May 20.
37. Plevraki K., Koutinas A.F., Kaldrymidou H., Roumpies N., Papazoglou L.G., Saridomichelakis M.N., Savvas I., Leondides L. 2006. Effects of allopurinol treatment on the progression of chronic nephritis in Canine leishmaniosis (*Leishmania infantum*). *Journal of Veterinary Internal Medicine*, 20, 2, 228–33. doi: 10.1892/0891-6640(2006)20[228:eoatot]2.0.co;2.
38. Poulaki A., Piperaki E-T., Voulgarelis M. 2021. Effects of Visceralising *Leishmania* on the Spleen, Liver, and Bone Marrow: A Pathophysiological Perspective. *Microorganisms*, 9, 4. doi: 10.3390/microorganisms9040759.
39. Proverbio D., Spada E., de Giorgi G.B., Perego A.R. 2016. Proteinuria reduction after treatment with miltefosine and allopurinol in dogs naturally infected with leishmaniasis. *Veterinary World*, 9, 8, 904–8. doi: 10.14202/vetworld.2016.904-908. Epub 2016 Aug 26.
40. Ribeiro V.M., Bahia E.M., Teles P.P.A. 2013. Evaluation of immunotherapy assessment Leishtec R associated with allopurinol in dogs naturally infec-

- ted by *Leishmania infantum*-Preliminary Studies. In *Fifth world congress on leishmaniasis*, Porto de Galinhas, Pernambuco, Brasil.
41. Sales E.T., de Almeida G.K.G., de Oliveira A.R.F., Ferreira T.M.V., Freitas J.C.C., Nunes-Pinheiro D.C.S. 2017. Neutrofilia e hipoalbuminemia em sangue periférico de cães naturalmente infectados por *Leishmania infantum*. *Ciência Animal*, 27, 1 64-74.
  42. Santos F.N., Borja-Cabrera G.P., Miyashiro L.M., Grechi J., Reis A.B., Moreira M.A.B., Martins Filho O.A., Luvizotto M.C.R., Menz I., Pessôa L.M., Gonçalves P.R., Palatnik M., Palatnik-de-Sousa C.B. 2007. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine. *Vaccine*, 25, 33, 6176-90. doi: 10.1016/j.vaccine.2007.06.005. Epub 2007 Jun 21.
  43. Schiffrin E.L., Lipman M.L., Mann J.F.E. 2007. Chronic kidney disease: effects on the cardiovascular system. *Circulation*, 116, 1, 85-97. doi: 10.1161/CIRCULATIONAHA.106.678342.
  44. Soares M.J.V., Moraes J.R.E., Palmeira Borges V., Miyazato L.G., Moraes F.R. 2005. Renal involvement in visceral leishmaniasis dogs. *Journal of Venomous Animals and Toxins including Tropical Diseases*, 11, 4, 579-93. doi: 10.1590/S1678-91992005000400014.
  45. Solano-Gallego L., Koutinas A., Miró G., Cardoso L., Pennisi M.G., Ferrer L., Bourdeau P., Oliva G., Baneth G. 2009. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. *Veterinary Parasitology*, 165, 1-2, 1-18. doi: 10.1016/j.vetpar.2009.05.022. Epub 2009 Jun 6.
  46. Solano-Gallego L., Miró G., Koutinas A., Cardoso L., Pennisi M.G., Ferrer L., Bourdeau P., Oliva G., Baneth G., The LeishVet Group. 2011. LeishVet guidelines for the practical management of canine leishmaniosis. *Parasites & Vectors*, 4, 86. doi: 10.1186/1756-3305-4-86.
  47. Thrall M. A. 2007. *Hematologia e bioquímica clínica veterinária*, Editora Roca, ISBN 8572416684.
  48. Vilela J. A. R., Sandes Pires M., da Silva C.B., Peixoto M.P., Falqueto A., Santos H.A., Sanavria A., Massard C.L., Faccini J.L.H. 2013. Alterações clínico-hematológicas da infecção por *Babesia canis vogeli* em cães do município de Seropédica. *Revista Brasileira de Medicina Veterinária*, 35,1, 63-68.
  49. Theuer J., Dechend R., Muller D.N., Park J-K., Fiebeler A., Barta P., Ganten D., Haller H., Dietz R., Luft F.C. 2002. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. *BMC Cardiovascular Disorders*, 2, 3. doi: 10.1186/1471-2261-2-3.



50. The R Project for Statistical Computing. 2019. Available at <https://www.r-project.org/>. Accessed 15.12.2022.
51. Torrent E., Planellas M., Ordeix L., Pastor J., Rodon J., Solano-Gallego L. 2018. Serum Symmetric Dimethylarginine as an Early Marker of Excretory Dysfunction in Canine Leishmaniosis (*L. infantum*) Induced Nephropathy. *Veterinary Medicine International*. doi: 10.1155/2018/7517359.
52. Vieira M.S., Marcondes N.A., Spindler B.M., Olivo L.D., Fernandes F.B. 2021. Diagnóstico de leishmaniose visceral em Medula óssea a partir de suspeita de neoplasia maligna: relato de caso. *Hematology, Transfusion and Cell Therapy*, 43, S425. doi: 10.1016/j.htct.2021.10.729.

Received: 03.06.2023.

Accepted: 20.11.2023.



Original research article

UDK 598.112:616.98

<https://doi.org/10.46784/e-avm.v16i2.350>

## INFECTIOUS STOMATITIS IN CAPTIVE *SALVATOR MERIANAE* LIZARDS

Olga Luz Sánchez-Loria<sup>1\*</sup>, Fernando Horacio Campos-Casal<sup>1</sup>

<sup>1</sup>Universidad Nacional de Tucumán, Facultad de Agronomía, Zootecnia y Veterinaria. Cátedra de Biología del Desarrollo, Tucumán, Argentina.

### Abstract

Infectious stomatitis is a common ailment in captive reptiles, it arises from a combination of predisposing factors such as poor nutritional conditions, habitat issues or stress, where normal oral flora microorganisms act as pathogens, facilitating the disease development. This study aims to describe infectious stomatitis in a captive population of adult *Salvator merianae* lizards and to propose prophylactic measures for their maintenance in captivity. Within a population of 57 animals, a morbidity rate of 19.2% and a mortality rate of 7% were estimated. Microbiological analysis of oral mucosa revealed *Pseudomonas aeruginosa* susceptible to ceftazidime, ciprofloxacin, gentamicin, and amikacin. Symptoms ranged from asymptomatic to animals with mild oral cavity lesions or severe stomatitis, with some cases exhibiting respiratory complications. Histopathological examination of lung samples was consistent with caseous pneumonia. Intramuscular ceftazidime treatment and oral disinfection yielded excellent results for lizards with stomatitis, although a favorable response was not observed in animals with pneumonia.

**Key words:** Black and white tegu, caseous pneumonia, oral diseases, *Pseudomonas aeruginosa*, reptiles

---

<sup>1\*</sup> Corresponding Author: [olga.sanchezloria@faz.unt.edu.ar](mailto:olga.sanchezloria@faz.unt.edu.ar)

## INFEKTIVNI STOMATITIS KOD GUŠTERA VRSTE *SALVATOR MERIANAE* KOJI SE DRŽE U ZATOČENIŠTVU

Olga Luz Sánchez-Loria<sup>1\*</sup>, Fernando Horacio Campos-Casal<sup>1</sup>

<sup>1</sup> Nacionalni Univerzitet Tucumán, Fakultet za poljoprivredu, zootehniku  
i veterinu, Katedra za razvojnu biologiju, Tucumán, Argentina.

### Kratak sadržaj

Infektivni stomatitis je česta bolest kod gmizavaca koji se drže u zatočeništvu. Uzrokuje ga kombinacija predisponirajućih faktora kao što su loša ishrana, problemi sa staništem ili stres, gde normalni mikroorganizmi oralne flore deluju kao patogeni, što potpomaže razvoj bolesti. Ova studija ima za cilj da opiše infektivni stomatitis u populaciji odraslih guštera *Salvator merianae* koji se drže u kavezima i da izloži predloge profilaktičkih mera za njihovo držanje u kavezima. U okviru populacije od 57 životinja utvrđena je stopa morbiditeta od 19,2% i mortaliteta od 7%. Mikrobiološka analiza oralne sluzokože pokazala je prisustvo *Pseudomonas aeruginosa* koji je osetljiv na ceftazidim, ciprofloksacin, gentamicin i amikacin. Simptomi su bili raznoliki- od asimptomatskih životinja do onih koje su ispoljile simptome teškog stomatitisa, blage lezije usne duplje, a neke su imale i respiratorne komplikacije. Histopatološki pregled uzoraka pluća ukazao je na kazeoznu pneumoniju. Intramuskularni tretman ceftazidimom i oralna dezinfekcija dali su odlične rezultate za guštere sa stomatitisom. Međutim, nije primećen povoljan odgovor kod životinja sa pneumonijom.

**Cljučne reči:** Crni i beli tegu, kazeozna pneumonija, oralne bolesti, *Pseudomonas aeruginosa*, reptili

### INTRODUCTION

Adequate zootechnical management stands out as the most crucial factor for maintaining healthy reptiles bred in captivity. Inappropriate breeding conditions, such as overcrowding, nutritional deficiencies, infections, and parasitosis lead to stress-induced immunosuppression (Cobos and Ribas 1987; Meredith and Redrobe, 2012; Zhou et al., 2020; Tian et al., 2022). Numerous microorganisms constitute oral microbiota in reptiles. Nevertheless, disrup-

tions in the homeostasis of the immune response caused by the captive environment transform the commensal oral microbiota into opportunistic pathogens (Grego et al., 2017; Vega-Manriquez et al., 2018).

Infectious stomatitis, or “mouth rots,” is a common oral mucosa infection in reptiles bred in captivity. While this disease has been predominantly described in snakes (Peñuela Gomez and Brieva Rico, 2007; Rojas-Sereno et al., 2015; Martins et al., 2021), it also affects turtles and some lizard species (Herrera Ramírez, 2008; Pereira et al., 2021). Symptoms of this pathology include sialorrhoea, petechiae, plaques around the lips and mouth, facial malformations, gingival abscesses, and teeth loss. In cases that are not promptly controlled, the exudate from ulcerative stomatitis may be swallowed or aspirated, leading to gastroenteritis or bacterial pneumonia. In severe cases, the pathogen may also enter the general circulation, causing septicemia and death (Cobos and Ribas 1987; Mader, 2006; Meredith and Redrobe, 2012; Rodríguez Molano, 2015; Pereira et al., 2021; Rojas-Sereno et al., 2015; Doneley et al., 2018).

In saurians, pathological processes tend to be multifactorial, slow-progressing, and challenging to diagnose due to their inherent resistance and ability to mask symptoms. For this reason, in most cases, diseases are detected at advanced stages, which complicates the success of treatment and, in the case of captive populations, epidemiological control (Mader, 2006; Meredith and Redrobe, 2012).

This study provides a detailed report on the clinical manifestations, lesions, and treatment in a captive population of *Salvator merianae* lizards with infectious stomatitis.

## MATERIALS AND METHODS

### *Animals*

The study included 57 adult individuals from the *Salvator merianae* lizard breeding facility at the Facultad de Agronomía, Zootecnia y Veterinaria of the Universidad Nacional de Tucumán, province of Tucumán, Argentina (26° 51'S and 65° 17'W). The animals were housed in open-air enclosures with masonry fences, equipped with shelters containing dry grass and shade. For the welfare of adult *Salvator merianae* individuals, the minimum living space of 2 m<sup>2</sup>, was provided (Manes, 2016). Ad-libitum feeding consisted of a diet specifically designed for this captive-bred species (Vega Parry and Manes, 2000). For individual health monitoring, radiofrequency identification devices (micro transponder ID-100, Trovan Electronic Identification, Rosenbusch, Buenos Aires, Argentina) were used.

All experiments, including all animal handling protocols, were carried out in accordance with the Principles of Laboratory Animal Care (National Institutes of Health, publication N° 85- 23, revised 1985), as well as specific national laws. All experiments were carried out and approved by the Ethics Committee of Consejo de Investigaciones de Universidad Nacional de Tucumán (CIUNT).

### ***Characterization of pathogens***

The samples from the buccal and gingival mucosa of animals exhibiting signs of advanced stomatitis were collected using swabs and transported and preserved in Stuart medium. Bacteriological culture and antibiogram testing were conducted using the agar diffusion method (Kirby-Bauer test).

### ***Histopathology***

Histopathological analysis of lung biopsies from recently deceased animals was performed using standard procedures, including fixation with 10% neutral buffered formalin, embedding, sectioning, and hematoxylin and eosin staining (Suvarna et al., 2018).

## **RESULTS**

### ***Epidemiology and clinical signs***

The disease affected both males and females. Out of a total number of 57 adult animals that were examined, 4 exhibited symptoms of advanced stomatitis, 7 showed signs of mild stomatitis, and another 4 were cases with respiratory and/or systemic complications. The remaining 42 animals did not show any lesions in the oral mucosa indicative of clinical stomatitis. As population indicators, the morbidity rate of stomatitis with clinical signs was estimated at 19.2%, with a mortality rate of 7%.

The 4 individuals with the signs of advanced stomatitis had petechiae and ecchymosis in the oral mucosa, periodontitis, they experienced loss of dental pieces, and granulomatous plaques in the oral and lingual mucosa. In some cases, these signs were accompanied by oral, ocular, or nasal discharge (Figure 1A).

The seven animals that manifested mild signs of stomatitis, had inflammation of the oral and gingival mucosa, but without hemorrhagic lesions or any type of plaques.

The 4 animals with severe stomatitis and caseous necrosis in the mouth and tongue died due to respiratory and systemic complications. Only two of them showed evident signs of respiratory distress with dyspnea, white foamy excretions, and loss of appetite. The other 2 did not show evident signs of respiratory complications, and the diagnosis was confirmed through post-mortem lesions (Figure 1B).




Figure 1. A. Adult female *S. merianae* lizard with stomatitis; arrow indicates granulomatous plaque on oral mucosa, asterisk indicates inflamed, congested, and ecchymotic area at oral commissure. B. Adult male *S. merianae* lizard with severe stomatitis; asterisk indicates apical region of the tongue and oral mucosa with caseous necrosis, arrow indicates granulomatous plaque on the body of the tongue.

### ***Macroscopic findings***

The necropsy of the recently deceased lizards revealed that the most affected organs were the lungs, although some macroscopic lesions were also found in the mouth, the fat bodies, and the liver. The fat bodies were notably congested and friable, with hemorrhagic lesions. Additionally, the friable liver had changed in its color. The lungs were the most affected organs, significantly hyperemic, and hemorrhagic with numerous pinpoint granulomatous plaques similar to those found in the oral cavity (Figure 2).




Figure 2. Lungs with numerous small granulomatous lesions (arrow).

### ***Histopathology findings***

In the submesothelial layer of the visceral serous tunic and the stroma of type III trabeculae in both lungs, inflammatory hyperplasia, characterized by the profusion of collagen fibers, was evident. Moreover, in the lumen of the pulmonary venules, there was a notable abundance of lymphocytes (Figure 3A). Necrotic lesions with infiltration of the pulmonary parenchyma and eosinophilic areas centrally located to the granulomatous lesion, composed of distinctive amorphous tissue of caseous necrosis, were also prominent (Figures 3B and 3C).






Figure 3. A. Detailed view of foveolar epithelium with marked hypertrophy of type III trabeculae (asterisks). Note the abundance of lymphocytes (arrow). NI, type I pneumocytes; NII, type II pneumocytes; E, erythrocytes. Scale bar 10 µm. B. Detailed view of visceral serous layer of the lung. Note the abundance of collagen fibers in the submesothelial layer (asterisks). Scale bar 10 µm. C. Lung section with granulomatous lesion (asterisk). Scale bar 50 µm. The insert shows characteristic necrotic tissue with absence of cellular boundaries and pyknotic nuclei. Scale bar 10 µm.

### ***Culturing and antibiogram***

Bacteriological culture of the oral mucosa of animals with the clinical disease revealed few Gram-positive cocci and few Gram-negative bacilli, as well as polymorphic nuclear cells. *Pseudomonas aeruginosa*, sensitive to antibiotics such as ceftazidime, ciprofloxacin, gentamicin, and amikacin, was isolated.

### ***Treatment and evolution of animals with clinical signs***

Based on the antibiogram results, intrinsic characteristics of each antibiotic (therapeutic margin, toxicity, duration of action, ease of application), and cost analysis, ceftazidime antibiotic therapy was chosen.

Animals with the signs of stomatitis with evident oral mucosa plaques and lesions underwent the following treatment: cleaning of wounds with 10 vol. hydrogen peroxide or 0.05% chlorhexidine and manual removal of oral plaques. Simultaneously, they were supplemented with 5000 IU of oral vitamin A once a week.

Depending on the characteristics of each patient and the severity of the clinical picture, between 3 and 6 applications of intramuscular ceftazidime at 30 mg/kg were performed every 72 hours until the reversal of symptoms.

In cases of mild or advanced stomatitis without respiratory complications, the treatment was highly effective, and the patient's evolution was favorable (Figure 4). However, in animals with clinical signs of pneumonia, the treatment was not effective.





Figure 4. Evolution of a stomatitis case: A and B. Initial state of oral wounds, left and right profiles, respectively. C. Oral wounds at 2 weeks after the start of treatment. Arrows indicate granulomatous plaques at both commissures, asterisk indicates petechiae. D. Resolution of oral wounds and patient's discharge 6 weeks after treatment initiation.

### ***Population Management Measures***

For metaphylactic treatment, the entire breeding stock received a single dose of 30 mg/kg of intramuscular ceftazidime. Weekly controls of the oral mucosa and body condition of 10 randomly selected animals were conducted for a month. When an individual showed any signs or suspected symptoms of stomatitis, it was isolated to start antibiotic treatment, vitamin A supplementation, and cleaning and disinfecting of the oral mucosa.

After a month, and in order to avoid stress from manipulation, inspections consisted of visual examination of animals in the corral, and only if suspicious, the animal was restrained for mucous membrane inspection. An animal was considered suspicious if it exhibited at least one of the following symptoms:

oral, ocular, or nasal discharge of any type, weight loss of body condition, or dehydration.

Sick or suspected animals were separated from the rest in an isolation area with the same shade, shelter, water, and ration conditions as the rest of the enclosures. Feeders, drinkers, and shelters throughout the breeding facility were disinfected with 0.1% sodium hypochlorite, and the substrate in all shelters was renewed.

## DISCUSSION

The oral and intestinal microbiota varies significantly among different groups of reptiles and is influenced by their habitat, physiology, and nutrition. Generally, the oral flora in saurians is primarily composed of Gram-negative bacteria, such as *Escherichia coli*, *Salmonella*, *Pseudomonas*, *Proteus*, and *Aeromonas* (Meredith and Redrobe, 2012; Tian et al., 2020, 2022). These bacteria can be isolated from both healthy and diseased animals. It is known that healthy reptiles can transmit *Salmonella* or *P. aeruginosa*, representing a major zoonotic risk associated with keeping reptiles (Meredith and Redrobe, 2012; Martins et al., 2021). This is the first study reporting *P. aeruginosa* as a potential opportunistic pathogen causing infectious stomatitis in *S. merianae*.

The clinical signs observed in our animals coincided with those reported for stomatitis in other captive reptiles (Cobos and Ribas 1987; Mader, 2006; Meredith and Redrobe, 2012; Rojas-Sereno, 2015; Hedley, 2016; Doneley et al., 2018; Pereira, 2021). The lesions found in the oral cavity of diseased animals were similar to those described for *Boa constrictor amarali* with caseous stomatitis caused by *P. aeruginosa* (Martins et al., 2021). In reptiles, pneumonia signs often appear late, when the infection is chronic with significant respiratory involvement (Mader, 2006; Rodríguez Molano, 2015). In most cases observed in this study, the condition was limited to oral infection. However, in animals with pneumonia, macroscopic and histopathological lesions were consistent with chronic inflammatory processes, characterized by a marked increase in collagen fibers and notable lymphocytic infiltration. Timely treatment with intramuscular ceftazidime every 72 hours and oral antiseptics proved to be the appropriate combination for treating stomatitis in *S. merianae*. The combination of clinical examination, oral culture and antibiogram, histopathology, and favorable response to treatment, enabled us to confirm the diagnosis without the need for more expensive complementary tests.

The incidence of bacterial diseases in captive lizards is often associated with a compromised immune system resulting from overcrowding, trauma, nutritional deficiencies, infections, and excessively low temperatures that can

predispose normal microbial flora to act as opportunistic pathogens (Mader, 2006; Hedley, 2016; Van Zanten and Simpson, 2021). Regarding predisposing factors, overcrowding and poor management as promoters of stomatitis were ruled out. Indeed, we have optimized the zootechnical management of captive *S. merianae*, as well as the breeding conditions in which these lizards are kept and reproduced. This includes spacious enclosures with over 2 m<sup>2</sup>/animal, shelters resembling their natural habitat, dirt floors for digging, and other elements of environmental enrichment (Manes, 2016; Van Zanten and Simpson, 2021). Although the animals are fed a diet specifically designed for this species (Vega Parry and Manes, 2000), maintaining a sustained mono diet for approximately 20 years, it is likely that they require supplementation of vitamins A, D, and E. Vitamin A deficiencies have been linked to stomatitis and inflammation of the upper respiratory tract (Herrera Ramírez, 2008; Rodríguez Molano, 2015). In this study, oral administration of vitamin A was chosen to coincide with the oral inspection of each patient, avoiding additional intramuscular injections that could be painful and stressful for the animal. Stress from increased frequency or duration of handling, including health management, predisposes the animals to illness and complicates the healing process (Doneley et al., 2018).

The immune response of reptiles is subjected to seasonal temperature-dependent alterations, with a maximum response observed when they are maintained near their preferred optimal body temperature (Mader, 2006; Doneley et al., 2018). Prolonged maintenance of reptiles at temperatures ranging from 15 °C to 21 °C predisposes them to opportunistic diseases. The innate and adaptive arms of the reptilian immune system are accepted to function optimally at the preferred body temperature of the animal. Many reptiles are kept at suboptimal temperatures, and simply warming them up can lead to significant improvements in their immunological defenses (Doneley et al., 2018). The monthly average temperature recorded in the region, where the breeding facility is located during the brumation period (May to September), was of 14.8 °C between 2018 and 2022 (EEAOC, 2023). This temperature would be at the limit of the suggested optimum for normal brumation (3.8 °C to 15 °C). Our results suggest that untimely winters with inappropriate temperatures for proper brumation may be a predisposing factor for stomatitis in captive *S. merianae*.

There is little knowledge about the immune system of reptiles. Some agents of reptiles are more or less infectious, but for most of them, the level of infectivity is unknown (Doneley et al., 2018). In our study, it is likely that *P. aeruginosa* acted as an opportunistic agent, and the great diversity of clinical

manifestations observed in our population may be attributed to the intrinsic immunity of each animal. The physiological state of each individual can impact susceptibility to diseases, even under similar captive conditions. Gravid females, males during breeding season, dominance of food sources, or other resources by enclosure mates, together with the effects of hierarchical stress, may predispose to illness (Meredith and Redrobe, 2012; Doneley et al., 2018).

## CONCLUSIONS

This article provides a detailed report of clinical manifestations and macroscopic and histopathological findings in a captive population of *S. merianae* lizards with stomatitis. Identification of each individual facilitated precise treatment monitoring and the evolution of each patient. Furthermore, periodic follow-ups within the population have allowed us to suggest sanitary management measures to reduce the prevalence of this disease in captive animals.

## ACKNOWLEDGEMENTS

This paper was funded by Secretaría de Ciencia, Arte e Innovación Tecnológica (SCAIT) of the Universidad Nacional de Tucumán. We are especially grateful to the technicians Roque Carranza and Juan Oliver for their help in the field work.

## Author's Contributions

OLSL: Animal management, diagnosis and treatment of patients, drafting the manuscript. FHCC: Histopathological analysis, drafting the manuscript.

## Competing interests

The author(s) declare that they have no competing interests.

## REFERENCES

1. Cobos R.M., Ribas R. 1987. Reptiles: tortugas, serpientes, lagartos. Revista de AVEPA, 7, 3, 133–150.
2. Doneley B., Monks D., Johnson, R., Carmel, B. 2018. Reptile medicine and surgery in clinical practice. John Wiley & Sons Ltd, UK, ISBN:9781118977675. doi: 10.1002/9781118977705.

3. EEAOC. 2023. Estación Experimental Agroindustrial Obispo Colombres. Available at: <https://www.eeaoc.gob.ar/servicios/> Accessed: 12 09. 2023.
4. Grego K.F., Carvalho M.P.N., Cunha M.P.V., Knöbl T., Pogliani F.C., Catão-Dias J. L., Sant'Anna, S.S., Ribeiro M.S., Sellera, F.P. 2017. Antimicrobial photodynamic therapy for infectious stomatitis in snakes: Clinical views and microbiological findings. Photodiagnosis and photodynamic therapy, 20, 196–200. doi:10.1016/j.pdpdt.2017.10.004.
5. Hedley J. 2016. Anatomy and Disorders of the Oral Cavity of Reptiles and Amphibians. The veterinary clinics of North America. Exotic animal practice, 19, 3, 689–706. doi:10.1016/j.cvex.2016.04.002.
6. Herrera Ramírez J. R. 2008. Estudio patológico retrospectivo de mortalidad en reptiles del zoológico Jaime Duque entre el año 1991 y el 2006. Thesis. Universidad de La Salle, Ciencia Unisalle. Medicina Veterinaria, Facultad de Ciencias Agropecuarias.
7. Mader D.R. 2006. Reptile Medicine and Surgery, Elsevier, St. Louis, Mo., 2nd ed., ISBN 9780721693279. doi: 10.1016/B0-7216-9327-X/X5001-9.
8. Manes M.E. 2016. Lagartos Tejú: fundamentos de la crianza productiva. Universidad Nacional de Tucumán. Tucumán, Argentina, Facultad de Agronomía y Zootecnia. 1st ed., ISBN 978-987-754-034-5.
9. Meredith A., Redrobe S. 2012. Manual de animales exóticos, Lexus Editores, Argentina, 4th ed, ISBN: 9788487736636.
10. Martins N., Arthur L., Ferreira R., Queiroz C., Buiatte A., Monteiro A., Rocha de Souza R., Oliveira W.J., Santos A. 2021. Caseous stomatitis caused by *Pseudomonas aeruginosa* in *Boa constrictor amarali*. Acta Scientiae Veterinariae, 49, 1, 615. doi:10.22456/1679-9216.105257.
11. Peñuela Gomez S.M., Brieva Rico C.A. 2007. Review of ulcerative stomatitis in snakes. Revista de la Facultad de Medicina Veterinaria y de Zootecnia, 54, 1, 43-49.
12. Pereira L.M., Prazeres Junior F.R., de Oliviera Curgel J.V., Santana V.S., Mayer L.L., da Silva Pereira A.W., de Medeiros M.O., Freitas C.I.A. 2021. Ozonized water used as complementary therapy for stomatitis in *Salvator merianae* – case report. Research, Society and Development. 10, 11, e280101119550. doi: 10.33448/rsd-v10i11.19550.
13. Rodríguez Molano H.R. 2015. Manual de diagnóstico y tratamiento de neumonías en saurios y quelonios, mantenidos como mascotas no convencionales. Thesis, Universidad de La Salle Ciencia Unisalle, Medicina Veterinaria, Facultad de Ciencias.

14. Rojas-Sereno Z., Gómez-Acosta X., Brieva-Rico C. 2015. Estomatitis ulcerativa infecciosa como consecuencia de un traumatismo en una Boa constrictor con desarrollo de neumonía bacteriana y septicemia. Memorias de la conferencia interna en medicina y aprovechamiento de fauna silvestre, Exótica Y No Convencional, 11, 2, 32–43.
15. Suvarna K.S., Layton C., Bancroft J.D. 2018. Bancroft's theory and practice of histological techniques. Elsevier, China, 8 ed., ISBN 9780702068645.
16. Tian Z., Gou D., Wu Y., Guo P. 2020. Gut and oral bacterial diversity of the lizard *Diploderma splendidum* investigated using metagenomic analysis. doi: 10.21203/rs.3.rs-128688/v1.
17. Tian Z., Pu H., Cai D., Luo G., Zhao L., Li K., Zou J., Zhao X., Yu M., Wu, Y., Yang, T., Guo, P., Hu, X. 2022. Characterization of the bacterial microbiota in different gut and oral compartments of splendid japalure (*Japalura sensu lato*). BMC veterinary research, 18, 1, 205. doi:10.1186/s12917-022-03300-w.
18. Van Zanten T.C., Simpson S.C. 2021. Managing the Health of Captive Groups of Reptiles and Amphibians. The veterinary clinics of North America. Exotic animal practice, 24, 3, 609–645. doi: 10.1016/j.cvex.2021.05.005.
19. Vega-Manriquez D.X., Dávila-Arellano R.P., Eslava-Campos C.A., Salazar Jiménez E., Negrete-Philipp, A.C., Raigoza-Figueras R. Muñoz-Tenería, F.A. 2018. Identification of bacteria present in ulcerative stomatitis lesions of captive sea turtles *Chelonia mydas*. Veterinary research communications, 42, 3, 251–254. doi: 10.1007/s11259-018-9728-y.
20. Vega Parry H.E., Manes M.E. 2000. Alimentación de lagartos overos *Tupinambis merianae* con subproductos avícolas. Revista Argentina de Producción Animal, 20, 2, 135–143.
21. Zhou J., Zhao Y.T., Dai Y.Y., Jiang Y.J., Lin L.H., Li H., Li P., Qu Y.F., Ji X. 2020. Captivity affects diversity, abundance, and functional pathways of gut microbiota in the northern grass lizard *Takydromus septentrionalis*. Microbiology Open, 9, 9, e1095. doi:10.1002/mbo3.1095.

Received: 27. 09.2023.

Accepted: 27.11.2023.



Case report

UDK 636.8:618.2

<https://doi.org/10.46784/e-avm.v16i2.329>

## ECTOPIC PRIMARY ABDOMINAL PREGNANCY IN A PERSIAN CAT

Ashraf M. Abu-Seida<sup>1\*</sup>

<sup>1</sup> Department of Surgery, Anesthesiology and Radiology, Faculty  
of Veterinary Medicine, Cairo University, Giza, Egypt

### Abstract

Ectopic pregnancies are common in human medicine, while they are rarely recorded in animals. This report describes a case of 2.5-year-old ectopic primary abdominal pregnancy in a 7-year-old Persian cat. The cat was admitted to the surgery clinic for routine ovariohysterectomy with no characteristic clinical symptoms. During surgery, ovaries, uterus and ligaments were normal, like in a non-pregnant cat. Four intra-abdominal fetuses of different developmental stages were found and carefully removed. Three fetuses were found free in the abdomen inside their gestational sacs. The fourth fetus was covered with omentum and had no gestational sac. The gestational sacs had different sizes (2-8 cm in diameter). Two of the fetuses were fully-haired with normal position of limbs. No complications were recorded during the surgery and 10 months post-operative. This case report adds to the database of ectopic pregnancies in cats and further illustrates their incidental nature.

**Key words:** Abdominal pregnancy, cat, ectopic pregnancy, fetuses, ovariohysterectomy.

---

<sup>1\*</sup> Corresponding Author: [ashrafseida@cu.edu.eg](mailto:ashrafseida@cu.edu.eg)

## VANMATERIČNI PRIMARNI ABDOMINALNI GRAVIDITET KOD PERSIJSKE MAČKE

Ashraf M. Abu-Seida<sup>1</sup>

<sup>1</sup>Departman za hirurgiju, anesteziologiju i radiologiju, Fakultet veterinarske Medicine, Univerzitet Kairo, Giza, Egipat

### Kratak sadržaj

Vanmaterične trudnoće su česte u humanoj medicini, dok se retko beleže kod životinja. Ovaj izveštaj opisuje slučaj 2,5-godišnjeg vanmateričnog primarnog abdominalnog graviditeta kod 7-godišnje persijske mačke. Mačka je primljena na Kliniku za hirurgiju radi rutinske ovariohisterektomije bez karakterističnih kliničkih simptoma. Tokom operacije jajnici, maternica i ligamenti bili su normalni, kao kod mačke koja nije gravidna. Pronađena su i pažljivo izvađena četiri intraabdominalna fetusa različitih razvojnih stadijuma. Tri fetusa pronadena su slobodna u abdomenu unutar svojih gestacijskih vrećica. Četvrti fetus bio je prekriven omentumom i nije imao gestacijsku vreću. Gestacijske vreće bile su različite veličine (2-8 cm u promeru). Dva fetusa su bila sa potpuno formiranim dlačnim pokrivačem s normalnim položajem udova. Tokom operacije i 10 meseci nakon operacije nisu zabeležene komplikacije. Ovaj prikaz slučaja predstavlja dodatni podatak za bazu podataka o vanmateričnom graviditetu kod mačaka i dodatno ilustruje njihovu slučajnu prirodu.

**Cljučne reči:** Abdominalni graviditet, mačka, vanmaterični graviditet, fetusi, ovariohisterektomija

### INTRODUCTION

Ectopic pregnancy refers to a pregnancy occurring outside of the cavity of the uterus. While this disorder is common in humans, it is rarely recorded in animals (Vidiastuti et al., 2022). Ectopic pregnancies are classified according to the site of implantation and they can be abdominal and tubal pregnancies. The etiology and pathogenesis of ectopic pregnancy are not always clearly defined (Chong, 2017; Zheng et al., 2018; Jiasan et al., 2019).

Abdominal pregnancies are also subdivided into primary and secondary



forms. The primary form occurs when fertilized oocytes are released into the abdomen and implanted on the abdomen (Osenko and Tarello, 2014; Zheng et al., 2018; Vidiastuti et al., 2022). Secondary form occurs when a pregnant uterus is ruptured due to trauma or wounds and the fetuses are released into the abdominal cavity where they continue their development (Tirgari, 1986; Findik et al., 1998; Ivanova et al., 2019). Differentiation between primary and secondary extra-uterine pregnancies is controversial due to the presence of an intact (Dzięcioł et al., 2012), altered (Kumru et al., 2007) or partially missing reproductive system (Johnston et al., 1983). Consequently, the absence of signs of uterine rupture is one of the most important inclusion criteria for the diagnosis of primary extra-uterine pregnancies in cats (Osenko and Tarello, 2014).

Diagnosis of ectopic pregnancy is based mainly using X-ray (Johnston et al., 1983; Osenko and Tarello, 2014; Mirsepehr et al., 2015), ultrasound (Findik et al., 1998; Mirsepehr et al., 2015; Vidiastuti et al., 2022) and exploratory laparotomy (Bodle, 1979; Tirgari, 1986). Nevertheless, several cases of ectopic pregnancies were recorded in cats as an accidental finding during routine clinical examination or radiography (Mirsepehr et al., 2015; Chong, 2017; Ivanova et al., 2019). Moreover, the histological examination of the ectopic fetuses did not definitively prove their extra-uterine development (Rosset et al., 2011).

Death of the abdominal fetuses is a typical outcome of recorded ectopic pregnancies in cats due to insufficient nutrition resulting from a lack of adequate blood supply inside the abdomen (Mirsepehr et al., 2015; Chong, 2017; Zheng et al., 2018). Therefore, laparotomy, removal of the ectopic fetuses and ovariohysterectomy are usually performed for treatment and prevention of recurrence of ectopic pregnancies in cats (Mirsepehr et al., 2015; Chong, 2017; Zheng et al., 2018; Ivanova et al., 2019). Nevertheless, spontaneous resolution of early ectopic pregnancies may occur, suggesting that many diagnosed cases in early stages require no treatment at all (Mirsepehr et al., 2015; Chong, 2017).

Ectopic pregnancy in cats has been recorded in the veterinary literature. However, it is quite uncommon, as shown in Table 1. Therefore, this case report adds to the available database of ectopic pregnancies in cats and further explains their accidental nature.

Table 1. Types of ectopic pregnancies recorded in different breeds of cats and characters of the ectopic fetuses

<b>Age/Breed</b>	<b>Type of ectopic pregnancy</b>	<b>Characters of the fetuses</b>	<b>Reference</b>
A 3-year-old Persian cat	Primary abdominal pregnancy	One mummified fetus, 7.25 x 4.74 cm	Vidiastuti et al. (2022)
Two European shorthair cats	Secondary abdominal pregnancies	Three fetuses, 3 cm in diameter Two, 6 x 3.5 cm and 5 x 4.5 cm	Ivanova et al. (2019)
A British shorthair	Tubal pregnancy	One fetus, not identified	Jiasan et al. (2019)
Unidentified cat	Primary abdominal pregnancy	One calcified fetus, 4 cm in diameter	Zheng et al. (2018)
A British shorthair cat	Tubal pregnancy	One immature fetus, unidentified size	
A domestic, short-haired cat	Secondary abdominal pregnancy	Two fetuses, 10 cm from crown to rump	Chong (2017)
A domestic short-haired cat	Secondary abdominal pregnancy	Three fetuses, fully developed	Mirsepehr et al. (2015)
A domestic short haired spayed cat	Primary abdominal pregnancy	Three calcified fetuses, 4-5 cm in size	Osenko and Tarello (2014)
A domestic shorthair	Secondary abdominal pregnancies	Two fetuses, different stages of development	Dzięcioł et al. (2012)
Unidentified cat		One outside the uterus and one inside, 30-35 days pregnancy	
A 1.5-year-old domestic short-haired cat	Secondary abdominal pregnancies	One mummified fetus, 7 cm in length	Rosset et al. (2011)
A 2-year-old crossbreed free-roaming cat	Secondary abdominal pregnancies	One dead fetus at 55 days' gestation	Kumru et al. (2007)
Angora cat	Secondary abdominal pregnancy	One fetus, 6 x 2.5 cm	Findik et al. (1998)
A 2.5- year-old short-haired cat	Secondary abdominal pregnancy	One encapsulated fetus, 7 x 4 x 4 cm and one embedded in the omentum, 7.5 x 3 cm	Tirgari (1986)

<b>Age/Breed</b>	<b>Type of ectopic pregnancy</b>	<b>Characters of the fetuses</b>	<b>Reference</b>
A 2.5- year-old domestic short-haired cat	Secondary abdominal pregnancy	Two necrotic fetuses, 7 x 4 cm	Johnston et al. (1983)
Unidentified cat	Primary abdominal pregnancy	Three mummified fetuses, 2,3 and 6 cm in diameter	Bodle (1979)

## CASE PRESENTATION

This study was approved by the ethical committee at Faculty of Veterinary Medicine, Cairo University, Egypt. The cat was treated in accordance with guidelines established by the international and institutional Animal Care and Use Committees.

A seven-year-old Persian cat was brought to the veterinary clinic for routine ovariohysterectomy. The owner adopted the cat when it was 2.5 years old from the street. The cat showed normal sings of regular estrous cycles. Detailed history of previous pregnancies could not be obtained. During the preoperative examination, two large intra-abdominal hard masses were palpated in the middle abdomen and no other abnormalities were detected. The masses were freely mobile inside the abdominal cavity.

The cat was given general anesthetic for ovariohysterectomy and exploratory laparotomy. During surgery, three freely movable encapsulated intra-abdominal masses were found and easily removed. A fourth mass covered with omentum was also removed by careful blunt dissection. The ovaries, uterus and ligaments had normal appearance without any abnormalities. Ovariohysterectomy was carried out according to a standard procedure. Prior to closing, the abdominal cavity was thoroughly examined and washed with sterile warm normal saline solution. The cat was monitored for 10 months after surgery. A successful recovery without any complications was reported.

The dimensions of the removed masses were 8 x 5 x 4 cm, 6 x 5 x 3cm, 4 x 2 x 2 cm and 1.5 x 1 x 0.5 cm as shown in Figure 1. Three of these masses were covered with calcified sacs while the fourth mass was covered with omentum and had no sac. After opening the sacs of the three masses and removal of the omental tissue from the fourth mass, four mummified and calcified fetuses were found. Two fetuses were well-developed, fully haired and had normal positions of limbs (Figure 2). One of the well-developed fetuses had a normal body, while the second one had open abdomen without viscera as shown in Figure 2.




Figure 1. Four masses of different sizes were removed from the abdominal cavity of the cat. Note that three of them were encapsulated by gestational sacs and one embedded in the omentum.



Figure 2. Four ectopic fetuses at different stages of development were identified after opening the gestational sacs and removal of the omentum.

## DISCUSSION

While ectopic pregnancy is a common pathology in humans, it is still rarely recorded in veterinary literature. No detailed epidemiological studies on ectopic pregnancy have been conducted on animals, particularly cats. Cats are less likely to have ectopic pregnancy due to a difference in their endotheliochorial placentation (Zheng et al., 2018). This report describes a rare case of long-standing (> 2.5 years) ectopic primary abdominal pregnancy in a Persian cat.

Diagnosis of this case depended on the case history and findings of the clinical examination as well as laparotomy. In addition, abdominal ectopic pregnancy is truly primary when placentation presents onto a peritoneal or omental surface (Zheng et al., 2018; Vidiastuti et al., 2022), as in the current case. The differences between this case and other recorded ectopic pregnancy cases in cats are the number (N = 4) and different developmental stages of the ectopic fetuses as shown in Table 1.

Regarding the cat breed, domestic short-haired cats were the most commonly affected breed with ectopic pregnancies as shown in Table 1. However, the reported cat in this case study is a Persian cat. Similarly, a Persian cat with ectopic pregnancy was recently diagnosed by Vidiastuti et al. (2022).

Similar to the current cat, cats with ectopic pregnancy generally exhibit no clear clinical signs due to the aseptic condition of the ectopic fetuses which can remain within the animal's body for months or even years without complications (> 2.5 years). This is in agreement with the previously reported results by other authors (Dzięcioł et al., 2012; Zheng et al., 2018). Nevertheless, some cats with ectopic pregnancies, particularly secondary abdominal ectopic pregnancies, show various clinical signs such as loss of appetite, fever, vomiting, vaginal bleeding and peritonitis (Rosset et al., 2011; Dzięcioł et al., 2012; Mirsepehr et al., 2015). In other cases, particularly in primary abdominal ectopic pregnancies, cats have no clinical signs and they are detected during abdominal radiography or routine spaying as in the current case. Similar findings have been recorded before (Osenko and Tarello, 2014; Ivanova et al., 2019; Vidiastuti et al., 2022). Therefore, ectopic pregnancy may be detected as an incidental finding during clinical examination prior to ovariohysterectomy, like in the present case. The lack of associated clinical signs appears to demonstrate that such pregnancy is compatible with a normal healthy life in cats. Similar finding was confirmed by other authors (Chong, 2017; Zheng et al., 2018; Ivanova et al., 2019).

In the present case, only two of the four fetuses were palpable prior to the surgery. This could be attributed to the small size of the other two fetuses. This

finding is similar to the findings of other recorded cases of ectopic pregnancies in cats (Dzięcioł et al., 2012; Osenko and Tarello, 2014; Zheng et al., 2018; Ivanova et al., 2019). Therefore, radiography and ultrasonography examinations are useful tools for diagnosis of this problem in cats (Osenko and Tarello, 2014; Zheng et al., 2018). The main limitation in the present case report is the lack of radiography and ultrasonography examinations due to their unavailability at the time of examination.

During surgery, the uterus, ovaries and ligaments were normal in the present case. Therefore, it was diagnosed as primary abdominal pregnancy. Similar findings were recorded by other authors (Zheng et al., 2018; Ivanova et al., 2019). Unlike in these findings, ectopic abdominal fetuses secondary to trauma were observed in cats with multiple uterine abnormalities (Johnston et al., 1983; Dzięcioł et al., 2012; Chong, 2017). Moreover, Zheng et al. (2018) and Jiasan et al. (2019) diagnosed tubal ectopic pregnancy in the fallopian tubes of cats, and Osenko and Tarello (2014) recorded a case of ectopic pregnancy in a spayed cat at necropsy.

In the current case, laparotomy, removal of the ectopic fetuses and ovariohysterectomy were performed for treatment and prevention of recurrence of ectopic pregnancy. The surgeries were simple and without any early or late complications. This can be explained by the lack of attachment of the fetuses to any of the internal organs. These findings are in accordance with the findings of other authors (Mirsepehr et al., 2015; Chong, 2017; Zheng et al., 2018; Ivanova et al., 2019).

The number of extra-uterine fetuses ranged between one and three as shown in Table 1. The cat had four extra-uterine fetuses. According to the available literature, this is the largest number of extra-uterine fetuses recorded in cats to this day. In addition, the removed fetuses here were grown to different stages of development. The difference in developmental stages of the removed fetuses can be explained by the difference in the time of death of each fetus. Therefore, there was a variation in the size of the removed ectopic fetuses. Development of abdominal fetuses to advanced stages without an elaborated placentation has been recorded previously in cats (Mirsepehr et al., 2015).

According to Knospe (2002), the removed ectopic fetuses died between three and eight weeks of gestation. At 60 days of gestation, pigmentation can occur on the skin, hair, and nails, the brain and bones ossification also are present at this time. Signs of fetal mummification and calcification were observed in all ectopic fetuses. This is the common end of all recorded cases of ectopic pregnancies in cats due to malnutrition of the ectopic fetuses (Mirsepehr et al., 2015).



## CONCLUSION

This is an interesting rare case of long-lasting ectopic primary abdominal pregnancy in a Persian cat. Four extra-uterine fetuses at different stages of development were present inside the abdomen for more than 2.5 years without any clinical signs or complications.

## Competing interest

The author declares no conflicts of interest affecting the work reported in this paper. This research received no external funding.

## REFERENCES

1. Bodle T.J. 1979. Ectopic pregnancy in a cat. *New Zealand Veterinary Journal*, 27, 279. doi:10.1080/00480169.1979.34673.
2. Chong A. 2017. A case of feline ectopic abdominal fetuses secondary to trauma. *The Canadian Veterinary Journal*, 58, 4, 400-402.
3. Dzięcioł M., Nizański W., Ochota M., Błasiak K., Kozdrowski R., Stanczyk E., Twardon J. 2012. Two separate cases of extrauterine pregnancy in queens. *Electronic Journal of Polish Agricultural Universities. Series Veterinary Medicine*, 15: 2.
4. Findik M., Vural O., Beşal T.Y., Gülbahar M. 1998. Secondary ectopic pregnancy in an Angora cat: A case report. *Ankara Üniversitesi Veteriner Fakültesi Dergisi*, 45, 239-241. doi:10.1501/Vetfak\_0000000600.
5. Ivanova M., Ivanova C., Marinkov T., Georgiev P. 2019. Two cases of ectopic abdominal pregnancy in queens. *Tradition and Modernity in Veterinary Medicine*, 4, 2, 21-25. doi:10.5281/zenodo.3066338.svg.
6. Jiasan Z., Tingting Z., Zheng W., Jiaren Z. 2019. Pathological analysis of feline fallopian tubal ectopic pregnancy. *Acta Veterinaria et Zootechnica Sinica*, 50, 9, 1936-1939. doi: 10.11843/j.issn.0366-6964.2019.09.023.
7. Johnston S.D., Harish G., Stevens J.B., Scheffler H.G. 1983. Ectopic pregnancy with uterine horn encapsulation in a cat. *Journal of the American Veterinary Medical Association*, 183, 9, 1001-1002.
8. Knospe C. 2002. Periods and stages of the prenatal development of the domestic cat. *Anatomia, Histologia, Embryologia*, 31, 1, 37-51. doi: 10.1046/j.1439-0264.2002.00360.x.
9. Kumru H., Seyrek-Intas K., Tuna B., Celimli N., Seyrek-Intas D. 2007. Severe abdominal dog bite wounds in a pregnant cat. *Journal of Feline Medicine and Surgery*, 9, 6, 499-502. doi: 10.1016/j.jfms.2007.03.011.

10. Mirsepehr P., Asheghian I., Hajinasrollah M., Javadi S.R., Bashiri A.R., Esmailinejad M.R., Taghipour H., Mojtahedzade S.M. 2015. Accidental finding of ectopic pregnancy in a cat with presence of three fetuses without gestational sac that were attached to the abdominal wall and mesentery (A case report). *International Journal of Advanced Biological and Biomedical Research*, 3, 3, 217-221.
11. Osenko A., Tarello W. 2014. A 7-year-old extrauterine pregnancy in a cat. *Case Reports in Veterinary Medicine*, Article ID: 145064. doi:10.1155/2014/145064.
12. Rosset E., Galet C., Buff S. 2011. A case report of an ectopic fetus in a cat. *Journal of Feline Medicine and Surgery*, 13, 610-613. doi:10.1016/j.jfms.2011.04.003.
13. Tirgari M. 1986. Secondary ectopic pregnancy in a cat: a case report. *Journal of Small Animal Practice*, 27, 6, 383-385. doi:10.1111/j.1748-5827.1986.tb02152.x.
14. Vidiastuti D., Fauzi A., Noviatrri A. 2022. Feline extrauterine pregnancy (EUP) in Persian cat with fetal mummification: a case study. *Journal of Experimental Biology and Agricultural Sciences*, 10, 3, 633-637. doi:10.18006/2022.10(3).633.637.
15. Zheng J.S., Wang Z., Zhang J.R., Qiu S., Wei R.Y., Nie J., Zhu T.T. 2018. Ectopic pregnancy in two cats. *Acta Scientiae Veterinariae*, 46, 5. doi:10.22456/1679-9216.85155.

Received: 25.06.2023.

Accepted: 01.10.2023.



## Note for Contributors

**ARCHIVES OF VETERINARY MEDICINE (AVM)** is a journal of the Scientific Veterinary Institute “Novi Sad” in Novi Sad. The journal publishes original research papers and review articles, short communications and case reports. The journal is devoted to the advancement and dissemination of scientific knowledge concerning veterinary sciences, biotechnology and related academic disciplines. The journal is published in the English language, with an abstract in English and Serbian language. All manuscripts are sent for a review and evaluation. In the case the reviewer suggests additional changes, the manuscript will be sent to the first author with a kind request to change the manuscript. In the case the author does not want to change, appropriate argumentation should be given. Final decision on accepting the manuscript is given by the Editor in Chief or Deputy Editor.

By submitting a manuscript, Authors warrant that their contribution to the Journal is their original work, that it has not been published before, that it is not under consideration for publication elsewhere, and that its publication has been approved by all co-authors, if any, and tacitly or explicitly by the responsible authorities at the institution where the work was carried out. Authors are exclusively responsible for the contents of their submissions, the validity of the experimental results and must make sure they have permission from all involved parties to make the data public. Authors wishing to include figures or text passages that have already been published elsewhere are required to obtain permission from the copyright holder(s) and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the Authors. Authors must make sure that only contributors who have significantly contributed to the submission are listed as authors and, conversely, that all contributors who have significantly contributed to the submission are listed as authors.

Peer review process is managed electronically. Authors have the possibility to provide the contact details of one or two potential peer reviewers, but the final decision on the choice of reviewers is on Editor decision without any obligation to contact any of the Author-recommended peer reviewers. The Editor nominates peer reviewers (at least two). The submitted manuscripts are sent to the reviewers together with the instructions for reviewers and accompanying reviewers' evaluation form. Acceptance of the manuscript is based on the reviews and on the final decisions of the reviewers regarding the acceptability of the manuscript. A reviewer's decision is one of following: “Accepted as it is”, “Accepted after minor revision”, “Accepted after major compulsory revision” or “Rejected”. If there is marked discrepancy in the decisions between the reviewers, the Editor can send the manuscript to another reviewer for additional comments and further decision, or make the decision based on the existing information.

Names of the reviewers are not transmitted to the author (single blind review). The peer review process is expected, in general, to start within two weeks after the submission of the manuscript. The Corresponding Author must indicate clearly in a separate letter what corrections have been made in response to the reviewers' comments point by point, and giving the relevant new line numbers using *Final show markup* view under Track Changes in MS Word Review ribbon. Corrected manuscripts are expected to be returned within three weeks. Accepted manuscripts are published on <https://niv.ns.ac.rs/e-avm/index.php/e-avm/issue/current> and then selected for a subsequent print issue.

The Journal *Archives of Veterinary Medicine* (AVM) uses open-source software for the management of peer-reviewed academic journals, the *Open Journal System* (OJS), created by the Public Knowledge Project (PKP), released under the GNU General Public License. Instructions for the submission using OJS 3.0 are available on the Open Journal Systems web page (OJS 3.0 User Guide" © by PKP <https://openjournal-systems.com/ojs-3-user-guide/>).

### General notes

The manuscript must be written in clear and concise English, and should be checked by a native-English speaker or certified English instructor with a good understanding of scientific terminology. The complete manuscript must be prepared according to instructions given in this section. Please read all instructions carefully. A manuscript that has not been prepared in accordance with the Journal's instructions for authors will not be considered for review.

All manuscripts submitted to *Archives of Veterinary Medicine*, must be accompanied by a Cover letter (see below). Also, authors are required to submit a scanned copy of the signed original, Competing interests, Authors contribution, and License to Publish which can be downloaded from the Journal homepage (see below).

Approval of the ethics committee must be obtained prior to the start of the study and be available upon request. Authors report this approval in their manuscript in the first paragraph of the Materials and Methods section, including the name of the regulatory group, reference number and date of the approval.

*Examples:*

*Ethical approval:* The research related to animal use complied with all the relevant national regulations and institutional policies for the care and use of animals (name of regulatory group, number and date).

*Ethical approval:* No ethical approval was obtained because this study did not involve laboratory animals and only involved non-invasive procedures (e.g. collection of waste tissue after surgery, fecal samples, voided urine etc.)

Registration and/or Login are required to submit items online and to check the

status of current submissions. Please note that by signing up and submitting your manuscript to *Archives of Veterinary Medicine* you agree to the Journal's terms and conditions. All correspondence, including notification of the Editor's decision and requests for revision, is done by e-mail. The Journal submission system guides you stepwise through the process of entering your article details and uploading your files. Editable files (Microsoft Word, .doc, or .docx format) are required to typeset your article for final publication. The text of the submitted manuscript should be written in good English language. The Editor reserves the right to amend submitted manuscripts to a suitable standard of formal, written English. Manuscripts are pre-evaluated at the Editorial Office in order to check whether they meet the basic publishing requirements and quality standards, and authors will be notified by email upon receiving their submission. Only those contributions which conform to the following instructions can be accepted for peer-review. Otherwise, the manuscripts will be returned to the authors with comments / suggestions.

Online submission (<https://niv.ns.ac.rs/e-avm/index.php/e-avm>)

- If you already have a username and password for Archives of Veterinary Medicine continue to Login Page (<https://niv.ns.ac.rs/e-avm/index.php/e-avm/login>).
- If you are not registered with this site, you need to fill in and submit the form available on Registration Page (<https://niv.ns.ac.rs/e-avm/index.php/e-avm/user/register>).

### **Layout of the manuscript, Style and Form**

The paper should be in Word program, Latin characters, size 12 pt., Times New Roman with justified alignment, double spaced. Left and right margins 20 mm, top and foot margins 30 mm, paper size A4. The journal requires continuous line numbering in submitted manuscripts. Number the pages consecutively with the title page being page 1. If special symbols are used, use font Symbol. The manuscript should be submitted on paper size A4 in electronic form. Pagination on the right side, starting from the title page.

The journal publishes the following types of articles: Original research articles, Review articles, Short communications and Case reports.

**Original research articles** describe the original research, previously unpublished and includes the following sections: Title Page, Abstract with Key words, Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgments, References, Tables/Figures (with legends). The writing style should be concise but clear enough to enable readers to reproduce the experimental methodology as described. The article must present a clear hypothesis and data expressed according to an appropriate experimental design. The Original research article should not contain more than 40 references, and usually have no more than 5000 words.

**Review articles** represent analysed and discussed summaries of different topics in the area of veterinary medicine, biotechnology and related scientific disciplines which are of broad interest to the target audience of *Archives of Veterinary Medicine*. The authors of a Review articles should be experts on the subject of the review, as proven by their own published peer-reviewed papers and by citations of these papers in the submitted review. It is essential that the authors of a review article are cited as authors of at least five other articles, published in Journals from the SCI list, addressing the same subject as the review article submitted. A review contains: Title Page, Abstract with Key words, Main Text, Conclusion, Acknowledgements, References, Tables/Figures/ Illustrations (with legends). The main text in reviews preferably has less than 6000 words.

**Short communications** represent the concise but complete descriptions of limited investigations, which will not be included in a later full research article. A short communication usually contains the following sections: Title Page, Abstract with Key words, Introduction, Materials and Methods, Results and Discussion, Conclusion, Acknowledgments, References, Tables/Figures/Illustrations (with legends). A short communication should not contain more than 15 references and preferably has less than 3000 words.

**Case Reports** are reports describing a novel case (or set of cases) with detailed documentation and diagnostic investigation. Authors are encouraged to describe how the subject of the Case report is novel or unusual in the covering letter that will accompany the submission of the Case report. Case reports usually contain the following sections: Title page, Abstract with Key words, Case presentation, Discussion, Acknowledgements, References, Tables/Figures/Illustrations (with Legends). Case reports usually have no more than 2500 words, and should not contain more than 15 references.

### **Title page**

On the title page the following should be written:

- The title of the paper in capital letters, without underlining and abbreviations
- The names of the authors (first name and surname, followed by a comma).
- Above the surname place a number in superscript (1,2,3) that denotes the institution where the author works (affiliation).
- Full name of the institutions should be given below the list of authors (the following order should be considered: university or organization/institution, department, city, and country for all authors).
- One of the authors must be designated as the Corresponding Author (add an asterisk next to the Author's surname). Full contact details including postal address, and e-mail address for the corresponding author must be provided at the bottom of the Title page.

## **Abstract**

An Abstract not exceeding 300 words must be provided with and three to eight key words. It should contain and summarize the most important facts from the submitted manuscript. For Original research articles, Short Communications and Case reports the material and techniques used must be mentioned without going into methodological detail, and the most important findings must be summarized. An Abstract for a Review paper *should contained* background, key findings and/or conclusions. Citations, tables and specialist abbreviations are not included in any Abstract.

Authors from Serbia must also submit an Abstract and Key words in Serbian, including the title of the paper, list of authors and their affiliations on a separate page after References. Translation of the Abstract and Key words from English to Serbian language will be performed by the Editorial Office for Authors who are not fluent in Serbian.

## **The main Text**

All the text headings should be typed in bold capital letters, and the subheadings, where necessary should be in bold italic with only an initial capital letter. Use short and concise sentences. Name the drugs as their International Nonproprietary Names (so called generic names). If the name of a specific drug is to be stressed, name it together with the producer (in brackets). The names of devices write as used in trade (name of the producer in brackets). When using an abbreviation for the first time, write the words that stand for. Abbreviations cannot be used in the title and summary. Text should not be longer than 8 pages. Avoid long enclosures.

## **Tables and Figures**

Tables and Figures (graphs, images, schemes etc.) must not be integrated into the main text. Instead, they must be submitted as separate, supplementary files. Tables and Figures are numbered consecutively using Arabic numerals (Figure 1, Figure 2, Figure 3, Table 1, Table 2, Table 3, *etc.*). Results which can be described as short statements within the text must not be presented as Figures or Tables. Data must not be replicated in Tables and Figures. The titles and legends help make the tables and figures understandable without the reader having to refer to the main text. However, they must also be concise and are not used to re-describe the methodology. Appropriate numbers and titles for tables and numbers and legends (including titles and explanations of markings) for figures are typed single line spaced using Times New Roman, 12 pt, in the main text and placed next to the relevant text in the article to enable the Editors to place them properly.

*Tables* are submitted as one document, with one table per page. Tables should be submitted as editable text and not as images. Each table is prepared on a separate page

and is appropriately numbered with a short, descriptive table title placed above. Tables can include footnotes, which are placed below the table and explain any abbreviations. Use superscript Arabic numbers (1, 2, 3 etc., in the correct order of reading the table, from top left to bottom right) to link each footnote to the appropriate item in the table requiring explanation.

Each *Figure* (graphs, images, schemes etc.) is submitted as a separate file. Uppercase letters A, B, C, etc. should be used to identify parts of multipart figure. Images must be at resolution 300 dpi or higher and allowable formats – JPG, TIFF. For micro-photographs, scale bars with appropriate units must be provided. Symbols, arrows or letters used in photographs should contrast with the background. Legends for figures do not appear in the figures. However, when uploading the figures in the submission procedures, please ensure that the files are appropriately identified as Figure 1, Figure 2, etc. Legends for figures include both the figure number and title and explanations of any symbol, line or marking used in the figure and are placed at the appropriate location within the main text.

## Headings

Headings in the paper are: **INTRODUCTION, MATERIAL and METHODS, RESULTS, DISCUSSION (or RESULTS and DISCUSSION for Short Communications), CONCLUSION and REFERENCES**. For Review articles instead M&M, Results and Discussion section, the Main text section should be subdivided by different subheadings describing topics presented/discussed/analysed. For Case studies this part could be the same or replaced by Case presentation part with or without different subheadings.

**INTRODUCTION** points on the most important, i.e. most recent data regarding the topic with a short presentation of the aims of this research. The essence of the problem and the purpose of the study should be pointed to in this section. The key aspects of the published literature and research should be reviewed. A detailed literature survey or a summary of the results should be avoided. The last part of the Introduction must contain the specific aim(s) of the study.

**MATERIAL and METHODS**. Here describe the conditions in the experiment, name the used methods, material and animals. The Ethical statement (or description why ethical statement is not applicable) should be provided at the beginning of the section. This section includes, as appropriate, a description of study design, experimental animals or data about the samples used, analytical methods and statistical analyses. Identify the methods and procedures in sufficient details to allow others to reproduce the study. If methods are widely known, they are not described, but appropriate references must be cited. For new methods, the detailed protocols for the method should be included. Authors must provide references for established methods including sta-

tistical methods. Specify any general computer program used. Identify all drugs and chemicals used with generic or chemical names, doses and route of administration. For diagnostic kits/reagents and instruments used in the study provide manufacturer, product number, city and country where applicable.

**RESULTS.** Results are presented in a logical order and in parallel with the Methods (for every Method, there should be a Result), using text descriptions and Tables and/or Figures without duplicating the results between these formats. To enhance clarity, this section can be divided into subsections, each with a concise subheading in italics and which provides details of findings that are required to support the conclusions made in the manuscript.

**DISCUSSION.** Here give analyses of the obtained results comparing to the results and opinions of other authors, pointing the importance of this research, without giving a conclusion. The Discussion section is not used to summarize current knowledge. The Discussion should clearly identify the main Conclusions of the study. Authors are to provide a clear explanation of the importance and relevance of these Conclusions. Any new information should be distinguished from the previous findings, and relevant hypotheses can be generated.

**CONCLUSION.** Here the authors gives his final conclusions. This part consists of a short integration of Results that refer directly to the stated aim(s) of the study and a statement on the practical implications of the results. The statements and conclusions not supported by data in the presented research should be avoided. This section should not exceed one short paragraph. Do not summarize the Discussion or current knowledge in this section.

**ACKNOWLEDGEMENT.** The source of funding for the study should be stated in this section. Also, those who have made a substantial contribution to the study in terms of design, execution, analysis or manuscript drafting/revision but do not fit the criteria for authorship should be mentioned in this section. It is the responsibility of the Authors to ensure that those being acknowledged have agreed to being named in this part.

## REFERENCES

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). The author should list the references, preferably the most recent one. Only essential references should be included in the text, and these are restricted to the necessary minimum. Cite in-text references by surname and year in parentheses (e.g. Petrović, 2014). In the case of two authors, use the word “and” (e.g. Petrović and Savić, 2015). The abbreviation “et al.” must be used in all cases where more than two authors are cited (e.g. Lazić et al., 2016). Multiple references within parentheses in the text are cited in chronological order (e.g. Petrović, 2014; Petrović and Savić, 2015;

Lazić et al., 2016). In case the same author has more publications in the same year, additional letters are added next to the year (Savić et al., 2008a; Savić et al., 2008b).

In the list of **REFERENCES**, references should be numbered with Arabic numerals, one under the other, written in alphabetical order (use the A-Z sort tool) according to the surname of the first author. In general, the number of references is not limited, but only essential references should be included in the text, and these are restricted to the necessary minimum.

### **Examples of references:**

#### **Articles in journals:**

1. Stojanović D., Maličević Ž., Ašanin R. 2002. The use a new model for the investigation of sepsis. *Acta Veterinaria*, 52, 2/3, 125-131.
2. Chen J. and McClane B.A. 2015. Characterization of *Clostridium perfringens* TpeL toxin gene carriage, production, cytotoxic contributions, and trypsin sensitivity. *Infection and Immunity*, 83, 2369–2381. doi:10.1128/IAI.03136-14.
3. Williams R.B. 2015. Intercurrent coccidiosis and necrotic enteritis of chickens: rational, integrated disease management by maintenance of gut integrity. *Avian Pathology*, 34, 159-180. doi: 10.1080/03079450500112195.
4. Bailey M.A., Macklin K.S., Krehling J.T. 2013. Use of a multiplex PCR for the detection of toxin-encoding genes *netB* and *tpeL* in strains of *Clostridium perfringens*. *ISRN Veterinary Science*, Article ID 865702, 1-4. doi:10.1155/2013/865702.

#### **Books:**

5. Ficken, M. D. and Wages, D. P. 1997. Necrotic enteritis in Diseases of Poultry, Eds. B.W. Calnek, H.J. Barnes, C.W. Beard, L.R. McDougald and Y.M. Saif, Iowa State University Press, Ames, Iowa, USA, 10th edition, ISBN xxx-xxx-xxxxx-xx-x.

#### **Chapters in books:**

6. Plumb J.A. and Hanson L.A. 2011. Sturgeon viruses. In *Health maintenance and principal microbial diseases of cultured fishes*. Eds. J.A. Plumb, L.A. Hanson, 3rd edition, Blackwell Publishing, 219-225.

#### **Articles in proceedings:**

7. Giangaspero A., Marangi M., Pati S., Cafiero M.A., Camarda C., Sparagano O.A.E. 2011. Investigating the presence of acaricide residues in laying hens naturally infected by the red mite *Dermanyssus gallinae*. In *Book of Abstracts*, The 12th Asian food conference 2011, BITEC Bangna, Bangkok, Thailand, 27.
8. Vidanović D., Petrović T., Šekler M., Debeljak Z., Vasković N., Matović K., Plavšić



- B., Dmitrić M. 2018. Avian influenza in Serbia: epidemiological situation during 2016–2017. In *Programme and Abstract book*, 11th International Congress for Veterinary Virology, 12th Annual Meeting of EPIZONE, 27-30.08.2018, University of Veterinary Medicine Vienna, Vienna, Austria, 118 (p187).
9. Lazić G., Lazić S., Bugarski D., Grubač S., Lupulović D., Samojlović M., Petrović T. 2018. Human enteroviruses in river water and sewage in Vojvodina. In *Book of Abstracts*, International Scientific Conference “Green economy and environment protection”, Belgrade, 23-25. April 2018, edited by Larisa Jovanović, Belgrade, Naučno stručno društvo za zaštitu životne sredine “ECOLOGICA“, 95-96. ISBN 978-86-89061-11-6.

#### **Laws and Regulations:**

10. European Union. 2003. Commission Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition, Official Journal of the European Union, L 268:29. <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2003R1831:20100901:EN:PDF>

#### **Citations with organisations as authors:**

11. European Food Safety Authority. 2016. Peer review of the pesticide risk assessment of the active substance benzoic acid. EFSA Journal, 14(12):4657-n/a. <http://dx.doi.org/10.2903/j.efsa.2016.4657>.

#### **Software:**

12. Statistica (Data Analysis Software System). 2006. v.7.1., StatSoft, Inc., USA ([www.statsoft.com](http://www.statsoft.com)).

#### **Web Links:**

13. OIE: Animal Diseases. Available at: <http://www.oie.int/en/animal-health-in-the-world/information-on-aquatic-and-terrestrial-animal-diseases/>. Accessed 07.08.2019.
14. European Centre for Disease Prevention and Control (ECDC). Historical data by year - West Nile fever seasonal surveillance. Available at: <https://ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/historical> Accessed 31.07.2019.

#### **Cover letter**

All submitted manuscripts must be accompanied by a cover letter which explains why the manuscript is suitable for publication in *Archives of Veterinary Medicine* and declaring that the manuscript has not been submitted or accepted for publication else-

where. Authors should suggest one or two potential unbiased reviewers who are qualified to review the manuscript (reviewers' affiliations with email addresses, and briefly explain why authors think the suggested scientists would be good reviewers). This letter must warrant that all authors have seen and approved the content.

### **Authors' contributions**

In order to give appropriate credit to each author of a paper, the individual contributions of authors to the manuscript are specified by initials in this section. An author is generally considered to be someone who has made significant contribution to a published study. All contributors who do not meet the criteria for authorship should be listed in the Acknowledgements section.

### **Competing interest**

A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with people or organizations. Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.

### **Note**

A paper that is not in accordance to the aforementioned instructions will not be sent for a review and will be returned to the authors for corrections.

### **Copyright**

Once the manuscript is accepted for publication, authors assign a *License to Publish*. Authors retain copyright of the published papers and grant the publisher the right to publish the article, to be cited as its original publisher in case of reuse, and to distribute it in all forms and media. The final proof will be sent to the Corresponding Author, together with a *License to Publish*, which all authors have to sign. When an issue is completed, a hard copy of the issue will be produced as well as electronic copy on the Journal webpage. If the submitted manuscript is not accepted for publication by the journal, all rights to the manuscript will be retained by the author(s).

Articles published in *Archives of Veterinary Medicine* will be Open-Access articles distributed under a **Creative Commons Attribution International License** (CC BY 4.0).

**Address of the journal**

Scientific Veterinary Institute “Novi Sad”,

21000 Novi Sad, Rumenački put 20

Tel. 381 (0)21 4895 321

E-mail: [arhiv@niv.ns.ac.rs](mailto:arhiv@niv.ns.ac.rs)

Web: <https://niv.ns.ac.rs/e-avm/>

Account No: 355-1006444-18 Vojvođanska banka,

ID No.: 08608857,

PIB 100236555

**Privacy Statement**

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.



### List of reviewers:

Sava Lazić, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Tamaš Petrović, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Milica Živkov Baloš, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Dubravka Milanov, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Dr Ljiljana Spalević, Research Fellow	Scientific Veterinary Institute of Serbia, Belgrade (Serbia)
Sara Savić, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Vladimir Polaček, Senior Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Aleksandar Potkonjak, Professor	Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad (Serbia)
Nada Plavša, Professor	Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad (Serbia)
Ljubo Barbić, Professor	Faculty of Veterinary Medicine, University of Zagreb (Croatia)
Ivan Toplak, Assoc. Professor	Faculty of Veterinary Medicine, University of Ljubljana (Slovenia)
Maja Velhner, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Dejan Vidanović, Senior Research Fellow	Veterinary Specialist Institute „Kraljevo“, Kraljevo (Serbia)
Dušan Petrić, Professor	Faculty of Agriculture, University of Novi Sad (Serbia)
Vladimir Petrović, Professor	Faculty of Medicine, University of Novi Sad (Serbia)
Neđeljko Karabasil, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Milorad Mirilović, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Jelena Petrović, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Tamara Ilić, Assoc. Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Igor Stojanov, Principal Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Sandra Jakšić, Senior Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)

### List of reviewers:

Jakov Nišavić, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Ksenija Nešić, Senior Research Fellow	Scientific Veterinary Institute of Serbia, Belgrade (Serbia)
Diana Lupulović, Senior Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Nikolina Novakov, Assoc. Professor	Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad (Serbia)
Jasna Prodanov Radulović, Senior Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Vesna Miličević, Research Fellow	Scientific Veterinary Institute of Serbia, Belgrade (Serbia)
Vladimir Radosavljević, Principal Research Fellow	Scientific Veterinary Institute of Serbia, Belgrade (Serbia)
Gospava Lazić, Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Vladimir Ivović, Assoc. Professor	The Faculty of Mathematics, Natural Science and Information Technologies, University of Primorska (Slovenia)
Dragana Ljubojević Pelić, Senior Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Branislav Kureljušić, Senior Research Fellow	Scientific Veterinary Institute of Serbia, Belgrade (Serbia)
Milanko Šekler, Senior Research Fellow	Veterinary Specialist Institute „Kraljevo“, Kraljevo (Serbia)
Sandra Stefan Mikić, Professor	Faculty of Medicine, University of Novi Sad (Serbia)
Ivana Hranjaković Cvjetković, Professor	Faculty of Medicine, University of Novi Sad (Serbia)
Juan Carlos Saiz, Principal Research Fellow	INIA, Madrid (Spain)
Kiril Krstevski, Assoc. Professor	Faculty of Veterinary Medicine, University Ss. Cyril and Methodius, Skopje (North Macedonia)
Vladimir Savić, Principal Research Fellow	Croatian Veterinary Institute, Zagreb (Croatia)
Lorena Jemeršić, Principal Research Fellow	Croatian Veterinary Institute, Zagreb (Croatia)
Aleksandar Mašić, Senior Research Fellow	ZOETIS, Global Bios Research (USA)
Alessio Lorusso, Principal Research Fellow	IZSAM, Teramo (Italy)

### List of reviewers:

Dejan Bugarski, Senior Research Fellow	Scientific Veterinary Institute "Novi Sad" (Serbia)
Tamas Bakonyi, Professor	European Centre for Disease Prevention and Control (ECDC), Solna, (Sweden)
Teufik Goletić, Professor	Faculty of Veterinary Medicine, University of Sarajevo (Bosnia and Herzegovina)
Igor Džadžovski, Assoc. Professor	Faculty of Veterinary Medicine, University Ss. Cyril and Methodius, Skopje (North Macedonia)
João R. Mesquita, Assoc. Professor	Institute of Biomedical Sciences Abel Salazar, University of Porto (Portugal)
Jasna Kureljušić, Research Fellow	Scientific Veterinary Institute of Serbia, Belgrade (Serbia)
Radmila Resanović, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Igor Jajić, Professor	Faculty of Agriculture, University of Novi Sad (Serbia)
Dušan Mišić, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Marija Zgomba, Professor	Faculty of Agriculture, University of Novi Sad (Serbia)
Vera Gusman, Professor	Faculty of Medicine, University of Novi Sad (Serbia)
Dragan Šefer, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Ljiljana Suvajdžić, Professor	Faculty of Medicine, University of Novi Sad (Serbia)
Abdeljelil Ghram, Research Fellow	Pasteur Institute of Tunis, Department of Veterinary Microbiology (Tunis)
Nadir Alloui, Assist. Professor	Veterinary Department, University of Batna (Algeria)
Dragica Stojanović, Professor	Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad (Serbia)
Mirjana Đukić Stojčić, Professor	Faculty of Agriculture, University of Novi Sad (Serbia)
Ljiljana Janković, Assoc. Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Stanimir Simin, Assist. Professor	Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad (Serbia)
Jovan Bojkovski, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)

### List of reviewers:

Nevenka Aleksić, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Marija Lesjak, Assoc. Professor	Faculty of natural science, University of Novi Sad, (Serbia)
Žolt Bečkei, Assist. Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Olivera Bjelić Čabrilo, Professor	Faculty of natural science, University of Novi Sad, (Serbia)
Jelena Nedeljковиć Trailović, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Kazimir Matović, Senior Research Fellow	Veterinary Specialist Institute „Kraljevo“, Kraljevo (Serbia)
Adnan Jažić, Professor	Faculty of Veterinary Medicine, University of Sarajevo (Bosnia and Herzegovina)
Goran Marković, Assoc. Professor	Faculty of Agronomy Čačak, University of Kragujevac (serbia)
Marko Stanković, Assist. Professor	Faculty of Agriculture, University of Belgrade (Serbia)
Peter Hostnik, Professor	Faculty of Veterinary Medicine, University of Ljubljana (Slovenia)
Vladimir Kukolj, Assoc. Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Bojan Toholj, Professor	Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad (Serbia)
Milan Hadži-Milić, Assist. Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Jasmin Omeragić, Professor	Faculty of Veterinary Medicine, University of Sarajevo (Bosnia and Herzegovina)
Aleksandar Jurišić, Assoc. Professor	Faculty of Agriculture, University of Novi Sad (Serbia)
Snežana Medić, Assist. Professor	Faculty of Medicine, University of Novi Sad (Serbia)
Slavica Maris, MD, MSc	Institute of Public Health, Belgrade (Serbia)
Dragiša Trailović, Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Jelena Francuski Andrić, Assist. Professor	Faculty of Veterinary Medicine, University of Belgrade (Serbia)
Dalibor Todorović, Research Fellow	Scientific Veterinary Institute “Novi Sad” (Serbia)
Nemanja Zdravković, Research Fellow	Scientific Veterinary Institute of Serbia, Belgrade (Serbia)





## Beleške / Notes



---

<b>Zahra Alinezhad, Mohammad Hashemi, Asma Afshari, Golshan Shakeri</b> COMBATTING METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) IN THE FOOD INDUSTRY BY HARNESSING THE POWER OF NATURE: A SYSTEMATIC REVIEW .....	5
<b>Saša Krstović, Darko Guljaš, Jelena Krulj, Marko Damjanović, Igor Jajić</b> POTENTIAL OF DIFFERENT MYCOTOXIN ADSORBENTS UNDER IN VITRO CONDITIONS .....	53
<b>Bishwajit Dashgupta, Md. Mahfujur Rahman, Sharmin Akter, Ruhena Begum, Md. Shahidur Rahman Chowdhury, Md. Mukter Hossain</b> ISOLATION, MOLECULAR IDENTIFICATION AND ANTIBIOTIC SENSITIVITY OF SALMONELLA FROM BUFFALO FECES IN SYLHET DISTRICT OF BANGLADESH .....	67
<b>Felipe Muniz dos Santos, Julio César Cambraia Veado, Vitor Márcio Ribeiro, Adriane Pimenta da Costa-Val</b> EVALUATION OF PHYSIOLOGICAL BIOMARKERS AS POSSIBLE PREDICTIVE FACTORS AND PROGNOSIS MARKERS OF KIDNEY INJURY IN DOGS NATURALLY INFECTED WITH LEISHMANIA INFANTUM .....	83
<b>Olga Luz Sánchez-Loria, Fernando Horacio Campos-Casal</b> INFECTIOUS STOMATITIS IN CAPTIVE SALVATOR MERIANAE LIZARDS.....	103
<b>Ashraf M. Abu-Seida</b> ECTOPIC PRIMARY ABDOMINAL PREGNANCY IN A PERSIAN CAT .....	117